<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">CNS Drugs</journal-id><journal-id journal-id-type="iso-abbrev">CNS Drugs</journal-id><journal-title-group><journal-title>CNS Drugs</journal-title></journal-title-group><issn pub-type="ppub">1172-7047</issn><issn pub-type="epub">1179-1934</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">37166702</article-id><article-id pub-id-type="pmc">10173947</article-id><article-id pub-id-type="publisher-id">1007</article-id><article-id pub-id-type="doi">10.1007/s40263-023-01007-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4253-9496</contrib-id><name><surname>Malar</surname><given-names>Dicson S.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1853-4073</contrib-id><name><surname>Thitilertdecha</surname><given-names>Premrutai</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0009-0006-3656-2269</contrib-id><name><surname>Ruckvongacheep</surname><given-names>Kanokphorn S.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3593-2601</contrib-id><name><surname>Brimson</surname><given-names>Sirikalaya</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4177-2165</contrib-id><name><surname>Tencomnao</surname><given-names>Tewin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2074-8262</contrib-id><name><surname>Brimson</surname><given-names>James M.</given-names></name><address><email>jamesmichael.b@chula.ac.th</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.7922.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 0244 7875</institution-id><institution>Natural Products for Neuroprotection and Anti-ageing Research Unit, </institution><institution>Chulalongkorn University, </institution></institution-wrap>Bangkok, Thailand </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.10223.32</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0490</institution-id><institution>Siriraj Research Group in Immunobiology and Therapeutic Sciences, Faculty of Medicine Siriraj Hospital, </institution><institution>Mahidol University, </institution></institution-wrap>Bangkok, Thailand </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.7922.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 0244 7875</institution-id><institution>Department of Clinical Microscopy, Faculty of Allied Health Sciences, </institution><institution>Chulalongkorn University, </institution></institution-wrap>Bangkok, Thailand </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.7922.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 0244 7875</institution-id><institution>Research, Innovation and International Affairs, Faculty of Allied Health Sciences, </institution><institution>Chulalongkorn University, </institution></institution-wrap>Room 409, ChulaPat-1 Building, 154 Rama 1 Road, Bangkok, 10330 Thailand </aff></contrib-group><pub-date pub-type="epub"><day>11</day><month>5</month><year>2023</year></pub-date><fpage>1</fpage><lpage>42</lpage><history><date date-type="accepted"><day>18</day><month>4</month><year>2023</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">The sigma-1 receptor is a 223 amino acid-long protein with a recently identified structure. The sigma-2 receptor is a genetically unrelated protein with a similarly shaped binding pocket and acts to influence cellular activities similar to the sigma-1 receptor. Both proteins are highly expressed in neuronal tissues. As such, they have become targets for treating neurological diseases, including Alzheimer&#x02019;s disease (AD), Huntington&#x02019;s disease (HD), Parkinson&#x02019;s disease (PD), multiple sclerosis (MS), Rett syndrome (RS), developmental and epileptic encephalopathies (DEE), and motor neuron disease/amyotrophic lateral sclerosis (MND/ALS). In recent years, there have been many pre-clinical and clinical studies of sigma receptor (1 and 2) ligands for treating neurological disease. Drugs such as blarcamesine, dextromethorphan and pridopidine, which have sigma-1 receptor activity as part of their pharmacological profile, are effective in treating multiple aspects of several neurological diseases. Furthermore, several sigma-2 receptor ligands are under investigation, including CT1812, rivastigmine and SAS0132. This review aims to provide a current and up-to-date analysis of the current clinical and pre-clinical data of drugs with sigma receptor activities for treating neurological disease.</p></abstract></article-meta></front><body><sec id="d32e241"><title>Key Points</title><p id="Par2">
<table-wrap id="Taba"><table frame="hsides" rules="groups"><tbody><tr><td align="left">The sigma receptors represent an interesting target for the treatment of neurodegenerative and neurodevelopmental disorders.</td></tr><tr><td align="left">Investigational sigma-1/2 drugs including blarcamesine (ANAVEX2-73), ANAVEX3-71 and CT1812 have shown promising results in clinical trials, and old drugs with sigma-1/2 affinities such as amantadine, dextromethorphan, fenfluramine, naluzotan, phenytoin, pridopidine and rivastigmine are finding new purpose.</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec2"><title>Introduction</title><sec id="Sec3"><title>The Sigma Receptors</title><p id="Par3">The sigma-1 receptor (&#x003c3;1R) is a 223 amino acid chaperone protein that resides at the endoplasmic reticulum (ER); it is also found at the mitochondria-associated ER membrane (MAM), and it can translocate to the plasma membrane (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). The &#x003c3;1R is coded by the <italic>SIGMAR1</italic> gene (found on chromosome 9 in humans and chromosome 4 in mice), which comprises four exons that code for the 223 amino acid protein. The &#x003c3;1R has no homology with any other mammalian protein; however, it does share some homology with the yeast <italic>ERG2</italic>, a fungal gene encoding a C8&#x02013;C7 sterol isomerase from <italic>Magnaporthe grisea</italic>, <italic>Saccharomyces cerevisiae</italic> and <italic>Ustilago maydis</italic> [<xref ref-type="bibr" rid="CR1">1</xref>], although the &#x003c3;1R has no isomerase activity.<fig id="Fig1"><label>Fig. 1</label><caption><p>Structure of the Xenopus sigma-1 receptor homotrimer (left) bound to (+)-pentazocine (ligand removed from image) and the Bovine sigma-2 receptor homodimer (right) bound to PB28, (ligand removed from image) at the membrane of the endoplasmic reticulum.</p></caption><graphic xlink:href="40263_2023_1007_Fig1_HTML" id="MO1"/></fig></p><p id="Par4">The &#x003c3;1R is concentrated in lipid-enriched microdomains at the ER and mitochondria. In NG108 neuroblastoma cells, the &#x003c3;1R was shown to be important in the compartmentalization of ER-synthesized lipids. At the ER, the &#x003c3;1R co-localizes with caveolin-2, a cholesterol-binding protein [<xref ref-type="bibr" rid="CR2">2</xref>]. The &#x003c3;1R also interacts with and modulates the actions of various other proteins, including the IP3R [<xref ref-type="bibr" rid="CR3">3</xref>], ion channels [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>] and the small molecule G-protein (Rac1) [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par5">The &#x003c3;1R has no confirmed endogenous ligand, although there are several candidates. The hallucinogen, <italic>N</italic>,<italic>N</italic>-dimethyltryptamine (DMT) [<xref ref-type="bibr" rid="CR8">8</xref>]; neuro-active steroids such as progesterone [but also testosterone, pregnenolone sulphate and dehydroepiandrosterone sulphate (DHEA-S) bind to the &#x003c3;1R] [<xref ref-type="bibr" rid="CR9">9</xref>]; and <italic>N</italic>-alkyl amines, such as the endogenous sphingolipids [<xref ref-type="bibr" rid="CR10">10</xref>], are all candidates as endogenous &#x003c3;1R ligands.</p><p id="Par6">The &#x003c3;1R ligands can be divided up into several categories: the traditional agonists and antagonists that, when used at physiologically relevant doses, provide a physiological response, and the &#x003c3;1R modulatory ligands, which do not provide a physiological response alone, rather they exhibit positive or negative modulatory effects when certain physiological processes are activated (such as during cellular stress or neuron firing).</p><p id="Par7">The &#x003c3;1R (allosteric) modulatory ligands may also act synergistically with subtherapeutic concentrations of &#x003c3;1R agonists or antagonists [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Defining &#x003c3;1R ligands into these groups can be difficult since there was confusion about the identity of the sigma binding site due to a lack of specific ligands [<xref ref-type="bibr" rid="CR13">13</xref>]. Furthermore, many early studies saw behavioural effects using what are now called &#x003c3;1R agonists. In contrast, molecular pharmacological studies have shown that what are now termed &#x003c3;1R antagonists produce cellular responses in calcium flux [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. In general terms, &#x003c3;1R agonists are ligands that have neuroprotective, mood modifying, analgesic or cognitive effects, and the antagonists mostly (there are several exceptions) have cytotoxic effects.</p><p id="Par8">More specifically, laboratory tests have been suggested to define &#x003c3;1R ligands into agonist or antagonist categories. One proposed, generally accepted test is to check for the dissociation of binding immunoglobulin protein (BiP), with agonists causing the dissociation whereas antagonists do not [<xref ref-type="bibr" rid="CR16">16</xref>]. The ability to potentiate neurite outgrowth in PC12 cells indicates agonistic activity at the &#x003c3;1R. Another proposed way to define &#x003c3;1R ligands is the Hill slope of their binding isotherms, with a standard slope factor (slope &#x02248; 1) indicating an agonist and a shallow slope factor (slope &#x02248; 0.5) indicating an antagonist [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par9">The &#x003c3;1R is found throughout much of the tissues in the body. However, it appears more concentrated in the central nervous system (CNS), heart, liver and eyes [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Many cancers also overexpress the &#x003c3;1R, suggesting that the &#x003c3;1R plays an important role in cell survival under stressful conditions [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par10">Another receptor with a similar ligand-binding profile is the sigma-2 receptor (&#x003c3;2R), although it is structurally and genetically unrelated to the &#x003c3;1R [<xref ref-type="bibr" rid="CR20">20</xref>]. The &#x003c3;2R has a molecular weight of 18&#x02013;21.5 kDa, is located on chromosome 17 (location: 17q11.2) and was previously thought to be part of the progesterone receptor membrane component 1 (PGRMC1) [<xref ref-type="bibr" rid="CR21">21</xref>]. A more recent study has identified the &#x003c3;2R to be the transmembrane protein 97 (TMEM97), also known as meningioma-associated protein 30 (MAC30) [<xref ref-type="bibr" rid="CR22">22</xref>]. The &#x003c3;2R is an endoplasmic reticulum (ER) resident membrane protein [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>] and is also located in the lipid raft containing cholesterol and sphingolipids [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>] of the plasma membrane [<xref ref-type="bibr" rid="CR27">27</xref>]. The structure of the &#x003c3;2R has been identified using x-ray crystallography showing four transmembrane helices (Fig. <xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR28">28</xref>]. Although genetically unrelated to the &#x003c3;1R, the binding pockets of the two proteins are remarkably similar. There are functionally comparable amino acids in similar spatial positions, which likely explains the convergent evolution of these two proteins and reveals why these two proteins bind such a similar portfolio of compounds [<xref ref-type="bibr" rid="CR28">28</xref>].&#x003c3;2Rs are found primarily in the CNS [<xref ref-type="bibr" rid="CR29">29</xref>], breast, colon, stomach, oesophagus and lung. The &#x003c3;2R is highly expressed in a large number of cancers [<xref ref-type="bibr" rid="CR30">30</xref>], such as colorectal cancer, oral/oropharyngeal squamous cell carcinoma, breast cancer cell lines (MCF7, MDA-MB-231), neuroblastoma SK-N-SH cells [<xref ref-type="bibr" rid="CR31">31</xref>], ovarian cancer cells [<xref ref-type="bibr" rid="CR32">32</xref>] and prostate cancer [<xref ref-type="bibr" rid="CR33">33</xref>].</p><p id="Par11">This review aims to cover the current understanding of the sigma receptors&#x02019; role in neurodegenerative and neurodevelopmental disorder development, discuss the relevant approved or investigational drugs and critically review the available clinical data.</p><p id="Par12">Literature searches were carried out (with the last search carried out in April 2023) using PubMed, Scopus and Google Scholar using search terms related to Alzheimer&#x02019;s disease, Parkinson&#x02019;s disease, motor neuron disease, multiple sclerosis, Rett syndrome, and developmental and epileptic encephalopathies in combination with the terms related to the &#x003c3;-1/2 receptors. Clinical trials were identified via <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link> and by refining searches on PubMed only to include clinical trials. No specific time period was chosen for article publication, although more emphasis was given to recent and up-to-date articles.</p></sec><sec id="Sec4"><title>Overview of Neurological Disease and the Role of the Sigma Receptors</title><sec id="Sec5"><title>Alzheimer&#x02019;s Disease</title><p id="Par13">Alzheimer&#x02019;s disease (AD) is a neurogenerative disorder with a progressive loss of cognitive functions, commonly associated with age and neuropathology. The noticeable symptoms, such as memory loss and language problems, begin when damage occurs to neurons responsible for these cognitive functions. Other symptoms involving basic bodily functions, such as walking and swallowing, subsequently occur along with the disease progression [<xref ref-type="bibr" rid="CR34">34</xref>]. The key components of the disease have been reported to be the accumulation of amyloid precursor protein (APP) fragment amyloid-beta (A&#x003b2;) from its overproduction or reduced clearance [<xref ref-type="bibr" rid="CR35">35</xref>], and the downstream process in hyperphosphorylation of the protein tau, leading to cell death, neurotransmitter deficits [<xref ref-type="bibr" rid="CR36">36</xref>], reduced synaptic strength and neurodegeneration [<xref ref-type="bibr" rid="CR37">37</xref>], as well as induction of inflammation related to dysregulated glucose metabolism [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>].</p><p id="Par14">The &#x003c3;1R is expressed highly throughout many organs in the body; however, it is particularly concentrated in the CNS. Much research into the &#x003c3;1R has focused on pain and neurotransmission [<xref ref-type="bibr" rid="CR40">40</xref>&#x02013;<xref ref-type="bibr" rid="CR44">44</xref>]. In studies of normal healthy ageing, in rats or monkeys, the levels of the &#x003c3;1R in the brain are maintained and possibly increased [<xref ref-type="bibr" rid="CR45">45</xref>&#x02013;<xref ref-type="bibr" rid="CR47">47</xref>]. Receptor increases with healthy ageing have only been reported for &#x003c3;1R and muscarinic M2 receptors. Furthermore, this increase in &#x003c3;1R has been seen in human ageing studies.</p><p id="Par15">Using <sup>11</sup>C-labelled donepezil, it was shown that cardiac levels of the &#x003c3;1R were elevated in aged healthy individuals [<xref ref-type="bibr" rid="CR48">48</xref>]. This apparent increase of &#x003c3;1Rs in the body appears to coincide with the age-related loss of other receptors such as the M<sub>1</sub> and M<sub>4</sub> muscarinic acetylcholine receptors [<xref ref-type="bibr" rid="CR49">49</xref>], serotonin 5HT<sub>2A</sub> receptors [<xref ref-type="bibr" rid="CR50">50</xref>] and D<sub>1</sub>/D<sub>2</sub> dopamine (DA) receptors [<xref ref-type="bibr" rid="CR51">51</xref>]. It has been hypothesized that the increase in &#x003c3;1R expression is a compensatory mechanism to offset the loss of the other receptors [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. In the early stages of AD, there is a significant loss of &#x003c3;1R expression in the brain [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>].</p><p id="Par16">Genetic studies have identified that gene mutations in apolipoprotein E (<italic>ApoE</italic>) are related to AD risk. The <italic>ApoE2</italic> allele is associated with a reduced risk of AD, and the <italic>ApoE3</italic> allele is the most frequently found and is considered a neutral allele regarding AD risk. Carriers of the <italic>ApoE4</italic> allele have an earlier onset of AD, and the amyloid plaques are more diffuse.</p><p id="Par17">The <italic>&#x003c3;1R</italic> gene is found on chromosome 9p13 and is approximately 7 kbp long, consisting of four exons coding for a 223 bp amino acid. There have been two reported variants of the &#x003c3;1R receptor that may affect AD development. The G&#x02013;241T/<italic>C&#x02013;240T</italic> (<italic>rs. 1799729</italic>) in the proximal promoter region and A61C (rs. 1800866 resulted in an amino acid substitution Q2P) in the first exon [<xref ref-type="bibr" rid="CR56">56</xref>]. The haplotype <italic>TT241-240P2 </italic>(TT-P) has been shown to express &#x003c3;1R receptor protein at a level 43% lower than the allele <italic>GC-241-240Q2</italic> [<xref ref-type="bibr" rid="CR56">56</xref>].</p><p id="Par18">Several studies have investigated the link between polymorphisms in the &#x003c3;1R and the risk of AD [<xref ref-type="bibr" rid="CR56">56</xref>&#x02013;<xref ref-type="bibr" rid="CR59">59</xref>]. A Japanese study has suggested that the TT-P haplotype is protective against AD [<xref ref-type="bibr" rid="CR56">56</xref>]. However, this would appear to go against what is already known about the &#x003c3;1R and has been contradicted by several other studies. Studies from Hungarian, Polish, Australian and Chinese populations have shown a link between the &#x003c3;1R <italic>TT-P</italic> haplotype and increased susceptibility to AD [<xref ref-type="bibr" rid="CR57">57</xref>&#x02013;<xref ref-type="bibr" rid="CR59">59</xref>].</p><p id="Par19">Furthermore, there is evidence that there may be an interaction between the effects of the <italic>ApoE4</italic> allele and the <italic>&#x003c3;1R</italic> allele. In the Hungarian study [<xref ref-type="bibr" rid="CR59">59</xref>], those who inherited both the TT-P haplotype and the E4 allele had a considerably higher risk for AD than those who carried only one. In the Australian/Chinese cohorts [<xref ref-type="bibr" rid="CR58">58</xref>], the study found the Q2P polymorphism to be associated with a less severe form of AD in non-<italic>E4</italic> allele carriers (i.e. <italic>ApoE2</italic> or <italic>ApoE3</italic>); however, expression of the Q2P polymorphism in combination with <italic>ApoE4</italic> had the potential to create a more severe cognitive dysfunction.</p><p id="Par20">Reduction or loss of expression of the &#x003c3;1R may make neuronal cells vulnerable to stress due to A&#x003b2;-mediated toxicity and damage to intracellular lipid metabolism, cell skeleton network and immune responses. These lead to neuronal cell death and contribute to the pathology of AD [<xref ref-type="bibr" rid="CR60">60</xref>]. &#x003c3;1R knockdown has been shown multiple times in primary hippocampal neurons to reduce dendritic spine formation [<xref ref-type="bibr" rid="CR61">61</xref>&#x02013;<xref ref-type="bibr" rid="CR63">63</xref>].</p><p id="Par21">The &#x003c3;1R also plays a role in controlling tau phosphorylation. The &#x003c3;1R is essential in proper tau phosphorylation and axon extension by promoting p35 turnover through the interaction of the receptor with myristic acid. Furthermore, <italic>&#x003c3;1R</italic> knockout (KO) in neurons results in the accumulation of p35 due to its slower degradation. Conversely, overexpression of the &#x003c3;1R results in a decrease of p35. In the &#x003c3;1R-KO, neurons show shorter axons with lower densities. Interestingly the &#x003c3;1R agonist myristic acid mitigates p35 accumulation, diminishes tau phosphorylation and restores axon elongation [<xref ref-type="bibr" rid="CR64">64</xref>].</p><p id="Par22">Autophagy is a cellular function that involves destroying and recycling cellular organelles and proteins, either when damaged or when the cell needs building blocks to survive. The &#x003c3;1R regulates autophagy, which may be an important target for treating neurodegenerative disease (reviewed in [<xref ref-type="bibr" rid="CR53">53</xref>]). &#x003c3;1R agonists can activate autophagy, reversing some of the effects of APP overexpression [<xref ref-type="bibr" rid="CR65">65</xref>]. The dysregulation of the autophagic process is thought to be a possible part of AD pathology [<xref ref-type="bibr" rid="CR66">66</xref>&#x02013;<xref ref-type="bibr" rid="CR68">68</xref>]. This, and the fact that the &#x003c3;1R is lost in the early stages of AD, could be a potential cause of, at least part of, the pathology of AD.</p><p id="Par23">Calcium homeostasis is significant in AD disease development (reviewed in [<xref ref-type="bibr" rid="CR69">69</xref>]). Vaccines/antibodies that have been trialled, which remove A&#x003b2; plaque build-up, have not stopped dementia progression despite their efficacy at removing A&#x003b2; [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>], suggesting that non-plaque forming A&#x003b2;-oligomers are responsible for neuron cell death [<xref ref-type="bibr" rid="CR72">72</xref>]. Oligomers of soluble A&#x003b2; can form ion channels and dysregulate calcium influx into neurons [<xref ref-type="bibr" rid="CR73">73</xref>]. Fibrillar A&#x003b2; aggregates may cause cell death via the induction of oxidative stress, depolarization of synaptic membranes, excessive calcium influx and mitochondrial stress [<xref ref-type="bibr" rid="CR74">74</xref>].</p><p id="Par24">The &#x003c3;1R appears to play an essential role in regulating calcium homeostasis. Disrupting the &#x003c3;1R in cancer cells with an antagonist such as IPAG (1-(4-iodophenyl)-3-(2-adamantyl)guanidine) or rimcazole results in a large influx of [Ca<sup>2+</sup>] into the cytosol, that can be reversed or prevented by &#x003c3;1R knockdown or a &#x003c3;1R agonists such as pentazocine, SKF10047 or PRE084 [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR75">75</xref>]. During stress, the &#x003c3;1R prevents cytosolic [Ca<sup>2+</sup>] dysregulation in neuron cells [<xref ref-type="bibr" rid="CR76">76</xref>]. The &#x003c3;1R potentially helps buffer cytosolic [Ca<sup>2+</sup>] by shuttling calcium from the ER via the MAM to the mitochondria, stimulating ATP production and improving cellular health [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>].</p></sec><sec id="Sec6"><title>Developmental and Epileptic Encephalopathies</title><p id="Par25">Developmental and epileptic encephalopathy (DEE) has recently been classified as gene-associated developmental encephalopathy without epilepsy which continues progressing even when seizures are controlled. It is then difficult to judge whether developmental or epileptic components contribute more to clinical presentation in DEE. On the other hand, developmental encephalopathy (DE) generally has only developmental impairment (e.g. intellectual disability and autistic spectrum disorder), without epileptic activity associated with regression or further slowing of development.</p><p id="Par26">In contrast, epileptic encephalopathy (EE) is the epileptic activity itself contributing to severe cognitive and behavioural impairments with no pre-existing developmental delay [<xref ref-type="bibr" rid="CR79">79</xref>]. Since most patients with DEE have aetiologies due to genetic variants, and patients with EE also have a molecular genetic basis, genetic testing to distinguish DEE becomes essential. The most frequent and studied DEE-associated genes include <italic>CDKL5</italic>, <italic>SCN1A</italic>, <italic>KCNQ2/KCNQ3</italic>, <italic>PCDH19</italic>, <italic>SCN2A/SCN8A</italic> and <italic>TSC1/TSC2</italic>. Other promising gene variants associated with an increased risk of expressing DEE comprise <italic>KCNT1</italic>, <italic>STXBP1</italic>, CACNA1A, SYNGAP1, GABRB3 and GRIN2A/GRIN2D [<xref ref-type="bibr" rid="CR80">80</xref>]. Besides genetic variants, the causation of DEE also includes structural disorder [e.g. tuberous sclerosis complex (TSC), hypothalamic hamartomas and hemimegalencephaly], metabolic disorder (e.g. pyridoxine or biotinidase deficiency and GLUT1 deficiency) and immune disorder (e.g. Rasmussen syndrome) [<xref ref-type="bibr" rid="CR81">81</xref>&#x02013;<xref ref-type="bibr" rid="CR83">83</xref>].</p><p id="Par27">The current DEE treatments are anti-seizure medications (ASMs). Other emerging pharmacologic agents to potentially treat DEE patients include serotonin modulators [e.g. EPX-100 (clemizole hydrochloride) [<xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR85">85</xref>], EPX-200, fenfluramine [<xref ref-type="bibr" rid="CR86">86</xref>] and lorcaserin [<xref ref-type="bibr" rid="CR87">87</xref>]], TAK935 (soticlestat, a cholesterol 24-hydroxylase inhibitor), huperzine analogue, stiripentol (an anti-convulsant with an unknown mechanism of action) [<xref ref-type="bibr" rid="CR86">86</xref>], ataluren (a suppressant of premature stop codons) [<xref ref-type="bibr" rid="CR87">87</xref>], selective sodium channel modulators (e.g. verapamil) [<xref ref-type="bibr" rid="CR87">87</xref>] and antisense oligonucleotide therapy (e.g. STK-001) [<xref ref-type="bibr" rid="CR87">87</xref>] are in the developmental stage [<xref ref-type="bibr" rid="CR88">88</xref>]. The first precision gene-targeted therapy specific to DEE remains challenging.</p><p id="Par28">The role of the &#x003c3;1R in the development of DEE is thoroughly reviewed by Martin et al. (2021) [<xref ref-type="bibr" rid="CR89">89</xref>]. The &#x003c3;1R, in the brain, acts on neuronal networks at the cellular level to fine tune neuronal signals, thus maintaining a balance between excitatory and inhibitory signals [<xref ref-type="bibr" rid="CR90">90</xref>]. The &#x003c3;1R achieves this by interacting with multiple signalling pathways and proteins and becoming activated by physiological stressors, including the excitatory/inhibitory neuronal imbalances that lead to seizure activity. In <italic>&#x003c3;1R</italic> KO mice, there is a higher susceptibility to convulsive seizures caused by GABA antagonists pentylenetetrazol and (+)-bicuculline [<xref ref-type="bibr" rid="CR90">90</xref>]. An imbalance in excitatory and inhibitory neuron signalling results in seizures. Inadequate control of glutamate signalling at the NMDAR by GABA receptors results in increased seizure activity and &#x003c3;1R activation. Since there are many psychoactive &#x003c3;1R ligands, there is the potential for treating DEEs [<xref ref-type="bibr" rid="CR22">22</xref>].</p></sec><sec id="Sec7"><title>Huntington&#x02019;s Disease</title><p id="Par29">Huntington's disease (HD) is a hereditary and progressive neurological disorder caused by a Huntingtin (<italic>HTT</italic>) gene mutation. The mutation results in an abnormal form of the protein that accumulates in brain cells, leading to impairment of several neuronal signalling [<xref ref-type="bibr" rid="CR91">91</xref>] and protein degradation [<xref ref-type="bibr" rid="CR92">92</xref>] pathways and mitochondrial function [<xref ref-type="bibr" rid="CR93">93</xref>], resulting in brain cell degeneration and eventual death.</p><p id="Par30">The symptoms of HD usually appear in adulthood but can sometimes start in childhood or adolescence. They include uncontrolled movements, such as chorea (involuntary jerking), and cognitive and psychiatric symptoms, including impaired judgment, difficulty concentrating, depression and personality changes [<xref ref-type="bibr" rid="CR94">94</xref>].</p><p id="Par31">HD is inherited in an autosomal dominant manner, meaning that if a person has the mutated <italic>HTT</italic> gene, they have a 50% chance of passing it on to their children. There is currently no cure for Huntington&#x02019;s disease, and treatment focuses on managing symptoms, such as through medication and therapy. The disease can have a significant impact on an individual&#x02019;s quality of life, as well as on their family and caregivers [<xref ref-type="bibr" rid="CR95">95</xref>].</p><p id="Par32">The &#x003c3;1R has been shown to play a role in HD. The exact mechanism by which the &#x003c3;1R contributes to the development and progression of the disease is still being studied. There are several possible ways in which it may be involved.</p><p id="Par33">One way the &#x003c3;1R is thought to be involved in HD is through its interaction with the mutant huntingtin protein. In cell models of HD that express the mutated HTT protein, the &#x003c3;1Rs are expressed in the nuclear inclusions and help to control the degradation of malformed proteins. Knockdown of the &#x003c3;1R using small interfering&#x000a0;RNA (siRNA) increased the volume of aggregates in the nucleus and cytoplasm and caused nuclear inclusions. Moreover, overexpression of the &#x003c3;1R reduced the nuclear inclusions [<xref ref-type="bibr" rid="CR96">96</xref>]. Studies have shown that the &#x003c3;1R can bind to mutant huntingtin and may help to promote its toxic effects on brain cells. In addition, the &#x003c3;1R may also be involved in regulating cellular processes disrupted in Huntington&#x02019;s disease, such as protein folding and calcium signalling.</p><p id="Par34">Studies have shown that expression of the &#x003c3;1R is increased in the striatum of mouse models and patients with severe HD [<xref ref-type="bibr" rid="CR97">97</xref>]. This contradicts the previous experiments; however, it may be explained by the fact that the huntingtin protein and the &#x003c3;1R are involved in transporting vesicles and proteins. Therefore, overexpression of one may lead to the downregulation of the other. In the case of HD, neither protein is overexpressed, but the mutated huntingtin protein causes loss of function. As a result, the &#x003c3;1R is upregulated to compensate for this loss of function.</p><p id="Par35">Evidence suggests that the &#x003c3;1R may be a potential target for treating Huntington&#x02019;s disease. Studies have shown that drugs that activate the &#x003c3;1R can help to reduce symptoms and slow the progression of the disease in animal models [<xref ref-type="bibr" rid="CR98">98</xref>, <xref ref-type="bibr" rid="CR99">99</xref>]. However, more research is needed to determine whether these drugs will be effective in humans.</p></sec><sec id="Sec8"><title>Motor Neuron Disease/Amyotrophic Lateral Sclerosis</title><p id="Par36">Motor neuron disease (MND) is a progressive neurological disorder with particular damage to motor neurons responsible for controlling skeletal muscle activities involving limbs, speech, swallowing and respiratory wall muscles.</p><p id="Par37">MND encompasses a spectrum of different motor neuron syndromes, including amyotrophic lateral sclerosis (ALS), progressive muscular atrophy (PMA), primary lateral sclerosis (PLS), and upper and lower motor neuron dominance [<xref ref-type="bibr" rid="CR100">100</xref>, <xref ref-type="bibr" rid="CR101">101</xref>]. Among them, the most common form of MND is ALS which affects both upper and lower motor neurons and begins with limb weakness (i.e. arms, hands and legs) before progressive paralysis and death within 2&#x02013;5 years after the symptom onset. The onset of MND is reported to be sporadic and varied among patients, and its pathogenesis is not yet fully understood.</p><p id="Par38">A complex interaction between genetic and environmental factors is reported to trigger pathologic development and expansions. This involves glutaminergic pathways leading to glutamate-induced excitotoxicity and mutations of genes such as <italic>c9orf72</italic>, <italic>TDP-43</italic> and fused in sarcoma (<italic>FUS</italic>), resulting in abnormalities of translation and formation of intracellular neuronal aggregates. In contrast, mutations in the superoxide dismuates-1 (<italic>SOD-1</italic>) gene increases oxidative stress [<xref ref-type="bibr" rid="CR102">102</xref>, <xref ref-type="bibr" rid="CR103">103</xref>].</p><p id="Par39">For treatment, palliative care is primarily advised. No effective medication is available apart from riluzole, a glutamatergic neurotransmission inhibitor, and sodium phenylbutyrate/ursodoxicoltaurine, an inhibitor of histone deacetylases (HDACs), the only drugs approved by the US Food and Drug Administration (FDA) that can delay ALS progression and improve survival by 2&#x02013;3 months [<xref ref-type="bibr" rid="CR104">104</xref>, <xref ref-type="bibr" rid="CR105">105</xref>].</p><p id="Par40">Another drug recently approved by the US FDA, but limited to use only in Japan and the USA, is edaravone, a free radical scavenger that halts progression in early stages [<xref ref-type="bibr" rid="CR106">106</xref>]. Although edaravone treatment has beneficial effects, its precise mechanism and cellular/molecular targets are uncertain. Masitinib, a tyrosine kinase inhibitor, has successfully passed a randomized controlled phase&#x000a0;II/III trial in ALS patients as an additional drug for riluzole by showing a significant improvement in ALS progression, quality of life, respiratory function and time delay to death [<xref ref-type="bibr" rid="CR107">107</xref>]. However, further trials were halted in 2021 when observational studies indicated an increased risk of ischaemic heart disease [<xref ref-type="bibr" rid="CR108">108</xref>].</p><p id="Par41">The &#x003c3;1R is highly expressed in motor neurons, particularly in the ER at the postsynaptic subsurface cisternae of cholinergic C-terminals. It is hypothesized to help transport ions across voltage-gated potassium and small conductance calcium-activated potassium channels (SK) channels, thereby reducing motor neuron excitability [<xref ref-type="bibr" rid="CR109">109</xref>, <xref ref-type="bibr" rid="CR110">110</xref>]. It is also speculated that higher conductance of potassium channels can also be indirectly mediated by the interaction of &#x003c3;1R with the IP3R3 receptor and the subsequent amplification of calcium release [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR111">111</xref>].</p><p id="Par42">Consistently, reports imply that genetic mutation in the <italic>&#x003c3;1R</italic> gene and the lack of functioning of the protein can result in MND [<xref ref-type="bibr" rid="CR112">112</xref>]. The <italic>&#x003c3;1R</italic><sup>E102Q</sup> mutation (familial ALS) causes the cytoplasmic aggregation of &#x003c3;1R, making them unable to bind with IP3R with loss of function to control Ca<sup>2+</sup> flux, activated calpain and reduced ATP synthesis alongside mitochondrial-associated membrane collapse [<xref ref-type="bibr" rid="CR113">113</xref>]. Also, studies from transgenic <italic>Drosophila</italic> expressing <italic>&#x003c3;1R</italic><sup>E102Q</sup> confirmed the same, and showed that overexpression of IP3R or glucose transporter GluT-3 could counteract &#x003c3;1R<sup>E102Q</sup> toxicity [<xref ref-type="bibr" rid="CR114">114</xref>]. Upon <italic>&#x003c3;1R</italic> knockdown, the lipid raft markers, including Flotillin-1, Erlin-2 and Caveolin-1, were observed to be localized in non-raft regions, indicating the disruption of lipid rafts and associated intracellular calcium dyshomeostasis [<xref ref-type="bibr" rid="CR115">115</xref>].</p><p id="Par43">Ectopic expression of &#x003c3;1R<sup>E102Q</sup> causes structural alteration in the mitochondria and ER, and induces defective autophagy, vesicular transport and mislocalization of RNA-binding proteins, leading to protein quality control modulation [<xref ref-type="bibr" rid="CR116">116</xref>]. In ALS model mice, <italic>SOD1</italic>*G93A, knockout of &#x003c3;1R exhibited deregulated motor performance, ultimately resulting in a faster death [<xref ref-type="bibr" rid="CR117">117</xref>]. Overexpression of <italic>&#x003c3;1R</italic><sup>E102Q</sup> missense mutation in motor neuron cellular models showed high susceptibility to apoptosis triggered by endoplasmic reticulum stress [<xref ref-type="bibr" rid="CR118">118</xref>].</p><p id="Par44">Furthermore, the cells overexpressing &#x003c3;1R<sup>E102Q</sup> exhibited abnormal mislocalization of the TAR DNA-binding protein (TDP-43), resulting in a toxic cytoplasmic gain of function [<xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR120">120</xref>]. Impaired TDP-43 regulation results in unfolded protein accumulation, defective RNA metabolism and oxidative damages [<xref ref-type="bibr" rid="CR121">121</xref>]. Misfolding or mutation in TDP-43 increases its aggregation propensity, and the intensity of motor neuron degeneration is directly correlated with TDP-43 aggregation [<xref ref-type="bibr" rid="CR122">122</xref>]. In the cellular ALS model, &#x003c3;1R stabilises nuclear pore proteins (Nups) by co-localizing with Ran-activating protein (RanGAP) and rescues nucleocytoplasmic transport deficit to reverse the ALS pathology, further extending the function and confirming the importance of the receptor [<xref ref-type="bibr" rid="CR123">123</xref>].</p></sec><sec id="Sec9"><title>Multiple Sclerosis</title><p id="Par45">Multiple sclerosis (MS) is a neurodegenerative disease of the CNS, predominantly mediated by the autoimmune system. The myelin sheaths of neurons are permanently destroyed by immune cells causing acute inflammation and axonal transection lesions. After that, the chronic phase enters with remyelination and an unrepaired inflammation [<xref ref-type="bibr" rid="CR124">124</xref>]. T- and B-cell infiltrates are correlated with demyelination [<xref ref-type="bibr" rid="CR124">124</xref>]. MS is commonly found in young adults, especially women, aged between 20 and 30 years [<xref ref-type="bibr" rid="CR125">125</xref>]. MS symptoms and the degree of severity are various, depending on the number, type and location of damaged nerves, and lead to a non-traumatic neurological disability affecting physical function, cognition, quality of life and employment. Fatigue has been reported to be a common symptom in 75% of individuals with MS [<xref ref-type="bibr" rid="CR126">126</xref>]. Fatigue could be due to the involvement of the immune system, axonal loss, sleep disorders and circadian rhythm abnormalities during MS [<xref ref-type="bibr" rid="CR127">127</xref>].</p><p id="Par46">The treatment of MS is considered according to the disease status, whether relapsing&#x02013;remitting MS (RRMS, defined as relapses at the onset with stable neurologic disability between episodes), secondary progressive MS with activity (SPMS, defined as steadily increasing neurologic disability following a relapsing course with evidence of ongoing inflammatory activity) or primary progressive MS (PPMS, defined as steadily progression from onset). Currently, there is no cure for MS, and disease-modifying therapies (DMTs) are primarily prescribed as they reduce annual relapse rates and short-term disability via modulation in immune systems, including sequestration of lymphocytes, Th1/Th2 shift, DNA synthesis in lymphocytes and cytokine production [<xref ref-type="bibr" rid="CR125">125</xref>]. Interferon (IFN)-&#x003b2;-1b was the first DMT approved by the US FDA to replace the former immunosuppressants such as azathioprine, methotrexate and corticosteroids [<xref ref-type="bibr" rid="CR128">128</xref>].</p><p id="Par47">Several monoclonal antibodies (mAbs) with well-clarified mechanisms of action, including ocrelizumab, natalizumab, ofatumumab and alemtuzumab, are also approved [<xref ref-type="bibr" rid="CR129">129</xref>]. Ocrelizumab is selective to B cells expressing CD20 and causes cell destruction and reduced inflammation. This is the only drug approved to treat PPMS. Natalizumab is specific to the &#x003b1;4 integrin subunit on lymphocytes and prevents lymphocytes from entering the CNS, whereas alemtuzumab selectively binds CD52 antigen on lymphocytes, leading to their depletion [<xref ref-type="bibr" rid="CR129">129</xref>].</p><p id="Par48">Besides those mAbs, sphingosine 1-phosphate receptor (S1P) modulators (e.g. fingolimod, siponimod, ponesimod and ozanimod) have been shown to bind a subtype of S1P receptors, resulting in sequestration of lymphocytes in lymph nodes [<xref ref-type="bibr" rid="CR130">130</xref>&#x02013;<xref ref-type="bibr" rid="CR132">132</xref>]. Glatiramer acetate is another relatively safe DMT, even though its action is unclear [<xref ref-type="bibr" rid="CR133">133</xref>]. Other DMTs, including fumarates (e.g. dimethyl fumarate and diroximel fumarate), teriflunomide (a pyrimidine synthesis inhibitor with anti-inflammatory and immunomodulatory activities) and cladribine (an immunomodulatory agent selectively targeting lymphocyte subtypes) are also available for treatment [<xref ref-type="bibr" rid="CR134">134</xref>, <xref ref-type="bibr" rid="CR135">135</xref>].</p><p id="Par49">In CNS, oligodendrocytes form myelin sheaths, including proliferation, migration and differentiation of oligodendrocyte precursor cells (OPCs). Studies have reported the co-localization of &#x003c3;1R in progenitor and matured oligodendrocytes, implying a role in myelination [<xref ref-type="bibr" rid="CR136">136</xref>]. In line with this, a study has indicated that &#x003c3;1R regulated oligodendrocyte differentiation and myelin sheath generation, while &#x003c3;1R siRNA showed the opposite effect [<xref ref-type="bibr" rid="CR137">137</xref>]. Also, &#x003c3;1R could interact with cholesterol, and dysfunction of the protein causes perturbations in cholesterol levels, which in turn can cause myelin degeneration [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR139">139</xref>]. The &#x003c3;1R agonist donepezil could restore mitochondrial functions in the induced circadian rhythm disruption cellular model, suggesting the role of the receptor in maintaining a healthy circadian rhythm and possibly reducing fatigue [<xref ref-type="bibr" rid="CR140">140</xref>]. Further, targeting &#x003c3;1R reduces neuroinflammation and demyelination in the experimental autoimmune encephalomyelitis MS model, indicating the potential of the receptor to counteract the pathological effects [<xref ref-type="bibr" rid="CR141">141</xref>].</p></sec><sec id="Sec10"><title>Parkinson&#x02019;s Disease</title><p id="Par50">Parkinson&#x02019;s disease (PD) is a common neurodegenerative disease with impairment in the CNS and motor symptoms. The early signs are usually tremors in one hand causing stiffness (rigid muscles) or slow movement (bradykinesia). Other symptoms can be poor balance; loss of automatic movements such as blinking, smiling and swinging arms while walking; and limitations in speech and writing.</p><p id="Par51">Several biomarkers have been introduced to identify PD at the early stage because most of the cardinal symptoms occur late and dopaminergic neurons are already destroyed [<xref ref-type="bibr" rid="CR142">142</xref>]. However, only a few have been implemented in clinical practice [<xref ref-type="bibr" rid="CR143">143</xref>]. Neuroimaging and biochemical measurements of biofluids are the current focus due to a better prediction of PD [<xref ref-type="bibr" rid="CR144">144</xref>].</p><p id="Par52">There is currently no therapy slowing or arresting the PD progression available, so symptomatic treatment using levodopa (or in combination with carbidopa) as the first-line drug together with personalized non-pharmacological management (e.g. deep brain stimulation, strength training, gait and balance training and hydrotherapy) from a multidisciplinary team approach are primarily suggested [<xref ref-type="bibr" rid="CR145">145</xref>, <xref ref-type="bibr" rid="CR146">146</xref>]. Although levodopa has been proven to improve disability and discomfort in PD patients through the conversion of l-3,4-dihydroxyphenylalanine (L-DOPA) into DA in striatum, the complete mechanism of actions and causes of its adverse events, such as dyskinesias and levodopa resistance from long-term use, are not fully understood [<xref ref-type="bibr" rid="CR147">147</xref>, <xref ref-type="bibr" rid="CR148">148</xref>].&#x003b1;-Synuclein deposition in the brain and the formation of Lewy bodies are thought to be a hallmark of PD-related dementia characterized by changes in thinking, movement, behaviour and mood [<xref ref-type="bibr" rid="CR149">149</xref>]. PD-related dementia and dementia with Lewy bodies are the second most common causes of dementia behind AD, accounting for 15&#x02013;20% of the incidences of dementia globally [<xref ref-type="bibr" rid="CR150">150</xref>]. Drugs targeting the build-up of Lewy bodies could potentially help prevent PD-related dementia.</p><p id="Par53">There is a reduction in &#x003c3;1R expression in PD, much like in AD [<xref ref-type="bibr" rid="CR151">151</xref>], plus there is an age-related loss of dopaminergic neurons in &#x003c3;1R knockout mice [<xref ref-type="bibr" rid="CR152">152</xref>]. The &#x003c3;1R may also alleviate DA toxicity in PD. High availability of DA may act as a neurotoxin, and ischaemia, hypoxia and local exposure to neurotoxins, such as high concentrations of excitatory amino acid and methamphetamine, all result in increased concentrations of DA. The DA neurotoxicity mechanism is linked to an imbalance in REDOX management. DA can spontaneously oxidize in vitro or in an enzyme-catalysed reaction in vivo to form reactive oxygen species (ROS) and DA-quinones. DA-quinones can bind to cysteine or cysteinyl residues on proteins, resulting in an imbalance of glutathione homeostasis (a key cellular antioxidant) [<xref ref-type="bibr" rid="CR153">153</xref>]. ROS is increased in wild-type CHO and &#x003c3;1R knockdown CHO cells treated with physiologically relevant DA concentrations (below 10 &#x000b5;M). However, apoptosis only increases in the &#x003c3;1R knockdown cells [<xref ref-type="bibr" rid="CR154">154</xref>]. Furthermore, DA-treated Neuro2A cells expressing APP<sup>SWE</sup> undergo ROS-mediated apoptosis [<xref ref-type="bibr" rid="CR155">155</xref>], and this can be prevented using this &#x003c3;1R agonist dipentylamine (this protective effect itself was reversed by &#x003c3;-1 antagonist BD1047) [<xref ref-type="bibr" rid="CR156">156</xref>].</p><p id="Par54">Mutations in genes associated with PD, such as <italic>&#x003b1;-synuclein</italic>, <italic>DJ-1</italic>, <italic>LRRK-2</italic> (which encodes leucine-rich repeat kinase 2) and <italic>GBA</italic> (which encodes glucocerebrosidase) have been identified, which cause abnormal &#x003b1;-synuclein proteostasis leading to mitochondrial dysfunction, oxidative stress, neuroinflammation and motor circuit pathophysiology [<xref ref-type="bibr" rid="CR157">157</xref>].</p><p id="Par55">Oxidative damage to the substantia nigra has been demonstrated in patients with PD [<xref ref-type="bibr" rid="CR158">158</xref>]. Oxidative stress accelerates &#x003b1;-synuclein aggregation and cell death [<xref ref-type="bibr" rid="CR159">159</xref>, <xref ref-type="bibr" rid="CR160">160</xref>]. Multiple studies have identified &#x003c3;1R ligands to reduce oxidative stress through multiple in vivo and in vitro models via various signalling pathways involving protecting the ER and mitochondria [<xref ref-type="bibr" rid="CR161">161</xref>&#x02013;<xref ref-type="bibr" rid="CR165">165</xref>].</p><p id="Par56">Similarly to A&#x003b2; in AD, &#x003b1;-synuclein oligomers bind to PGRMC1 at synaptosomes in the brain [<xref ref-type="bibr" rid="CR166">166</xref>]. Furthermore, in chaperone-controlled autophagy, &#x003b1;-synuclein binds to lysosome-associated membrane protein 2A (LAMP-2A) [<xref ref-type="bibr" rid="CR167">167</xref>, <xref ref-type="bibr" rid="CR168">168</xref>] (LAMP-2A is the receptor for chaperone-mediated autophagy). &#x003b1;-Synuclein disrupts cholesterol-rich lipid membranes where the &#x003c3;2R is located and disrupts downstream signalling events, including autophagy [<xref ref-type="bibr" rid="CR169">169</xref>&#x02013;<xref ref-type="bibr" rid="CR171">171</xref>]. Without efficient autophagy, neurons gather ubiquitinated protein aggregates (proteins tagged with ubiquitin for degradation). Thus, allosteric antagonists of the &#x003c3;2R may prevent the effects of &#x003b1;-synuclein oligomers via various mechanisms (possibly similar to AD and A&#x003b2; accumulation at the synaptosomes).</p><p id="Par57">A high-throughput screening assay making use of the National Institutes of Health (NIH) small molecule repository (725 compounds that have been tested in phase I/III clinical trials) and the CogRx library of high-affinity &#x003c3;2R allosteric antagonists, investigated the effects of these compounds on lipid vesicle trafficking deficits caused by &#x003b1;-synuclein [<xref ref-type="bibr" rid="CR172">172</xref>]. The study found that the most effective compounds were the &#x003c3;2R allosteric antagonists [<xref ref-type="bibr" rid="CR172">172</xref>]. Furthermore, an &#x003b1;-synuclein oligomer-induced increase in LAMP-2A expression was blocked by the &#x003c3;2R allosteric antagonists.</p></sec><sec id="Sec11"><title>Rett Syndrome</title><p id="Par58">Rett syndrome (RS) is a rare genetic neurodevelopmental disorder affecting brain development and consequently developing into physical, cognitive and intellectual disabilities. RS is mostly found in females [<xref ref-type="bibr" rid="CR173">173</xref>]. The most precise cause of RS is demonstrated to be the loss-of-function mutation of methyl CpG binding protein 2 (<italic>MECP2</italic>) gene located at the X chromosome Xq28 [<xref ref-type="bibr" rid="CR174">174</xref>].</p><p id="Par59">Dysfunction of MeCP2, an epigenetic modulator of gene expression acting as both a transcriptional activator and repressor, induces either positive or negative changes in many other gene expressions at transcriptional and post-transcriptional levels [<xref ref-type="bibr" rid="CR175">175</xref>, <xref ref-type="bibr" rid="CR176">176</xref>]. MeCP2 deficiency also impacts successive stages of brain development and contributes to mitochondria dysfunction [<xref ref-type="bibr" rid="CR177">177</xref>], impaired protein synthesis [<xref ref-type="bibr" rid="CR178">178</xref>] and reduced synaptogenesis [<xref ref-type="bibr" rid="CR179">179</xref>], leading to pathology of RS. The important symptoms for differential diagnoses are cerebral palsy, autism, Angelman syndrome and non-specific developmental delay [<xref ref-type="bibr" rid="CR173">173</xref>]. Spectrums of these symptoms, together with progression and severity, are also broad and individualized [<xref ref-type="bibr" rid="CR180">180</xref>].</p><p id="Par60">There is no cure available [<xref ref-type="bibr" rid="CR181">181</xref>], so medical care and management aim to provide symptomatic relief through pharmacological and non-pharmacological approaches. Medication is needed for breathing and motor difficulties. Since over half of RS patients have seizures, anti-convulsant/anti-epileptic drugs such as valproate, lamotrigine, levetiracetam and carbamazepine are usually prescribed [<xref ref-type="bibr" rid="CR182">182</xref>]. Serotonin-based therapy, such as serotonin 1A receptor agonists and serotonin reuptake inhibitors (SSRIs) are also reported to help reduce symptoms of sleep apnoea [<xref ref-type="bibr" rid="CR183">183</xref>].</p><p id="Par61">A wide variety of neurologic impairments characterizes RS. Unlike some neurodegenerative diseases (PD and AD in particular), there appears to be little or no causal link established between the &#x003c3;1R and the progression of RS. However, due to the promiscuous relationship of the &#x003c3;1R with multiple proteins and signalling pathways in the brain and its relative success as a target for treating other neurodegenerative diseases, the &#x003c3;1R is a target for treating the neurological damage seen in RS.</p><p id="Par62">Most patients carry a mutation in the <italic>MeCP2</italic> gene [<xref ref-type="bibr" rid="CR184">184</xref>]. MeCP2 is found at high levels in neurons and is associated with the maturation and synaptic plasticity of the CNS [<xref ref-type="bibr" rid="CR185">185</xref>, <xref ref-type="bibr" rid="CR186">186</xref>]. MeCP2 is largely thought to negatively regulate gene expression (although there is some evidence that it activates some genes).</p><p id="Par63">However, when mutated in Rett syndrome, MeCP2 target genes that would normally be activated remain inactive, and genes that would be inactivated remain active, thus producing unneeded proteins. Brain-derived neurotrophic factor (BDNF) is one protein that MeCP2 is thought to negatively regulate [<xref ref-type="bibr" rid="CR187">187</xref>], along with the mTOR/AKT signalling pathways [<xref ref-type="bibr" rid="CR178">178</xref>]. The &#x003c3;1R is known to have a role in regulating BDNF expression in multiple cellular systems, including the brain [<xref ref-type="bibr" rid="CR188">188</xref>], eyes [<xref ref-type="bibr" rid="CR189">189</xref>] and heart [<xref ref-type="bibr" rid="CR190">190</xref>]. Furthermore, many studies have identified that &#x003c3;1R agonist treatment of various cells results in AKT phosphorylation [<xref ref-type="bibr" rid="CR191">191</xref>]. Also, &#x003c3;1R activity has a role in autophagy regulation, becoming a novel target for treating neurological disease [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR192">192</xref>].</p></sec><sec id="Sec12"><title>Wolfram Syndrome</title><p id="Par64">Wolfram syndrome (WS), also known as diabetes insipidus, diabetes mellitus, optic atrophy and deafness (DIDMOAD), is a rare genetic disorder affecting many body parts. It is caused by mutations in the <italic>WFS1</italic> gene, which provides instructions for making a protein called wolframin [<xref ref-type="bibr" rid="CR193">193</xref>].</p><p id="Par65">The most common features of the disorder include diabetes mellitus (a condition that affects how the body uses and stores glucose), diabetes insipidus (a disorder that causes excessive thirst and urination), optic atrophy (damage to the optic nerve that can cause vision loss) and deafness. WS may also include neurological problems such as ataxia (difficulty with coordination and balance), seizures, behavioural problems, urinary tract problems and psychiatric disorders.</p><p id="Par66">There is no cure for WS, and treatment is based on the individual&#x02019;s symptoms. Management may involve regularly monitoring blood sugar levels, hormone replacement therapy and other supportive measures such as hearing aids and visual aids [<xref ref-type="bibr" rid="CR194">194</xref>].</p><p id="Par67">Wolframin protein is expressed at the ER, interacts with the MAM and is involved in calcium transfer between the ER and the mitochondria. The mutated form of wolframin disrupts calcium transfer, leading to mitochondrial dysfunction and cell death [<xref ref-type="bibr" rid="CR195">195</xref>]. The &#x003c3;1R is heavily involved in chaperoning proteins, such as the IP3R, in calcium shuttling between the ER and mitochondria. &#x003c3;1R activation, either during cellular stress or with an agonist, results in calcium transfer from the ER to the mitochondria reducing ER stress, protecting the mitochondria and improving cellular ATP levels and the general health of the cell [<xref ref-type="bibr" rid="CR196">196</xref>]. In mouse and zebrafish models of WS, overexpression of the &#x003c3;1R alleviated the symptoms and restored calcium homeostasis in vivo and in vitro [<xref ref-type="bibr" rid="CR197">197</xref>].</p></sec></sec></sec><sec id="Sec13"><title>Sigma Receptor Ligands for Neurological Disease</title><sec id="Sec14"><title>Amantadine</title><p id="Par68">Amantadine (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) is a weak NMDA antagonist that increases DA release and blocks DA reuptake [<xref ref-type="bibr" rid="CR198">198</xref>, <xref ref-type="bibr" rid="CR199">199</xref>]. Amantadine also has a reported affinity for the &#x003c3;1R of 7 &#x000b5;M ([<sup>3</sup>H]-(+)-SKF-10,047 in rat cerebellum or forebrain homogenates [<xref ref-type="bibr" rid="CR200">200</xref>]) or 740 &#x000b5;M ([<sup>3</sup>H]-(+)-pentazocine in permeabilized MDA-MB-468 breast cancer cells [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]), and also has an affinity for the &#x003c3;2R of 9 &#x000b5;M ([<sup>3</sup>H]-DTG in membranes prepared from MCF7 breast cancer cells [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR201">201</xref>]). Amantadine was previously used to treat influenza-A in the early 1960s and 1970s, although it is no longer recommended due to widespread resistance [<xref ref-type="bibr" rid="CR202">202</xref>]. Amantadine has a mild side effect profile. The common neurological side effects include drowsiness, lightheadedness, dizziness and confusion [<xref ref-type="bibr" rid="CR203">203</xref>].<fig id="Fig2"><label>Fig. 2</label><caption><p>Chemical structures of drugs with sigma receptor activity discussed within this manuscript.</p></caption><graphic xlink:href="40263_2023_1007_Fig2_HTML" id="MO2"/></fig></p><sec id="Sec15"><title>Parkinson&#x02019;s Disease</title><p id="Par69">Amantadine is a drug long used in treating PD [<xref ref-type="bibr" rid="CR204">204</xref>] and has been used for treating movement disorders in PD for over 50 years. Despite its long use in treating PD, the pharmacological activity of amantadine is still not fully understood. Its use in PD has declined since the introduction of L-DOPA treatment. However, it is still used in 10% of patients today, alone or in combination with L-DOPA [<xref ref-type="bibr" rid="CR205">205</xref>].</p><p id="Par70">The blocking of [<sup>3</sup>H]-(+)-SKF-10,047 binding by amantadine in vivo in various mouse brain structures correlated with the data from the rat cerebellum or forebrain homogenates [<xref ref-type="bibr" rid="CR200">200</xref>], and in post-mortem studies of human brains [<xref ref-type="bibr" rid="CR206">206</xref>], suggesting a physiologically relevant interaction of amantadine with the &#x003c3;1R.</p><p id="Par71">The use of amantadine in treating PD and L-DOPA-induced dyskinesia has been debated, with one systematic review suggesting there is no evidence for its safety and benefit in treating PD [<xref ref-type="bibr" rid="CR207">207</xref>]. This may be due to the dose used and the pharmacokinetics of amantadine. As plasma concentrations of amantadine increase, there is a greater risk for toxicity, particularly in patients with renal diseases (the kidneys remove most amantadine) [<xref ref-type="bibr" rid="CR208">208</xref>]. New formulations of amantadine that release over a longer period have been trialled and approved for PD in the USA [<xref ref-type="bibr" rid="CR209">209</xref>&#x02013;<xref ref-type="bibr" rid="CR212">212</xref>] (Table <xref rid="Tab1" ref-type="table">1</xref>). The extended-release formulation is typically used to help manage PD symptoms throughout the day rather than providing short-term relief. Slowly releasing the medication over several hours can help control motor symptoms such as tremors, stiffness and difficulty with movement during both dyskinesia and OFF episodes. Immediate-release amantadine is typically taken two to four times a day, and its effects can wear off relatively quickly, which may result in fluctuations in symptom control [<xref ref-type="bibr" rid="CR209">209</xref>]. On the other hand, extended-release amantadine is designed to slowly release the medication over several hours, providing a more stable blood level of the medication and, therefore, more stable symptom control.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Clinical trials of extended-release amantadine</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Study title</th><th align="left">Conditions studied</th><th align="left">Primary outcome measures</th><th align="left">Study results</th><th align="left">Trial Phase</th><th align="left">Trial number</th></tr></thead><tbody><tr><td align="left">E-R amantadine safety and efficacy study in LID (EASED Study)</td><td align="left"><p>Dyskinesia</p><p>LID</p><p>PD</p></td><td align="left">Change in UDysRS total score from baseline to week 8</td><td align="left">E-R amantadine appeared relatively safe with minimal adverse effects at doses of 260 and 340 mg. There was also a statistically significant reduction in LID (measured using the change in UDysRS) total score. Amantadine reduced LID compared with placebo</td><td align="left">2/3</td><td align="left">NCT01397422</td></tr><tr><td align="left">Efficacy and safety study of ADS-5102 in PD patients with LID (EASE LID 3)</td><td align="left"><p>Dyskinesia</p><p>LID</p><p>PD</p></td><td align="left">Change in UDysRS total score from baseline to week 12</td><td align="left">A statistically significant improvement was measured using UDysRS total score for 340 mg amantadine compared with placebo [<xref ref-type="bibr" rid="CR210">210</xref>&#x02013;<xref ref-type="bibr" rid="CR212">212</xref>, <xref ref-type="bibr" rid="CR214">214</xref>].</td><td align="left">3</td><td align="left">NCT02274766</td></tr><tr><td align="left">ADS-5102 for the treatment of LID (EASE LID Study)</td><td align="left"><p>Dyskinesia</p><p>LID</p><p>PD</p></td><td align="left">Change in UDysRS total score from baseline to week 12</td><td align="left">A statistically significant change in UDysRS of &#x02212;15.9 (1.6) for ADS-5102. A statistically significant change in OFF time, which decreased by a mean (SE) of 0.6 (0.3) hours for ADS-5102 and increased by 0.3 (0.3) hours for placebo [<xref ref-type="bibr" rid="CR214">214</xref>].</td><td align="left">3</td><td align="left">NCT02136914</td></tr><tr><td align="left">Open-Label safety study of ADS-5102 in PD patients with LID</td><td align="left"><p>Dyskinesia</p><p>LID</p><p>PD</p></td><td align="left">Number of participants with reported AEs and safety-related study drug discontinuations</td><td align="left">Patients switching from IR to E-R amantadine experienced an improvement in motor complications, without exacerbating adverse events. Plus a statistically significant reduction in their MDS&#x02010;UPDRS Part IV scores at the first post&#x02010;baseline visit (week 8) plus many patients were able to reduce their levodopa use [<xref ref-type="bibr" rid="CR212">212</xref>].</td><td align="left">3</td><td align="left">NCT02202551</td></tr></tbody></table><table-wrap-foot><p><italic>AEs</italic> adverse events, <italic>E-R</italic> extended release, <italic>IR</italic> immediate release <italic>LID</italic> levodopa-induced dyskinesia, <italic>PD</italic> Parkinson&#x02019;s disease, <italic>SE</italic> standard error, <italic>UDysRS</italic> Unified Dyskinesia Rating Scale</p></table-wrap-foot></table-wrap></p><p id="Par72">Extended-release amantadine may also have a lower incidence of certain side effects, such as nausea and dizziness, compared with immediate-release amantadine. This is because extended-release amantadine releases the medication more slowly, which can reduce the peak concentration of the drug in the blood and potentially minimize side effects [<xref ref-type="bibr" rid="CR213">213</xref>&#x02013;<xref ref-type="bibr" rid="CR215">215</xref>].</p></sec><sec id="Sec16"><title>Multiple Sclerosis</title><p id="Par73">Amantadine treatment improved fatigability associated with MS in several randomized controlled studies [<xref ref-type="bibr" rid="CR216">216</xref>&#x02013;<xref ref-type="bibr" rid="CR219">219</xref>]. Amantadine treatment has been earlier reported to induce sleep spindles in PD individuals, implying the role in rectifying sleep disorders and associated fatigue during MS [<xref ref-type="bibr" rid="CR220">220</xref>]. Amantadine has been trialled to relieve fatigue in MS patients (NCT03185065). Using a randomized cross-over study design, 100 mg of amantadine (increasing to 200 mg if tolerated) was given for 6 weeks per treatment period, followed by a 2-week washout. Fatigue (the primary endpoint) was measured using the modified fatigue impact scale (MFIS) between days 26 and 35. However, the study showed no significant improvement over the placebo and increased adverse events [<xref ref-type="bibr" rid="CR221">221</xref>]. There have been three other clinical trials for MS with extended-release formulations of amantadine concerning drug safety and walking impairment (NCT02471222, NCT03567057 and NCT03436199). Amantadine extended release at 137 mg, (165 patients) and 274 mg (132 patients) improved walking speed in the Timed 25 Foot Walk compared with the placebo (174 patients) (NCT03436199). Furthermore, these improvements were also seen in the open-label follow-up study (NCT03567057). The data from NCT02471222 have not been made available.</p></sec></sec><sec id="Sec17"><title>ANAVEX2-73 (Blarcamesine)</title><p id="Par74">Blarcamesine (ANAVEX2-73; Fig. <xref rid="Fig2" ref-type="fig">2</xref>) is a &#x003c3;1R receptor agonist with an affinity of 860 nM (IC<sub>50</sub>) [<xref ref-type="bibr" rid="CR222">222</xref>] developed for treating AD. Blarcamesine also has agonist activity at the muscarinic M1 receptor, and the NMDA receptor with affinities of 5 and 8 &#x000b5;M, respectively [<xref ref-type="bibr" rid="CR222">222</xref>].</p><sec id="Sec18"><title>Alzheimer&#x02019;s Disease</title><p id="Par75">Pre-clinical studies have shown that blarcamesine can reverse scopolamine's long-term amnesic effects in mice [<xref ref-type="bibr" rid="CR222">222</xref>]. Furthermore, blarcamesine can reverse the effect of learning deficits in mice injected with A&#x003b2;<sub>25&#x02013;35</sub> [<xref ref-type="bibr" rid="CR222">222</xref>&#x02013;<xref ref-type="bibr" rid="CR224">224</xref>]. Blarcamesine given to mice injected with A&#x003b2;<sub>25&#x02013;35</sub> restored respiration rates in hippocampal mitochondria and reduced lipid peroxidation levels. Blarcamesine could also prevent tau-hyperphosphorylation and amyloid-&#x003b2; (1&#x02013;42) generation in mouse models of AD [<xref ref-type="bibr" rid="CR223">223</xref>]. Furthermore, indicators of increased toxicity, including Bax/Bcl-2 ratio and cytochrome C release into the cytosol, were reduced [<xref ref-type="bibr" rid="CR224">224</xref>]. Blarcamesine has protective effects in <italic>Caenorhabditis elegans</italic> and cell culture models of AD by enhancing autophagic flux and increasing proteostasis [<xref ref-type="bibr" rid="CR65">65</xref>].</p><p id="Par76">A phase 1 clinical study in healthy male volunteers showed that doses up to 50 mg were well tolerated, with no serious adverse events reported in a poster at the CNS summit in 2014 [<xref ref-type="bibr" rid="CR225">225</xref>]. At 60 mg, three out of four subjects presented dose-limiting CNS symptoms (dizziness and headache). The study concluded with pharmacokinetic analysis showing extensive biotransformation of blarcamesine to AV19-144 (the bioactive form of the drug) with assumed linear pharmacokinetics after single oral dosing of 1 to 60 mg blarcamesine [<xref ref-type="bibr" rid="CR225">225</xref>].</p><p id="Par77">A biomarker analysis, phase 2a study (NCT02244541), that include some exploratory study into the benefits of blarcamesine, where blarcamesine was administered over 57 weeks, showed a significant reduction in cognitive decline [<xref ref-type="bibr" rid="CR226">226</xref>]. When the study was extended to 265 weeks (NCT02756858), there was confirmation of this prevention of decline at 148 weeks with analysis of blood concentrations of blarcamesine and its metabolite AV19-144, showing that those with high concentrations of blarcamesine had improved therapeutic responses of 78% and 88% in adjusted MMSE and adjusted AD cooperative study&#x02013;activities of daily living (ADCS&#x02013;ADL), respectively, relative to the low/medium concentrations of blarcamesine.</p><p id="Par78">Furthermore, genomic analysis also indicated the significant effects of biomarkers on clinical outcomes of blarcamesine. Two patients showed an exceptional therapeutic response at 148 weeks. Both subjects had &#x003c3;1R wild type and a high mean concentration of blarcamesine in plasma, with a baseline MMSE &#x0003e; 20 [<xref ref-type="bibr" rid="CR226">226</xref>].</p><p id="Par79">The study of biomarkers that predict the potential therapeutic outcome of a drug is especially useful in a disease with such heterogeneity as AD [<xref ref-type="bibr" rid="CR226">226</xref>]. The ApoE &#x003b5;4 genotype alone lacks predictive power since only approximately 25% of people carry this genotype. The study discussed above identified that patients with a baseline MMSE greater than 20 who had the &#x003c3;1R wild type with a high mean blarcamesine serum concentration and <italic>ApoE3</italic> alleles had significantly better outcomes in the ADCS&#x02013;ADL. The <italic>SIGMAR1</italic> Q2P variant, having a baseline MMSE score lower than 20 and a low mean serum concentration of blarcamesine were predictive of poor outcomes in the ADCS&#x02013;ADL [<xref ref-type="bibr" rid="CR226">226</xref>].</p><p id="Par80">Blarcamesine is undergoing further phase 2b/3 clinical trials (ongoing: NCT04314934; completed with data yet to be published: NCT03790709). The results of these clinical trials will be interesting, given the promise blarcamesine has shown in the pre-clinical studies.</p></sec><sec id="Sec19"><title>Multiple Sclerosis</title><p id="Par81">Blarcamesine increased the proliferation of oligodendrocyte progenitor cells to myelin sheath-producing oligodendrocytes in a &#x003c3;1R-dependent manner and protected them from excitotoxic insults [<xref ref-type="bibr" rid="CR227">227</xref>]. There are no currently listed clinical trials for blarcamesine in MS on <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link>.</p></sec><sec id="Sec20"><title>Rett Syndrome</title><p id="Par82">Long-term administration of blarcamesine to mice deficient in MeCP2 restores physiological and neurological abnormalities that mimic the human Rett syndrome, including ameliorating motor and acoustic startle deficits and reversing expiratory apnoea [<xref ref-type="bibr" rid="CR228">228</xref>]. Several &#x003c3;1R-related mechanisms could benefit the neurological and motor symptoms seen in this and other models of Rett syndrome. Enhancement of calcium homeostasis via &#x003c3;1R shuttling of calcium to the mitochondria leads to improved mitochondrial function and the activation of autophagy via &#x003c3;1R activation, resulting in a reduction of misfolded proteins and fewer damaged organelles or the restoring/upregulation of BDNF [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR228">228</xref>, <xref ref-type="bibr" rid="CR229">229</xref>]. This leads to potential improvements in synaptic function in multiple brain regions.</p><p id="Par83">Blarcamesine is currently in phase 2/3 clinical trials (NCT03758924, NCT03941444 and NCT04304482). Blarcamesine has shown positive results in a phase 2 clinical trial (NCT03758924) in female patients diagnosed with Rett syndrome (positive <italic>MeCP2</italic> gene mutation), meeting both primary and secondary endpoints with no reported serious adverse events (press release) [<xref ref-type="bibr" rid="CR230">230</xref>]. In another phase 3 (NCT03941444) clinical trial the primary and secondary endpoints were met with significant improvements versus placebo in the clinical global-impression of improvement scale (CGI-I); the anxiety, depression and mood scale (ADAMS); and drug exposure-dependent response of the Rett Syndrome Behaviour Questionnaire (RSBQ), all with a low incidence of adverse events (press release) [<xref ref-type="bibr" rid="CR230">230</xref>]. It is important to note that the data available from these studies has not been peer reviewed and formally published. There are further ongoing phase 3 studies organized by Anavex Life Sciences (NCT04304482). However, while the data look promising, it will be important to see some independent studies with peer-reviewed results to fully assess the efficacy and safety of blarcamesine for Rett syndrome treatment.</p></sec></sec><sec id="Sec21"><title>ANAVEX3-71</title><p id="Par84">ANAVEX3-71 (AF710B) (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) is an agonist at the muscarinic M<sub>1</sub> receptor and &#x003c3;1R, and the second drug developed by for AD treatment. ANAVEX3-71 has an affinity for the &#x003c3;1R of 1.3 nM and an affinity for the &#x003c3;2R of 10 &#x000b5;M [<xref ref-type="bibr" rid="CR62">62</xref>]. The affinity for the M<sub>1</sub> receptor is approximately 0.05 nM. ANAVEX3-71 also has affinities for the &#x000b5; opioid receptor and serotonin receptor (approximately 10 &#x000b5;M for each) [<xref ref-type="bibr" rid="CR62">62</xref>].</p><sec id="Sec22"><title>Alzheimer&#x02019;s Disease</title><p id="Par85">Given the complex pathology of AD, it is of interest that a drug such as AF710B may interact with multiple target sites to have a beneficial effect in AD [<xref ref-type="bibr" rid="CR52">52</xref>].</p><p id="Par86">Pre-clinical studies have shown ANAVEX3-71 to be worthy of further study. AF710B has been shown to modify the disease-defining hallmarks of AD in transgenic (3&#x000d7;Tg-AD) mice, such as cognitive deficits, amyloid and tau pathologies, and beneficial effects on mitochondrial dysfunction and neuroinflammation [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR231">231</xref>].</p><p id="Par87">Phase 1 clinical trials (NCT04442945) in healthy individuals have been reported on Anavex Life Sciences&#x02019; website, suggesting that in healthy volunteers, 5&#x02013;200 mg daily had no serious adverse events. The pharmacokinetics of ANAVEX3-71 (serum concentration of AF710B) was also proportional to the dose for doses up to 160 mg. Furthermore, there were no clinically significant electrocardiogram (ECG) parameters throughout the study (press release) [<xref ref-type="bibr" rid="CR232">232</xref>].</p><p id="Par88">There are no further registered (<ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link>) ongoing clinical trials with ANAVEX3-71. However, Anavex states on its website that they plan further phase 2 clinical trials. More independent studies are required. However, pre-clinical data on ANAVEX3-71 suggest it could be useful in treating dementia and AD.</p></sec></sec><sec id="Sec23"><title>CogTX Compounds</title><p id="Par89">CT1812 (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) is one of several &#x003c3;2R antagonist compounds developed by Cognitive Therapeutics Inc. (CogTx) for treating AD [<xref ref-type="bibr" rid="CR233">233</xref>]. Other similar &#x003c3;2R compounds from this company that have a strong affinity for the &#x003c3;2R are CT1978 (Kd = 9.2 nM), CT1970 (Kd = 1.8 nM), CT2168 (Kd = 2 nM), CT1681 (Kd = 12 nM), CT1696 (Kd = 11 nM) and CT1925 (Kd = 18 nM), and act as allosteric &#x003c3;2R antagonists [<xref ref-type="bibr" rid="CR172">172</xref>].</p><p id="Par90">CT1812 has become the company&#x02019;s lead compound, with higher selectivity of the &#x003c3;2R and improved metabolic stability. Compounds CT01346 and CT01344 had a low polar surface area and off-target effects at the Ether-a-go-go-related gene (<italic>ERG</italic>) and at other sites. CT1812 has an affinity of 8.5 nM for the &#x003c3;2R [<xref ref-type="bibr" rid="CR233">233</xref>].</p><sec id="Sec24"><title>Alzheimer&#x02019;s Disease</title><p id="Par91">CT1812 has been demonstrated in rats to prevent A&#x003b2;-oligomer binding to neurons and to displace bound A&#x003b2;-oligomers from neuronal receptors [<xref ref-type="bibr" rid="CR234">234</xref>, <xref ref-type="bibr" rid="CR235">235</xref>]. CT1812 does not block oligomer formation, suggesting that its ability to stop A&#x003b2;-oligomer binding and trafficking deficits are a result of &#x003c3;2R binding. A&#x003b2; oligomer concentrations were measured in the brain interstitial fluid (ISF) of 12-month-old APP<sup>Swe</sup>/PS1dE9 transgenic mice using electrodes coated with the oligomer-specific antibody placed in the hippocampus. CT1812 resulted in a rapid and significant increase in A&#x003b2;-oligomer levels (not seen with the vehicle control) but did not affect A&#x003b2; monomer levels.</p><p id="Par92">Furthermore, post-mortem tissue samples observed a similar displacement of A&#x003b2;-oligomers after treatment with CT1812 [<xref ref-type="bibr" rid="CR175">175</xref>]. CT1812 is the first drug for AD to work by displacing A&#x003b2;-oligomer from synaptic receptors and being the first &#x003c3;2R antagonist. Interestingly, CT1812 mimics the protective effects of the Icelandic A673T mutation in the <italic>APP</italic> gene, which may be predictive of clinical success [<xref ref-type="bibr" rid="CR236">236</xref>].</p><p id="Par93">CT1812 has been studied in phase 1 clinical trials and is relatively safe (NCT03716427 and NCT02907567) at doses up to 560 mg, resulting in minimal adverse events in healthy volunteers (reported in an abstract from the Alzheimer&#x02019;s Association) [<xref ref-type="bibr" rid="CR237">237</xref>, <xref ref-type="bibr" rid="CR238">238</xref>]. In a placebo-controlled biomarker study (NCT02907567) in mild AD patients treated with CT1812, there was a significant increase in CSF A&#x003b2;-oligomer concentrations and decreased synaptic protein fragments neurogranin and synaptotagmin relative to baseline compared with placebo-treated patients [<xref ref-type="bibr" rid="CR235">235</xref>]. There are several phase II clinical trials, either ongoing (SEQUEL study, NCT04735536, SHINE study, NCT03507790, NCT05225415 and NCT05531656) or completed, without published results or results made available (SNAP study: NCT03522129, NCT05225389, NCT05248672 and NCT02570997). The SPARC study (NCT03493282) aimed to assess the effects of CT1812 on synaptic density and suggests an increase in synaptic density based on the available data found at <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link>, along with imaging results and statistical analysis, which have yet to be formally published. In the same study, results posted online appear to show a reduction in CSF A&#x003b2;<sub>40</sub>, CSF A&#x003b2;<sub>42</sub>, CSF tau, CSF phospho-tau, CSF neurogranin (NRGN), CSF(SNAP25) and CSF, and increases in CSF synaptotagmin and neurofilament light (NFL). However, there appeared to be no obvious improvements in the cognition scores, MMSE or the AD Assessment Scale&#x02013;Cognitive Subscale (ADAS&#x02013;COG), although without complete data analysis and statistical study, it is difficult to comment on these study aspects.</p></sec><sec id="Sec25"><title>Parkinson&#x02019;s Disease</title><p id="Par94">&#x003b1;-Synuclein binds to LAMP-2A, and mutated forms bind to LAMP-2A tighter, preventing degradation of other substrates and inhibiting the autophagic process. The CogTx compounds were screened in primary neuronal cells against &#x003b1;-synuclein oligomers. Each compound inhibited &#x003b1;-synuclein oligomer-induced lipid vesicle trafficking deficits in a dose-dependent manner [CT1978 (EC50 = 1.48 &#x003bc;M), CT1970 (EC50 = 6.50 &#x003bc;M), CT2168 (EC50 = 1.5 &#x003bc;M), CT1681 (EC50 = 9.44 &#x003bc;M), CT1696 (EC50 = 15.53 &#x003bc;M) and CT1925 (EC50 = 8.95 &#x003bc;M)]. Two more potent compounds, CT1978 and CT2168, were also tested against LAMP-2A expression, and both prevented &#x003b1;-synuclein-induced upregulation of LAMP-2A [<xref ref-type="bibr" rid="CR172">172</xref>]. Taken together, the data from this study suggest that &#x003c3;2R ligands (antagonists) may potentially regulate chaperone-mediated (LAMP-2A) autophagy and have a potential role in PD therapy.</p><p id="Par95">The CogTx &#x003c3;2R compound CT1812 discussed above regarding AD is also in phase 2 clinical trials to assess the efficacy of CT1812 in patients with Lewy body dementia (NCT05225415).</p><p id="Par96">No other studies/trials are registered at <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link> regarding the above compounds or any other &#x003c3;2R ligand. However, these compounds appear to have potential in treating PD, and their activities through the &#x003c3;2R warrant studying other &#x003c3;2R antagonists in relation to PD.</p></sec></sec><sec id="Sec26"><title>Dextromethorphan</title><p id="Par97">Dextromethorphan (DXM) (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) is a drug used in cough-suppressing medicines and targets multiple receptors, including inhibiting serotonin reuptake [<xref ref-type="bibr" rid="CR239">239</xref>] and acting as an agonist at the &#x003c3;1R [<xref ref-type="bibr" rid="CR240">240</xref>]. DXM has an affinity for the &#x003c3;1R of between 142 and 652 nM, and between 2 and 9 &#x000b5;M for the NMDA receptor [<xref ref-type="bibr" rid="CR241">241</xref>]. DXM is metabolized into its active metabolite dextrorphan (DXO) by the enzyme cytochrome P450 (CYP)2D6, a much more potent NMDA receptor antagonist (400&#x02013;900 nM) but a much less potent serotonin reuptake inhibitor than (400&#x02013;800 nM) DXM (20&#x02013;40 nM) [<xref ref-type="bibr" rid="CR240">240</xref>]. Dextromethorphan/quinidine (AVP-923; Nuedexta) is developed and marketed by Avanir Pharmaceuticals. Adding quinidine to the DXM reduces its metabolism to DXO by inhibiting CYP2D6. Deuteration of DXM (AVP-786, also produced by Avanir Pharmaceuticals) further hinders its metabolism by CYP2D6, allowing for lower doses of quinidine in the combination. AXS-05 combines DXM and the atypical antidepressant drug bupropion (developed and marketed by Axsome Therapeutics). In this combination, bupropion also acts as a potent CYP2D6 inhibitor, preventing the bioactivation of DXM.</p><sec id="Sec27"><title>Alzheimer&#x02019;s Disease</title><p id="Par98">Pseudobulbar affect (PBA) is a condition linked to various neurological disorders and manifests as uncontrollable laughing or crying. There is evidence to suggest that &#x003c3;1R agonists act to reduce PBA in patients with neurological diseases. The mechanism by which DXM is thought to treat PBA is related to NMDA and &#x003c3;1R binding; it is also noted that dextromethorphan most prominently binds in the brainstem and cerebellum, areas particularly rich in &#x003c3;1R and is implicated in PBA [<xref ref-type="bibr" rid="CR242">242</xref>]. DXM, with the addition of quinidine inhibiting its metabolism, has been shown to positively affect the symptoms of PBA [<xref ref-type="bibr" rid="CR243">243</xref>]. Dextromethorphan/quinidine is the first FDA-approved drug for the treatment of PBA.</p><p id="Par99">Agitation is another symptom of AD and is one of the most distressing for caregivers, resulting in institutionalization, further isolation and reduced quality of life for the AD patient. There have been multiple studies investigating DXM in combination with other drugs (AVP-923 and AXS-05) or the deuterated form of DXM in combination with quinidine (AVP-786) [<xref ref-type="bibr" rid="CR244">244</xref>&#x02013;<xref ref-type="bibr" rid="CR246">246</xref>]. The registered trials with DXM and DXM-related drug combinations are listed in Table <xref rid="Tab2" ref-type="table">2</xref>.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Clinical trials of dextromethorphan, and drug formulations of dextromethorphan for AD and AD-related symptoms.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Study title</th><th align="left">Conditions studied</th><th align="left">Primary outcome measures</th><th align="left">Study results</th><th align="left">Trial phase</th><th align="left">Trial number</th></tr></thead><tbody><tr><td align="left">Efficacy, safety and tolerability study of AVP-923 (dextromethorphan/quinidine) for treatment of symptoms of agitation in participants with Alzheimer&#x02019;s disease</td><td align="left">Agitation in AD</td><td align="left">Change in the NIP Agitation/Aggression Domain Score from day 1 to day 36 and from day 36 to day 70</td><td align="left">A significantly reduced NPI Agitation/Aggression scores for dextromethorphan-quinidine versus placebo [<xref ref-type="bibr" rid="CR244">244</xref>]</td><td align="left">2</td><td align="left">NCT01584440</td></tr><tr><td align="left">Nuedexta in the treatment of pseudobulbar affect in patients with Alzheimer&#x02019;s disease</td><td align="left">PBA in AD</td><td align="left">Reduction of PBA frequency</td><td align="left">No results posted (last update 2019)</td><td align="left">4</td><td align="left">NCT01832350</td></tr><tr><td align="left">Open-label safety study of AXS-05 in subjects with Alzheimer&#x02019;s disease agitation</td><td align="left">Agitation in AD</td><td align="left">Incidence of treatment-emergent adverse events following dosing with AXS-05</td><td align="left">Study ongoing (last update 2023)</td><td align="left">3</td><td align="left">NCT04947553</td></tr><tr><td align="left">A study to assess the efficacy and safety of AXS-05 in subjects with Alzheimer&#x02019;s disease agitation</td><td align="left">Agitation in AD</td><td align="left">Cohen&#x02013;Mansfield Agitation Inventory (CMAI)</td><td align="left">AXS-05 significantly relieved agitation, a mean percentage reduction from baseline of 48% for AXS-05 versus 38% for placebo [<xref ref-type="bibr" rid="CR246">246</xref>]</td><td align="left">3</td><td align="left">NCT05557409</td></tr><tr><td align="left">Assessing clinical outcomes in Alzheimer&#x02019;s disease agitation (AXS-05)</td><td align="left">Agitation in AD</td><td align="left">Time from randomization to relapse of agitation symptoms</td><td align="left">Study ongoing (last update 2022)</td><td align="left">3</td><td align="left">NCT04797715</td></tr><tr><td align="left">Long-term extension study of the safety and efficacy of AVP-786 for the treatment of agitation in patients with dementia of the Alzheimer&#x02019;s type</td><td align="left">Agitation in AD</td><td align="left">Number of participants with any type of adverse event. Sheehan Suicidality Tracking Scale, Mini-Mental State Examination and Epworth Sleepiness Scale</td><td align="left">Study ongoing (last update 2023)</td><td align="left">3</td><td align="left">NCT02446132</td></tr><tr><td align="left">Efficacy, safety and tolerability of AVP-786 for the treatment of agitation in patients with dementia of the Alzheimer&#x02019;s type</td><td align="left">Agitation in AD</td><td align="left">Change from baseline in the CMAI Composite Score to week 6 and week 12</td><td align="left">AVP-786 showed some statistically significant reductions in agitation measured by CMAI and mADCS-CGIC-Agitation score</td><td align="left">3</td><td align="left">NCT02442765</td></tr><tr><td align="left">Efficacy, safety and tolerability of AVP-786 for the treatment of agitation in participants with dementia of the Alzheimer&#x02019;s type</td><td align="left">Agitation in AD</td><td align="left">Change from baseline to week 12 in the CMAI Composite Score</td><td align="left">AVP-786 showed some statistically significant improvement versus placebo in the secondary outcome in change from baseline to week 12 in the NPI Agitation/Aggression Domain score</td><td align="left">3</td><td align="left">NCT02442778</td></tr><tr><td align="left">Comparative effectiveness of MCI and dementia treatments in a community-based dementia practice</td><td align="left">Mild cognitive impairment</td><td align="left">Cognitive testing &#x02013; Memory Orientation Screening Test (MOST)</td><td align="left">No results published (last update 2016)</td><td align="left">3</td><td align="left">NCT02860338</td></tr><tr><td align="left">Safety study of AVP-923 in the treatment of IEED also known as PBA</td><td align="left">PBA in AD</td><td align="left">Emotional control</td><td align="left">No results published (last update 2016)</td><td align="left">3</td><td align="left">NCT00056524</td></tr></tbody></table><table-wrap-foot><p><italic>AD</italic> Alzheimer&#x02019;s disease, <italic>CIMA</italic> Cohen&#x02013;Mansfield Agitation Inventory, <italic>mADCS-CGIC</italic> Mean Modified Alzheimer&#x02019;s Disease Cooperative Study&#x02013;Clinical Global Impression of Change, <italic>IEED</italic> Involuntary Emotional Expression Disorder, <italic>NIP</italic> Neuropsychiatric Inventory, <italic>PBA</italic> pseudobulbar affect.</p></table-wrap-foot></table-wrap></p><p id="Par100">DXM has an affinity of 205 nM for the &#x003c3;1R, whereas its metabolites DN and dimemorfan (DF) have affinities of 151 and 144 nM, respectively. All three compounds have a low affinity for the &#x003c3;2R (4&#x02013;11 &#x003bc;M). DN has a higher affinity for the PCP site of the NDMAR (900 nM), whereas DXM and DF have affinities of 7 and 17 &#x000b5;M, respectively [<xref ref-type="bibr" rid="CR247">247</xref>].</p></sec><sec id="Sec28"><title>Parkinson&#x02019;s Disease</title><p id="Par101">Intraperitoneal injections (IP) of DXM (20 mg/kg) to 6-OHDA-treated rats significantly attenuated 6-OHDA-induced DAT and SERT loss, correlating to rotational behaviours [<xref ref-type="bibr" rid="CR4">4</xref>]. DXM also has anti-dyskinetic activity [<xref ref-type="bibr" rid="CR248">248</xref>, <xref ref-type="bibr" rid="CR249">249</xref>]. For a long time, it was assumed that these effects were mediated via the NMDA receptor since DXM has moderate to low affinity at this receptor and acts as an antagonist. However, it has been confirmed that the &#x003c3;1R is responsible (at least in part) for the anti-dyskinetic effects since other NMDA antagonists, MK-801 and HA-966, failed to suppress dyskinesias in the 6-OHDA rat model, whereas DXM did and the &#x003c3;1R antagonist BMY-14802 could reverse this [<xref ref-type="bibr" rid="CR250">250</xref>].</p><p id="Par102">Analysis of patient data between January 2005 and December 2013 showed that low cumulative doses of DXM may potentially achieve a protective effect for PD; however, high cumulative doses seem to be a risk for PD [<xref ref-type="bibr" rid="CR251">251</xref>].</p><p id="Par103">DXM/quinidine 45&#x02009;mg/10&#x02009;mg twice daily has been clinically trialled (NCT01767129) to treat levodopa-induced dyskinesia in PD. The small study provided evidence of the clinical benefit of the drug 10&#x02009;mg twice daily (BID) for treating L-DOPA-induced dyskinesia in patients with PD [<xref ref-type="bibr" rid="CR252">252</xref>]. These results aligned with two older studies showing similar anti-dyskinetic effects of DXM alone [<xref ref-type="bibr" rid="CR249">249</xref>, <xref ref-type="bibr" rid="CR253">253</xref>]. However, at the time of writing, DXM (and its formulations) have only been approved for the treatment of PBA and uses in other conditions have been discontinued.</p><p id="Par104">In a case study of a patient with Lewy body dementia who exhibited agitation and aggression (common behavioural and psychological symptoms of Lewy body dementia), the patient was prescribed an acetylcholinesterase inhibitor (rivastigmine) in combination with different anti-psychotics, antidepressants with anti-histaminic effects, anti-convulsants and benzodiazepines, without effect on the outbursts of aggression (paradoxically, the agitation and aggression worsened). The caregiving physician then tried DXM in combination with the CYP2D6 enzyme-inhibiting drug paroxetine. Within 1 day, the patient&#x02019;s behaviour improved with the cessation of the aggression. The patient remained on the DXM/paroxetine combination plus the anti-psychotic drugs. However, 6 weeks post-discharge from the hospital, the patient committed suicide. It is unclear whether any prescribed drugs had a causal relationship with the patient taking their life [<xref ref-type="bibr" rid="CR254">254</xref>]. However, there is reported evidence that DMX abuse can lead to assault, suicide or homicide [<xref ref-type="bibr" rid="CR255">255</xref>].</p></sec><sec id="Sec29"><title>Motor Neuron Disease/Amyotrophic Lateral Sclerosis</title><p id="Par105">As the first FDA-approved drug for the treatment of PBA, dextromethorphan/quinidine enhanced the bulbar function (speech, swallowing and salivation) in ALS individuals in a randomized clinical trial [<xref ref-type="bibr" rid="CR256">256</xref>, <xref ref-type="bibr" rid="CR257">257</xref>], and several other trials have been completed (NCT01806857, NCT03883581, NCT01806857 and NCT00573443). However, in the long term, the drug does not affect the deterioration of bulbar function or avert non-invasive respiratory management in ALS individuals [<xref ref-type="bibr" rid="CR258">258</xref>].</p></sec><sec id="Sec30"><title>Multiple Sclerosis</title><p id="Par106">Long-term treatment with DXM in experimental animal models of MS showed a reduction in neutrophil infiltration through the inhibition of NOX-2 and attenuated axonal demyelination through the upregulation of &#x003c3;1R [<xref ref-type="bibr" rid="CR259">259</xref>]. In addition, DXM stimulated the proliferation and maturation of oligodendroglia progenitor cells to oligodendrocytes and protected against excitotoxicity, indicating neuroprotective effects [<xref ref-type="bibr" rid="CR260">260</xref>].</p><p id="Par107">Two placebo-controlled trials with dextromethorphan/quinidine have shown an effective therapy for PBA in MS patients [<xref ref-type="bibr" rid="CR261">261</xref>, <xref ref-type="bibr" rid="CR262">262</xref>], and treatment with fluoxetine and DXM also produced a similar effect in women with MS [<xref ref-type="bibr" rid="CR263">263</xref>].</p><p id="Par108">A common symptom of MS is chronic pain [<xref ref-type="bibr" rid="CR264">264</xref>]. The &#x003c3;1R has long been associated with pain since its identification and misidentification as a novel opioid receptor [<xref ref-type="bibr" rid="CR265">265</xref>]. Panitch et al. [<xref ref-type="bibr" rid="CR266">266</xref>] showed evidence supporting the off-label use of dextromethorphan/quinidine for pain reduction in MS. However, pain measurement was not a primary outcome measure for those particular trials. DXM has been trialled for treating central neuropathic pain in multiple sclerosis (NCT01324232). There have been at least five studies into the use of DXM in pain treatment from various conditions other than MS, with the results pointing towards a possible pain-relieving effect of DXM (unrelated to MS) [<xref ref-type="bibr" rid="CR266">266</xref>&#x02013;<xref ref-type="bibr" rid="CR271">271</xref>]. Concerning the &#x003c3;1R, pain-relieving drugs studied tend to be antagonists [<xref ref-type="bibr" rid="CR40">40</xref>], and DXM is a &#x003c3;1R agonist. Thus, any pain-relieving effect may not be due to DXM&#x02019;s activation of the &#x003c3;1R.</p></sec><sec id="Sec31"><title>Rett Syndrome</title><p id="Par109">DXM has also been trialled in Rett syndrome patients (NCT00593957, NCT01520363, NCT00069550 and NCT00004807). Two trials have published results at <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link> (NCT01520363 and NCT00593957) [<xref ref-type="bibr" rid="CR272">272</xref>]. In the two groups (PCTDMRTT&#x02013;NCT01520363), 24 patients in DXM (5 mg/kg per day) and 26 in placebo, were evaluated in the Mullen Scales of Early Learning (Mullen) at the end of the three-month treatment period. The open-label study had three groups, each receiving either 0.25, 2.5 or 5 mg/kg/day. At six&#x000a0;months, the improvement in receptive language was measured by the Mullen Scale and the Screen for Social Interaction (SSI) score (mean and difference from baseline) were recorded. The data from these studies do not look promising. While the safety of the drug was not an issue, with only a few minor adverse events, the study showed little efficacy in the primary and secondary outcomes in both studies.</p></sec></sec><sec id="Sec32"><title>Dipentylammonium</title><p id="Par110">Dipentylammonium (DPA) (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) is an <italic>N</italic>-alkyl-amine similar in structure to that of (2R-trans)-2-butyl-5-hetylpyrrolidine (&#x003c3;1R K<sub>i</sub> 2nM [<xref ref-type="bibr" rid="CR273">273</xref>]), tridemorph (&#x003c3;1R K<sub>i</sub> 0.3&#x02013;30 nM [<xref ref-type="bibr" rid="CR274">274</xref>]), stearylamine (&#x003c3;1R K<sub>i</sub> 8 &#x000b5;M [<xref ref-type="bibr" rid="CR275">275</xref>]), dodecylamine (&#x003c3;1R K<sub>i</sub> 183 nM [<xref ref-type="bibr" rid="CR274">274</xref>]) and endogenous sphingolipids [<xref ref-type="bibr" rid="CR276">276</xref>]. DPA has an affinity for the &#x003c3;1R (K<sub>i</sub> 17 nM), and it binds to the same binding site as (+)-pentazocine in a competitive fashion [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR156">156</xref>].</p><sec id="Sec33"><title>Alzheimer&#x02019;s Disease</title><p id="Par111">DPA has been shown to prevent oxidative stress and ER stress in HT-22 cells exposed to 5 mM glutamate. Reducing cell death and ROS production in a &#x003c3;1R antagonist sensitive manner. Furthermore, DPA increased neurite outgrowth in Neuro2A cells and prevented DA toxicity in APP<sup>(Swe)</sup> overexpressing Neuro2A cells [<xref ref-type="bibr" rid="CR156">156</xref>].</p><p id="Par112">There are no clinical safety or efficacy data for DPA, and its simple structure will likely hinder potential clinical studies due to concerns about its specificity. DPA, however, is particularly selective for the &#x003c3;1R, over the &#x003c3;2R, monoamine transporters, DA receptors and muscarinic AchR [<xref ref-type="bibr" rid="CR2">2</xref>].</p></sec></sec><sec id="Sec34"><title>Donepezil</title><p id="Par113">Donepezil (Aricept) (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) is one of the current standard acetylcholinesterase inhibitors (AChEI) that are prescribed for mild-to-moderate AD, along with galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa), according to the online guidance from the National Institute for Health and Care Excellence (NICE) in the UK [<xref ref-type="bibr" rid="CR276">276</xref>]. Donepezil appears to provide improved cognition in mild-to-moderate AD, although it does not halt the progression of the disease. Donepezil has an affinity for the &#x003c3;1R (Ki 14.6 nM) [<xref ref-type="bibr" rid="CR277">277</xref>], and studies using rats have shown that there is 90% occupancy of &#x003c3;1Rs in the brain when dosed with 10 mg/kg [<xref ref-type="bibr" rid="CR278">278</xref>].</p><sec id="Sec35"><title>Alzheimer&#x02019;s Disease</title><p id="Par114">Donepezil has been associated with reduced cardiovascular mortality in patients with AD [<xref ref-type="bibr" rid="CR279">279</xref>, <xref ref-type="bibr" rid="CR280">280</xref>], likely due to cardioprotective effects of &#x003c3;1R ligands [<xref ref-type="bibr" rid="CR281">281</xref>]. Studies investigating donepezil&#x02019;s &#x003c3;1R targeting activities have shown that it can potentiate nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells [<xref ref-type="bibr" rid="CR282">282</xref>] (a common test for &#x003c3;1R agonist activity). Furthermore, positron emission tomography (PET) scans in mice have shown that donepezil can displace <sup>11</sup>C-SA4503 from the brain dose dependently at physiologically relevant doses [<xref ref-type="bibr" rid="CR278">278</xref>].</p><p id="Par115">Donepezil has been thoroughly tested clinically in moderate-to-severe AD, with many studies (discussed in multiple meta-analyses and systematic reviews [<xref ref-type="bibr" rid="CR283">283</xref>&#x02013;<xref ref-type="bibr" rid="CR285">285</xref>]) indicating a statistically significant improvement in the standardized Mini-Mental State Examination (SMMSE, on which scores range from 0 to 30, with higher scores indicating better cognitive function) and the Bristol Activities of Daily Living Scale (BADLS, on which scores range from 0 to 60, with higher scores indicating greater impairment) compared with baseline [<xref ref-type="bibr" rid="CR286">286</xref>]. In most clinical studies of donepezil, patients treated with donepezil maintained or improved cognition and overall dementia severity in contrast to placebo-treated patients who showed a decline in cognition [<xref ref-type="bibr" rid="CR287">287</xref>].</p><p id="Par116">The accumulation of A&#x003b2; in the brain is part of the pathology of AD, and in animal studies, donepezil reduces brain A&#x003b2; accumulation [<xref ref-type="bibr" rid="CR288">288</xref>, <xref ref-type="bibr" rid="CR289">289</xref>]. However, using <sup>11</sup>C-Pittsburgh compound B, a clinical study of AD patients receiving donepezil (5 or 10 mg) for at least 1 year showed that there was no reduction in A&#x003b2; accumulation at either dose [<xref ref-type="bibr" rid="CR290">290</xref>]. Another symptom of AD, other than memory loss, is agitation [<xref ref-type="bibr" rid="CR245">245</xref>]. Despite appearing to be effective in the cognition portions of clinical trials, donepezil does not appear to be effective at managing agitation in AD patients [<xref ref-type="bibr" rid="CR291">291</xref>].</p></sec></sec><sec id="Sec36"><title>Eliprodil</title><p id="Par117">Eliprodil (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) is an NMDA antagonist that selectively inhibits the NR2B (GLUN2B) and is a &#x003c3;1R agonist. Eliprodil failed a phase III clinical trial to treat acute ischaemic stroke [<xref ref-type="bibr" rid="CR292">292</xref>], and has also been trialled for schizophrenia [<xref ref-type="bibr" rid="CR293">293</xref>]. Eliprodil has a moderate affinity for the &#x003c3;1R (K<sub>i</sub> = 630 nM) [<xref ref-type="bibr" rid="CR294">294</xref>].</p><sec id="Sec37"><title>Parkinson&#x02019;s Disease</title><p id="Par118">In a pre-clinical study of eliprodil, a low dose of eliprodil stimulated locomotion in mouse PD models, whereas a high dose had more sedative action. In the same study of reserpine-treated mice, eliprodil reversed akinesia, although this was not statistically significant. Furthermore, eliprodil failed to improve motor recovery from the DA D1 agonist SKF38393, or the DA D2 agonist RU24213, and inhibited the motor stimulation induced by L-DOPA [<xref ref-type="bibr" rid="CR295">295</xref>]. Eliprodil has been clinically trialled for movement disorders, including PD (NCT00001929), although the data were never published. Based on this limited evidence, eliprodil is unlikely to be an effective PD treatment.</p></sec><sec id="Sec38"><title>Multiple Sclerosis</title><p id="Par119">Eliprodil has been reported to exhibit a neuroprotectant effect against toxic insults. A study by Demerens et al. [<xref ref-type="bibr" rid="CR296">296</xref>] has indicated the ability of eliprodil to induce myelination in cellular models, suggesting that the molecule can be of therapeutic interest for the treatment of MS.</p></sec></sec><sec id="Sec39"><title>Fabomotizole</title><p id="Par120">Fabomotizole (Afobazole) (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) was launched in Russia in the early 2000s as an anxiolytic drug. As well as acting on the melatonin receptor 1 and 3 (MT1 and MT3), Afobazole has GABAergic [<xref ref-type="bibr" rid="CR297">297</xref>], NGF and BDNF-releasing properties [<xref ref-type="bibr" rid="CR298">298</xref>]. Afobazole is a mixed &#x003c3;1/2R ligand [<xref ref-type="bibr" rid="CR299">299</xref>].</p><sec id="Sec40"><title>Alzheimer&#x02019;s Disease</title><p id="Par121">Afobazole has been shown to inhibit A&#x003b2;<sub>25-35</sub>-induced calcium increase and nitric oxide production in both rat cortical neurons and microglial cultures [<xref ref-type="bibr" rid="CR300">300</xref>, <xref ref-type="bibr" rid="CR301">301</xref>]. Afobazole shows some promise as a &#x003c3;1/2R ligand; however, its use in AD is still in the pre-clinical stage, and there appear to be no current or planned clinical trials.</p></sec></sec><sec id="Sec41"><title>Fenfluramine</title><p id="Par122">Fenfluramine (Fintepla) (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) is a positive modulator at the &#x003c3;1R [<xref ref-type="bibr" rid="CR89">89</xref>], with an affinity of 266 nM (K<sub>i</sub> guinea pig brain) [<xref ref-type="bibr" rid="CR302">302</xref>]. It also acts to cause the release of serotonin by disrupting the vesicular storage of the neurotransmitter and reversing serotonin transporter function.</p><sec id="Sec42"><title>Developmental and Epileptic Encephalopathies</title><p id="Par123">The serotonin activity of fenfluramine fails to explain its efficacy in Dravet syndrome (a genetic epilepsy characterized by temperature-sensitive/febrile seizures). Furthermore, fenfluramine could potentiate the BiP dissociating effects of &#x003c3;1R agonist PRE084 (although it did not affect BiP dissociation by itself), indicating that fenfluramine is a positive modulator of the &#x003c3;1R rather than a &#x003c3;1R agonist. However, while the positive modulator SOMCL-668 reduced epileptic activity in zebrafish, the &#x003c3;1R agonist PRE084 inhibited fenfluramine-mediated anti-epileptic activity in zebrafish models [<xref ref-type="bibr" rid="CR303">303</xref>]. This may be explained by the biphasic nature of many &#x003c3;1R ligands in vivo [<xref ref-type="bibr" rid="CR304">304</xref>].</p><p id="Par124">In a clinical trial of fenfluramine (NCT03355209) in patients with Lennox&#x02013;Gastaut syndrome (another developmental and epileptic encephalopathy), fenfluramine, compared with placebo, decreased drop seizures and may be particularly good for patients who experience generalized tonic&#x02013;clonic seizures [<xref ref-type="bibr" rid="CR304">304</xref>]. In another pair of fenfluramine studies in Dravet syndrome, where the two identical studies were merged (NCT02682927 and NCT02826863), fenfluramine provided a significantly greater reduction in convulsive seizure frequency compared with placebo [<xref ref-type="bibr" rid="CR305">305</xref>]. In total, 119 patients, with a minimum number of convulsive seizures per 4-week period for 12 weeks before screening, were randomized to receive placebo, fenfluramine 0.2 mg/kg/day or fenfluramine 0.7 mg/kg/day. The study met its primary efficacy endpoint, with 0.7 mg/kg/day showing a 62% greater reduction in mean monthly convulsive seizure frequency than placebo. Furthermore, the low dosage of fenfluramine (0.2 mg/kg/day) showed a 32% reduction in mean MCSF compared with placebo [<xref ref-type="bibr" rid="CR305">305</xref>].</p><p id="Par125">Another study of fenfluramine provided a clinically meaningful reduction in convulsive seizure frequency in most patients in a real-world study (71.1% of patients had a greater than 50% reduction of convulsive seizures, 53.3% had a more than 75% reduction and 11.1% were seizure free) [<xref ref-type="bibr" rid="CR306">306</xref>]. Several other studies are ongoing, and studies with data yet to be published are detailed in Table <xref rid="Tab3" ref-type="table">3</xref>.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Ongoing clinical trials of fenfluramine</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Study title</th><th align="left">Conditions</th><th align="left">Primary outcome measures</th><th align="left">Study results</th><th align="left">Phase</th><th align="left">Trial number</th></tr></thead><tbody><tr><td align="left">Fenfluramine for adult Dravet patients</td><td align="left"><p>Dravet syndrome</p><p>Dravet syndrome, intractable</p></td><td align="left"><p>Seizure reduction</p><p>Comparing the proportion of participants with &#x0003e;50% reduction in the monthly countable convulsive seizure frequency between 4 week baseline period (observational phase) and after 12 week treatment phase using seizure diary</p></td><td align="left">No results posted (last update 2022)</td><td align="left">3</td><td align="left">NCT05560282</td></tr><tr><td align="left">Treatment of Dravet syndrome with fenfluramine (expanded access protocol)</td><td align="left">Dravet syndrome</td><td align="left">Evaluate the safety of fenfluramine</td><td align="left">No results posted (last update 2020)</td><td align="left">Unknown</td><td align="left">NCT04437004</td></tr><tr><td align="left">A study to investigate the long-term safety of ZX008 (fenfluramine hydrochloride) oral solution in children and adults with epileptic encephalopathy including Dravet syndrome and Lennox&#x02013;Gastaut syndrome</td><td align="left"><p>Dravet syndrome</p><p>Lennox&#x02013;Gastaut syndrome</p><p>Epileptic encephalopathy</p></td><td align="left"><p>Evaluate the safety of fenfluramine</p><p>Change in convulsive seizure response</p><p>Change in cognitive CGI by parent/caregiver and investigator</p><p>Change in behavioral CGI by parent/caregiver and investigator</p><p>Change in motor CGI by parent/caregiver and investigator</p><p>Change in clinical global impression by parent/caregiver and investigator</p></td><td align="left">No results posted (last update 2023)</td><td align="left">3</td><td align="left">NCT03936777</td></tr><tr><td align="left">Fenfluramine for the treatment of different types of developmental and epileptic encephalopathies: a pilot trial exploring epileptic and non-epileptic outcomes (FENDEEP)</td><td align="left"><p>Refractory epilepsy</p><p>SYNGAP1 encephalopathy</p><p>STXBP1 encephalopathy with epilepsy</p><p>Inv Dup(15) Encephalopathy</p><p>Multifocal or bilateral malformations of cortical development</p><p>Continuous spike and waves during slow sleep</p></td><td align="left">Seizure frequency, measured using a seizure diary</td><td align="left">No results posted (last update 2022)</td><td align="left">4</td><td align="left">NCT05232630</td></tr></tbody></table><table-wrap-foot><p><italic>CGI</italic> clinical global impression</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec43"><title>Fluoxetine</title><p id="Par126">Fluoxetine (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) is an SSRI, broadly administered as an antidepressant. Besides its use as an antidepressant, fluoxetine has been suggested for many off-label uses, such as cancer treatment [<xref ref-type="bibr" rid="CR307">307</xref>] and COVID-19 [<xref ref-type="bibr" rid="CR308">308</xref>]. Fluoxetine can regulate the inflammatory response by reducing tumour necrosis factor (TNF)-&#x003b1;; interleukin (IL)-1&#x003b2;, -2 and -6; and interferon (INF)-&#x003b3;, while increasing IL-2, -4 and -10 [<xref ref-type="bibr" rid="CR309">309</xref>]. Fluoxetine has an affinity for the &#x003c3;1R of 214&#x02013;240 nM [<xref ref-type="bibr" rid="CR310">310</xref>].</p><sec id="Sec44"><title>Multiple Sclerosis</title><p id="Par127">In a pilot study with relapsing MS patients, fluoxetine reduced the formation of new-enhancing inflammatory lesions in the brain [<xref ref-type="bibr" rid="CR311">311</xref>]. Fluoxetine attenuated microglial activation and protected oligodendrocytes from apoptosis, preventing myelin loss through the inhibition of c-Jun [<xref ref-type="bibr" rid="CR312">312</xref>]. Oral administration of fluoxetine (NCT01910259) in MS patients was found to reduce axonal degeneration as measured by proton magnetic resonance spectroscopy [<xref ref-type="bibr" rid="CR309">309</xref>]. However, in secondary progressive MS individuals, fluoxetine treatment did not exhibit any significant changes in brain atrophy [<xref ref-type="bibr" rid="CR313">313</xref>&#x02013;<xref ref-type="bibr" rid="CR317">317</xref>].</p></sec></sec><sec id="Sec45"><title>Fluvoxamine</title><p id="Par128">The SSRI fluvoxamine is a strong &#x003c3;1R agonist and has been proven to have strong efficacy against depression. Recent studies indicate it may help treat COVID-19 [<xref ref-type="bibr" rid="CR318">318</xref>]. It could potentiate neurite outgrowth in PC12 cells in a &#x003c3;1R-dependent mechanism, indicating its neuroprotective potential [<xref ref-type="bibr" rid="CR319">319</xref>]. In an open-label study, the administration of fluvoxamine exhibited antidepressant activity in MS individuals [<xref ref-type="bibr" rid="CR320">320</xref>].</p><sec id="Sec46"><title>Multiple Sclerosis</title><p id="Par129">Fluvoxamine increased the proliferation of neural stem cells and facilitated their differentiation into oligodendrocytes through the Notch signalling pathway. Further, in an experimental autoimmune encephalitis animal model, fluvoxamine treatment reduced the severity of the condition by inhibiting IFN-&#x003b3;, and reducing inflammatory infiltration and demyelination, suggesting therapeutic potential against MS [<xref ref-type="bibr" rid="CR321">321</xref>].</p></sec></sec><sec id="Sec47"><title>Ketamine</title><p id="Par130">Ketamine (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) is an NMDA receptor antagonist acting to block the open ion channel similarly to memantine. Ketamine also has a moderate affinity for the &#x003c3;1R (K<sub>i</sub> = 139.60 &#x003bc;M). It can potentiate PC12 cell neurite outgrowth in response to NGF (a common assay of &#x003c3;1R agonism) in a bell-shaped dose-response curve (also a common feature among &#x003c3;1R agonists), with the optimal concentration being 1 nM [<xref ref-type="bibr" rid="CR322">322</xref>]. Furthermore, NE100 (a potent &#x003c3;1R antagonist) could inhibit the neurite outgrowth potentiation. As we have discussed above, developing new neuron connections in the hippocampus is important in the progression and treatment of AD. Treatment of mice with low-dose ketamine (8 mg/kg) reduced behavioural abnormalities and improved cognitive function in mouse models of Rett syndrome (a neurodegenerative disease discussed further below). Furthermore, 10 mg/kg ketamine improved cognitive flexibility in rats subjected to repeated restraint stress [<xref ref-type="bibr" rid="CR323">323</xref>].</p><sec id="Sec48"><title>Alzheimer&#x02019;s Disease</title><p id="Par131">Ketamine has been shown to prevent lipopolysaccharide (LPS)-induced TNF-&#x003b1; production in glial cells, astrocyte cultures and microglial cultures [<xref ref-type="bibr" rid="CR324">324</xref>], suggesting that ketamine can prevent neuroinflammation.</p><p id="Par132">A clinical trial (NCT02433041) investigating ketamine to prevent post-operative delirium found, as part of the secondary outcomes, a significant decrease in inflammatory markers with the use of ketamine post-operatively when compared with the placebo [<xref ref-type="bibr" rid="CR325">325</xref>]. This suggests ketamine has neuroprotective action on neurons, glial cells and astrocytes.</p><p id="Par133">Several studies have shown that low doses of ketamine helped improve visual memory, simple working memory and complex working memory in patients with treatment-resistant depression [<xref ref-type="bibr" rid="CR326">326</xref>, <xref ref-type="bibr" rid="CR327">327</xref>]. Depression is a common symptom of AD; furthermore, depression is linked to AD development [<xref ref-type="bibr" rid="CR328">328</xref>]. Ketamine relieves depressive symptoms within hours of treatment, especially in cases where other antidepressants have failed [<xref ref-type="bibr" rid="CR329">329</xref>]. In a case report of a 76-year-old female AD patient suffering from depression who had not responded to conventional antidepressant therapy, the patient was reported to have recovered from severe treatment-resistant depressive decline after only two doses of ketamine [<xref ref-type="bibr" rid="CR330">330</xref>].</p><p id="Par134">Recently, a meta-analysis review of 25 randomized controlled trials that included 14 commonly prescribed antidepressants failed to show efficacy in AD patients [<xref ref-type="bibr" rid="CR331">331</xref>]. Thus, with ketamine&#x02019;s potential for neuroprotection and its efficacy in treating depression, it is possible that ketamine could be a useful intervention in treating depression in AD. However, studies of prolonged treatment (3 months) with ketamine in mice and monkeys show an increase in tau hyperphosphorylation, a key part of AD pathology, before the formation of neurofibril tangles (NFTs). The study did not show A&#x003b2; plaque formation, another pathological hallmark of AD [<xref ref-type="bibr" rid="CR332">332</xref>].</p><p id="Par135">There are several safety issues concerning ketamine use over long-term treatment (discussed below regarding PD, although many concerns also apply to AD). Therefore, further study of the efficacy and safety of ketamine at various doses and over short- and long-term treatment is required before ketamine can be seriously considered as a treatment for AD.</p></sec><sec id="Sec49"><title>Parkinson&#x02019;s Disease</title><p id="Par136">Ketamine in combination with xylazine (&#x003b1;2 adrenergic agonist) has been studied pre-clinically in rat models of PD (MPTP and 6-OHDA). The ketamine/xylazine (85/3 mg/kg) combination given before the MPTP or 6-OHDA significantly reduced the loss of tyrosine hydroxylase immune-stained cells. Furthermore, ketamine/xylazine treatment reversed the amnestic effects of the two neurotoxins, with ketamine/xylazine-treated rats performing the same as control rats in the hidden platform test (MPTP- or 6-OHDA-treated rats showed a 10-second latency in finding the hidden platform) [<xref ref-type="bibr" rid="CR333">333</xref>]. Another study of rats subjected to 6-OHDA showed reduced mobility time in the forced swim test (suggesting depressive-like behaviour). Rats treated with ketamine for 28 days (starting 21 days after the brain lesions were created with 6-OHDA) increased mobility times in the water at all doses of ketamine. Furthermore, ketamine also reduced symptoms of anhedonia (caused by the 6-OHDA lesions) measured using the sucrose preference test. The same study also investigated short-term memory in the rats using the social recognition test, and ketamine significantly (at all doses 5&#x02013;15 mg/kg) reversed the amnesic effects of 6-OHDA treatment [<xref ref-type="bibr" rid="CR334">334</xref>]. In a mouse model of PD using MPTP to induce PD-like symptoms in the mice, ketamine (8 mg/kg) improved the coordinating movement, learning and memory ability of PD model mice.</p><p id="Par137">Furthermore, ketamine also prevented tyrosine hydroxylase-positive neurons from being attacked by MPTP, therefore, protecting nigra dopaminergic neurons. MPTP treatment of mice significantly increased mTOR expression and lowered the expression of several autophagy markers (LC3-II, Beclin1, Parkin and PINK). Ketamine restored expression levels of LC3-II, Beclin1, Parkin and PINK1 to levels of the untreated controls, and reduced the expression of mTOR. This indicates that the subanaesthetic dose of ketamine can restore autophagy in the PD mouse model [<xref ref-type="bibr" rid="CR335">335</xref>].</p><p id="Par138">In a case report of an 88-year-old female patient with PD exhibiting severe bilateral dyskinesia who required surgery, ketamine [20 mg intravenous (IV)] followed a dose of midazolam (1 mg IV) (to prevent the possible psychotomimetic effects of ketamine). It resolved her severe tremor both at rest and during intentional movement. Following the ketamine, the patient remained responsive, communicative and able to follow commands. Several days later, during post-operative care, she remembered receiving the pre-operative ketamine with no adverse consequences [<xref ref-type="bibr" rid="CR336">336</xref>]. Two previous cases have used ketamine to permit surgery in cases of PD, both of which were completed with this drug combination resulting in no major side effects [<xref ref-type="bibr" rid="CR337">337</xref>]. Ketamine has now entered phase 2 clinical trials for treating depression in PD (NCT04944017) and treating levodopa-induced dyskinesia (NCT04912115). Both studies are still ongoing.</p><p id="Par139">There are several possible drawbacks to the use of ketamine in the treatment of depression and levodopa-induced dyskinesia in PD. In treating depression (in general), ketamine IV injection relieves depression symptoms for 1&#x02013;2 weeks, with some patients reporting only a few days. One study of eight patients where ketamine (0.5&#x02009;mg/kg IV) was administered up to every two&#x000a0;weeks showed promising results [<xref ref-type="bibr" rid="CR338">338</xref>]. Furthermore, ketamine dosing requires injections, as it has poor bioavailability and a high first-pass hepatic metabolism, thus requiring hospital/clinical visits. Trips to the hospital/clinic every 3&#x02013;7 days for an IV infusion of ketamine are not practical. Ketamine also has psychotomimetic effects and dissociative symptoms (although these tend to dissipate within 4 hours of treatment) [<xref ref-type="bibr" rid="CR339">339</xref>] and has the potential for addiction [<xref ref-type="bibr" rid="CR340">340</xref>]. There are also concerns about the long-term safety of ketamine treatment as transient tachycardia, hypertension, neurotoxicity, bladder toxicity and tolerance are reported with repeated ketamine infusion [<xref ref-type="bibr" rid="CR341">341</xref>].</p></sec><sec id="Sec50"><title>Multiple Sclerosis</title><p id="Par140">In the experimental autoimmune encephalitis mice model, (R)-ketamine reduced microglial activation, preserved blood&#x02013;brain barrier (BBB) integrity and ameliorated the demyelination [<xref ref-type="bibr" rid="CR342">342</xref>]. Further, under cuprizone-induced demyelination in mice, (R)-ketamine facilitated remyelination through activating TrkB and altered the abnormal amount of <italic>Eisenbergiella massiliensis</italic> in the gut microbiota, which is positively correlated with demyelination [<xref ref-type="bibr" rid="CR343">343</xref>]. Oral administration of ketamine in a 60-year-old woman with MS reduced neuropathic pain (allodynia) associated with the disease [<xref ref-type="bibr" rid="CR344">344</xref>]. In a patient with treatment-resistant depression associated with MS, IV ketamine administration significantly reduced the depression index score with no worsening of her condition over a two-year observation period [<xref ref-type="bibr" rid="CR345">345</xref>]. Likewise, ketamine also improved fatigue, which is associated with MS, in an active placebo-controlled double-blind trial (NCT03500289), suggesting its beneficial effects. Many of the drawbacks mentioned above regarding ketamine and PD also apply here.</p></sec><sec id="Sec51"><title>Rett Syndrome</title><p id="Par141">In a pre-clinical study, daily treatment with ketamine reduced Rett syndrome-like symptoms and extended the life span of MeCP2-null mice without adverse side effects. Furthermore, cortical processing and connectivity were fully restored to wild-type levels [<xref ref-type="bibr" rid="CR346">346</xref>]. Functional deficits in forebrain circuits in mutant MeCP2 mice can be restored by ketamine treatment [<xref ref-type="bibr" rid="CR347">347</xref>].</p><p id="Par142">Two clinical trials (phase 1 and phase 2) are registered at <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link> (NCT02562820 and NCT03633058). The phase 1 safety study was terminated due to funding withdrawal, and the phase 2 study is listed as complete; however, there are no listed results or peer-reviewed publications yet. As well as the drawbacks of ketamine described above, ketamine may also provoke epileptic discharges in some patients with a seizure disorder [<xref ref-type="bibr" rid="CR348">348</xref>].</p></sec></sec><sec id="Sec52"><title>Memantine</title><p id="Par143">Memantine (Ebixa, Axura, Namenda, Akatinol) (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) is a low&#x02013;moderate affinity NMDA receptor antagonist often prescribed for AD patients who do not tolerate AChEI drugs such as donepezil [<xref ref-type="bibr" rid="CR349">349</xref>]. Memantine, in combination with donepezil, is approved as a treatment for AD in many countries [<xref ref-type="bibr" rid="CR350">350</xref>]. Memantine is prescribed for moderate-to-severe AD. It acts as an uncompetitive channel blocker of the NMDA receptor, i.e. memantine does not interact with the binding sites of the NMDA agonists, rather it fits into the channel, competing with magnesium ions, blocking ion flow through the channel into and out of the cell. It is somewhat surprising that an antagonist of the glutamate receptor can benefit AD symptoms since AD sees a reduction in glutamate and glutamate receptors [<xref ref-type="bibr" rid="CR351">351</xref>].</p><sec id="Sec53"><title>Alzheimer&#x02019;s Disease</title><p id="Par144">It has been hypothesized that several mechanisms mediate the beneficial effects of memantine in AD, including decreasing synaptic &#x02018;noise&#x02019; from excessive NMDAR activation and reducing the excitotoxicity [<xref ref-type="bibr" rid="CR351">351</xref>, <xref ref-type="bibr" rid="CR352">352</xref>] or inhibiting A&#x003b2; production or toxicity [<xref ref-type="bibr" rid="CR353">353</xref>]. It is hypothesized that memantine&#x02019;s fast on/off pharmacokinetics allow for the physiological activation of NMDARs, while at the same time inhibiting pathological overactivation because of its mechanism of NMDAR inhibition.</p><p id="Par145">The &#x003c3;1R has been shown to play a role in regulating the NMDA receptor and has been well documented [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR354">354</xref>, <xref ref-type="bibr" rid="CR355">355</xref>]. For example, &#x003c3;1R KO impairs neurogenesis in the hippocampus of adult mice via the downregulation of the NMDA receptor [<xref ref-type="bibr" rid="CR356">356</xref>]. Furthermore, activation of the &#x003c3;1R results in the upregulation and transport to the plasma membrane of NMDA receptors [<xref ref-type="bibr" rid="CR357">357</xref>].</p><p id="Par146">Memantine, like other NMDA ion-channel blockers (amantadine [<xref ref-type="bibr" rid="CR5">5</xref>] and ketamine [<xref ref-type="bibr" rid="CR358">358</xref>], among others), has some affinity for the &#x003c3;1R. However, the affinity of memantine is rather low (2.5 &#x000b5;M) [<xref ref-type="bibr" rid="CR200">200</xref>], and thus the &#x003c3;1R is unlikely to play a full role in memantine&#x02019;s therapeutic effects. However, since activating the &#x003c3;1R receptor modulates NMDA function and upregulates NMDA expression and trafficking to the plasma membrane, it is possible that the combination of drugs such as memantine and a &#x003c3;1R agonist could be beneficial in AD. Monotherapy with memantine has been clinically trialled in multiple studies and is generally safe and well tolerated, plus it has beneficial effects compared with a placebo. A meta-analysis of six placebo-controlled phase 3 trials supports the clinically relevant efficacy of memantine in patients with moderate-to-severe AD [<xref ref-type="bibr" rid="CR359">359</xref>]. The combination therapy of memantine and donepezil has been trialled in several studies with mixed results (NCT00866060, NCT02580305, NCT03316898 and NCT02162251). Multiple studies have identified significant improvements in preventing cognitive decline when memantine is added to stabilize the treatment of patients with stable donepezil treatment for moderate-to-severe AD [<xref ref-type="bibr" rid="CR360">360</xref>&#x02013;<xref ref-type="bibr" rid="CR364">364</xref>]. However, other studies have been less convincing, with the data suggesting only a mild to no benefit to the combination therapy over monotherapy with either donepezil or memantine [<xref ref-type="bibr" rid="CR365">365</xref>].</p></sec><sec id="Sec54"><title>Parkinson&#x02019;s Disease</title><p id="Par147">Memantine is not used in treating the motor symptoms of PD. However, it has been trialled for treating PD-related dementia [<xref ref-type="bibr" rid="CR366">366</xref>, <xref ref-type="bibr" rid="CR369">369</xref>]. Memantine is relatively safe and well tolerated in PD-related dementia treatment, and there appear to be some studies with positive outcomes [<xref ref-type="bibr" rid="CR367">367</xref>].</p><p id="Par148">However, a meta-analysis study of ten trials indicates that memantine does not improve scores on the MMSE, whereas cholinesterase inhibitors did [<xref ref-type="bibr" rid="CR370">370</xref>]. The study did find that there was a reported improvement in global impression but not cognitive function. The clinical trials are listed in Table <xref rid="Tab4" ref-type="table">4</xref>.<table-wrap id="Tab4"><label>Table 4</label><caption><p>Clinical trials of memantine for Parkinson&#x02019;s disease and dementia-related symptoms</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Study title</th><th align="left">Primary outcome measures</th><th align="left">Study results</th><th align="left">Phase</th><th align="left">Trial Number</th></tr></thead><tbody><tr><td align="left">Namenda (memantine) for non-motor symptoms in Parkinson&#x02019;s disease</td><td align="left"><p>UPDRS</p><p>Analyses will be computed for the categorical DV: Global Tremor Assessment by examiner</p></td><td align="left">Memantine was well tolerated in Parkinson&#x02019;s disease with few adverse events. However, specific measures of sleepiness, fatigue, depression and attention did not significantly improve [<xref ref-type="bibr" rid="CR367">367</xref>]</td><td align="left">4</td><td align="left">NCT00646204</td></tr><tr><td align="left">Parkinson&#x02019;s disease evaluated by PET and the effect of memantine</td><td align="left">Decreases in cerebral blood flow and oxygen metabolism in these areas will be the consequence and this can be detected by PET</td><td align="left">No results posted (last update 2006)</td><td align="left">N/A</td><td align="left">NCT00375778</td></tr><tr><td align="left">Study of memantine for gait disorders and attention deficit In Parkinson&#x02019;s disease</td><td align="left">Stride length by gait analysis with an optoelectronic system</td><td align="left">In the memantine treated group, statistically significantly better results (versus placebo) were observed for the overall UPDRS score [<xref ref-type="bibr" rid="CR368">368</xref>]</td><td align="left">4</td><td align="left">NCT01108029</td></tr><tr><td align="left">Memantine versus placebo in Parkinson&#x02019;s disease dementia or DLB</td><td align="left">Assess the global benefits of memantine compared with placebo in outpatients with a diagnosis of PDD or DLB (mild to moderate severity) over a 6 month period</td><td align="left">Patients with DLB treated with memantine showed greater improvement according to Alzheimer&#x02019;s disease cooperative study (ADCS)-clinical global impression of change scores than those who received placebo. No significant differences were noted between the two treatments in patients with PDD [<xref ref-type="bibr" rid="CR366">366</xref>]</td><td align="left">4</td><td align="left">NCT00855686</td></tr><tr><td align="left">Memantine for treatment of cognitive impairment in patients with Parkinson&#x02019;s disease and dementia</td><td align="left"><p>DRS Memory Subscore</p><p>CIBIC&#x02013;Plus Score</p></td><td align="left">DRS scores appeared to improve with a score of 1.6 (95% CI &#x02212;0.13 to 3.33) in memantine treated compared with &#x02212;1.4 (95% CI &#x02212;3.19 to 0.39) in placebo treated. There was also an apparent improvement in the CIBIC&#x02013;Plus Score in the memantine treated group<sup>e</sup></td><td align="left">N/A</td><td align="left">NCT00294554</td></tr><tr><td align="left">Efficacy and safety of memantine for PDD and dementia with Lewy bodies (DLB) (MEMPDD)</td><td align="left">Clinical Global Impression of Change</td><td align="left">No results posted (last update 2015)</td><td align="left">2</td><td align="left">NCT00630500</td></tr><tr><td align="left">Monitoring anti-dementia drugs by serum levels (MONANTI)</td><td align="left"><p>Change of MMSE</p><p>Change of ACE</p><p>Change of NPI-Q</p><p>Change of DAD</p><p>Change of clinical serum level of memantine</p><p>Change in GDS</p></td><td align="left">No results posted (last update 2020)</td><td align="left">4</td><td align="left">NCT04117178</td></tr></tbody></table><table-wrap-foot><p><italic>ACE</italic> Adenbrooke&#x02019;s Cognitive Exam, <italic>DV</italic> dependent variable, <italic>DAD</italic> Disability Assessment for Dementia, <italic>DRS</italic> Dementia Rating Scale, <italic>DLB</italic> dementia with Lewy bodies, <italic>GDS</italic> Geriatric Depression Scale, <italic>MMSE</italic> Mini Mental State Examination, <italic>NPI-Q</italic> Neuropsychiatric Inventory Questionnaire, <italic>PDD</italic> Parkinson&#x02019;s disease dementia, <italic>PET</italic> positron emission tomography, <italic>UPDRS</italic> Unified Parkinson Disease Rating Scale</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec55"><title>Naluzotan</title><p id="Par149">Naluzotan (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) acts as a selective and potent 5-HT1A receptor partial agonist, and it has been claimed that it binds to and activates the &#x003c3;1R, although the evidence for this is weak. Naluzotan has a claimed affinity of 100 nM for the &#x003c3;1R; however, few references to the &#x003c3;1R of naluzotan can be found, with no binding data to back up the claims [<xref ref-type="bibr" rid="CR371">371</xref>]. It has been trialled for depression and anxiety, with the study suggesting that naluzotan is relatively safe and higher doses of naluzotan may be effective in anxiety and depression [<xref ref-type="bibr" rid="CR372">372</xref>].</p><sec id="Sec56"><title>Developmental and Epileptic Encephalopathies</title><p id="Par150">Naluzotan has been tested for its effects in localization-related epilepsy (NCT01281956) [<xref ref-type="bibr" rid="CR373">373</xref>], with the data suggesting that there is no significant difference between placebo and naluzotan; furthermore, the number of seizures in the naluzotan group appeared to be higher than that of the placebo and the trial was terminated.</p><p id="Par151">Given the lack of evidence for the role of the &#x003c3;1R in the pharmacology of naluzotan, and that it had no effect of seizure frequency when trialled, naluzotan is unlikely to benefit DEE patients.</p></sec></sec><sec id="Sec57"><title>Phenytoin</title><p id="Par152">Phenytoin (Dilantin, amongst others) (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) has long been used clinically for seizures [<xref ref-type="bibr" rid="CR374">374</xref>]. The primary mechanism for phenytoin is thought to be the inhibition of voltage-gated sodium channels [<xref ref-type="bibr" rid="CR375">375</xref>]. Phenytoin is a non-selective allosteric modulator of the &#x003c3;1R. There is much evidence that the &#x003c3;1R interacts with and modulates the function of various ion channels, including calcium channels, with many studies indicating that the &#x003c3;1R acts to negatively regulate calcium movement [<xref ref-type="bibr" rid="CR376">376</xref>&#x02013;<xref ref-type="bibr" rid="CR379">379</xref>].</p><p id="Par153">Phenytoin is a positive modulator of the &#x003c3;1R as it increases &#x003c3;1R agonist binding to the receptor when co-administered with a &#x003c3;1R agonist. Furthermore, it can be used to distinguish between &#x003c3;1R agonists and antagonists as phenytoin does not increase antagonist binding [<xref ref-type="bibr" rid="CR380">380</xref>].</p><sec id="Sec58"><title>Developmental and Epileptic Encephalopathies</title><p id="Par154">Many clinical studies have investigated phenytoin (a total of 123 listed on <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link>, of which 36 involve seizures). However, phenytoin is considered a last resort for treating encephalopathy since the severe side effects of phenytoin maintenance therapy, especially cognitive impairment, are undesirable in these already cognitively impaired patients [<xref ref-type="bibr" rid="CR381">381</xref>]. There has been one case report that suggests phenytoin treatment in a two-year-old male with epileptic encephalopathy that did not improve with phenobarbital, pyridoxine, pyridoxal phosphate and levetiracetam showed dramatic response to an IV loading dose of phenytoin, followed by a transfer over to carbamazepine to prevent seizure relapses because of the difficulty in maintaining appropriate blood levels of phenytoin [<xref ref-type="bibr" rid="CR382">382</xref>].</p></sec></sec><sec id="Sec59"><title>PRE-084</title><p id="Par155">The selective &#x003c3;1R agonist, 2-(4-morpholino ethyl)1 phenylcyclohexanecarboxylate (PRE-084) (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) contains the three pharmacophoric moieties for a &#x003c3;1R ligand: a hydrophobic cluster, an amine group and an intermediate chain [<xref ref-type="bibr" rid="CR383">383</xref>], and has an affinity of 2.2 nM. PRE-084 has been a very useful pharmacological tool in the discovery of other &#x003c3;1R ligands [<xref ref-type="bibr" rid="CR384">384</xref>]. Although thought to be specific to the &#x003c3;1R, a study has shown that it can have some off-target effects. PRE-084 could elicit an enhanced barrier function of&#x000a0;human umbilical vein endothelial cell (HUVEC) monolayers in a dose-dependent fashion, and even with significant siRNA knockdown of the &#x003c3;1R, PRE-084 maintained the barrier function effect, meaning that either only a low occupancy of &#x003c3;1R is required for the barrier function effect, or that another receptor is involved [<xref ref-type="bibr" rid="CR385">385</xref>].</p><sec id="Sec60"><title>Alzheimer&#x02019;s Disease</title><p id="Par156">PRE-084 has many characteristics that could make it a potential treatment for AD. Pre-clinical data have shown that PRE-084 can attenuate the blood&#x02013;brain barrier (BBB) disruption caused by A&#x003b2;. The study showed that PRE-084 protected the integrity of the BBB by preventing the deposition of A&#x003b2; (insoluble) A&#x003b2;<sub>1&#x02013;40</sub> and A&#x003b2;<sub>1&#x02013;42</sub> levels in the brains of mice, and increasing vascular endothelial growth factor (VEGF) and ApoE receptor [<xref ref-type="bibr" rid="CR386">386</xref>]. PRE-084 also increases the expression of glial cell line-derived neurotrophic factor (GDNF) [<xref ref-type="bibr" rid="CR387">387</xref>] and BDNF [<xref ref-type="bibr" rid="CR388">388</xref>].</p><p id="Par157">The hippocampal region of the brain is responsible for learning and memory and is one of the first regions to show damage in AD [<xref ref-type="bibr" rid="CR389">389</xref>]. Neurogenesis occurs in the adult hippocampus, although with age, this begins to slow [<xref ref-type="bibr" rid="CR390">390</xref>]. A decreased rate of neurogenesis, increased destruction of mature neurons, and increased inflammation could contribute to the cognitive symptoms seen in AD. It is thought that this damage in the hippocampus can occur up to 10 years before cognitive symptoms appear in the patient. Studies using A&#x003b2;<sub>1&#x02013;42</sub> [<xref ref-type="bibr" rid="CR391">391</xref>] or A&#x003b2;<sub>25&#x02013;35</sub> [<xref ref-type="bibr" rid="CR392">392</xref>] injections into mouse brains have shown reduced proliferation and neurite growth, increased death of newly formed cells and an increase in the number of immature cells in mice brains. PRE-084 treatment promotes neurogenesis in mice treated with A&#x003b2;<sub>1&#x02013;42</sub> or A&#x003b2;<sub>25&#x02013;35</sub> [<xref ref-type="bibr" rid="CR391">391</xref>, <xref ref-type="bibr" rid="CR392">392</xref>]. Furthermore, the density of hyper-reactive astrocytes was reduced by the administration of PRE-084 [<xref ref-type="bibr" rid="CR391">391</xref>], suggesting PRE-084 may play an anti-inflammatory role. PRE-084 could also increase mushroom dendritic spine formation in the hippocampus of transgenic rats expressing presenilin-1 (PS1) and human APP<sup>(Swe)</sup> [<xref ref-type="bibr" rid="CR393">393</xref>].</p><p id="Par158">There has been no clinical study registered or completed with PRE-084 for AD or any other neurodegenerative disease, and there are no data on the safety or pharmacokinetic profile for PRE-084 in human trials. PRE-084 is a well-known selective &#x003c3;1R agonist [<xref ref-type="bibr" rid="CR380">380</xref>] and has been used over the past 30 years as an important prototypical drug to uncover potential therapeutic benefits of the &#x003c3;1R. However, it has yet to be investigated clinically, possibly due to its potential off-target effects, which are thought to increase with dose [<xref ref-type="bibr" rid="CR384">384</xref>].</p></sec><sec id="Sec61"><title>Amyotrophic Lateral Sclerosis/Motor Neuron Disease</title><p id="Par159">PRE-084 protected spinal cord organotypic culture explants from glutamate toxicity and induced the elongation of neurites in motor neurons through the activation of PKC [<xref ref-type="bibr" rid="CR394">394</xref>]. Administration of PRE-084 in adult rats prevented the loss of axotomized motoneurons upon spinal root avulsion injury with decreased astroglial immunoreactivity, alongside increased BiP and GDNF expression in motor neurons and astrocytes, respectively [<xref ref-type="bibr" rid="CR387">387</xref>]. In SOD1<sup>G93A</sup> mice, PRE-084 treatment improved locomotor performance, preserved motor neurons, extended survival of animals and modulated NMDA receptor calcium influx through the PKC pathway [<xref ref-type="bibr" rid="CR395">395</xref>&#x02013;<xref ref-type="bibr" rid="CR397">397</xref>]. In wobbler mice, chronic treatment of PRE-084 increased BDNF expression, reduced reactive astrocytes and induced the survival of motor neurons indicating &#x003c3;1R and their agonists can also be used for treating non-SOD1-linked ALS [<xref ref-type="bibr" rid="CR398">398</xref>]. Nrf-2 co-localization with &#x003c3;1R has been reported in photoreceptor cells, implying Nrf-2 could be directly targeted by &#x003c3;1R [<xref ref-type="bibr" rid="CR399">399</xref>]. However, possibly due to a difference in the study design, there are also data suggesting that NRF-2 does not interact with the Nrf-2 [<xref ref-type="bibr" rid="CR400">400</xref>]. PRE-084 treatment rescued motor neuron defects in TDP43G348C zebrafish by enhancing ATP generation, boosting the unfolded protein response (UPR) and activating the Nrf-2 pathway [<xref ref-type="bibr" rid="CR401">401</xref>].</p></sec><sec id="Sec62"><title>Huntington&#x02019;s Disease</title><p id="Par160">PRE-084 has been tested pre-clinically as a therapeutic agent for HD. A study in 2013 [<xref ref-type="bibr" rid="CR402">402</xref>] showed that PRE-084 promotes cell survival and counteracts the detrimental effects of mutant N-terminal huntingtin protein in neuronal PC6.3 cells. PRE-084 increased cellular antioxidants through the NF-&#x003ba;B pathway (a pathway normally compromised by the mutant huntingtin proteins), supporting the future use of &#x003c3;1R agonists as therapeutics for HD.</p><p id="Par161">Treatment of transgenic cortical cultures from mice expressing 128 CAG repeat expansion in the <italic>Htt</italic> gene (YAC128 transgenic mice) with PRE-084 (100 nM) restored synaptic connections between the cortical and striatal neurons but did not affect their number in the cultures when compared with wild-type mice; furthermore, this was reversed with the &#x003c3;1R antagonist NE-100 [<xref ref-type="bibr" rid="CR403">403</xref>].</p></sec><sec id="Sec63"><title>Wolfram Syndrome</title><p id="Par162">PRE-084 has been shown in a pre-clinical study to attenuate learning deficits in male Wfs1<sup>&#x00394;Exon8</sup> mice (a transgenic WS model) and reduce anxiety in female <italic>Wfs1</italic><sup>&#x00394;Exon8</sup> mice [<xref ref-type="bibr" rid="CR197">197</xref>]. In the same study, <italic>wfs1ab</italic><sup>KO</sup> (zebrafish larvae with the <italic>Wfs1</italic>&#x000a0;gene knocked out) showed a clear locomotor alteration when their response to light variation was tested. PRE-084 treatment (0.1&#x02013;10&#x000a0;&#x000b5;M) in the fish water resulted in a dose-dependent decrease in the hyperlocomotion response, back down to the level of the wild-type larvae (<italic>W</italic><italic>fs1ab</italic><sup>WT</sup>) [<xref ref-type="bibr" rid="CR197">197</xref>]. Furthermore, these effects were reversed by the &#x003c3;1R antagonist NE-100, suggesting that the &#x003c3;1R is responsible for these beneficial effects.</p></sec></sec><sec id="Sec64"><title>Pridopidine</title><p id="Par163">Pridopidine (Fig. <xref rid="Fig2" ref-type="fig">2</xref>), developed by Prilenia Therapeutics, is a drug currently in the late stages of clinical trials for PD, ALS and HD [<xref ref-type="bibr" rid="CR52">52</xref>]. Pridopidine is a selective &#x003c3;1R ligand with low affinity for DA D2/D3 receptors, the adrenergic a2C receptor and the &#x003c3;2R [<xref ref-type="bibr" rid="CR404">404</xref>], and has the potential as an AD therapy. At clinically relevant doses, positron emission tomography (PET) imaging studies in rats and humans show high occupancy of the &#x003c3;1R, with no or negligible occupancy of the D<sub>2</sub>/D<sub>3</sub> receptors [<xref ref-type="bibr" rid="CR405">405</xref>, <xref ref-type="bibr" rid="CR406">406</xref>].</p><sec id="Sec65"><title>Alzheimer&#x02019;s Disease</title><p id="Par164">AD cognitive impairment results from damage to synaptic connections and neuronal atrophy. The plasticity of dendritic spine structures in developing neurons underlies memory formation, as thin spines convert into mushroom spines during information storage in response to long-term potentiation (LTPs) [<xref ref-type="bibr" rid="CR407">407</xref>&#x02013;<xref ref-type="bibr" rid="CR409">409</xref>]; mushroom spine deficiency may reflect learning and memory defects in models of AD. Pre-clinical studies have shown that pridopidine stabilizes mushroom spines in mouse models of AD. In PS1 knock-in (PS1-KI) mouse hippocampal cultures and wild-type cultures treated with A&#x003b2;<sub>1&#x02013;42</sub>, the percentage of mushroom spines was significantly reduced. This reduction could be prevented by 100 nM pridopidine. Furthermore, this was repeated in vivo in PS1-KI mice [<xref ref-type="bibr" rid="CR63">63</xref>].</p><p id="Par165">Pridopidine protects against NMDA-induced oxidative stress in primary hippocampal cultures and can increase mushroom dendritic spine formation in the hippocampus of transgenic rats expressing presenilin-1 (PS1) and human APP<sup>(Swe)</sup>, as well as reduce deficits in spatial learning [<xref ref-type="bibr" rid="CR393">393</xref>]. The study also showed that pridopidine induced ERK and AKT phosphorylation. Thus, the involvement of the mitogen-activated protein kinase/extracellular signal-regulated kinases (MAPK/ERK) and phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signalling pathways, through which the &#x003c3;1R may control the neuroprotective properties and synaptogenesis [<xref ref-type="bibr" rid="CR393">393</xref>].</p><p id="Par166">Pridopidine has yet to be studied clinically for AD; however, given the success of pridopidine in treating other neurodegenerative diseases (discussed further below) and its pre-clinical data in AD, it is possible that pridopidine could show some benefit in patients with AD.</p></sec><sec id="Sec66"><title>Amyotrophic Lateral Sclerosis</title><p id="Par167">Pridopidine targets &#x003c3;1R in SOD1<sup>G93A</sup> ALS models (both in vitro and in vivo) and ameliorates the pathology by maintaining neuromuscular junction integrity and enhancing axonal transport through the activation of ERK pathway [<xref ref-type="bibr" rid="CR410">410</xref>]. Also, cachexia and motor neuron deficits were prevented in SOD1G93A mice upon pridopidine administration [<xref ref-type="bibr" rid="CR411">411</xref>]. One of the important steps during autophagy is the transport of transcription factor EB (TFEB) into the nucleus through POM121/KPNB1/importin&#x003b2;1. The occurrence of hexanucleotide RNA expansion (HRE) because of defective <italic>C9orf72</italic> gene interferes with the &#x003c3;1R and POM121 interaction, causing reduced TFEB transport and autophagy. In NSC34-expressing (G4C2)31 RNA repeats potentiated &#x003c3;1R chaperone activity, and enhanced POM121 and autophagy [<xref ref-type="bibr" rid="CR412">412</xref>]. Under the HEALEY ALS Platform Trial umbrella, two ongoing phase 2/3 clinical trials are active for ALS patients to study pridopidine (as well as other drugs, such as zilucoplan, verdiperstat, CNM-Au8, SLS-005 Trehalose and ABBV-CLS-7262) on disease progression, respiratory function, muscle strength, bulbar function and survival (NCT04615923 and NCT04297683).</p></sec><sec id="Sec67"><title>Huntington&#x02019;s Disease</title><p id="Par168">Treatment of YAC128 HD mice with pridopidine reduces anxiety and depression-like symptoms [<xref ref-type="bibr" rid="CR413">413</xref>], prevents striatal medium spiny neuron (MSN) loss and facilitates Ca<sup>2+</sup> homeostasis and signalling at the ER via activation of the &#x003c3;1R [<xref ref-type="bibr" rid="CR97">97</xref>]. In both animal and human studies of HD, the BDNF pathway has been shown to be affected [<xref ref-type="bibr" rid="CR414">414</xref>]. Under non-disease conditions, the Htt protein is involved in the transport of BDNF. However, the mutated version of Htt protein reduces BDNF release [<xref ref-type="bibr" rid="CR415">415</xref>]. Furthermore, BDNF overexpression can rescue HD phenotypes in YAC128 mice [<xref ref-type="bibr" rid="CR416">416</xref>]. This is particularly relevant to the &#x003c3;1R, as &#x003c3;1R activation has been shown in multiple studies to induce BDNF expression and activity [<xref ref-type="bibr" rid="CR188">188</xref>, <xref ref-type="bibr" rid="CR416">416</xref>&#x02013;<xref ref-type="bibr" rid="CR418">418</xref>].</p><p id="Par169">Pridopidine has undergone randomized, double-blind clinical trials for HD treatment [<xref ref-type="bibr" rid="CR419">419</xref>, <xref ref-type="bibr" rid="CR420">420</xref>]. Pridopidine treatment was ineffective at 20 mg/day and 45 mg/day. However, the higher 90 mg/day improved movement ability measured by the total motor scores (TMS) [<xref ref-type="bibr" rid="CR419">419</xref>].</p><p id="Par170">Higher doses of pridopidine or longer treatment periods could show further improvements. However, another larger study failed to replicate the improvements in TMS. However, some improvements were seen at 26 and 52 weeks in an exploratory assessment of rater-independent Q-Motor and total functional capacity (TFC) using a dose of 45 mg BID (90 mg/day) [<xref ref-type="bibr" rid="CR421">421</xref>].</p><p id="Par171">Furthermore, an open label study of pridopidine covering 60 months showed that 45 mg BID (90 mg/day) can maintain stable TFC and TMS, when using historical placebo controls as a comparison [<xref ref-type="bibr" rid="CR422">422</xref>]. Pridopidine, although not a cure-all drug, does show some promising improvements in some aspects of HD and is tolerable orally at doses up to 112.5 mg BID (225 mg/day), therefore, further investigation is warranted into its benefits for HD treatment.</p></sec><sec id="Sec68"><title>Parkinson&#x02019;s Disease</title><p id="Par172">Pridopidine has been investigated pre-clinically for its use in PD. In a mouse model of PD where 6-OHDA was used to create lesions that resulted in several PD-like symptoms in the mice, pridopidine significantly improved deficits in forelimb use, offered significant protection of nigral DA cell bodies and increased dopaminergic fibre density in the striatum. In &#x003c3;1R KO mice, pridopidine did not protect against 6-OHDA-induced lesions. The study also showed the upregulation of GDNF, BDNF and phosphorylated ERK1/2 in the striatal region of the brain [<xref ref-type="bibr" rid="CR226">226</xref>]. In a similar rat model, pridopidine decreased L-DOPA-induced sensitized locomotor activity while permitting a beneficial motor-stimulant effect of the L-DOPA [<xref ref-type="bibr" rid="CR423">423</xref>]. In primates [macaques treated with the neurotoxin 1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP)], Pridopidine produced a dose-dependent reduction in dyskinesia caused by L-DOPA without modulating the anti-parkinsonian benefit of L-DOPA [<xref ref-type="bibr" rid="CR302">302</xref>].</p><p id="Par173">Dyskinesia is involuntary hyperkinetic movements, and the risk of developing dyskinesia is approximately 25&#x02013;40% after 4&#x02013;6 years of levodopa therapy [<xref ref-type="bibr" rid="CR424">424</xref>]. It is thought that L-DOPA does not cause the development of dyskinesia in PD. Rather it sensitizes the nigrostriatal system, since multiple clinical studies have shown that delaying L-DOPA treatment does not prolong the time before dyskinesia onset [<xref ref-type="bibr" rid="CR425">425</xref>]. In a clinical trial of pridopidine in PD patients with dyskinesia (NCT03922711), pridopidine appeared to reduce Unified Dyskinesia Rating Scale (UDysRS) scores compared with the placebo after 5 weeks (the trial was terminated due to the COVID-19 outbreak). At time of writing, this is the only trial of pridopidine concerning PD, and, unfortunately, this trial was stopped early due to COVID, as the results looked promising.</p></sec></sec><sec id="Sec69"><title>Rivastigmine</title><p id="Par174">Rivastigmine (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) is a therapeutic agent that acts as an AChEI and is used in treating mild-to-moderate AD [<xref ref-type="bibr" rid="CR426">426</xref>]. Rivastigmine is also thought to be active at the &#x003c3;2R [<xref ref-type="bibr" rid="CR29">29</xref>].</p><sec id="Sec70"><title>Alzheimer&#x02019;s Disease</title><p id="Par175">Rivastigmine enhances NGF-induced neurite outgrowth in PC12 cells via &#x003c3;1R and &#x003c3;2R since antagonists of each were both required to block the NGF-induced neurite outgrowth fully. Furthermore, &#x003c3;1R and &#x003c3;2R knockdown also abolished NGF-induced neurite outgrowth in PC12 cells [<xref ref-type="bibr" rid="CR427">427</xref>].</p><p id="Par176">Rivastigmine provides meaningful management of symptoms, maintains cognitive ability and daily function, and prevents some behavioural problems in AD [<xref ref-type="bibr" rid="CR428">428</xref>&#x02013;<xref ref-type="bibr" rid="CR430">430</xref>].</p></sec></sec><sec id="Sec71"><title>SAS0132</title><p id="Par177">SAS0132 (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) is a novel potent &#x003c3;2R ligand with a nine-fold selectivity over the &#x003c3;1R. SAS0132 has an affinity of 90 nM for the &#x003c3;2R, acting as a &#x003c3;2R antagonist reversing intracellular calcium influx in human SK-N-SH neuroblastoma cells in response to &#x003c3;2R agonist DKR-1051 [<xref ref-type="bibr" rid="CR431">431</xref>].</p><sec id="Sec72"><title>Alzheimer&#x02019;s Disease</title><p id="Par178">In transgenic <italic>C. elegans</italic> overexpressing the APP gene, SAS0132 reduced the age-dependent neurodegeneration compared with controls. Furthermore, in the Thy-1 hAPP<sup>Lond/Swe+</sup> transgenic mouse model of AD, SAS0132 improves cognitive performance [<xref ref-type="bibr" rid="CR431">431</xref>]. SAS0132 is a promising &#x003c3;2R antagonist with interesting results in pre-clinical studies; however, it has yet to enter clinical trials.</p></sec></sec><sec id="Sec73"><title>T-817 MA</title><p id="Par179">T-817MA (edonerpic maleate) (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) is a &#x003c3;1R ligand with an affinity (K<sub>i</sub>) of 16 nM. It has been shown to induce the outgrowth of neurites in cultured rat cortical neurons and protect against sodium nitroprusside-induced ROS production and cell death, which could be reversed by the &#x003c3;-1 R antagonist BD1047 [<xref ref-type="bibr" rid="CR432">432</xref>].</p><sec id="Sec74"><title>Alzheimer&#x02019;s Disease</title><p id="Par180">In animal studies of AD, edonerpic maleate ameliorated the deficits in adult neurogenesis and spatial memory in rats infused intra-cerebroventricularly (ICV) with A&#x003b2; peptide and showed neuroprotective effects on learning deficits induced by continuous infusion of A&#x003b2; peptide (1&#x02013;40) [<xref ref-type="bibr" rid="CR433">433</xref>, <xref ref-type="bibr" rid="CR434">434</xref>]. The doses required to see a therapeutic effect in these studies are higher than the reported K<sub>i</sub> of 16 nM, with doses of 0.5&#x02013;1 &#x000b5;M required to see positive effects. This possibly rules out the &#x003c3;-1 R as the drug target of edonerpic maleate. However, this phenomenon is seen with other &#x003c3;1R ligands, including IPAG and dipentylammonium [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR156">156</xref>]. It is possibly explained by a non-sigmoidal dose-response curve, such as a bell-shaped or a multiple-binding sites curve [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par181">In phase 1 clinical trials, edonerpic maleate was well tolerated at a single dose of up to 896 mg and once-daily doses of 672 mg for up to two&#x000a0;weeks [<xref ref-type="bibr" rid="CR435">435</xref>]. An initial phase 2 proof of concept study (NCT00663936) demonstrated the safety and tolerability of edonerpic maleate at a 224 mg/day dose for one year. Although it did not meet its primary and secondary outcome targets, post hoc analysis of a positive cognitive effect was seen in patients with moderate impairment (MMSE scores &#x0003c; 20) (reported in a poster at the Alzheimer&#x02019;s Association international conference in 2013 [<xref ref-type="bibr" rid="CR436">436</xref>]). When a larger phase 2 study of edonerpic maleate (NCT02079909) was conducted, it was shown to be generally safe and tolerable at the two doses studied (224 and 448 mg/day). However, in the primary measures of AD [AD Assessment Scale&#x02013;Cognitive Subscale (ADAS&#x02013;COG) and AD Cooperative Study&#x02013;Clinical Global Impression of Change (ADCS&#x02013;CGIC)], no significant difference was observed compared with the placebo. Furthermore, there were no significant improvements in secondary outcome, the AD Cooperative Study&#x02013;Activities of Daily Living (ADCS&#x02013;ADL) scale [<xref ref-type="bibr" rid="CR435">435</xref>].</p><p id="Par182">It is possible that since edonerpic maleate was tested at too high a dose, it fell on the far side of the bell-shaped dose-response curve, and therefore the positive effects were not seen. However, two doses were tested, one low and one high (224 and 448 mg/day), all of which put the expected serum concentrations well above that needed to occupy the &#x003c3;1R. It is also possible that, like with blarcamesine, the heterogeneity of AD means that only a certain population of AD patients may benefit from edonerpic maleate treatment. However, further clinical study, including patient biomarker analysis, is required. Therefore, with the available (albeit limited) clinical evidence, it is likely that edonerpic maleate will not significantly help treat AD.</p></sec></sec></sec><sec id="Sec75"><title>Conclusions</title><p id="Par183">The &#x003c3;1R interacts with multiple other protein complexes to modulate multiple signalling pathways and influence cellular health and survival (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). This makes the &#x003c3;1R an interesting target for the development of drugs for neurological diseases such as AD, HD, PD, MS and MND where neuron cell loss is a key part of the pathology. The fact that the expression of &#x003c3;1R diminishes early on in AD and PD, and that there are genotypes for the &#x003c3;1R that increase the risk of AD, PD and MS also add to the weight of evidence that the &#x003c3;1R is important to these diseases and that &#x003c3;1R ligands may be of benefit.<fig id="Fig3"><label>Fig. 3</label><caption><p>Some of the documented roles of the sigma-1 receptor in preventing neurological disease. (1) Activation of the sigma-1 receptor by an agonist result in the disassociation from binding immunoglobulin protein (BiP) and chaperoning of calcium channels at the mitochondria-associated ER membrane (MAM), resulting in calcium shuttling into the mitochondria and increased ATP production. (2) NMDA receptors are upregulated on sigma-1 activation and trafficked to the plasma membrane, and the sigma-1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels. (3) Sigma-1 activation down-regulates calcium currents in L-type Ca2+ channels in retinal ganglion cells and upregulates calcium currents through L-type Ca2+ channels in the hippocampus. (4) Sigma-1 activation down-regulates Na+ currents through voltage-gated Na+ channels in intracardiac ganglion neurons. (5) Sigma-1 activation upregulates potassium currents through A-type K+ channels in neurohypophysial terminals and <italic>Xenopus</italic> oocytes. Parasympathetic intracardiac neurons CA1 field of hippocampus. Sigma-1 activation can upregulate human ether-a-go go K+ currents in <italic>Xenopus</italic> oocytes.</p></caption><graphic xlink:href="40263_2023_1007_Fig3_HTML" id="MO3"/></fig></p><p id="Par184">There have been vast strides taken in recent years for the early detection of diseases such as AD [<xref ref-type="bibr" rid="CR437">437</xref>&#x02013;<xref ref-type="bibr" rid="CR440">440</xref>] and PD [<xref ref-type="bibr" rid="CR441">441</xref>, <xref ref-type="bibr" rid="CR442">442</xref>], which means that new drug treatments targeting the &#x003c3;1R may benefit more if they can prevent damage to the brain before the disease can progress. Drugs that target multiple targets, including the &#x003c3;1R, such as blarcamesine or pridopidine in combination with A&#x003b2; antibodies, may prove to be effective in preventing neurological decline in AD. This possibly could result in the repurposing of older drugs, less specific to the &#x003c3;1R in a multi-targeting and repurposing approach to drug development [<xref ref-type="bibr" rid="CR52">52</xref>].</p><p id="Par185">With the ever-evolving understanding of genetic variations and other biomarkers in the populations of people with these neurological diseases, there is a great opportunity to select medicines that are more likely to work in a specific population. For example, in AD, patients with the wild-type &#x003c3;1R and higher scores on the MMSE fared better with blarcamesine than those with lower scores and a mutant &#x003c3;1R.</p><p id="Par186">The &#x003c3;2R is often investigated concerning cancer treatment and imaging. However, in recent years, there has been a growing interest in both the &#x003c3;2R and &#x003c3;1R for treatments in neurological diseases. Despite their lack of homology, their similar binding profile and activity of the proteins mean both receptors need to be considered when designing novel drugs, since the &#x003c3;1R agonists and &#x003c3;2R antagonists are neuroprotective and &#x003c3;1R antagonists and &#x003c3;2R agonists are used in cancer study. In brief, with the current research and planned clinical studies, it is expected that there will be an advancement of new &#x003c3;1R drugs for the treatment of the neurological disease including AD, HD and MS.</p></sec></body><back><fn-group><fn><p>Dicson S. Malar and Premrutai Thitilertdecha contributed equally to this manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>D.S.M. was supported by The Second Century Fund (C2F) for Postdoctoral Fellowship, Chulalongkorn University. The Chulalongkorn University Graduate School Thesis Grant supported K.S.R. All figures were created with <ext-link ext-link-type="uri" xlink:href="http://www.biorender.com">www.biorender.com</ext-link>.</p></ack><notes><title>Declarations</title><notes id="FPar1" notes-type="funding"><title>Funding</title><p id="Par187">No funding was received for this manuscript.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par188">The authors have no conflicts of interest to declare.</p></notes><notes id="FPar3"><title>Availability of data and material</title><p id="Par189">Data sharing does not apply to this article as no datasets were generated or analysed during the current study.</p></notes><notes id="FPar4"><title>Ethics approval</title><p id="Par190">Not applicable to this article.</p></notes><notes id="FPar5"><title>Consent to participate:</title><p id="Par191">Not applicable to this article.</p></notes><notes id="FPar6"><title>Consent for publication</title><p id="Par192">Not applicable to this article.</p></notes><notes id="FPar7"><title>Code availability</title><p id="Par193">Not applicable to this article.</p></notes><notes id="FPar8" notes-type="author-contribution"><title>Author contributions</title><p id="Par194">Drafting manuscript: JMB, DSM, PT, KSR, SB, TT. Editing Manuscript: JMB, SB. Preparation of Figures: TT, JMB. Literature searching: JMB, PT, KSR, SB, DSM. Manuscript revision: JMB, PT, DSM. All authors have read and approved the final version of the manuscript and agree to be accountable for the work.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanner</surname><given-names>M</given-names></name><name><surname>Moebius</surname><given-names>FF</given-names></name><name><surname>Flandorfer</surname><given-names>A</given-names></name><name><surname>Knaus</surname><given-names>HG</given-names></name><name><surname>Striessnig</surname><given-names>J</given-names></name><name><surname>Kempner</surname><given-names>E</given-names></name><etal/></person-group><article-title>Purification, molecular cloning, and expression of the mammalian sigma1-binding site</article-title><source>Proc Natl Acad Sci USA</source><year>1996</year><volume>93</volume><issue>15</issue><fpage>8072</fpage><lpage>8077</lpage><pub-id pub-id-type="doi">10.1073/pnas.93.15.8072</pub-id><pub-id pub-id-type="pmid">8755605</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Su</surname><given-names>TP</given-names></name></person-group><article-title>&#x003c3;-1 Receptors (&#x003c3;1 binding sites) form raft-like microdomains and target lipid droplets on the endoplasmic reticulum: roles in endoplasmic reticulum lipid compartmentalization and export</article-title><source>J Pharmacol Exp Ther</source><year>2003</year><volume>306</volume><issue>2</issue><fpage>718</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1124/jpet.103.051284</pub-id><pub-id pub-id-type="pmid">12730355</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Su</surname><given-names>TP</given-names></name></person-group><article-title>Regulating ankyrin dynamics: roles of sigma-1 receptors</article-title><source>Proc Natl Acad Sci USA</source><year>2001</year><volume>98</volume><issue>2</issue><fpage>491</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1073/pnas.021413698</pub-id><pub-id pub-id-type="pmid">11149946</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinoshita</surname><given-names>M</given-names></name><name><surname>Matsuoka</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Mirrielees</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name></person-group><article-title>Sigma-1 receptor alters the kinetics of Kv1.3 voltage gated potassium channels but not the sensitivity to receptor ligands</article-title><source>Brain Res</source><year>2012</year><volume>1452</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2012.02.070</pub-id><pub-id pub-id-type="pmid">22433979</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brimson</surname><given-names>JM</given-names></name><name><surname>Akula</surname><given-names>KK</given-names></name><name><surname>Abbas</surname><given-names>H</given-names></name><name><surname>Ferry</surname><given-names>DR</given-names></name><name><surname>Kulkarni</surname><given-names>SK</given-names></name><name><surname>Russell</surname><given-names>ST</given-names></name><etal/></person-group><article-title>Simple ammonium salts acting on sigma-1 receptors yield potential treatments for cancer and depression</article-title><source>Sci Rep</source><year>2020</year><volume>10</volume><issue>1</issue><fpage>9251</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-65849-6</pub-id><pub-id pub-id-type="pmid">32514120</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brimson</surname><given-names>JM</given-names></name><name><surname>Brown</surname><given-names>CA</given-names></name><name><surname>Safrany</surname><given-names>ST</given-names></name></person-group><article-title>Antagonists show GTP-sensitive high-affinity binding to the sigma-1 receptor</article-title><source>Br J Pharmacol</source><year>2011</year><volume>164</volume><issue>2B</issue><fpage>772</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01417.x</pub-id><pub-id pub-id-type="pmid">21486275</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Natsvlishvili</surname><given-names>N</given-names></name><name><surname>Goguadze</surname><given-names>N</given-names></name><name><surname>Zhuravliova</surname><given-names>E</given-names></name><name><surname>Mikeladze</surname><given-names>D</given-names></name></person-group><article-title>Sigma-1 receptor directly interacts with Rac1-GTPase in the brain mitochondria</article-title><source>BMC Biochem</source><year>2015</year><volume>16</volume><issue>1</issue><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1186/s12858-015-0040-y</pub-id><pub-id pub-id-type="pmid">25588515</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fontanilla</surname><given-names>D</given-names></name><name><surname>Johannessen</surname><given-names>M</given-names></name><name><surname>Hajipour</surname><given-names>AR</given-names></name><name><surname>Cozzi</surname><given-names>NV</given-names></name><name><surname>Jackson</surname><given-names>MB</given-names></name><name><surname>Ruoho</surname><given-names>AE</given-names></name></person-group><article-title>The hallucinogen N, N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator</article-title><source>Science</source><year>2009</year><volume>323</volume><issue>5916</issue><fpage>934</fpage><lpage>937</lpage><pub-id pub-id-type="doi">10.1126/science.1166127</pub-id><pub-id pub-id-type="pmid">19213917</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Su</surname><given-names>TP</given-names></name></person-group><article-title>Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders</article-title><source>CNS Drugs</source><year>2004</year><volume>18</volume><issue>5</issue><fpage>269</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.2165/00023210-200418050-00001</pub-id><pub-id pub-id-type="pmid">15089113</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruoho</surname><given-names>AE</given-names></name><name><surname>Chu</surname><given-names>UB</given-names></name><name><surname>Ramachandran</surname><given-names>S</given-names></name><name><surname>Fontanilla</surname><given-names>D</given-names></name><name><surname>Mavlyutov</surname><given-names>T</given-names></name><name><surname>Hajipour</surname><given-names>AR</given-names></name></person-group><article-title>The ligand binding region of the sigma-1 receptor: studies utilizing photoaffinity probes, sphingosine and N-alkylamines</article-title><source>Curr Pharm Des</source><year>2012</year><volume>18</volume><issue>7</issue><fpage>920</fpage><lpage>929</lpage><pub-id pub-id-type="doi">10.2174/138161212799436584</pub-id><pub-id pub-id-type="pmid">22288412</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vavers</surname><given-names>E</given-names></name><name><surname>Zvejniece</surname><given-names>L</given-names></name><name><surname>Maurice</surname><given-names>T</given-names></name><name><surname>Dambrova</surname><given-names>M</given-names></name></person-group><article-title>Allosteric modulators of sigma-1 receptor: a review</article-title><source>Front Pharmacol</source><year>2019</year><volume>10</volume><fpage>223</fpage><pub-id pub-id-type="doi">10.3389/fphar.2019.00223</pub-id><pub-id pub-id-type="pmid">30941035</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Su</surname><given-names>TP</given-names></name></person-group><article-title>The sigma receptor: evolution of the concept in neuropsychopharmacology</article-title><source>Curr Neuropharmacol</source><year>2005</year><volume>3</volume><issue>4</issue><fpage>267</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.2174/157015905774322516</pub-id><pub-id pub-id-type="pmid">18369400</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quirion</surname><given-names>R</given-names></name><name><surname>Chicheportiche</surname><given-names>R</given-names></name><name><surname>Contreras</surname><given-names>PC</given-names></name><name><surname>Johnson</surname><given-names>KM</given-names></name><name><surname>Lodge</surname><given-names>D</given-names></name><name><surname>Tam</surname><given-names>SW</given-names></name><etal/></person-group><article-title>Classification and nomenclature of phencyclidine and sigma receptor sites</article-title><source>Trends Neurosci</source><year>1987</year><volume>10</volume><issue>11</issue><fpage>444</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1016/0166-2236(87)90094-4</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spruce</surname><given-names>BA</given-names></name><name><surname>Campbell</surname><given-names>LA</given-names></name><name><surname>McTavish</surname><given-names>N</given-names></name><name><surname>Cooper</surname><given-names>MA</given-names></name><name><surname>Appleyard</surname><given-names>MVL</given-names></name><name><surname>O&#x02019;Neill</surname><given-names>M</given-names></name><etal/></person-group><article-title>Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><issue>14</issue><fpage>4875</fpage><lpage>4886</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-3180</pub-id><pub-id pub-id-type="pmid">15256458</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Prescott</surname><given-names>AR</given-names></name><name><surname>Spruce</surname><given-names>BA</given-names></name><name><surname>Sanderson</surname><given-names>J</given-names></name><name><surname>Duncan</surname><given-names>G</given-names></name></person-group><article-title>Sigma receptor antagonists inhibit human lens cell growth and induce pigmentation</article-title><source>Invest Ophthalmol Vis Sci</source><year>2005</year><volume>46</volume><issue>4</issue><fpage>1403</fpage><lpage>1408</lpage><pub-id pub-id-type="doi">10.1167/iovs.04-1209</pub-id><pub-id pub-id-type="pmid">15790908</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Su</surname><given-names>TP</given-names></name></person-group><article-title>Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival</article-title><source>Cell</source><year>2007</year><volume>131</volume><issue>3</issue><fpage>596</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.08.036</pub-id><pub-id pub-id-type="pmid">17981125</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hellewell</surname><given-names>SB</given-names></name><name><surname>Bruce</surname><given-names>A</given-names></name><name><surname>Feinstein</surname><given-names>G</given-names></name><name><surname>Orringer</surname><given-names>J</given-names></name><name><surname>Williams</surname><given-names>W</given-names></name><name><surname>Bowen</surname><given-names>WD</given-names></name></person-group><article-title>Rat liver and kidney contain high densities of &#x003c3;1 and &#x003c3;2 receptors: characterization by ligand binding and photoaffinity labeling</article-title><source>Eur J Pharmacol</source><year>1994</year><volume>268</volume><issue>1</issue><fpage>9</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/0922-4106(94)90115-5</pub-id><pub-id pub-id-type="pmid">7925616</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolfe</surname><given-names>SA</given-names><suffix>Jr</suffix></name><name><surname>Culp</surname><given-names>SG</given-names></name><name><surname>De Souza</surname><given-names>EB</given-names></name></person-group><article-title>&#x003c3;-Receptors in endocrine organs: identification, characterization, and autoradiographic localization in rat pituitary, adrenal, testis, and ovary</article-title><source>Endocrinology</source><year>1989</year><volume>124</volume><issue>3</issue><fpage>1160</fpage><lpage>1172</lpage><pub-id pub-id-type="doi">10.1210/endo-124-3-1160</pub-id><pub-id pub-id-type="pmid">2537173</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borde</surname><given-names>P</given-names></name><name><surname>Cosgrove</surname><given-names>N</given-names></name><name><surname>Charmsaz</surname><given-names>S</given-names></name><name><surname>Safrany</surname><given-names>ST</given-names></name><name><surname>Young</surname><given-names>L</given-names></name></person-group><article-title>An investigation of Sigma-1 receptor expression and ligand-induced endoplasmic reticulum stress in breast cancer</article-title><source>Cancer Gene Ther</source><year>2023</year><volume>30</volume><issue>2</issue><fpage>368</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1038/s41417-022-00552-4</pub-id><pub-id pub-id-type="pmid">36352093</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>YS</given-names></name><name><surname>Lu</surname><given-names>HL</given-names></name><name><surname>Zhang</surname><given-names>LJ</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name></person-group><article-title>Sigma-2 receptor ligands and their perspectives in cancer diagnosis and therapy</article-title><source>Med Res Rev</source><year>2014</year><volume>34</volume><issue>3</issue><fpage>532</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1002/med.21297</pub-id><pub-id pub-id-type="pmid">23922215</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicholson</surname><given-names>H</given-names></name><name><surname>Mesangeau</surname><given-names>C</given-names></name><name><surname>McCurdy</surname><given-names>CR</given-names></name><name><surname>Bowen</surname><given-names>WD</given-names></name></person-group><article-title>Sigma-2 receptors play a role in cellular metabolism: stimulation of glycolytic hallmarks by CM764 in human SK-N-SH neuroblastoma</article-title><source>J Pharmacol Exp Ther</source><year>2016</year><volume>356</volume><issue>2</issue><fpage>232</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1124/jpet.115.228387</pub-id><pub-id pub-id-type="pmid">26574517</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rousseaux</surname><given-names>CG</given-names></name><name><surname>Greene</surname><given-names>SF</given-names></name></person-group><article-title>Sigma receptors [&#x003c3;Rs]: biology in normal and diseased states</article-title><source>J Recept Signal Transduct Res</source><year>2016</year><volume>36</volume><issue>4</issue><fpage>327</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.3109/10799893.2015.1015737</pub-id><pub-id pub-id-type="pmid">26056947</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>CF</given-names></name><name><surname>Wang</surname><given-names>SC</given-names></name><name><surname>Li</surname><given-names>HY</given-names></name><name><surname>Lin</surname><given-names>CM</given-names></name><name><surname>Wang</surname><given-names>HH</given-names></name><etal/></person-group><article-title>Sigma-2 receptor/TMEM97 agonist PB221 as an alternative drug for brain tumor</article-title><source>BMC Cancer</source><year>2019</year><volume>19</volume><issue>1</issue><fpage>473</fpage><pub-id pub-id-type="doi">10.1186/s12885-019-5700-7</pub-id><pub-id pub-id-type="pmid">31109310</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name></person-group><article-title>The roles of intracellular chaperone proteins, sigma receptors, in Parkinson's disease (PD) and major depressive disorder (MDD)</article-title><source>Front Pharmacol</source><year>2019</year><volume>10</volume><fpage>528</fpage><pub-id pub-id-type="doi">10.3389/fphar.2019.00528</pub-id><pub-id pub-id-type="pmid">31178723</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Georgiadis</surname><given-names>MO</given-names></name><name><surname>Karoutzou</surname><given-names>O</given-names></name><name><surname>Foscolos</surname><given-names>AS</given-names></name><name><surname>Papanastasiou</surname><given-names>I</given-names></name></person-group><article-title>Sigma receptor (&#x003c3;R) ligands with antiproliferative and anticancer activity</article-title><source>Molecules</source><year>2017</year><volume>22</volume><fpage>9</fpage><pub-id pub-id-type="doi">10.3390/molecules22091408</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gebreselassie</surname><given-names>D</given-names></name><name><surname>Bowen</surname><given-names>WD</given-names></name></person-group><article-title>Sigma-2 receptors are specifically localized to lipid rafts in rat liver membranes</article-title><source>Eur J Pharmacol</source><year>2004</year><volume>493</volume><issue>1&#x02013;3</issue><fpage>19</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2004.04.005</pub-id><pub-id pub-id-type="pmid">15189760</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munro</surname><given-names>S</given-names></name></person-group><article-title>Lipid rafts: elusive or illusive?</article-title><source>Cell</source><year>2003</year><volume>115</volume><issue>4</issue><fpage>377</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(03)00882-1</pub-id><pub-id pub-id-type="pmid">14622593</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alon</surname><given-names>A</given-names></name><name><surname>Lyu</surname><given-names>J</given-names></name><name><surname>Braz</surname><given-names>JM</given-names></name><name><surname>Tummino</surname><given-names>TA</given-names></name><name><surname>Craik</surname><given-names>V</given-names></name><name><surname>O&#x02019;Meara</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Structures of the &#x003c3;2 receptor enable docking for bioactive ligand discovery</article-title><source>Nature</source><year>2021</year><volume>600</volume><issue>7890</issue><fpage>759</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-04175-x</pub-id><pub-id pub-id-type="pmid">34880501</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terada</surname><given-names>K</given-names></name><name><surname>Migita</surname><given-names>K</given-names></name><name><surname>Matsushima</surname><given-names>Y</given-names></name><name><surname>Kamei</surname><given-names>C</given-names></name></person-group><article-title>Sigma-2 receptor as a potential therapeutic target for treating central nervous system disorders</article-title><source>Neural Regen Res</source><year>2019</year><volume>14</volume><issue>11</issue><fpage>1893</fpage><lpage>1894</lpage><pub-id pub-id-type="doi">10.4103/1673-5374.259609</pub-id><pub-id pub-id-type="pmid">31290438</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abate</surname><given-names>C</given-names></name><name><surname>Niso</surname><given-names>M</given-names></name><name><surname>Berardi</surname><given-names>F</given-names></name></person-group><article-title>Sigma-2 receptor: past, present and perspectives on multiple therapeutic exploitations</article-title><source>Future Med Chem</source><year>2018</year><volume>10</volume><issue>16</issue><fpage>1997</fpage><lpage>2018</lpage><pub-id pub-id-type="doi">10.4155/fmc-2018-0072</pub-id><pub-id pub-id-type="pmid">29966437</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantonero</surname><given-names>C</given-names></name><name><surname>Camello</surname><given-names>PJ</given-names></name><name><surname>Abate</surname><given-names>C</given-names></name><name><surname>Berardi</surname><given-names>F</given-names></name><name><surname>Salido</surname><given-names>GM</given-names></name><name><surname>Rosado</surname><given-names>JA</given-names></name><etal/></person-group><article-title>NO1, a new Sigma 2 receptor/TMEM97 fluorescent ligand, downregulates SOCE and promotes apoptosis in the triple negative breast cancer cell lines</article-title><source>Cancers (Basel).</source><year>2020</year><volume>12</volume><issue>2</issue><fpage>257</fpage><pub-id pub-id-type="doi">10.3390/cancers12020257</pub-id><pub-id pub-id-type="pmid">31973006</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>C</given-names></name><name><surname>Vangveravong</surname><given-names>S</given-names></name><name><surname>McDunn</surname><given-names>JE</given-names></name><name><surname>Hawkins</surname><given-names>WG</given-names></name><name><surname>Mach</surname><given-names>RH</given-names></name></person-group><article-title>Sigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer</article-title><source>Br J Cancer</source><year>2013</year><volume>109</volume><issue>9</issue><fpage>2368</fpage><lpage>2377</lpage><pub-id pub-id-type="doi">10.1038/bjc.2013.593</pub-id><pub-id pub-id-type="pmid">24104966</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>C</given-names></name><name><surname>Riad</surname><given-names>A</given-names></name><name><surname>Mach</surname><given-names>RH</given-names></name></person-group><article-title>The biological function of Sigma-2 receptor/TMEM97 and its utility in PET imaging studies in cancer</article-title><source>Cancers (Basel).</source><year>2020</year><volume>12</volume><issue>7</issue><fpage>1877</fpage><pub-id pub-id-type="doi">10.3390/cancers12071877</pub-id><pub-id pub-id-type="pmid">32668577</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">2021 Alzheimer's disease facts and figures. Alzheimers Dement. 2021;17(3):327&#x02013;406. 10.1002/alz.12328.</mixed-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Querfurth</surname><given-names>HW</given-names></name><name><surname>LaFerla</surname><given-names>FM</given-names></name></person-group><article-title>Alzheimer's disease</article-title><source>N Engl J Med</source><year>2010</year><volume>362</volume><issue>4</issue><fpage>329</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1056/NEJMra0909142</pub-id><pub-id pub-id-type="pmid">20107219</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hyman</surname><given-names>BT</given-names></name></person-group><article-title>Amyloid-dependent and amyloid-independent stages of Alzheimer disease</article-title><source>Arch Neurol</source><year>2011</year><volume>68</volume><issue>8</issue><fpage>1062</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.1001/archneurol.2011.70</pub-id><pub-id pub-id-type="pmid">21482918</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soria Lopez</surname><given-names>JA</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>HM</given-names></name><name><surname>L&#x000e9;ger</surname><given-names>GC</given-names></name></person-group><article-title>Alzheimer's disease</article-title><source>Handb Clin Neurol</source><year>2019</year><volume>167</volume><fpage>231</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1016/b978-0-12-804766-8.00013-3</pub-id><pub-id pub-id-type="pmid">31753135</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Caraci</surname><given-names>F</given-names></name><name><surname>Cuello</surname><given-names>AC</given-names></name><name><surname>Caruso</surname><given-names>G</given-names></name><name><surname>Nistic&#x000f2;</surname><given-names>R</given-names></name><name><surname>Corbo</surname><given-names>M</given-names></name><etal/></person-group><article-title>A path toward precision medicine for neuroinflammatory mechanisms in Alzheimer's disease</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><fpage>456</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.00456</pub-id><pub-id pub-id-type="pmid">32296418</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>ECB</given-names></name><name><surname>Dammer</surname><given-names>EB</given-names></name><name><surname>Duong</surname><given-names>DM</given-names></name><name><surname>Ping</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Yin</surname><given-names>L</given-names></name><etal/></person-group><article-title>Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation</article-title><source>Nat Med</source><year>2020</year><volume>26</volume><issue>5</issue><fpage>769</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0815-6</pub-id><pub-id pub-id-type="pmid">32284590</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000e1;nchez-Fern&#x000e1;ndez</surname><given-names>C</given-names></name><name><surname>Entrena</surname><given-names>JM</given-names></name><name><surname>Baeyens</surname><given-names>JM</given-names></name><name><surname>Cobos</surname><given-names>EJ</given-names></name></person-group><article-title>Sigma-1 receptor antagonists: a new class of neuromodulatory analgesics</article-title><source>Adv Exp Med Biol</source><year>2017</year><volume>964</volume><fpage>109</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1007/978-3-319-50174-1_9</pub-id><pub-id pub-id-type="pmid">28315268</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>TP</given-names></name><name><surname>Hayashi</surname><given-names>T</given-names></name></person-group><article-title>Understanding the molecular mechanism of sigma-1 receptors: towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction</article-title><source>Curr Med Chem</source><year>2003</year><volume>10</volume><issue>20</issue><fpage>2073</fpage><lpage>2080</lpage><pub-id pub-id-type="doi">10.2174/0929867033456783</pub-id><pub-id pub-id-type="pmid">12871086</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De</surname><given-names>B</given-names></name><name><surname>Nadal</surname><given-names>X</given-names></name><name><surname>Portillo-salido</surname><given-names>E</given-names></name><name><surname>S&#x000e1;nchez-arroyos</surname><given-names>R</given-names></name><name><surname>Ovalle</surname><given-names>S</given-names></name><name><surname>Palacios</surname><given-names>G</given-names></name><etal/></person-group><article-title>Sigma-1 receptors regulate activity-induced spinal sensitization and neuropathic pain after peripheral nerve injury</article-title><source>Pain</source><year>2009</year><volume>145</volume><issue>3</issue><fpage>294</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2009.05.013</pub-id><pub-id pub-id-type="pmid">19505761</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieto</surname><given-names>FR</given-names></name><name><surname>Cend&#x000e1;n</surname><given-names>CM</given-names></name><name><surname>S&#x000e1;nchez-Fern&#x000e1;ndez</surname><given-names>C</given-names></name><name><surname>Cobos</surname><given-names>EJ</given-names></name><name><surname>Entrena</surname><given-names>JM</given-names></name><name><surname>Tejada</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Role of sigma-1 receptors in paclitaxel-induced neuropathic pain in mice</article-title><source>J Pain</source><year>2012</year><volume>13</volume><issue>11</issue><fpage>1107</fpage><lpage>1121</lpage><pub-id pub-id-type="doi">10.1016/j.jpain.2012.08.006</pub-id><pub-id pub-id-type="pmid">23063344</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zamanillo</surname><given-names>D</given-names></name><name><surname>Romero</surname><given-names>L</given-names></name><name><surname>Merlos</surname><given-names>M</given-names></name><name><surname>Vela</surname><given-names>JM</given-names></name></person-group><article-title>Sigma 1 receptor: a new therapeutic target for pain</article-title><source>Eur J Pharmacol</source><year>2013</year><volume>716</volume><issue>1&#x02013;3</issue><fpage>78</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2013.01.068</pub-id><pub-id pub-id-type="pmid">23500210</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawamura</surname><given-names>K</given-names></name><name><surname>Kimura</surname><given-names>Y</given-names></name><name><surname>Tsukada</surname><given-names>H</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Nishiyama</surname><given-names>S</given-names></name><name><surname>Kakiuchi</surname><given-names>T</given-names></name><etal/></person-group><article-title>An increase of sigma1 receptors in the aged monkey brain</article-title><source>Neurobiol Aging</source><year>2003</year><volume>24</volume><issue>5</issue><fpage>745</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1016/S0197-4580(02)00152-5</pub-id><pub-id pub-id-type="pmid">12885582</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>DR</given-names></name><name><surname>Mactutus</surname><given-names>CF</given-names></name><name><surname>Booze</surname><given-names>RM</given-names></name></person-group><article-title>Sigma binding sites identified by [3H] DTG are elevated in aged Fischer-344&#x000d7; Brown Norway (F1) rats</article-title><source>Synapse</source><year>2000</year><volume>35</volume><issue>4</issue><fpage>311</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1098-2396(20000315)35:4&#x0003c;311::AID-SYN9&#x0003e;3.0.CO;2-5</pub-id><pub-id pub-id-type="pmid">10657041</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishiwata</surname><given-names>K</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Kawamura</surname><given-names>K</given-names></name><name><surname>Matsuno</surname><given-names>K</given-names></name></person-group><article-title>Age-related changes of the binding of [3H] SA4503 to sigma1 receptors in the rat brain</article-title><source>Ann Nucl Med</source><year>2003</year><volume>17</volume><issue>1</issue><fpage>73</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1007/BF02988264</pub-id><pub-id pub-id-type="pmid">12691135</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horsager</surname><given-names>J</given-names></name><name><surname>Fedorova</surname><given-names>TD</given-names></name><name><surname>Berge</surname><given-names>NV</given-names></name><name><surname>Klinge</surname><given-names>MW</given-names></name><name><surname>Knudsen</surname><given-names>K</given-names></name><name><surname>Hansen</surname><given-names>AK</given-names></name><etal/></person-group><article-title>Cardiac 11C-donepezil binding increases with age in healthy humans: potentially signifying Sigma-1 receptor upregulation</article-title><source>J Cardiovasc Pharmacol Ther</source><year>2019</year><volume>24</volume><issue>4</issue><fpage>365</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1177/1074248419838509</pub-id><pub-id pub-id-type="pmid">30913922</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norbury</surname><given-names>R</given-names></name><name><surname>Travis</surname><given-names>MJ</given-names></name><name><surname>Erlandsson</surname><given-names>K</given-names></name><name><surname>Waddington</surname><given-names>W</given-names></name><name><surname>Owens</surname><given-names>J</given-names></name><name><surname>Pimlott</surname><given-names>S</given-names></name><etal/></person-group><article-title>In vivo imaging of muscarinic receptors in the aging female brain with (R, R)[123I]-I-QNB and single photon emission tomography</article-title><source>Exp Gerontol</source><year>2005</year><volume>40</volume><issue>3</issue><fpage>137</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1016/j.exger.2004.10.002</pub-id><pub-id pub-id-type="pmid">15763390</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheline</surname><given-names>YI</given-names></name><name><surname>Mintun</surname><given-names>MA</given-names></name><name><surname>Moerlein</surname><given-names>SM</given-names></name><name><surname>Snyder</surname><given-names>AZ</given-names></name></person-group><article-title>Greater loss of 5-HT2A receptors in midlife than in late life</article-title><source>Am J Psychiatry</source><year>2002</year><volume>159</volume><issue>3</issue><fpage>430</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.159.3.430</pub-id><pub-id pub-id-type="pmid">11870007</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>M</given-names></name><name><surname>Suhara</surname><given-names>T</given-names></name><name><surname>Sudo</surname><given-names>Y</given-names></name><name><surname>Okubo</surname><given-names>Y</given-names></name><name><surname>Yasuno</surname><given-names>F</given-names></name><name><surname>Kishimoto</surname><given-names>T</given-names></name><etal/></person-group><article-title>Age-related reduction of extrastriatal dopamine D2 receptor measured by PET</article-title><source>Life Sci</source><year>2001</year><volume>69</volume><issue>9</issue><fpage>1079</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.1016/s0024-3205(01)01205-x</pub-id><pub-id pub-id-type="pmid">11508650</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brimson</surname><given-names>JM</given-names></name><name><surname>Brimson</surname><given-names>S</given-names></name><name><surname>Chomchoei</surname><given-names>C</given-names></name><name><surname>Tencomnao</surname><given-names>T</given-names></name></person-group><article-title>Using Sigma-ligands as part of a multi-receptor approach to target diseases of the brain</article-title><source>Expert Opin Ther Targets</source><year>2020</year><volume>24</volume><issue>10</issue><fpage>1009</fpage><lpage>1028</lpage><pub-id pub-id-type="doi">10.1080/14728222.2020.1805435</pub-id><pub-id pub-id-type="pmid">32746649</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasanth</surname><given-names>MI</given-names></name><name><surname>Malar</surname><given-names>D</given-names></name><name><surname>Tencomnao</surname><given-names>T</given-names></name><name><surname>Brimson</surname><given-names>J</given-names></name></person-group><article-title>The emerging role of the sigma-1 receptor in autophagy: hand-in-hand targets for the treatment of Alzheimer&#x02019;s Disease</article-title><source>Expert Opin Ther Targets</source><year>2021</year><volume>25</volume><issue>5</issue><fpage>401</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1080/14728222.2021.1939681</pub-id><pub-id pub-id-type="pmid">34110944</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishina</surname><given-names>M</given-names></name><name><surname>Ohyama</surname><given-names>M</given-names></name><name><surname>Ishii</surname><given-names>K</given-names></name><name><surname>Kitamura</surname><given-names>S</given-names></name><name><surname>Kimura</surname><given-names>Y</given-names></name><name><surname>Oda</surname><given-names>K</given-names></name><etal/></person-group><article-title>Low density of sigma 1 receptors in early Alzheimer&#x02019;s disease</article-title><source>Ann Nucl Med</source><year>2008</year><volume>22</volume><issue>3</issue><fpage>151</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1007/s12149-007-0094-z</pub-id><pub-id pub-id-type="pmid">18498028</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minoshima</surname><given-names>S</given-names></name><name><surname>Giordani</surname><given-names>B</given-names></name><name><surname>Berent</surname><given-names>S</given-names></name><name><surname>Frey</surname><given-names>KA</given-names></name><name><surname>Foster</surname><given-names>NL</given-names></name><name><surname>Kuhl</surname><given-names>DE</given-names></name></person-group><article-title>Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease</article-title><source>Ann Neurol</source><year>1997</year><volume>42</volume><issue>1</issue><fpage>85</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1002/ana.410420114</pub-id><pub-id pub-id-type="pmid">9225689</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uchida</surname><given-names>N</given-names></name><name><surname>Ujike</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Sakai</surname><given-names>A</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Fujisawa</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A variant of the sigma receptor type-1 gene is a protective factor for Alzheimer disease</article-title><source>Am J Geriatr Psychiatry</source><year>2005</year><volume>13</volume><issue>12</issue><fpage>1062</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1176/appi.ajgp.13.12.1062</pub-id><pub-id pub-id-type="pmid">16319298</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maruszak</surname><given-names>A</given-names></name><name><surname>Safranow</surname><given-names>K</given-names></name><name><surname>Gacia</surname><given-names>M</given-names></name><name><surname>Gabryelewicz</surname><given-names>T</given-names></name><name><surname>S&#x00142;owik</surname><given-names>A</given-names></name><name><surname>Styczy&#x00144;ska</surname><given-names>M</given-names></name><etal/></person-group><article-title>Sigma receptor type 1 gene variation in a group of polish patients with Alzheimer&#x02019;s disease and mild cognitive impairment</article-title><source>Dement Geriatr Cogn Disord</source><year>2007</year><volume>23</volume><issue>6</issue><fpage>432</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1159/000101990</pub-id><pub-id pub-id-type="pmid">17457031</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Halliday</surname><given-names>G</given-names></name><name><surname>Dobson-Stone</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>H-D</given-names></name><etal/></person-group><article-title>Genetic polymorphisms in sigma-1 receptor and apolipoprotein E interact to influence the severity of Alzheimer's disease</article-title><source>Curr Alzheimer Res</source><year>2011</year><volume>8</volume><issue>7</issue><fpage>765</fpage><lpage>770</lpage><pub-id pub-id-type="doi">10.2174/156720511797633232</pub-id><pub-id pub-id-type="pmid">21605063</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feher</surname><given-names>A</given-names></name><name><surname>Juhasz</surname><given-names>A</given-names></name><name><surname>Laszlo</surname><given-names>A</given-names></name><name><surname>Kalman</surname><given-names>J</given-names><suffix>Jr</suffix></name><name><surname>Pakaski</surname><given-names>M</given-names></name><name><surname>Kalman</surname><given-names>J</given-names></name><etal/></person-group><article-title>Association between a variant of the sigma-1 receptor gene and Alzheimer's disease</article-title><source>Neurosci Lett</source><year>2012</year><volume>517</volume><issue>2</issue><fpage>136</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2012.04.046</pub-id><pub-id pub-id-type="pmid">22561649</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>JL</given-names></name><name><surname>Fang</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>YX</given-names></name><name><surname>Liu</surname><given-names>XY</given-names></name></person-group><article-title>Roles of sigma-1 receptors in Alzheimer&#x02019;s disease</article-title><source>Int J Clin Exp Med</source><year>2015</year><volume>8</volume><issue>4</issue><fpage>4808</fpage><lpage>4820</lpage><pub-id pub-id-type="pmid">26131055</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>SY</given-names></name><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Harvey</surname><given-names>BK</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>WW</given-names></name><name><surname>Shen</surname><given-names>RF</given-names></name><etal/></person-group><article-title>Sigma-1 receptors regulate hippocampal dendritic spine formation via a free radical-sensitive mechanism involving Rac1&#x02022;GTP pathway</article-title><source>Proc Natl Acad Sci USA</source><year>2009</year><volume>106</volume><issue>52</issue><fpage>22468</fpage><lpage>22473</lpage><pub-id pub-id-type="doi">10.1073/pnas.0909089106</pub-id><pub-id pub-id-type="pmid">20018732</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>A</given-names></name><name><surname>Bezprozvanny</surname><given-names>I</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Ryskamp</surname><given-names>DA</given-names></name><name><surname>Bar-Ner</surname><given-names>N</given-names></name><name><surname>Natan</surname><given-names>N</given-names></name><etal/></person-group><article-title>AF710B, a novel M1/&#x003c3;1 agonist with therapeutic efficacy in animal models of Alzheimer's disease</article-title><source>Neurodegener Dis</source><year>2016</year><volume>16</volume><issue>1&#x02013;2</issue><fpage>95</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1159/000440864</pub-id><pub-id pub-id-type="pmid">26606130</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryskamp</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Rammes</surname><given-names>G</given-names></name><name><surname>Geva</surname><given-names>M</given-names></name><etal/></person-group><article-title>Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor</article-title><source>Neurobiol Dis</source><year>2019</year><volume>124</volume><fpage>489</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2018.12.022</pub-id><pub-id pub-id-type="pmid">30594810</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>SYA</given-names></name><name><surname>Pokrass</surname><given-names>MJ</given-names></name><name><surname>Klauer</surname><given-names>NR</given-names></name><name><surname>Nohara</surname><given-names>H</given-names></name><name><surname>Su</surname><given-names>TP</given-names></name></person-group><article-title>Sigma-1 receptor regulates Tau phosphorylation and axon extension by shaping p35 turnover via myristic acid</article-title><source>Proc Natl Acad Sci USA</source><year>2015</year><volume>112</volume><issue>21</issue><fpage>6742</fpage><lpage>6747</lpage><pub-id pub-id-type="doi">10.1073/pnas.1422001112</pub-id><pub-id pub-id-type="pmid">25964330</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christ</surname><given-names>MG</given-names></name><name><surname>Huesmann</surname><given-names>H</given-names></name><name><surname>Nagel</surname><given-names>H</given-names></name><name><surname>Kern</surname><given-names>A</given-names></name><name><surname>Behl</surname><given-names>C</given-names></name></person-group><article-title>Sigma-1 receptor activation induces autophagy and increases proteostasis capacity in vitro and in vivo</article-title><source>Cells</source><year>2019</year><volume>8</volume><issue>3</issue><fpage>211</fpage><pub-id pub-id-type="doi">10.3390/cells8030211</pub-id><pub-id pub-id-type="pmid">30832324</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romeo</surname><given-names>MA</given-names></name><name><surname>Faggioni</surname><given-names>A</given-names></name><name><surname>Cirone</surname><given-names>M</given-names></name></person-group><article-title>Could autophagy dysregulation link neurotropic viruses to Alzheimer&#x02019;s disease?</article-title><source>Neural Regen Res</source><year>2019</year><volume>14</volume><issue>9</issue><fpage>1503</fpage><lpage>1506</lpage><pub-id pub-id-type="doi">10.4103/1673-5374.253508</pub-id><pub-id pub-id-type="pmid">31089040</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McBrayer</surname><given-names>M</given-names></name><name><surname>Nixon</surname><given-names>RA</given-names></name></person-group><article-title>Lysosome and calcium dysregulation in Alzheimer's disease: partners in crime</article-title><source>Biochem Soc Trans</source><year>2013</year><volume>41</volume><issue>6</issue><fpage>1495</fpage><lpage>1502</lpage><pub-id pub-id-type="doi">10.1042/BST20130201</pub-id><pub-id pub-id-type="pmid">24256243</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uddin</surname><given-names>MS</given-names></name><name><surname>Stachowiak</surname><given-names>A</given-names></name><name><surname>Mamun</surname><given-names>AA</given-names></name><name><surname>Tzvetkov</surname><given-names>NT</given-names></name><name><surname>Takeda</surname><given-names>S</given-names></name><name><surname>Atanasov</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Autophagy and Alzheimer&#x02019;s disease: from molecular mechanisms to therapeutic implications</article-title><source>Front Aging Neurosci.</source><year>2018</year><volume>10</volume><fpage>04</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2018.00004</pub-id><pub-id pub-id-type="pmid">29441009</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callens</surname><given-names>M</given-names></name><name><surname>Loncke</surname><given-names>J</given-names></name><name><surname>Bultynck</surname><given-names>G</given-names></name></person-group><article-title>Dysregulated Ca2+ homeostasis as a central theme in neurodegeneration: lessons from Alzheimer&#x02019;s disease and Wolfram syndrome</article-title><source>Cells</source><year>2022</year><volume>11</volume><issue>12</issue><fpage>1963</fpage><pub-id pub-id-type="doi">10.3390/cells11121963</pub-id><pub-id pub-id-type="pmid">35741091</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname><given-names>C</given-names></name><name><surname>Boche</surname><given-names>D</given-names></name><name><surname>Wilkinson</surname><given-names>D</given-names></name><name><surname>Yadegarfar</surname><given-names>G</given-names></name><name><surname>Hopkins</surname><given-names>V</given-names></name><name><surname>Bayer</surname><given-names>A</given-names></name><etal/></person-group><article-title>Long-term effects of A&#x003b2;42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial</article-title><source>Lancet</source><year>2008</year><volume>372</volume><issue>9634</issue><fpage>216</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)61075-2</pub-id><pub-id pub-id-type="pmid">18640458</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Dyck</surname><given-names>CH</given-names></name><name><surname>Swanson</surname><given-names>CJ</given-names></name><name><surname>Aisen</surname><given-names>P</given-names></name><name><surname>Bateman</surname><given-names>RJ</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Gee</surname><given-names>M</given-names></name><etal/></person-group><article-title>Lecanemab in early Alzheimer&#x02019;s disease</article-title><source>N Engl J Med</source><year>2023</year><volume>388</volume><issue>1</issue><fpage>9</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2212948</pub-id><pub-id pub-id-type="pmid">36449413</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacor</surname><given-names>PN</given-names></name><name><surname>Buniel</surname><given-names>MC</given-names></name><name><surname>Furlow</surname><given-names>PW</given-names></name><name><surname>Clemente</surname><given-names>AS</given-names></name><name><surname>Velasco</surname><given-names>PT</given-names></name><name><surname>Wood</surname><given-names>M</given-names></name><etal/></person-group><article-title>A&#x003b2; oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease</article-title><source>J Neurosci</source><year>2007</year><volume>27</volume><issue>4</issue><fpage>796</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3501-06.2007</pub-id><pub-id pub-id-type="pmid">17251419</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pannuzzo</surname><given-names>M</given-names></name></person-group><article-title>On the physiological/pathological link between A&#x003b2; peptide, cholesterol, calcium ions and membrane deformation: a molecular dynamics study</article-title><source>Biochim Biophys Acta</source><year>2016</year><volume>1858</volume><issue>6</issue><fpage>1380</fpage><lpage>1389</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2016.03.018</pub-id><pub-id pub-id-type="pmid">27003127</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Games</surname><given-names>D</given-names></name><name><surname>Adams</surname><given-names>D</given-names></name><name><surname>Alessandrini</surname><given-names>R</given-names></name><name><surname>Barbour</surname><given-names>R</given-names></name><name><surname>Borthelette</surname><given-names>P</given-names></name><name><surname>Blackwell</surname><given-names>C</given-names></name><etal/></person-group><article-title>Alzheimer-type neuropathology in transgenic mice overexpressing V717F &#x003b2;-amyloid precursor protein</article-title><source>Nature</source><year>1995</year><volume>373</volume><issue>6514</issue><fpage>523</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1038/373523a0</pub-id><pub-id pub-id-type="pmid">7845465</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><mixed-citation publication-type="other">Brimson JM. The Pharmacology of the Sigma-1 Receptor [Doctoral Thesis]. In: The University of Bath online repository. 2010. <ext-link ext-link-type="uri" xlink:href="http://opus.bath.ac.uk/19712/">http://opus.bath.ac.uk/19712/</ext-link>. Accessed 1 Dec 2022.</mixed-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katnik</surname><given-names>C</given-names></name><name><surname>Guerrero</surname><given-names>WR</given-names></name><name><surname>Pennypacker</surname><given-names>KR</given-names></name><name><surname>Herrera</surname><given-names>Y</given-names></name><name><surname>Cuevas</surname><given-names>J</given-names></name></person-group><article-title>Sigma-1 receptor activation prevents intracellular calcium dysregulation in cortical neurons during in vitro ischemia</article-title><source>J Pharmacol Exp Ther</source><year>2006</year><volume>319</volume><issue>3</issue><fpage>1355</fpage><lpage>1365</lpage><pub-id pub-id-type="doi">10.1124/jpet.106.107557</pub-id><pub-id pub-id-type="pmid">16988055</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delprat</surname><given-names>B</given-names></name><name><surname>Crouzier</surname><given-names>L</given-names></name><name><surname>Su</surname><given-names>TP</given-names></name><name><surname>Maurice</surname><given-names>T</given-names></name></person-group><article-title>At the crossing of ER stress and MAMs: a key role of sigma-1 receptor?</article-title><source>Adv Exp Med Biol</source><year>2020</year><volume>1131</volume><fpage>699</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.1007/978-3-030-12457-1_2878</pub-id><pub-id pub-id-type="pmid">31646531</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Rizzuto</surname><given-names>R</given-names></name><name><surname>Hajnoczky</surname><given-names>G</given-names></name><name><surname>Su</surname><given-names>TP</given-names></name></person-group><article-title>MAM: more than just a housekeeper</article-title><source>Trends Cell Biol</source><year>2009</year><volume>19</volume><issue>2</issue><fpage>81</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2008.12.00279</pub-id><pub-id pub-id-type="pmid">19144519</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheffer</surname><given-names>IE</given-names></name><name><surname>Berkovic</surname><given-names>S</given-names></name><name><surname>Capovilla</surname><given-names>G</given-names></name><name><surname>Connolly</surname><given-names>MB</given-names></name><name><surname>French</surname><given-names>J</given-names></name><name><surname>Guilhoto</surname><given-names>L</given-names></name><etal/></person-group><article-title>ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology</article-title><source>Epilepsia</source><year>2017</year><volume>58</volume><issue>4</issue><fpage>512</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1111/epi.13709</pub-id><pub-id pub-id-type="pmid">28276062</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Specchio</surname><given-names>N</given-names></name><name><surname>Curatolo</surname><given-names>P</given-names></name></person-group><article-title>Developmental and epileptic encephalopathies: what we do and do not know</article-title><source>Brain</source><year>2021</year><volume>144</volume><issue>1</issue><fpage>32</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1093/brain/awaa371</pub-id><pub-id pub-id-type="pmid">33279965</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raga</surname><given-names>S</given-names></name><name><surname>Specchio</surname><given-names>N</given-names></name><name><surname>Rheims</surname><given-names>S</given-names></name><name><surname>Wilmshurst</surname><given-names>JM</given-names></name></person-group><article-title>Developmental and epileptic encephalopathies: recognition and approaches to care</article-title><source>Epileptic Disord</source><year>2021</year><volume>23</volume><issue>1</issue><fpage>40</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1684/epd.2021.1244</pub-id><pub-id pub-id-type="pmid">33632673</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheffer</surname><given-names>IE</given-names></name><name><surname>Liao</surname><given-names>J</given-names></name></person-group><article-title>Deciphering the concepts behind &#x0201c;Epileptic encephalopathy&#x0201d; and &#x0201c;Developmental and epileptic encephalopathy&#x0201d;</article-title><source>Eur J Paediatr Neurol</source><year>2020</year><volume>24</volume><fpage>11</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.ejpn.2019.12.023</pub-id><pub-id pub-id-type="pmid">31926847</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trivisano</surname><given-names>M</given-names></name><name><surname>Specchio</surname><given-names>N</given-names></name></person-group><article-title>What are the epileptic encephalopathies?</article-title><source>Curr Opin Neurol</source><year>2020</year><volume>33</volume><issue>2</issue><fpage>179</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1097/wco.0000000000000793</pub-id><pub-id pub-id-type="pmid">32049741</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><mixed-citation publication-type="other">EPX-100 (Clemizole Hydrochloride) as add-on therapy to control convulsive seizures in patients with Dravet syndrome (ARGUS). In: NIH U.S. National Library of Medicine. 2020. https://clinicaltrials.gov/ct2/show/NCT04462770. Accessed 1 Dec 2022.</mixed-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffin</surname><given-names>A</given-names></name><name><surname>Hamling</surname><given-names>KR</given-names></name><name><surname>Knupp</surname><given-names>K</given-names></name><name><surname>Hong</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>LP</given-names></name><name><surname>Baraban</surname><given-names>SC</given-names></name></person-group><article-title>Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome</article-title><source>Brain</source><year>2017</year><volume>140</volume><issue>3</issue><fpage>669</fpage><lpage>683</lpage><pub-id pub-id-type="doi">10.1093/brain/aww342</pub-id><pub-id pub-id-type="pmid">28073790</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasquez</surname><given-names>A</given-names></name><name><surname>Buraniqi</surname><given-names>E</given-names></name><name><surname>Wirrell</surname><given-names>EC</given-names></name></person-group><article-title>New and emerging pharmacologic treatments for developmental and epileptic encephalopathies</article-title><source>Curr Opin Neurol</source><year>2022</year><volume>35</volume><issue>2</issue><fpage>145</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1097/wco.0000000000001029</pub-id><pub-id pub-id-type="pmid">35102126</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miziak</surname><given-names>B</given-names></name><name><surname>Czuczwar</surname><given-names>S</given-names></name></person-group><article-title>Advances in the design and discovery of novel small molecule drugs for the treatment of Dravet Syndrome</article-title><source>Expert Opin Drug Discov</source><year>2021</year><volume>16</volume><issue>5</issue><fpage>579</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1080/17460441.2021.1857722</pub-id><pub-id pub-id-type="pmid">33275464</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samanta</surname><given-names>D</given-names></name></person-group><article-title>Changing landscape of Dravet syndrome management: an overview</article-title><source>Neuropediatrics</source><year>2020</year><volume>51</volume><issue>2</issue><fpage>135</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1055/s-0040-1701694</pub-id><pub-id pub-id-type="pmid">32079034</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>P</given-names></name><name><surname>Reeder</surname><given-names>T</given-names></name><name><surname>Sourbron</surname><given-names>J</given-names></name><name><surname>de Witte</surname><given-names>PAM</given-names></name><name><surname>Gammaitoni</surname><given-names>AR</given-names></name><name><surname>Galer</surname><given-names>BS</given-names></name></person-group><article-title>An emerging role for Sigma-1 receptors in the treatment of developmental and epileptic encephalopathies</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><issue>16</issue><fpage>8416</fpage><pub-id pub-id-type="doi">10.3390/ijms22168416</pub-id><pub-id pub-id-type="pmid">34445144</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vavers</surname><given-names>E</given-names></name><name><surname>Zvejniece</surname><given-names>B</given-names></name><name><surname>Stelfa</surname><given-names>G</given-names></name><name><surname>Svalbe</surname><given-names>B</given-names></name><name><surname>Vilks</surname><given-names>K</given-names></name><name><surname>Kupats</surname><given-names>E</given-names></name><etal/></person-group><article-title>Genetic inactivation of the sigma-1 chaperone protein results in decreased expression of the R2 subunit of the GABA-B receptor and increased susceptibility to seizures</article-title><source>Neurobiol Dis</source><year>2021</year><volume>150</volume><fpage>105244</fpage><pub-id pub-id-type="doi">10.1016/j.nbd.2020.105244</pub-id><pub-id pub-id-type="pmid">33385516</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaffar</surname><given-names>G</given-names></name><name><surname>Breuer</surname><given-names>P</given-names></name><name><surname>Boteva</surname><given-names>R</given-names></name><name><surname>Behrends</surname><given-names>C</given-names></name><name><surname>Tzvetkov</surname><given-names>N</given-names></name><name><surname>Strippel</surname><given-names>N</given-names></name><etal/></person-group><article-title>Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation</article-title><source>Mol Cell</source><year>2004</year><volume>15</volume><issue>1</issue><fpage>95</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2004.06.029</pub-id><pub-id pub-id-type="pmid">15225551</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Vicente</surname><given-names>M</given-names></name><name><surname>Talloczy</surname><given-names>Z</given-names></name><name><surname>Wong</surname><given-names>E</given-names></name><name><surname>Tang</surname><given-names>G</given-names></name><name><surname>Koga</surname><given-names>H</given-names></name><name><surname>Kaushik</surname><given-names>S</given-names></name><etal/></person-group><article-title>Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease</article-title><source>Nat Neurosci</source><year>2010</year><volume>13</volume><issue>5</issue><fpage>567</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1038/nn.2528</pub-id><pub-id pub-id-type="pmid">20383138</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mochel</surname><given-names>F</given-names></name><name><surname>Haller</surname><given-names>RG</given-names></name></person-group><article-title>Energy deficit in Huntington disease: why it matters</article-title><source>J Clin Invest</source><year>2011</year><volume>121</volume><issue>2</issue><fpage>493</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1172/JCI45691</pub-id><pub-id pub-id-type="pmid">21285522</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><mixed-citation publication-type="other">Caron NS, Wright GEB, Hayden MR. Huntington Disease. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, et al., editors. GeneReviews, University of Washington, Seattle. 1993. <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK1305/">https://www.ncbi.nlm.nih.gov/books/NBK1305/</ext-link>.</mixed-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>S</given-names></name></person-group><article-title>Treatment of Huntington&#x02019;s disease</article-title><source>Neurotherapeutics</source><year>2014</year><volume>11</volume><issue>1</issue><fpage>153</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1007/s13311-013-0244-z</pub-id><pub-id pub-id-type="pmid">24366610</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miki</surname><given-names>Y</given-names></name><name><surname>Tanji</surname><given-names>K</given-names></name><name><surname>Mori</surname><given-names>F</given-names></name><name><surname>Wakabayashi</surname><given-names>K</given-names></name></person-group><article-title>Sigma-1 receptor is involved in degradation of intranuclear inclusions in a cellular model of Huntington&#x02019;s disease</article-title><source>Neurobiol Dis</source><year>2015</year><volume>74</volume><fpage>25</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2014.11.005</pub-id><pub-id pub-id-type="pmid">25449906</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryskamp</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Geva</surname><given-names>M</given-names></name><name><surname>Kusko</surname><given-names>R</given-names></name><name><surname>Grossman</surname><given-names>I</given-names></name><name><surname>Hayden</surname><given-names>M</given-names></name><etal/></person-group><article-title>The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease</article-title><source>Neurobiol Dis</source><year>2017</year><volume>97</volume><fpage>46</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2016.10.006</pub-id><pub-id pub-id-type="pmid">27818324</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jab&#x00142;o&#x00144;ska</surname><given-names>M</given-names></name><name><surname>Grzelakowska</surname><given-names>K</given-names></name><name><surname>Wi&#x0015b;niewski</surname><given-names>B</given-names></name><name><surname>Mazur</surname><given-names>E</given-names></name><name><surname>Leis</surname><given-names>K</given-names></name><name><surname>Ga&#x00142;&#x00105;zka</surname><given-names>P</given-names></name></person-group><article-title>Pridopidine in the treatment of Huntington&#x02019;s disease</article-title><source>Rev Neurosci</source><year>2020</year><volume>31</volume><issue>4</issue><fpage>441</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1515/revneuro-2019-0085</pub-id><pub-id pub-id-type="pmid">32083454</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>L</given-names></name><name><surname>Lucke-Wold</surname><given-names>BP</given-names></name><name><surname>Mookerjee</surname><given-names>SA</given-names></name><name><surname>Cavendish</surname><given-names>JZ</given-names></name><name><surname>Robson</surname><given-names>MJ</given-names></name><name><surname>Scandinaro</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Role of sigma-1 receptors in neurodegenerative diseases</article-title><source>J Pharmacol Sci</source><year>2015</year><volume>127</volume><issue>1</issue><fpage>17</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.jphs.2014.12.005</pub-id><pub-id pub-id-type="pmid">25704014</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swinnen</surname><given-names>B</given-names></name><name><surname>Robberecht</surname><given-names>W</given-names></name></person-group><article-title>The phenotypic variability of amyotrophic lateral sclerosis</article-title><source>Nat Rev Neurol</source><year>2014</year><volume>10</volume><issue>11</issue><fpage>661</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2014.184</pub-id><pub-id pub-id-type="pmid">25311585</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machts</surname><given-names>J</given-names></name><name><surname>Keute</surname><given-names>M</given-names></name><name><surname>Kaufmann</surname><given-names>J</given-names></name><name><surname>Schreiber</surname><given-names>S</given-names></name><name><surname>Kasper</surname><given-names>E</given-names></name><name><surname>Petri</surname><given-names>S</given-names></name><etal/></person-group><article-title>Longitudinal clinical and neuroanatomical correlates of memory impairment in motor neuron disease</article-title><source>Neuroimage Clin.</source><year>2021</year><volume>29</volume><fpage>102545</fpage><pub-id pub-id-type="doi">10.1016/j.nicl.2020.102545</pub-id><pub-id pub-id-type="pmid">33387861</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roggenbuck</surname><given-names>J</given-names></name><name><surname>Quick</surname><given-names>A</given-names></name><name><surname>Kolb</surname><given-names>SJ</given-names></name></person-group><article-title>Genetic testing and genetic counseling for amyotrophic lateral sclerosis: an update for clinicians</article-title><source>Genet Med</source><year>2017</year><volume>19</volume><issue>3</issue><fpage>267</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1038/gim.2016.107</pub-id><pub-id pub-id-type="pmid">27537704</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Bos</surname><given-names>MAJ</given-names></name><name><surname>Geevasinga</surname><given-names>N</given-names></name><name><surname>Higashihara</surname><given-names>M</given-names></name><name><surname>Menon</surname><given-names>P</given-names></name><name><surname>Vucic</surname><given-names>S</given-names></name></person-group><article-title>Pathophysiology and diagnosis of ALS: insights from advances in neurophysiological techniques</article-title><source>Int J Mol Sci</source><year>2019</year><volume>20</volume><issue>11</issue><fpage>2818</fpage><pub-id pub-id-type="doi">10.3390/ijms20112818</pub-id><pub-id pub-id-type="pmid">31185581</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bensimon</surname><given-names>G</given-names></name><name><surname>Lacomblez</surname><given-names>L</given-names></name><name><surname>Meininger</surname><given-names>V</given-names></name></person-group><article-title>A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group</article-title><source>N Engl J Med</source><year>1994</year><volume>330</volume><issue>9</issue><fpage>585</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1056/nejm199403033300901</pub-id><pub-id pub-id-type="pmid">8302340</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heo</surname><given-names>YA</given-names></name></person-group><article-title>Sodium phenylbutyrate and ursodoxicoltaurine: first approval</article-title><source>CNS Drugs</source><year>2022</year><volume>36</volume><issue>9</issue><fpage>1007</fpage><lpage>1013</lpage><pub-id pub-id-type="doi">10.1007/s40263-022-00945-x</pub-id><pub-id pub-id-type="pmid">35907175</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaiswal</surname><given-names>MK</given-names></name></person-group><article-title>Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs</article-title><source>Med Res Rev</source><year>2019</year><volume>39</volume><issue>2</issue><fpage>733</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1002/med.21528</pub-id><pub-id pub-id-type="pmid">30101496</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mora</surname><given-names>JS</given-names></name><name><surname>Genge</surname><given-names>A</given-names></name><name><surname>Chio</surname><given-names>A</given-names></name><name><surname>Estol</surname><given-names>CJ</given-names></name><name><surname>Chaverri</surname><given-names>D</given-names></name><name><surname>Hern&#x000e1;ndez</surname><given-names>M</given-names></name><etal/></person-group><article-title>Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial</article-title><source>Amyotroph Lateral Scler Frontotemporal Degener.</source><year>2020</year><volume>21</volume><issue>1&#x02013;2</issue><fpage>5</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1080/21678421.2019.1632346</pub-id><pub-id pub-id-type="pmid">31280619</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Latham</surname><given-names>BD</given-names></name><name><surname>Oskin</surname><given-names>DS</given-names></name><name><surname>Crouch</surname><given-names>RD</given-names></name><name><surname>Vergne</surname><given-names>MJ</given-names></name><name><surname>Jackson</surname><given-names>KD</given-names></name></person-group><article-title>Cytochromes P450 2C8 and 3A catalyze the metabolic activation of the tyrosine kinase inhibitor masitinib</article-title><source>Chem Res Toxicol</source><year>2022</year><volume>35</volume><issue>9</issue><fpage>1467</fpage><lpage>1481</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrestox.2c00057</pub-id><pub-id pub-id-type="pmid">36048877</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casanovas</surname><given-names>A</given-names></name><name><surname>Salvany</surname><given-names>S</given-names></name><name><surname>Lahoz</surname><given-names>V</given-names></name><name><surname>Tarabal</surname><given-names>O</given-names></name><name><surname>Piedrafita</surname><given-names>L</given-names></name><name><surname>Sabater</surname><given-names>R</given-names></name><etal/></person-group><article-title>Neuregulin 1-ErbB module in C-bouton synapses on somatic motor neurons: molecular compartmentation and response to peripheral nerve injury</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>40155</fpage><pub-id pub-id-type="doi">10.1038/srep40155</pub-id><pub-id pub-id-type="pmid">28065942</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrando-Grabulosa</surname><given-names>M</given-names></name><name><surname>Gaja-Capdevila</surname><given-names>N</given-names></name><name><surname>Vela</surname><given-names>JM</given-names></name><name><surname>Navarro</surname><given-names>X</given-names></name></person-group><article-title>Sigma 1 receptor as a therapeutic target for amyotrophic lateral sclerosis</article-title><source>Br J Pharmacol</source><year>2021</year><volume>178</volume><issue>6</issue><fpage>1336</fpage><lpage>1352</lpage><pub-id pub-id-type="doi">10.1111/bph.15224</pub-id><pub-id pub-id-type="pmid">32761823</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mavlyutov</surname><given-names>TA</given-names></name><name><surname>Epstein</surname><given-names>ML</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Verbny</surname><given-names>YI</given-names></name><name><surname>Ziskind-Conhaim</surname><given-names>L</given-names></name><name><surname>Ruoho</surname><given-names>AE</given-names></name></person-group><article-title>Development of the sigma-1 receptor in C-terminals of motoneurons and colocalization with the N, N&#x02032;-dimethyltryptamine forming enzyme, indole-N-methyl transferase</article-title><source>Neuroscience</source><year>2012</year><volume>206</volume><fpage>60</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2011.12.040</pub-id><pub-id pub-id-type="pmid">22265729</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mavlyutov</surname><given-names>TA</given-names></name><name><surname>Epstein</surname><given-names>ML</given-names></name><name><surname>Andersen</surname><given-names>KA</given-names></name><name><surname>Ziskind-Conhaim</surname><given-names>L</given-names></name><name><surname>Ruoho</surname><given-names>AE</given-names></name></person-group><article-title>The sigma-1 receptor is enriched in postsynaptic sites of C-terminals in mouse motoneurons. An anatomical and behavioral study</article-title><source>Neuroscience</source><year>2010</year><volume>167</volume><issue>2</issue><fpage>247</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2010.02.022</pub-id><pub-id pub-id-type="pmid">20167253</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>Ilieva</surname><given-names>H</given-names></name><name><surname>Tamada</surname><given-names>H</given-names></name><name><surname>Nomura</surname><given-names>H</given-names></name><name><surname>Komine</surname><given-names>O</given-names></name><name><surname>Endo</surname><given-names>F</given-names></name><etal/></person-group><article-title>Mitochondria-associated membrane collapse is a common pathomechanism in SIGMAR 1-and SOD 1-linked ALS</article-title><source>EMBO Mol Med</source><year>2016</year><volume>8</volume><issue>12</issue><fpage>1421</fpage><lpage>1437</lpage><pub-id pub-id-type="doi">10.15252/emmm.201606403</pub-id><pub-id pub-id-type="pmid">27821430</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Couly</surname><given-names>S</given-names></name><name><surname>Khalil</surname><given-names>B</given-names></name><name><surname>Viguier</surname><given-names>V</given-names></name><name><surname>Roussel</surname><given-names>J</given-names></name><name><surname>Maurice</surname><given-names>T</given-names></name><name><surname>Li&#x000e9;vens</surname><given-names>J-C</given-names></name></person-group><article-title>Sigma-1 receptor is a key genetic modulator in amyotrophic lateral sclerosis</article-title><source>Hum Mol Genet</source><year>2020</year><volume>29</volume><issue>4</issue><fpage>529</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddz267</pub-id><pub-id pub-id-type="pmid">31696229</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vollrath</surname><given-names>J</given-names></name><name><surname>Sechi</surname><given-names>A</given-names></name><name><surname>Dreser</surname><given-names>A</given-names></name><name><surname>Katona</surname><given-names>I</given-names></name><name><surname>Wiemuth</surname><given-names>D</given-names></name><name><surname>Vervoorts</surname><given-names>J</given-names></name><etal/></person-group><article-title>Loss of function of the ALS protein SigR1 leads to ER pathology associated with defective autophagy and lipid raft disturbances</article-title><source>Cell Death Dis</source><year>2014</year><volume>5</volume><issue>6</issue><fpage>e1290</fpage><pub-id pub-id-type="doi">10.1038/cddis.2014.243</pub-id><pub-id pub-id-type="pmid">24922074</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dreser</surname><given-names>A</given-names></name><name><surname>Vollrath</surname><given-names>JT</given-names></name><name><surname>Sechi</surname><given-names>A</given-names></name><name><surname>Johann</surname><given-names>S</given-names></name><name><surname>Roos</surname><given-names>A</given-names></name><name><surname>Yamoah</surname><given-names>A</given-names></name><etal/></person-group><article-title>The ALS-linked E102Q mutation in Sigma receptor-1 leads to ER stress-mediated defects in protein homeostasis and dysregulation of RNA-binding proteins</article-title><source>Cell Death Differ</source><year>2017</year><volume>24</volume><issue>10</issue><fpage>1655</fpage><lpage>1671</lpage><pub-id pub-id-type="doi">10.1038/cdd.2017.88</pub-id><pub-id pub-id-type="pmid">28622300</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mavlyutov</surname><given-names>TA</given-names></name><name><surname>Epstein</surname><given-names>ML</given-names></name><name><surname>Verbny</surname><given-names>YI</given-names></name><name><surname>Huerta</surname><given-names>MS</given-names></name><name><surname>Zaitoun</surname><given-names>I</given-names></name><name><surname>Ziskind-Conhaim</surname><given-names>L</given-names></name><etal/></person-group><article-title>Lack of sigma-1 receptor exacerbates ALS progression in mice</article-title><source>Neuroscience</source><year>2013</year><volume>240</volume><fpage>129</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2013.02.035</pub-id><pub-id pub-id-type="pmid">23458708</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Saif</surname><given-names>A</given-names></name><name><surname>Al-Mohanna</surname><given-names>F</given-names></name><name><surname>Bohlega</surname><given-names>S</given-names></name></person-group><article-title>A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis</article-title><source>Ann Neurol</source><year>2011</year><volume>70</volume><issue>6</issue><fpage>913</fpage><lpage>919</lpage><pub-id pub-id-type="doi">10.1002/ana.22534</pub-id><pub-id pub-id-type="pmid">21842496</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukunaga</surname><given-names>K</given-names></name><name><surname>Shinoda</surname><given-names>Y</given-names></name><name><surname>Tagashira</surname><given-names>H</given-names></name></person-group><article-title>The role of SIGMAR1 gene mutation and mitochondrial dysfunction in amyotrophic lateral sclerosis</article-title><source>J Pharmacol Sci</source><year>2015</year><volume>127</volume><issue>1</issue><fpage>36</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.jphs.2014.12.012</pub-id><pub-id pub-id-type="pmid">25704016</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barmada</surname><given-names>SJ</given-names></name><name><surname>Skibinski</surname><given-names>G</given-names></name><name><surname>Korb</surname><given-names>E</given-names></name><name><surname>Rao</surname><given-names>EJ</given-names></name><name><surname>Wu</surname><given-names>JY</given-names></name><name><surname>Finkbeiner</surname><given-names>S</given-names></name></person-group><article-title>Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis</article-title><source>J Neurosci</source><year>2010</year><volume>30</volume><issue>2</issue><fpage>639</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4988-09.2010</pub-id><pub-id pub-id-type="pmid">20071528</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>A</given-names></name><name><surname>Bharathi</surname><given-names>V</given-names></name><name><surname>Sivalingam</surname><given-names>V</given-names></name><name><surname>Girdhar</surname><given-names>A</given-names></name><name><surname>Patel</surname><given-names>BK</given-names></name></person-group><article-title>Molecular mechanisms of TDP-43 misfolding and pathology in amyotrophic lateral sclerosis</article-title><source>Front Mol Neurosci</source><year>2019</year><volume>12</volume><fpage>25</fpage><pub-id pub-id-type="doi">10.3389/fnmol.2019.00025</pub-id><pub-id pub-id-type="pmid">30837838</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brettschneider</surname><given-names>J</given-names></name><name><surname>Del Tredici</surname><given-names>K</given-names></name><name><surname>Toledo</surname><given-names>JB</given-names></name><name><surname>Robinson</surname><given-names>JL</given-names></name><name><surname>Irwin</surname><given-names>DJ</given-names></name><name><surname>Grossman</surname><given-names>M</given-names></name><etal/></person-group><article-title>Stages of pTDP-43 pathology in amyotrophic lateral sclerosis</article-title><source>Ann Neurol</source><year>2013</year><volume>74</volume><issue>1</issue><fpage>20</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1002/ana.23937</pub-id><pub-id pub-id-type="pmid">23686809</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>P-T</given-names></name><name><surname>Li&#x000e9;vens</surname><given-names>J-C</given-names></name><name><surname>Wang</surname><given-names>S-M</given-names></name><name><surname>Chuang</surname><given-names>J-Y</given-names></name><name><surname>Khalil</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>H-E</given-names></name><etal/></person-group><article-title>Sigma-1 receptor chaperones rescue nucleocytoplasmic transport deficit seen in cellular and Drosophila ALS/FTD models</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><issue>1</issue><fpage>5580</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-19396-3</pub-id><pub-id pub-id-type="pmid">33149115</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frischer</surname><given-names>JM</given-names></name><name><surname>Bramow</surname><given-names>S</given-names></name><name><surname>Dal-Bianco</surname><given-names>A</given-names></name><name><surname>Lucchinetti</surname><given-names>CF</given-names></name><name><surname>Rauschka</surname><given-names>H</given-names></name><name><surname>Schmidbauer</surname><given-names>M</given-names></name><etal/></person-group><article-title>The relation between inflammation and neurodegeneration in multiple sclerosis brains</article-title><source>Brain</source><year>2009</year><volume>132</volume><issue>Pt 5</issue><fpage>1175</fpage><lpage>1189</lpage><pub-id pub-id-type="doi">10.1093/brain/awp070</pub-id><pub-id pub-id-type="pmid">19339255</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGinley</surname><given-names>MP</given-names></name><name><surname>Goldschmidt</surname><given-names>CH</given-names></name><name><surname>Rae-Grant</surname><given-names>AD</given-names></name></person-group><article-title>Diagnosis and treatment of multiple sclerosis: a review</article-title><source>JAMA</source><year>2021</year><volume>325</volume><issue>8</issue><fpage>765</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.26858</pub-id><pub-id pub-id-type="pmid">33620411</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krupp</surname><given-names>L</given-names></name></person-group><article-title>Fatigue is intrinsic to multiple sclerosis (MS) and is the most commonly reported symptom of the disease</article-title><source>Mult Scler</source><year>2006</year><volume>12</volume><issue>4</issue><fpage>367</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1191/135248506ms1373ed</pub-id><pub-id pub-id-type="pmid">16900749</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braley</surname><given-names>TJ</given-names></name><name><surname>Chervin</surname><given-names>RD</given-names></name></person-group><article-title>Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment</article-title><source>Sleep</source><year>2010</year><volume>33</volume><issue>8</issue><fpage>1061</fpage><lpage>1067</lpage><pub-id pub-id-type="doi">10.1093/sleep/33.8.1061</pub-id><pub-id pub-id-type="pmid">20815187</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobs</surname><given-names>LD</given-names></name><name><surname>Beck</surname><given-names>RW</given-names></name><name><surname>Simon</surname><given-names>JH</given-names></name><name><surname>Kinkel</surname><given-names>RP</given-names></name><name><surname>Brownscheidle</surname><given-names>CM</given-names></name><name><surname>Murray</surname><given-names>TJ</given-names></name><etal/></person-group><article-title>Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group</article-title><source>N Engl J Med</source><year>2000</year><volume>343</volume><issue>13</issue><fpage>898</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1056/nejm200009283431301</pub-id><pub-id pub-id-type="pmid">11006365</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lycke</surname><given-names>J</given-names></name></person-group><article-title>Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes</article-title><source>Ther Adv Neurol Disord</source><year>2015</year><volume>8</volume><issue>6</issue><fpage>274</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1177/1756285615605429</pub-id><pub-id pub-id-type="pmid">26600872</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kappos</surname><given-names>L</given-names></name><name><surname>Radue</surname><given-names>EW</given-names></name><name><surname>O'Connor</surname><given-names>P</given-names></name><name><surname>Polman</surname><given-names>C</given-names></name><name><surname>Hohlfeld</surname><given-names>R</given-names></name><name><surname>Calabresi</surname><given-names>P</given-names></name><etal/></person-group><article-title>A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis</article-title><source>N Engl J Med</source><year>2010</year><volume>362</volume><issue>5</issue><fpage>387</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0909494</pub-id><pub-id pub-id-type="pmid">20089952</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kappos</surname><given-names>L</given-names></name><name><surname>Bar-Or</surname><given-names>A</given-names></name><name><surname>Cree</surname><given-names>BAC</given-names></name><name><surname>Fox</surname><given-names>RJ</given-names></name><name><surname>Giovannoni</surname><given-names>G</given-names></name><name><surname>Gold</surname><given-names>R</given-names></name><etal/></person-group><article-title>Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study</article-title><source>Lancet</source><year>2018</year><volume>391</volume><issue>10127</issue><fpage>1263</fpage><lpage>1273</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(18)30475-6</pub-id><pub-id pub-id-type="pmid">29576505</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Comi</surname><given-names>G</given-names></name><name><surname>Kappos</surname><given-names>L</given-names></name><name><surname>Selmaj</surname><given-names>KW</given-names></name><name><surname>Bar-Or</surname><given-names>A</given-names></name><name><surname>Arnold</surname><given-names>DL</given-names></name><name><surname>Steinman</surname><given-names>L</given-names></name><etal/></person-group><article-title>Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial</article-title><source>Lancet Neurol</source><year>2019</year><volume>18</volume><issue>11</issue><fpage>1009</fpage><lpage>1020</lpage><pub-id pub-id-type="doi">10.1016/s1474-4422(19)30239-x</pub-id><pub-id pub-id-type="pmid">31492651</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>KP</given-names></name><name><surname>Brooks</surname><given-names>BR</given-names></name><name><surname>Cohen</surname><given-names>JA</given-names></name><name><surname>Ford</surname><given-names>CC</given-names></name><name><surname>Goldstein</surname><given-names>J</given-names></name><name><surname>Lisak</surname><given-names>RP</given-names></name><etal/></person-group><article-title>Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group</article-title><source>Neurology</source><year>1995</year><volume>45</volume><issue>7</issue><fpage>1268</fpage><lpage>1276</lpage><pub-id pub-id-type="doi">10.1212/wnl.45.7.1268</pub-id><pub-id pub-id-type="pmid">7617181</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Confavreux</surname><given-names>C</given-names></name><name><surname>O'Connor</surname><given-names>P</given-names></name><name><surname>Comi</surname><given-names>G</given-names></name><name><surname>Freedman</surname><given-names>MS</given-names></name><name><surname>Miller</surname><given-names>AE</given-names></name><name><surname>Olsson</surname><given-names>TP</given-names></name><etal/></person-group><article-title>Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial</article-title><source>Lancet Neurol</source><year>2014</year><volume>13</volume><issue>3</issue><fpage>247</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1016/s1474-4422(13)70308-9</pub-id><pub-id pub-id-type="pmid">24461574</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giovannoni</surname><given-names>G</given-names></name><name><surname>Comi</surname><given-names>G</given-names></name><name><surname>Cook</surname><given-names>S</given-names></name><name><surname>Rammohan</surname><given-names>K</given-names></name><name><surname>Rieckmann</surname><given-names>P</given-names></name><name><surname>Soelberg S&#x000f8;rensen</surname><given-names>P</given-names></name><etal/></person-group><article-title>A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis</article-title><source>N Engl J Med</source><year>2010</year><volume>362</volume><issue>5</issue><fpage>416</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0902533</pub-id><pub-id pub-id-type="pmid">20089960</pub-id></element-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palacios</surname><given-names>G</given-names></name><name><surname>Muro</surname><given-names>A</given-names></name><name><surname>Verd&#x000fa;</surname><given-names>E</given-names></name><name><surname>Pumarola</surname><given-names>M</given-names></name><name><surname>Vela</surname><given-names>JM</given-names></name></person-group><article-title>Immunohistochemical localization of the sigma1 receptor in Schwann cells of rat sciatic nerve</article-title><source>Brain Res</source><year>2004</year><volume>1007</volume><issue>1&#x02013;2</issue><fpage>65</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2004.02.013</pub-id><pub-id pub-id-type="pmid">15064136</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Su</surname><given-names>T-P</given-names></name></person-group><article-title>Sigma-1 receptors at galactosylceramide-enriched lipid microdomains regulate oligodendrocyte differentiation</article-title><source>Proc Natl Acad Sci USA</source><year>2004</year><volume>101</volume><issue>41</issue><fpage>14949</fpage><lpage>14954</lpage><pub-id pub-id-type="doi">10.1073/pnas.0402890101</pub-id><pub-id pub-id-type="pmid">15466698</pub-id></element-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhemkov</surname><given-names>V</given-names></name><name><surname>Geva</surname><given-names>M</given-names></name><name><surname>Hayden</surname><given-names>MR</given-names></name><name><surname>Bezprozvanny</surname><given-names>I</given-names></name></person-group><article-title>Sigma-1 receptor (S1R) interaction with cholesterol: mechanisms of S1R activation and its role in neurodegenerative diseases</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><issue>8</issue><fpage>4082</fpage><pub-id pub-id-type="doi">10.3390/ijms22084082</pub-id><pub-id pub-id-type="pmid">33920913</pub-id></element-citation></ref><ref id="CR139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berghoff</surname><given-names>SA</given-names></name><name><surname>Spieth</surname><given-names>L</given-names></name><name><surname>Saher</surname><given-names>G</given-names></name></person-group><article-title>Local cholesterol metabolism orchestrates remyelination</article-title><source>Trends Neurosci</source><year>2022</year><volume>45</volume><issue>4</issue><fpage>272</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2022.01.001</pub-id><pub-id pub-id-type="pmid">35153084</pub-id></element-citation></ref><ref id="CR140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenche</surname><given-names>H</given-names></name><name><surname>Singh</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>K</given-names></name></person-group><article-title>Neuronal mitochondrial dysfunction in a cellular model of circadian rhythm disruption is rescued by donepezil</article-title><source>Biochem Biophys Res Commun</source><year>2021</year><volume>567</volume><fpage>56</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2021.06.029</pub-id><pub-id pub-id-type="pmid">34144501</pub-id></element-citation></ref><ref id="CR141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oxombre</surname><given-names>B</given-names></name><name><surname>Lee-Chang</surname><given-names>C</given-names></name><name><surname>Duhamel</surname><given-names>A</given-names></name><name><surname>Toussaint</surname><given-names>M</given-names></name><name><surname>Giroux</surname><given-names>M</given-names></name><name><surname>Donnier-Mar&#x000e9;chal</surname><given-names>M</given-names></name><etal/></person-group><article-title>High-affinity &#x003c3;1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis</article-title><source>Br J Pharmacol</source><year>2015</year><volume>172</volume><issue>7</issue><fpage>1769</fpage><lpage>1782</lpage><pub-id pub-id-type="doi">10.1111/bph.13037</pub-id><pub-id pub-id-type="pmid">25521311</pub-id></element-citation></ref><ref id="CR142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lotankar</surname><given-names>S</given-names></name><name><surname>Prabhavalkar</surname><given-names>KS</given-names></name><name><surname>Bhatt</surname><given-names>LK</given-names></name></person-group><article-title>Biomarkers for Parkinson&#x02019;s disease: recent advancement</article-title><source>Neurosci Bull</source><year>2017</year><volume>33</volume><issue>5</issue><fpage>585</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1007/s12264-017-0183-5</pub-id><pub-id pub-id-type="pmid">28936761</pub-id></element-citation></ref><ref id="CR143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen-Plotkin</surname><given-names>AS</given-names></name><name><surname>Albin</surname><given-names>R</given-names></name><name><surname>Alcalay</surname><given-names>R</given-names></name><name><surname>Babcock</surname><given-names>D</given-names></name><name><surname>Bajaj</surname><given-names>V</given-names></name><name><surname>Bowman</surname><given-names>D</given-names></name><etal/></person-group><article-title>Finding useful biomarkers for Parkinson&#x02019;s disease</article-title><source>Sci Transl Med.</source><year>2018</year><volume>10</volume><issue>454</issue><fpage>eaam6003</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aam6003</pub-id><pub-id pub-id-type="pmid">30111645</pub-id></element-citation></ref><ref id="CR144"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Le</surname><given-names>W</given-names></name></person-group><article-title>Biomarkers for Parkinson&#x02019;s disease: how good are they?</article-title><source>Neurosci Bull</source><year>2020</year><volume>36</volume><issue>2</issue><fpage>183</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1007/s12264-019-00433-1</pub-id><pub-id pub-id-type="pmid">31646434</pub-id></element-citation></ref><ref id="CR145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloem</surname><given-names>BR</given-names></name><name><surname>Okun</surname><given-names>MS</given-names></name><name><surname>Klein</surname><given-names>C</given-names></name></person-group><article-title>Parkinson&#x02019;s disease</article-title><source>Lancet</source><year>2021</year><volume>397</volume><issue>10291</issue><fpage>2284</fpage><lpage>2303</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(21)00218-x</pub-id><pub-id pub-id-type="pmid">33848468</pub-id></element-citation></ref><ref id="CR146"><label>146.</label><mixed-citation publication-type="other">Parkinson disease. In: World Health Organization website. 2022. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/fact-sheets/detail/parkinson-disease">https://www.who.int/news-room/fact-sheets/detail/parkinson-disease</ext-link>. Accessed 1 Dec 2022.</mixed-citation></ref><ref id="CR147"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LeWitt</surname><given-names>PA</given-names></name></person-group><article-title>Levodopa therapy for Parkinson&#x02019;s disease: pharmacokinetics and pharmacodynamics</article-title><source>Mov Disord</source><year>2015</year><volume>30</volume><issue>1</issue><fpage>64</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1002/mds.26082</pub-id><pub-id pub-id-type="pmid">25449210</pub-id></element-citation></ref><ref id="CR148"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nonnekes</surname><given-names>J</given-names></name><name><surname>Timmer</surname><given-names>MH</given-names></name><name><surname>de Vries</surname><given-names>NM</given-names></name><name><surname>Rascol</surname><given-names>O</given-names></name><name><surname>Helmich</surname><given-names>RC</given-names></name><name><surname>Bloem</surname><given-names>BR</given-names></name></person-group><article-title>Unmasking levodopa resistance in Parkinson&#x02019;s disease</article-title><source>Mov Disord</source><year>2016</year><volume>31</volume><issue>11</issue><fpage>1602</fpage><lpage>1609</lpage><pub-id pub-id-type="doi">10.1002/mds.26712</pub-id><pub-id pub-id-type="pmid">27430479</pub-id></element-citation></ref><ref id="CR149"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>Z</given-names></name><name><surname>Possin</surname><given-names>KL</given-names></name><name><surname>Boeve</surname><given-names>BF</given-names></name><name><surname>Aarsland</surname><given-names>D</given-names></name></person-group><article-title>Lewy body dementias</article-title><source>Lancet</source><year>2015</year><volume>386</volume><issue>10004</issue><fpage>1683</fpage><lpage>1697</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(15)00462-6</pub-id><pub-id pub-id-type="pmid">26595642</pub-id></element-citation></ref><ref id="CR150"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Andersen</surname><given-names>K</given-names></name><name><surname>Larsen</surname><given-names>J</given-names></name><name><surname>Lolk</surname><given-names>A</given-names></name><name><surname>Nielsen</surname><given-names>H</given-names></name><name><surname>Kragh-S&#x000f8;rensen</surname><given-names>P</given-names></name></person-group><article-title>Risk of dementia in Parkinson&#x02019;s disease: a community-based, prospective study</article-title><source>Neurology</source><year>2001</year><volume>56</volume><issue>6</issue><fpage>730</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1212/wnl.56.6.730</pub-id><pub-id pub-id-type="pmid">11274306</pub-id></element-citation></ref><ref id="CR151"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishina</surname><given-names>M</given-names></name><name><surname>Ishiwata</surname><given-names>K</given-names></name><name><surname>Ishii</surname><given-names>K</given-names></name><name><surname>Kitamura</surname><given-names>S</given-names></name><name><surname>Kimura</surname><given-names>Y</given-names></name><name><surname>Kawamura</surname><given-names>K</given-names></name><etal/></person-group><article-title>Function of sigma 1 receptors in Parkinson&#x02019;s disease</article-title><source>Acta Neurol Scand</source><year>2005</year><volume>112</volume><issue>2</issue><fpage>103</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0404.2005.00432.x</pub-id><pub-id pub-id-type="pmid">16008536</pub-id></element-citation></ref><ref id="CR152"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><article-title>Sigma-1 receptor knockout increases &#x003b1;-synuclein aggregation and phosphorylation with loss of dopaminergic neurons in substantia nigra</article-title><source>Neurobiol Aging</source><year>2017</year><volume>59</volume><fpage>171</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2017.08.007</pub-id><pub-id pub-id-type="pmid">28870519</pub-id></element-citation></ref><ref id="CR153"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Roth</surname><given-names>GS</given-names></name></person-group><article-title>The roles of dopamine oxidative stress and dopamine receptor signaling in aging and age-related neurodegeneration</article-title><source>Antioxid Redox Signal</source><year>2000</year><volume>2</volume><issue>3</issue><fpage>449</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1089/15230860050192224</pub-id><pub-id pub-id-type="pmid">11229358</pub-id></element-citation></ref><ref id="CR154"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>T</given-names></name><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Su</surname><given-names>TP</given-names></name></person-group><article-title>Compromising &#x003c3;-1 receptors at the endoplasmic reticulum render cytotoxicity to physiologically relevant concentrations of dopamine in a nuclear factor-&#x003ba;B/Bcl-2-dependent mechanism: Potential relevance to Parkinson&#x02019;s disease</article-title><source>J Pharmacol Exp Ther</source><year>2012</year><volume>341</volume><issue>3</issue><fpage>663</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1124/jpet.111.190868</pub-id><pub-id pub-id-type="pmid">22399814</pub-id></element-citation></ref><ref id="CR155"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cagnin</surname><given-names>M</given-names></name><name><surname>Ozzano</surname><given-names>M</given-names></name><name><surname>Bellio</surname><given-names>N</given-names></name><name><surname>Fiorentino</surname><given-names>I</given-names></name><name><surname>Follo</surname><given-names>C</given-names></name><name><surname>Isidoro</surname><given-names>C</given-names></name></person-group><article-title>Dopamine induces apoptosis in APPswe-expressing Neuro2A cells following Pepstatin-sensitive proteolysis of APP in acid compartments</article-title><source>Brain Res</source><year>2012</year><volume>1471</volume><fpage>102</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2012.06.025</pub-id><pub-id pub-id-type="pmid">22771396</pub-id></element-citation></ref><ref id="CR156"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brimson</surname><given-names>JM</given-names></name><name><surname>Safrany</surname><given-names>ST</given-names></name><name><surname>Qassam</surname><given-names>H</given-names></name><name><surname>Tencomnao</surname><given-names>T</given-names></name></person-group><article-title>Dipentylammonium binds to the Sigma-1 receptor and protects against glutamate toxicity, attenuates dopamine toxicity and potentiates neurite outgrowth in various cultured cell lines</article-title><source>Neurotox Res</source><year>2018</year><volume>34</volume><issue>2</issue><fpage>263</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1007/s12640-018-9883-5</pub-id><pub-id pub-id-type="pmid">29589276</pub-id></element-citation></ref><ref id="CR157"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poewe</surname><given-names>W</given-names></name><name><surname>Seppi</surname><given-names>K</given-names></name><name><surname>Tanner</surname><given-names>CM</given-names></name><name><surname>Halliday</surname><given-names>GM</given-names></name><name><surname>Brundin</surname><given-names>P</given-names></name><name><surname>Volkmann</surname><given-names>J</given-names></name><etal/></person-group><article-title>Parkinson disease</article-title><source>Nat Rev Dis Primers</source><year>2017</year><volume>3</volume><fpage>17013</fpage><pub-id pub-id-type="doi">10.1038/nrdp.2017.13</pub-id><pub-id pub-id-type="pmid">28332488</pub-id></element-citation></ref><ref id="CR158"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenner</surname><given-names>P</given-names></name><name><surname>Olanow</surname><given-names>CW</given-names></name></person-group><article-title>Oxidative stress and the pathogenesis of Parkinson&#x02019;s disease</article-title><source>Neurology</source><year>1996</year><volume>47</volume><issue>6 Suppl 3</issue><fpage>S161</fpage><lpage>S170</lpage><pub-id pub-id-type="doi">10.1212/wnl.47.6_suppl_3.161s</pub-id><pub-id pub-id-type="pmid">8959985</pub-id></element-citation></ref><ref id="CR159"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crist&#x000f3;v&#x000e3;o</surname><given-names>AC</given-names></name><name><surname>Guhathakurta</surname><given-names>S</given-names></name><name><surname>Bok</surname><given-names>E</given-names></name><name><surname>Je</surname><given-names>G</given-names></name><name><surname>Yoo</surname><given-names>SD</given-names></name><name><surname>Choi</surname><given-names>D-H</given-names></name><etal/></person-group><article-title>NADPH oxidase 1 mediates &#x003b1;-synucleinopathy in Parkinson&#x02019;s disease</article-title><source>J Neurosci</source><year>2012</year><volume>32</volume><issue>42</issue><fpage>14465</fpage><lpage>14477</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2246-12.2012</pub-id><pub-id pub-id-type="pmid">23077033</pub-id></element-citation></ref><ref id="CR160"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>JD</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>GR</given-names></name><name><surname>Liu</surname><given-names>XL</given-names></name></person-group><article-title>Damage to dopaminergic neurons by oxidative stress in Parkinson&#x02019;s disease</article-title><source>Int J Mol Med</source><year>2018</year><volume>41</volume><issue>4</issue><fpage>1817</fpage><lpage>1825</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2018.3406</pub-id><pub-id pub-id-type="pmid">29393357</pub-id></element-citation></ref><ref id="CR161"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pal</surname><given-names>A</given-names></name><name><surname>Fontanilla</surname><given-names>D</given-names></name><name><surname>Gopalakrishnan</surname><given-names>A</given-names></name><name><surname>Chae</surname><given-names>Y-K</given-names></name><name><surname>Markley</surname><given-names>JL</given-names></name><name><surname>Ruoho</surname><given-names>AE</given-names></name></person-group><article-title>The sigma-1 receptor protects against cellular oxidative stress and activates antioxidant response elements</article-title><source>Eur J Pharmacol</source><year>2012</year><volume>682</volume><issue>1&#x02013;3</issue><fpage>12</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2012.01.030</pub-id><pub-id pub-id-type="pmid">22381068</pub-id></element-citation></ref><ref id="CR162"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Shanmugam</surname><given-names>A</given-names></name><name><surname>Markand</surname><given-names>S</given-names></name><name><surname>Zorrilla</surname><given-names>E</given-names></name><name><surname>Ganapathy</surname><given-names>V</given-names></name><name><surname>Smith</surname><given-names>SB</given-names></name></person-group><article-title>Sigma 1 receptor regulates the oxidative stress response in primary retinal M&#x000fc;ller glial cells via NRF2 signaling and system xc&#x02212;, the Na+-independent glutamate&#x02013;cystine exchanger</article-title><source>Free Radic Biol Med</source><year>2015</year><volume>86</volume><fpage>25</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2015.04.009</pub-id><pub-id pub-id-type="pmid">25920363</pub-id></element-citation></ref><ref id="CR163"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasanth</surname><given-names>MI</given-names></name><name><surname>Tencomnao</surname><given-names>T</given-names></name><name><surname>Brimson</surname><given-names>JM</given-names></name></person-group><article-title>The Sigma-1 receptors role in neuroprotection: Comment on Nrf2 as a therapeutic target in ischemic stroke</article-title><source>Expert Opin Ther Targets</source><year>2021</year><volume>25</volume><issue>7</issue><fpage>613</fpage><lpage>614</lpage><pub-id pub-id-type="doi">10.1080/14728222.2021.1948016</pub-id><pub-id pub-id-type="pmid">34180350</pub-id></element-citation></ref><ref id="CR164"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brimson</surname><given-names>JM</given-names></name><name><surname>Prasanth</surname><given-names>MI</given-names></name><name><surname>Isidoro</surname><given-names>C</given-names></name><name><surname>Sukprasansap</surname><given-names>M</given-names></name><name><surname>Tencomnao</surname><given-names>T</given-names></name></person-group><article-title><italic>Cleistocalyx nervosum</italic> var. paniala seed extracts exhibit sigma-1 antagonist sensitive neuroprotective effects in PC12 cells and protect <italic>C. elegans</italic> from stress via the SKN-1/NRF-2 pathway</article-title><source>Nutr Healthy Aging.</source><year>2021</year><volume>6</volume><issue>2</issue><fpage>131</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.3233/NHA-200108</pub-id></element-citation></ref><ref id="CR165"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brimson</surname><given-names>JM</given-names></name><name><surname>Prasanth</surname><given-names>MI</given-names></name><name><surname>Malar</surname><given-names>DS</given-names></name><name><surname>Verma</surname><given-names>K</given-names></name><name><surname>Plaingam</surname><given-names>W</given-names></name><name><surname>Tencomnao</surname><given-names>T</given-names></name></person-group><article-title>Bacopa monnieri protects neuronal cell line and <italic>Caenorhabditis elegans</italic> models of Alzheimer&#x02019;s disease through sigma-1 receptor antagonist sensitive and antioxidant pathways</article-title><source>Nutr Healthy Aging.</source><year>2022</year><volume>7</volume><issue>3</issue><fpage>173</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.3233/NHA-220161</pub-id></element-citation></ref><ref id="CR166"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Betzer</surname><given-names>C</given-names></name><name><surname>Movius</surname><given-names>AJ</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Gai</surname><given-names>W-P</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Jensen</surname><given-names>PH</given-names></name></person-group><article-title>Identification of synaptosomal proteins binding to monomeric and oligomeric &#x003b1;-synuclein</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><issue>2</issue><fpage>e0116473</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0116473</pub-id><pub-id pub-id-type="pmid">25659148</pub-id></element-citation></ref><ref id="CR167"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>JL</given-names></name><name><surname>Cuervo</surname><given-names>AM</given-names></name></person-group><article-title>Autophagy and human disease: emerging themes</article-title><source>Curr Opin Genet Dev</source><year>2014</year><volume>26</volume><fpage>16</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.gde.2014.04.003</pub-id><pub-id pub-id-type="pmid">24907664</pub-id></element-citation></ref><ref id="CR168"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogiatzi</surname><given-names>T</given-names></name><name><surname>Xilouri</surname><given-names>M</given-names></name><name><surname>Vekrellis</surname><given-names>K</given-names></name><name><surname>Stefanis</surname><given-names>L</given-names></name></person-group><article-title>Wild type &#x003b1;-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells</article-title><source>J Biol Chem</source><year>2008</year><volume>283</volume><issue>35</issue><fpage>23542</fpage><lpage>23556</lpage><pub-id pub-id-type="doi">10.1074/jbc.M801992200</pub-id><pub-id pub-id-type="pmid">18566453</pub-id></element-citation></ref><ref id="CR169"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galvagnion</surname><given-names>C</given-names></name></person-group><article-title>The role of lipids interacting with &#x003b1;-synuclein in the pathogenesis of Parkinson&#x02019;s disease</article-title><source>J Parkinsons Dis</source><year>2017</year><volume>7</volume><issue>3</issue><fpage>433</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.3233/JPD-171103</pub-id><pub-id pub-id-type="pmid">28671142</pub-id></element-citation></ref><ref id="CR170"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galvagnion</surname><given-names>C</given-names></name><name><surname>Brown</surname><given-names>JW</given-names></name><name><surname>Ouberai</surname><given-names>MM</given-names></name><name><surname>Flagmeier</surname><given-names>P</given-names></name><name><surname>Vendruscolo</surname><given-names>M</given-names></name><name><surname>Buell</surname><given-names>AK</given-names></name><etal/></person-group><article-title>Chemical properties of lipids strongly affect the kinetics of the membrane-induced aggregation of &#x003b1;-synuclein</article-title><source>Proc Natl Acad Sci USA</source><year>2016</year><volume>113</volume><issue>26</issue><fpage>7065</fpage><lpage>7070</lpage><pub-id pub-id-type="doi">10.1073/pnas.1601899113</pub-id><pub-id pub-id-type="pmid">27298346</pub-id></element-citation></ref><ref id="CR171"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plotegher</surname><given-names>N</given-names></name><name><surname>Berti</surname><given-names>G</given-names></name><name><surname>Ferrari</surname><given-names>E</given-names></name><name><surname>Tessari</surname><given-names>I</given-names></name><name><surname>Zanetti</surname><given-names>M</given-names></name><name><surname>Lunelli</surname><given-names>L</given-names></name><etal/></person-group><article-title>DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>40699</fpage><pub-id pub-id-type="doi">10.1038/srep40699</pub-id><pub-id pub-id-type="pmid">28084443</pub-id></element-citation></ref><ref id="CR172"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Limegrover</surname><given-names>CS</given-names></name><name><surname>Yurko</surname><given-names>R</given-names></name><name><surname>Izzo</surname><given-names>NJ</given-names></name><name><surname>LaBarbera</surname><given-names>KM</given-names></name><name><surname>Rehak</surname><given-names>C</given-names></name><name><surname>Look</surname><given-names>G</given-names></name><etal/></person-group><article-title>Sigma-2 receptor antagonists rescue neuronal dysfunction induced by Parkinson&#x02019;s patient brain-derived &#x003b1;-synuclein</article-title><source>J Neurosci Res</source><year>2021</year><volume>99</volume><issue>4</issue><fpage>1161</fpage><lpage>1176</lpage><pub-id pub-id-type="doi">10.1002/jnr.24782</pub-id><pub-id pub-id-type="pmid">33480104</pub-id></element-citation></ref><ref id="CR173"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gold</surname><given-names>WA</given-names></name><name><surname>Krishnarajy</surname><given-names>R</given-names></name><name><surname>Ellaway</surname><given-names>C</given-names></name><name><surname>Christodoulou</surname><given-names>J</given-names></name></person-group><article-title>Rett syndrome: a genetic update and clinical review focusing on comorbidities</article-title><source>ACS Chem Neurosci</source><year>2018</year><volume>9</volume><issue>2</issue><fpage>167</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1021/acschemneuro.7b00346</pub-id><pub-id pub-id-type="pmid">29185709</pub-id></element-citation></ref><ref id="CR174"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vidal</surname><given-names>S</given-names></name><name><surname>Xiol</surname><given-names>C</given-names></name><name><surname>Pascual-Alonso</surname><given-names>A</given-names></name><name><surname>O'Callaghan</surname><given-names>M</given-names></name><name><surname>Pineda</surname><given-names>M</given-names></name><name><surname>Armstrong</surname><given-names>J</given-names></name></person-group><article-title>Genetic landscape of Rett syndrome spectrum: improvements and challenges</article-title><source>Int J Mol Sci</source><year>2019</year><volume>20</volume><issue>16</issue><fpage>3925</fpage><pub-id pub-id-type="doi">10.3390/ijms20163925</pub-id><pub-id pub-id-type="pmid">31409060</pub-id></element-citation></ref><ref id="CR175"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chahrour</surname><given-names>M</given-names></name><name><surname>Jung</surname><given-names>SY</given-names></name><name><surname>Shaw</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Wong</surname><given-names>ST</given-names></name><name><surname>Qin</surname><given-names>J</given-names></name><etal/></person-group><article-title>MeCP2, a key contributor to neurological disease, activates and represses transcription</article-title><source>Science</source><year>2008</year><volume>320</volume><issue>5880</issue><fpage>1224</fpage><lpage>1229</lpage><pub-id pub-id-type="doi">10.1126/science.1153252</pub-id><pub-id pub-id-type="pmid">18511691</pub-id></element-citation></ref><ref id="CR176"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyst</surname><given-names>MJ</given-names></name><name><surname>Bird</surname><given-names>A</given-names></name></person-group><article-title>Rett syndrome: a complex disorder with simple roots</article-title><source>Nat Rev Genet</source><year>2015</year><volume>16</volume><issue>5</issue><fpage>261</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1038/nrg3897</pub-id><pub-id pub-id-type="pmid">25732612</pub-id></element-citation></ref><ref id="CR177"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kriaucionis</surname><given-names>S</given-names></name><name><surname>Paterson</surname><given-names>A</given-names></name><name><surname>Curtis</surname><given-names>J</given-names></name><name><surname>Guy</surname><given-names>J</given-names></name><name><surname>Macleod</surname><given-names>N</given-names></name><name><surname>Bird</surname><given-names>A</given-names></name></person-group><article-title>Gene expression analysis exposes mitochondrial abnormalities in a mouse model of Rett syndrome</article-title><source>Mol Cell Biol</source><year>2006</year><volume>26</volume><issue>13</issue><fpage>5033</fpage><lpage>5042</lpage><pub-id pub-id-type="doi">10.1128/mcb.01665-05</pub-id><pub-id pub-id-type="pmid">16782889</pub-id></element-citation></ref><ref id="CR178"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricciardi</surname><given-names>S</given-names></name><name><surname>Boggio</surname><given-names>EM</given-names></name><name><surname>Grosso</surname><given-names>S</given-names></name><name><surname>Lonetti</surname><given-names>G</given-names></name><name><surname>Forlani</surname><given-names>G</given-names></name><name><surname>Stefanelli</surname><given-names>G</given-names></name><etal/></person-group><article-title>Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model</article-title><source>Hum Mol Genet</source><year>2011</year><volume>20</volume><issue>6</issue><fpage>1182</fpage><lpage>1196</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddq563</pub-id><pub-id pub-id-type="pmid">21212100</pub-id></element-citation></ref><ref id="CR179"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmer</surname><given-names>A</given-names></name><name><surname>Qayumi</surname><given-names>J</given-names></name><name><surname>Ronnett</surname><given-names>G</given-names></name></person-group><article-title>MeCP2 mutation causes distinguishable phases of acute and chronic defects in synaptogenesis and maintenance, respectively</article-title><source>Mol Cell Neurosci</source><year>2008</year><volume>37</volume><issue>4</issue><fpage>794</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1016/j.mcn.2008.01.005</pub-id><pub-id pub-id-type="pmid">18295506</pub-id></element-citation></ref><ref id="CR180"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fonzo</surname><given-names>M</given-names></name><name><surname>Sirico</surname><given-names>F</given-names></name><name><surname>Corrado</surname><given-names>B</given-names></name></person-group><article-title>Evidence-based physical therapy for individuals with Rett syndrome: a systematic review</article-title><source>Brain Sci</source><year>2020</year><volume>10</volume><issue>7</issue><fpage>410</fpage><pub-id pub-id-type="doi">10.3390/brainsci10070410</pub-id><pub-id pub-id-type="pmid">32630125</pub-id></element-citation></ref><ref id="CR181"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehinger</surname><given-names>Y</given-names></name><name><surname>Matagne</surname><given-names>V</given-names></name><name><surname>Villard</surname><given-names>L</given-names></name><name><surname>Roux</surname><given-names>JC</given-names></name></person-group><article-title>Rett syndrome from bench to bedside: recent advances</article-title><source>F1000Res</source><year>2018</year><volume>7</volume><fpage>398</fpage><pub-id pub-id-type="doi">10.12688/f1000research.14056.1</pub-id><pub-id pub-id-type="pmid">29636907</pub-id></element-citation></ref><ref id="CR182"><label>182.</label><mixed-citation publication-type="other">Chahil G, Bollu PC. Rett Syndrome. In: Aboubakr S, Abu-Ghosh A, Acharya A, Adibi Sedeh P, Aeby T, Aeddula N, Et al. Editors. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2023. <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK482252/">https://www.ncbi.nlm.nih.gov/books/NBK482252/</ext-link>.</mixed-citation></ref><ref id="CR183"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohno</surname><given-names>K</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Ueda</surname><given-names>R</given-names></name><name><surname>Togawa</surname><given-names>M</given-names></name><name><surname>Ohmae</surname><given-names>T</given-names></name><name><surname>Matsuda</surname><given-names>E</given-names></name><etal/></person-group><article-title>Effect of serotonin 1A agonists and selective serotonin reuptake inhibitors on behavioral and nighttime respiratory symptoms in Rett syndrome</article-title><source>Pediatr Neurol</source><year>2016</year><volume>60</volume><fpage>54</fpage><lpage>9.e1</lpage><pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2016.03.016</pub-id><pub-id pub-id-type="pmid">27212420</pub-id></element-citation></ref><ref id="CR184"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neul</surname><given-names>JL</given-names></name><name><surname>Lane</surname><given-names>JB</given-names></name><name><surname>Lee</surname><given-names>H-S</given-names></name><name><surname>Geerts</surname><given-names>S</given-names></name><name><surname>Barrish</surname><given-names>JO</given-names></name><name><surname>Annese</surname><given-names>F</given-names></name><etal/></person-group><article-title>Developmental delay in Rett syndrome: data from the natural history study</article-title><source>J Neurodev Disord</source><year>2014</year><volume>6</volume><issue>1</issue><fpage>20</fpage><pub-id pub-id-type="doi">10.1186/1866-1955-6-20</pub-id><pub-id pub-id-type="pmid">25071871</pub-id></element-citation></ref><ref id="CR185"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luikenhuis</surname><given-names>S</given-names></name><name><surname>Giacometti</surname><given-names>E</given-names></name><name><surname>Beard</surname><given-names>CF</given-names></name><name><surname>Jaenisch</surname><given-names>R</given-names></name></person-group><article-title>Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice</article-title><source>Proc Natl Acad Sci USA</source><year>2004</year><volume>101</volume><issue>16</issue><fpage>6033</fpage><lpage>6038</lpage><pub-id pub-id-type="doi">10.1073/pnas.0401626101</pub-id><pub-id pub-id-type="pmid">15069197</pub-id></element-citation></ref><ref id="CR186"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>DR</given-names></name><name><surname>Matarazzo</surname><given-names>V</given-names></name><name><surname>Palmer</surname><given-names>AM</given-names></name><name><surname>Tu</surname><given-names>Y</given-names></name><name><surname>Jeon</surname><given-names>O-H</given-names></name><name><surname>Pevsner</surname><given-names>J</given-names></name><etal/></person-group><article-title>Expression of MeCP2 in olfactory receptor neurons is developmentally regulated and occurs before synaptogenesis</article-title><source>Mol Cell Neurosci</source><year>2003</year><volume>22</volume><issue>4</issue><fpage>417</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1016/s1044-7431(03)00026-5</pub-id><pub-id pub-id-type="pmid">12727440</pub-id></element-citation></ref><ref id="CR187"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>WG</given-names></name><name><surname>Chang</surname><given-names>Q</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Meissner</surname><given-names>A</given-names></name><name><surname>West</surname><given-names>AE</given-names></name><name><surname>Griffith</surname><given-names>EC</given-names></name><etal/></person-group><article-title>Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2</article-title><source>Science</source><year>2003</year><volume>302</volume><issue>5646</issue><fpage>885</fpage><lpage>889</lpage><pub-id pub-id-type="doi">10.1126/science.1086446</pub-id><pub-id pub-id-type="pmid">14593183</pub-id></element-citation></ref><ref id="CR188"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kikuchi-Utsumi</surname><given-names>K</given-names></name><name><surname>Nakaki</surname><given-names>T</given-names></name></person-group><article-title>Chronic treatment with a selective ligand for the sigma-1 receptor chaperone, SA4503, up-regulates BDNF protein levels in the rat hippocampus</article-title><source>Neurosci Lett</source><year>2008</year><volume>440</volume><issue>1</issue><fpage>19</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2008.05.055</pub-id><pub-id pub-id-type="pmid">18547721</pub-id></element-citation></ref><ref id="CR189"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mysona</surname><given-names>BA</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>S</given-names></name><name><surname>Bollinger</surname><given-names>KE</given-names></name></person-group><article-title>Relationship between Sigma-1 receptor and BDNF in the visual system</article-title><source>Exp Eye Res</source><year>2018</year><volume>167</volume><fpage>25</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.exer.2017.10.012</pub-id><pub-id pub-id-type="pmid">29031856</pub-id></element-citation></ref><ref id="CR190"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>K</given-names></name></person-group><article-title>Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression</article-title><source>Prog Neurobiol</source><year>2013</year><volume>100</volume><fpage>15</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.pneurobio.2012.09.001</pub-id><pub-id pub-id-type="pmid">23044468</pub-id></element-citation></ref><ref id="CR191"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakano</surname><given-names>M</given-names></name><name><surname>Osada</surname><given-names>K</given-names></name><name><surname>Misonoo</surname><given-names>A</given-names></name><name><surname>Fujiwara</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Ogawa</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Fluvoxamine and sigma-1 receptor agonists dehydroepiandrosterone (DHEA)-sulfate induces the Ser473-phosphorylation of Akt-1 in PC12 cells</article-title><source>Life Sci</source><year>2010</year><volume>86</volume><issue>9&#x02013;10</issue><fpage>309</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2009.11.017</pub-id><pub-id pub-id-type="pmid">19995565</pub-id></element-citation></ref><ref id="CR192"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christ</surname><given-names>MG</given-names></name><name><surname>Clement</surname><given-names>AM</given-names></name><name><surname>Behl</surname><given-names>C</given-names></name></person-group><article-title>The sigma-1 receptor at the crossroad of proteostasis, neurodegeneration, and autophagy</article-title><source>Trends Neurosci</source><year>2020</year><volume>43</volume><issue>2</issue><fpage>79</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2019.12.002</pub-id><pub-id pub-id-type="pmid">31918966</pub-id></element-citation></ref><ref id="CR193"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urano</surname><given-names>F</given-names></name></person-group><article-title>Wolfram syndrome: diagnosis, management, and treatment</article-title><source>Curr Diab Rep</source><year>2016</year><volume>16</volume><issue>1</issue><fpage>6</fpage><pub-id pub-id-type="doi">10.1007/s11892-015-0702-6</pub-id><pub-id pub-id-type="pmid">26742931</pub-id></element-citation></ref><ref id="CR194"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abreu</surname><given-names>D</given-names></name><name><surname>Urano</surname><given-names>F</given-names></name></person-group><article-title>Current landscape of treatments for Wolfram syndrome</article-title><source>Trends Pharmacol Sci</source><year>2019</year><volume>40</volume><issue>10</issue><fpage>711</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2019.07.011</pub-id><pub-id pub-id-type="pmid">31420094</pub-id></element-citation></ref><ref id="CR195"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delprat</surname><given-names>B</given-names></name><name><surname>Maurice</surname><given-names>T</given-names></name><name><surname>Delettre</surname><given-names>C</given-names></name></person-group><article-title>Wolfram syndrome: MAMs&#x02019; connection?</article-title><source>Cell Death Dis</source><year>2018</year><volume>9</volume><issue>3</issue><fpage>364</fpage><pub-id pub-id-type="doi">10.1038/s41419-018-0406-3</pub-id><pub-id pub-id-type="pmid">29511163</pub-id></element-citation></ref><ref id="CR196"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>T</given-names></name><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Hayashi</surname><given-names>E</given-names></name><name><surname>Su</surname><given-names>TP</given-names></name></person-group><article-title>Sigma-1 receptor chaperone at the ER-mitochondrion interface mediates the mitochondrion-ER-nucleus signaling for cellular survival</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><issue>10</issue><fpage>e76941</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0076941</pub-id><pub-id pub-id-type="pmid">24204710</pub-id></element-citation></ref><ref id="CR197"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crouzier</surname><given-names>L</given-names></name><name><surname>Danese</surname><given-names>A</given-names></name><name><surname>Yasui</surname><given-names>Y</given-names></name><name><surname>Richard</surname><given-names>EM</given-names></name><name><surname>Li&#x000e9;vens</surname><given-names>J-C</given-names></name><name><surname>Patergnani</surname><given-names>S</given-names></name><etal/></person-group><article-title>Activation of the sigma-1 receptor chaperone alleviates symptoms of Wolfram syndrome in preclinical models</article-title><source>Sci Transl Med.</source><year>2022</year><volume>14</volume><issue>631</issue><fpage>eabh3763</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.abh3763</pub-id><pub-id pub-id-type="pmid">35138910</pub-id></element-citation></ref><ref id="CR198"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kornhuber</surname><given-names>J</given-names></name><name><surname>Bormann</surname><given-names>J</given-names></name><name><surname>H&#x000fc;bers</surname><given-names>M</given-names></name><name><surname>Rusche</surname><given-names>K</given-names></name><name><surname>Riederer</surname><given-names>P</given-names></name></person-group><article-title>Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study</article-title><source>Eur J Pharmacol</source><year>1991</year><volume>206</volume><issue>4</issue><fpage>297</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1016/0922-4106(91)90113-v</pub-id><pub-id pub-id-type="pmid">1717296</pub-id></element-citation></ref><ref id="CR199"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanpied</surname><given-names>TA</given-names></name><name><surname>Clarke</surname><given-names>RJ</given-names></name><name><surname>Johnson</surname><given-names>JW</given-names></name></person-group><article-title>Amantadine inhibits NMDA receptors by accelerating channel closure during channel block</article-title><source>J Neurosci</source><year>2005</year><volume>25</volume><issue>13</issue><fpage>3312</fpage><lpage>3322</lpage><pub-id pub-id-type="doi">10.1523/jneurosci.4262-04.2005</pub-id><pub-id pub-id-type="pmid">15800186</pub-id></element-citation></ref><ref id="CR200"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peeters</surname><given-names>M</given-names></name><name><surname>Romieu</surname><given-names>P</given-names></name><name><surname>Maurice</surname><given-names>T</given-names></name><name><surname>Su</surname><given-names>TP</given-names></name><name><surname>Maloteaux</surname><given-names>JM</given-names></name><name><surname>Hermans</surname><given-names>E</given-names></name></person-group><article-title>Involvement of the sigma1 receptor in the modulation of dopaminergic transmission by amantadine</article-title><source>Eur J Neurosci</source><year>2004</year><volume>19</volume><issue>8</issue><fpage>2212</fpage><lpage>2220</lpage><pub-id pub-id-type="doi">10.1111/j.0953-816X.2004.03297.x</pub-id><pub-id pub-id-type="pmid">15090047</pub-id></element-citation></ref><ref id="CR201"><label>201.</label><mixed-citation publication-type="other">Abbas H. Expression of sigma receptors in human cancer cell lines and effects of novel sigma-2 ligands on their proliferation [Doctoral Thesis]. In. The University of Wolverhampton open repository. 2018. <ext-link ext-link-type="uri" xlink:href="http://hdl.handle.net/2436/621768">http://hdl.handle.net/2436/621768</ext-link><underline>.</underline> Accessed 1 Dec 2022.</mixed-citation></ref><ref id="CR202"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hubsher</surname><given-names>G</given-names></name><name><surname>Haider</surname><given-names>M</given-names></name><name><surname>Okun</surname><given-names>MS</given-names></name></person-group><article-title>Amantadine: the journey from fighting flu to treating Parkinson disease</article-title><source>Neurology</source><year>2012</year><volume>78</volume><issue>14</issue><fpage>1096</fpage><lpage>1099</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e31824e8f0d</pub-id><pub-id pub-id-type="pmid">22474298</pub-id></element-citation></ref><ref id="CR203"><label>203.</label><mixed-citation publication-type="other">Chang C, Ramphul K. Amantadine. In: Aboubakr S, Abu-Ghosh A, Acharya A, Adibi Sedeh P, Aeby T, Aeddula N, et al. Editors. StatPearls. Treasure Island (FL): StatPearls Publishing. 2023. <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK499953/">https://www.ncbi.nlm.nih.gov/books/NBK499953/</ext-link>.</mixed-citation></ref><ref id="CR204"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwab</surname><given-names>RS</given-names></name><name><surname>England</surname><given-names>AC</given-names></name><name><surname>Poskanzer</surname><given-names>DC</given-names></name><name><surname>Young</surname><given-names>RR</given-names></name></person-group><article-title>Amantadine in the treatment of Parkinson&#x02019;s disease</article-title><source>JAMA</source><year>1969</year><volume>208</volume><issue>7</issue><fpage>1168</fpage><lpage>1170</lpage><pub-id pub-id-type="doi">10.1001/jama.1969.03160070046011</pub-id><pub-id pub-id-type="pmid">5818715</pub-id></element-citation></ref><ref id="CR205"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rascol</surname><given-names>O</given-names></name><name><surname>Fabbri</surname><given-names>M</given-names></name><name><surname>Poewe</surname><given-names>W</given-names></name></person-group><article-title>Amantadine in the treatment of Parkinson&#x02019;s disease and other movement disorders</article-title><source>Lancet Neurol</source><year>2021</year><volume>20</volume><issue>12</issue><fpage>1048</fpage><lpage>1056</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(21)00249-0</pub-id><pub-id pub-id-type="pmid">34678171</pub-id></element-citation></ref><ref id="CR206"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kornhuber</surname><given-names>J</given-names></name><name><surname>Schoppmeyer</surname><given-names>K</given-names></name><name><surname>Riederer</surname><given-names>P</given-names></name></person-group><article-title>Affinity of 1-aminoadamantanes for the &#x003c3; binding site in post-mortem human frontal cortex</article-title><source>Neurosci Lett</source><year>1993</year><volume>163</volume><issue>2</issue><fpage>129</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/0304-3940(93)90362-O</pub-id><pub-id pub-id-type="pmid">8309617</pub-id></element-citation></ref><ref id="CR207"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crosby</surname><given-names>NJ</given-names></name><name><surname>Deane</surname><given-names>KH</given-names></name><name><surname>Clarke</surname><given-names>CE</given-names></name></person-group><article-title>Amantadine for dyskinesia in Parkinson&#x02019;s disease</article-title><source>Cochrane Database Syst Rev</source><year>2003</year><volume>2003</volume><issue>2</issue><fpage>CD003467</fpage><pub-id pub-id-type="doi">10.1002/14651858.Cd003467</pub-id><pub-id pub-id-type="pmid">12804468</pub-id></element-citation></ref><ref id="CR208"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aoki</surname><given-names>FY</given-names></name><name><surname>Sitar</surname><given-names>DS</given-names></name></person-group><article-title>Clinical pharmacokinetics of amantadine hydrochloride</article-title><source>Clin Pharmacokinet</source><year>1988</year><volume>14</volume><issue>1</issue><fpage>35</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.2165/00003088-198814010-00003</pub-id><pub-id pub-id-type="pmid">3280212</pub-id></element-citation></ref><ref id="CR209"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Salama</surname><given-names>ZT</given-names></name></person-group><article-title>Amantadine extended release capsules (GOCOVRI) in Parkinson&#x02019;s disease: a profile of its use in the USA</article-title><source>Drugs Ther Perspect.</source><year>2022</year><volume>38</volume><issue>5</issue><fpage>203</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1007/s40267-022-00912-y</pub-id></element-citation></ref><ref id="CR210"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauser</surname><given-names>RA</given-names></name><name><surname>Mehta</surname><given-names>SH</given-names></name><name><surname>Kremens</surname><given-names>D</given-names></name><etal/></person-group><article-title>Effects of Gocovri (amantadine) extended-release capsules on motor aspects of experiences of daily living in people with Parkinson&#x02019;s disease and dyskinesia</article-title><source>Neurol Ther.</source><year>2021</year><volume>10</volume><issue>2</issue><fpage>739</fpage><lpage>751</lpage><pub-id pub-id-type="doi">10.1007/s40120-021-00256-1</pub-id><pub-id pub-id-type="pmid">34024025</pub-id></element-citation></ref><ref id="CR211"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elmer</surname><given-names>LW</given-names></name><name><surname>Juncos</surname><given-names>JL</given-names></name><name><surname>Singer</surname><given-names>C</given-names></name><etal/></person-group><article-title>Pooled analyses of phase III studies of ADS-5102 (amantadine) extended-release capsules for dyskinesia in Parkinson&#x02019;s disease</article-title><source>CNS Drugs</source><year>2018</year><volume>32</volume><fpage>387</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1007/s40263-018-0498-4</pub-id><pub-id pub-id-type="pmid">29532440</pub-id></element-citation></ref><ref id="CR212"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isaacson</surname><given-names>SH</given-names></name><name><surname>Fahn</surname><given-names>S</given-names></name><name><surname>Pahwa</surname><given-names>R</given-names></name><etal/></person-group><article-title>Parkinson&#x02019;s patients with dyskinesia switched from immediate release amantadine to open-label ADS-5102</article-title><source>Mov Disord Clin Pract.</source><year>2018</year><volume>5</volume><fpage>183</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1002/mdc3.12595</pub-id><pub-id pub-id-type="pmid">29780852</pub-id></element-citation></ref><ref id="CR213"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oertel</surname><given-names>W</given-names></name><name><surname>Eggert</surname><given-names>K</given-names></name><name><surname>Pahwa</surname><given-names>R</given-names></name><name><surname>Tanner</surname><given-names>CM</given-names></name><name><surname>Hauser</surname><given-names>RA</given-names></name><name><surname>Trenkwalder</surname><given-names>C</given-names></name><etal/></person-group><article-title>Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson&#x02019;s disease (EASE LID 3)</article-title><source>Mov Disord</source><year>2017</year><volume>32</volume><issue>12</issue><fpage>1701</fpage><lpage>1709</lpage><pub-id pub-id-type="doi">10.1002/mds.27131</pub-id><pub-id pub-id-type="pmid">28833562</pub-id></element-citation></ref><ref id="CR214"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pahwa</surname><given-names>R</given-names></name><name><surname>Tanner</surname><given-names>CM</given-names></name><name><surname>Hauser</surname><given-names>RA</given-names></name><name><surname>Isaacson</surname><given-names>SH</given-names></name><name><surname>Nausieda</surname><given-names>PA</given-names></name><name><surname>Truong</surname><given-names>DD</given-names></name><etal/></person-group><article-title>ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID study): a randomized clinical trial</article-title><source>JAMA Neurol</source><year>2017</year><volume>74</volume><issue>8</issue><fpage>941</fpage><lpage>949</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2017.0943</pub-id><pub-id pub-id-type="pmid">28604926</pub-id></element-citation></ref><ref id="CR215"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanner</surname><given-names>CM</given-names></name><name><surname>Pahwa</surname><given-names>R</given-names></name><name><surname>Hauser</surname><given-names>RA</given-names></name><name><surname>Oertel</surname><given-names>WH</given-names></name><name><surname>Isaacson</surname><given-names>SH</given-names></name><name><surname>Jankovic</surname><given-names>J</given-names></name><etal/></person-group><article-title>EASE LID 2: a 2-year open-label trial of gocovri (amantadine) extended release for dyskinesia in Parkinson&#x02019;s disease</article-title><source>J Parkinsons Dis</source><year>2020</year><volume>10</volume><issue>2</issue><fpage>543</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.3233/JPD-191841</pub-id><pub-id pub-id-type="pmid">31929122</pub-id></element-citation></ref><ref id="CR216"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>GA</given-names></name><name><surname>Appenzeller</surname><given-names>O</given-names></name></person-group><article-title>Amantadine, fatigue, and multiple sclerosis</article-title><source>Arch Neurol</source><year>1988</year><volume>45</volume><issue>10</issue><fpage>1104</fpage><lpage>1106</lpage><pub-id pub-id-type="doi">10.1001/archneur.1988.00520340058012</pub-id><pub-id pub-id-type="pmid">2972270</pub-id></element-citation></ref><ref id="CR217"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaygannejad</surname><given-names>V</given-names></name><name><surname>Janghorbani</surname><given-names>M</given-names></name><name><surname>Ashtari</surname><given-names>F</given-names></name><name><surname>Zakeri</surname><given-names>H</given-names></name></person-group><article-title>Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study</article-title><source>Neurol Res</source><year>2012</year><volume>34</volume><issue>9</issue><fpage>854</fpage><lpage>858</lpage><pub-id pub-id-type="doi">10.1179/1743132812Y.0000000081</pub-id><pub-id pub-id-type="pmid">22979982</pub-id></element-citation></ref><ref id="CR218"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ledinek</surname><given-names>AH</given-names></name><name><surname>Sajko</surname><given-names>MC</given-names></name><name><surname>Rot</surname><given-names>U</given-names></name></person-group><article-title>Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis&#x02013;result of a pilot randomized, blind study</article-title><source>Clin Neurol Neurosurg</source><year>2013</year><volume>115</volume><fpage>S86</fpage><lpage>S89</lpage><pub-id pub-id-type="doi">10.1016/j.clineuro.2013.09.029</pub-id><pub-id pub-id-type="pmid">24321164</pub-id></element-citation></ref><ref id="CR219"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khazaei</surname><given-names>M</given-names></name><name><surname>Karevan</surname><given-names>A</given-names></name><name><surname>Taheri</surname><given-names>M</given-names></name><name><surname>Ghafouri-Fard</surname><given-names>S</given-names></name></person-group><article-title>Comparison of the effects of amantadine and ondansetron in treatment of fatigue in patients with multiple sclerosis</article-title><source>Clin Transl Med</source><year>2019</year><volume>8</volume><issue>1</issue><fpage>20</fpage><pub-id pub-id-type="doi">10.1186/s40169-019-0239-4</pub-id><pub-id pub-id-type="pmid">31263986</pub-id></element-citation></ref><ref id="CR220"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puca</surname><given-names>F</given-names></name><name><surname>Bricolo</surname><given-names>A</given-names></name><name><surname>Turella</surname><given-names>G</given-names></name></person-group><article-title>Effect of L-dopa or amantadine therapy on sleep spindles in Parkinsonism</article-title><source>Electroencephalogr Clin Neurophysiol</source><year>1973</year><volume>35</volume><issue>3</issue><fpage>327</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1016/0013-4694(73)90245-9</pub-id><pub-id pub-id-type="pmid">4126184</pub-id></element-citation></ref><ref id="CR221"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nourbakhsh</surname><given-names>B</given-names></name><name><surname>Revirajan</surname><given-names>N</given-names></name><name><surname>Morris</surname><given-names>B</given-names></name><name><surname>Cordano</surname><given-names>C</given-names></name><name><surname>Creasman</surname><given-names>J</given-names></name><name><surname>Manguinao</surname><given-names>M</given-names></name><etal/></person-group><article-title>Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial</article-title><source>Lancet Neurol</source><year>2021</year><volume>20</volume><issue>1</issue><fpage>38</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/s1474-4422(20)30354-9</pub-id><pub-id pub-id-type="pmid">33242419</pub-id></element-citation></ref><ref id="CR222"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villard</surname><given-names>V</given-names></name><name><surname>Espallergues</surname><given-names>J</given-names></name><name><surname>Keller</surname><given-names>E</given-names></name><name><surname>Vamvakides</surname><given-names>A</given-names></name><name><surname>Maurice</surname><given-names>T</given-names></name></person-group><article-title>Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma1 (&#x003c3;1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative</article-title><source>J Psychopharmacol</source><year>2011</year><volume>25</volume><issue>8</issue><fpage>1101</fpage><lpage>1117</lpage><pub-id pub-id-type="doi">10.1177/0269881110379286</pub-id><pub-id pub-id-type="pmid">20829307</pub-id></element-citation></ref><ref id="CR223"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lahmy</surname><given-names>V</given-names></name><name><surname>Meunier</surname><given-names>J</given-names></name><name><surname>Malmstr&#x000f6;m</surname><given-names>S</given-names></name><name><surname>Naert</surname><given-names>G</given-names></name><name><surname>Givalois</surname><given-names>L</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Blockade of Tau hyperphosphorylation and A&#x003b2; 1&#x02013;42 generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and &#x003c3; 1 receptor agonist, in a nontransgenic mouse model of Alzheimer&#x02019;s disease</article-title><source>Neuropsychopharmacology</source><year>2013</year><volume>38</volume><issue>9</issue><fpage>1706</fpage><pub-id pub-id-type="doi">10.1038/npp.2013.70</pub-id><pub-id pub-id-type="pmid">23493042</pub-id></element-citation></ref><ref id="CR224"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lahmy</surname><given-names>V</given-names></name><name><surname>Long</surname><given-names>R</given-names></name><name><surname>Morin</surname><given-names>D</given-names></name><name><surname>Villard</surname><given-names>V</given-names></name><name><surname>Maurice</surname><given-names>T</given-names></name></person-group><article-title>Mitochondrial protection by the mixed muscarinic/&#x003c3;1 ligand ANAVEX2-73, a tetrahydrofuran derivative, in A&#x003b2;25&#x02013;35 peptide-injected mice, a nontransgenic Alzheimer&#x02019;s disease model</article-title><source>Front Cell Neurosci</source><year>2015</year><volume>8</volume><fpage>463</fpage><pub-id pub-id-type="doi">10.3389/fncel.2014.00463</pub-id><pub-id pub-id-type="pmid">25653589</pub-id></element-citation></ref><ref id="CR225"><label>225.</label><mixed-citation publication-type="other">Voges O, Weigmann I, Bitterlich N, Missling C, Schindler C. A Phase I dose escalation study to investigate safety, tolerability, and pharmacokinetics of ANAVEX 2&#x02010;73 in Healthy Male Subjects. Innov Clin Neurosci. 2014;12(Suppl B), 1-20; CNS Summit 2014, Boca Raton, Florida.</mixed-citation></ref><ref id="CR226"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Williams</surname><given-names>C</given-names></name><name><surname>Etcheto</surname><given-names>A</given-names></name><name><surname>Goodsaid</surname><given-names>F</given-names></name><name><surname>Parmentier</surname><given-names>F</given-names></name><name><surname>Sallantin</surname><given-names>J</given-names></name><etal/></person-group><article-title>A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study</article-title><source>Alzheimers Dement</source><year>2020</year><volume>6</volume><issue>1</issue><fpage>e12013</fpage><pub-id pub-id-type="doi">10.1002/trc2.12013</pub-id></element-citation></ref><ref id="CR227"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lisak</surname><given-names>RP</given-names></name><name><surname>Nedelkoska</surname><given-names>L</given-names></name><name><surname>Benjamins</surname><given-names>JA</given-names></name></person-group><article-title>Sigma-1 receptor agonists as potential protective therapies in multiple sclerosis</article-title><source>J Neuroimmunol</source><year>2020</year><volume>342</volume><fpage>577188</fpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2020.577188</pub-id><pub-id pub-id-type="pmid">32179326</pub-id></element-citation></ref><ref id="CR228"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufmann</surname><given-names>WE</given-names></name><name><surname>Sprouse</surname><given-names>J</given-names></name><name><surname>Rebowe</surname><given-names>N</given-names></name><name><surname>Hanania</surname><given-names>T</given-names></name><name><surname>Klamer</surname><given-names>D</given-names></name><name><surname>Missling</surname><given-names>CU</given-names></name></person-group><article-title>ANAVEX 2&#x02013;73 (blarcamesine), a Sigma-1 receptor agonist, ameliorates neurologic impairments in a mouse model of Rett syndrome</article-title><source>Pharmacol Biochem Behav</source><year>2019</year><volume>187</volume><fpage>172796</fpage><pub-id pub-id-type="doi">10.1016/j.pbb.2019.172796</pub-id><pub-id pub-id-type="pmid">31704481</pub-id></element-citation></ref><ref id="CR229"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reyes</surname><given-names>ST</given-names></name><name><surname>Deacon</surname><given-names>RM</given-names></name><name><surname>Guo</surname><given-names>SG</given-names></name><name><surname>Altimiras</surname><given-names>FJ</given-names></name><name><surname>Castillo</surname><given-names>JB</given-names></name><name><surname>van der Wildt</surname><given-names>B</given-names></name><etal/></person-group><article-title>Effects of the sigma-1 receptor agonist blarcamesine in a murine model of fragile X syndrome: neurobehavioral phenotypes and receptor occupancy</article-title><source>Sci Rep</source><year>2021</year><volume>11</volume><issue>1</issue><fpage>17150</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-94079-7</pub-id><pub-id pub-id-type="pmid">34433831</pub-id></element-citation></ref><ref id="CR230"><label>230.</label><mixed-citation publication-type="other">Anavex-Life-Sciences-Corp. ANAVEX2-73 (Blarcamesine) AVATAR phase 3 trial met primary and secondary efficacy endpoints. In: Anavex press release. 2022. <ext-link ext-link-type="uri" xlink:href="https://www.anavex.com/post/anavex-2-73-blarcamesine-avatar-phase-3-trial-met-primary-and-secondary-efficacy-endpoints">https://www.anavex.com/post/anavex-2-73-blarcamesine-avatar-phase-3-trial-met-primary-and-secondary-efficacy-endpoints</ext-link>. Accessed 1 Nov 2022.</mixed-citation></ref><ref id="CR231"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>H</given-names></name><name><surname>Iulita</surname><given-names>MF</given-names></name><name><surname>Gubert</surname><given-names>P</given-names></name><name><surname>Flores Aguilar</surname><given-names>L</given-names></name><name><surname>Ducatenzeiler</surname><given-names>A</given-names></name><name><surname>Fisher</surname><given-names>A</given-names></name><etal/></person-group><article-title>AF710B, an M1/sigma-1 receptor agonist with long-lasting disease-modifying properties in a transgenic rat model of Alzheimer&#x02019;s disease</article-title><source>Alzheimers Dement</source><year>2018</year><volume>14</volume><issue>6</issue><fpage>811</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2017.11.009</pub-id><pub-id pub-id-type="pmid">29291374</pub-id></element-citation></ref><ref id="CR232"><label>232.</label><mixed-citation publication-type="other">Anavex-life-Sciences-Corp. Anavex Life Sciences reports positive results from phase 1 clinical trial of ANAVEX3-71. In: Anavex press release. 2022. <ext-link ext-link-type="uri" xlink:href="https://www.anavex.com/post/anavex-life-sciences-reports-positive-results-from-phase-1-clinical-trial-of-anavex-3-71">https://www.anavex.com/post/anavex-life-sciences-reports-positive-results-from-phase-1-clinical-trial-of-anavex-3-71</ext-link>. Accessed 1 Nov 2022.</mixed-citation></ref><ref id="CR233"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rishton</surname><given-names>GM</given-names></name><name><surname>Look</surname><given-names>GC</given-names></name><name><surname>Ni</surname><given-names>ZJ</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Discovery of investigational drug CT1812, an antagonist of the Sigma-2 receptor complex for Alzheimer&#x02019;s disease</article-title><source>ACS Med Chem Lett</source><year>2021</year><volume>12</volume><issue>9</issue><fpage>1389</fpage><lpage>1395</lpage><pub-id pub-id-type="doi">10.1021/acsmedchemlett.1c00048</pub-id><pub-id pub-id-type="pmid">34531947</pub-id></element-citation></ref><ref id="CR234"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Izzo</surname><given-names>NJ</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Zeng</surname><given-names>C</given-names></name><name><surname>Kirk</surname><given-names>MJ</given-names></name><name><surname>Mozzoni</surname><given-names>K</given-names></name><name><surname>Silky</surname><given-names>C</given-names></name><etal/></person-group><article-title>Alzheimer's therapeutics targeting amyloid beta 1&#x02013;42 oligomers II: sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><issue>11</issue><fpage>e111899</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0111899</pub-id><pub-id pub-id-type="pmid">25390692</pub-id></element-citation></ref><ref id="CR235"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Izzo</surname><given-names>NJ</given-names></name><name><surname>Yuede</surname><given-names>CM</given-names></name><name><surname>LaBarbera</surname><given-names>KM</given-names></name><name><surname>Limegrover</surname><given-names>CS</given-names></name><name><surname>Rehak</surname><given-names>C</given-names></name><name><surname>Yurko</surname><given-names>R</given-names></name><etal/></person-group><article-title>Preclinical and clinical biomarker studies of CT1812: a novel approach to Alzheimer's disease modification</article-title><source>Alzheimers Dement</source><year>2021</year><volume>17</volume><issue>8</issue><fpage>1365</fpage><lpage>1382</lpage><pub-id pub-id-type="doi">10.1371/journal.pone.0111899</pub-id><pub-id pub-id-type="pmid">33559354</pub-id></element-citation></ref><ref id="CR236"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harper</surname><given-names>AR</given-names></name><name><surname>Nayee</surname><given-names>S</given-names></name><name><surname>Topol</surname><given-names>EJ</given-names></name></person-group><article-title>Protective alleles and modifier variants in human health and disease</article-title><source>Nat Rev Genet</source><year>2015</year><volume>16</volume><issue>12</issue><fpage>689</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1038/nrg4017</pub-id><pub-id pub-id-type="pmid">26503796</pub-id></element-citation></ref><ref id="CR237"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grundman</surname><given-names>M</given-names></name><name><surname>Morgan</surname><given-names>R</given-names></name><name><surname>Lickliter</surname><given-names>JD</given-names></name><name><surname>Schneider</surname><given-names>LS</given-names></name><name><surname>DeKosky</surname><given-names>S</given-names></name><name><surname>Izzo</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer&#x02019;s disease</article-title><source>Alzheimers Dement</source><year>2019</year><volume>5</volume><fpage>20</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.trci.2018.11.001</pub-id></element-citation></ref><ref id="CR238"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catalano</surname><given-names>S</given-names></name><name><surname>Grundman</surname><given-names>M</given-names></name><name><surname>Schneider</surname><given-names>LS</given-names></name><name><surname>DeKosky</surname><given-names>S</given-names></name><name><surname>Morgan</surname><given-names>R</given-names></name><name><surname>Guttendorf</surname><given-names>R</given-names></name><etal/></person-group><article-title>[P4&#x02013;567]: a phase 1 safety trial of the A&#x003b2; oligomer receptor antagonist CT1812</article-title><source>Alzheimers Dement</source><year>2017</year><volume>13</volume><issue>7S</issue><fpage>P1523</fpage><lpage>P1580</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2017.07.730</pub-id></element-citation></ref><ref id="CR239"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>AR</given-names></name><name><surname>Pizon</surname><given-names>AF</given-names></name><name><surname>Brooks</surname><given-names>DE</given-names></name></person-group><article-title>Dextromethorphan-induced serotonin syndrome</article-title><source>Clin Toxicol</source><year>2008</year><volume>46</volume><issue>8</issue><fpage>771</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1080/15563650701668625</pub-id></element-citation></ref><ref id="CR240"><label>240.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>EJ</given-names></name><name><surname>Nah</surname><given-names>SY</given-names></name><name><surname>Chae</surname><given-names>JS</given-names></name><name><surname>Bing</surname><given-names>G</given-names></name><name><surname>Shin</surname><given-names>SW</given-names></name><name><surname>Yen</surname><given-names>TP</given-names></name><etal/></person-group><article-title>Dextromethorphan attenuates trimethyltin-induced neurotoxicity via sigma1 receptor activation in rats</article-title><source>Neurochem Int</source><year>2007</year><volume>50</volume><issue>6</issue><fpage>791</fpage><lpage>799</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2007.01.008</pub-id><pub-id pub-id-type="pmid">17386960</pub-id></element-citation></ref><ref id="CR241"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>L</given-names></name><name><surname>Thomas</surname><given-names>KL</given-names></name><name><surname>Lucke-Wold</surname><given-names>BP</given-names></name><name><surname>Cavendish</surname><given-names>JZ</given-names></name><name><surname>Crowe</surname><given-names>MS</given-names></name><name><surname>Matsumoto</surname><given-names>RR</given-names></name></person-group><article-title>Dextromethorphan: an update on its utility for neurological and neuropsychiatric disorders</article-title><source>Pharmacol Ther</source><year>2016</year><volume>159</volume><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2016.01.016</pub-id><pub-id pub-id-type="pmid">26826604</pub-id></element-citation></ref><ref id="CR242"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauv&#x000e9;</surname><given-names>WM</given-names></name></person-group><article-title>Recognizing and treating pseudobulbar affect</article-title><source>CNS Spectr</source><year>2016</year><volume>21</volume><issue>S1</issue><fpage>34</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1017/S1092852916000791</pub-id><pub-id pub-id-type="pmid">28044945</pub-id></element-citation></ref><ref id="CR243"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garnock-Jones</surname><given-names>KP</given-names></name></person-group><article-title>Dextromethorphan/quinidine</article-title><source>CNS Drugs</source><year>2011</year><volume>25</volume><issue>5</issue><fpage>435</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.2165/11207260-000000000-00000</pub-id><pub-id pub-id-type="pmid">21476614</pub-id></element-citation></ref><ref id="CR244"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cummings</surname><given-names>JL</given-names></name><name><surname>Lyketsos</surname><given-names>CG</given-names></name><name><surname>Peskind</surname><given-names>ER</given-names></name><name><surname>Porsteinsson</surname><given-names>AP</given-names></name><name><surname>Mintzer</surname><given-names>JE</given-names></name><name><surname>Scharre</surname><given-names>DW</given-names></name><etal/></person-group><article-title>Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial</article-title><source>JAMA</source><year>2015</year><volume>314</volume><issue>12</issue><fpage>1242</fpage><lpage>1254</lpage><pub-id pub-id-type="doi">10.1001/jama.2015.10214</pub-id><pub-id pub-id-type="pmid">26393847</pub-id></element-citation></ref><ref id="CR245"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senanarong</surname><given-names>V</given-names></name><name><surname>Cummings</surname><given-names>J</given-names></name><name><surname>Fairbanks</surname><given-names>L</given-names></name><name><surname>Mega</surname><given-names>M</given-names></name><name><surname>Masterman</surname><given-names>D</given-names></name><name><surname>O&#x02019;connor</surname><given-names>S</given-names></name><etal/></person-group><article-title>Agitation in Alzheimer&#x02019;s disease is a manifestation of frontal lobe dysfunction</article-title><source>Dement Geriatr Cogn Disord</source><year>2004</year><volume>17</volume><issue>1&#x02013;2</issue><fpage>14</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1159/000074080</pub-id><pub-id pub-id-type="pmid">14560060</pub-id></element-citation></ref><ref id="CR246"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Gorman</surname><given-names>C</given-names></name><name><surname>Jones</surname><given-names>A</given-names></name><name><surname>Cummings</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Efficacy and safety of AXS&#x02010;05, a novel, oral, NMDA&#x02010;receptor antagonist with multimodal activity, in agitation associated with Alzheimer&#x02019;s disease: results from ADVANCE&#x02010;1, a phase 2/3, double&#x02010;blind, active and placebo&#x02010;controlled trial: developments in clinical trials and cognitive assessment</article-title><source>Alzheimer Dement</source><year>2020</year><volume>16</volume><fpage>e047684</fpage><pub-id pub-id-type="doi">10.1002/alz.047684</pub-id></element-citation></ref><ref id="CR247"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>Y-C</given-names></name><name><surname>Liao</surname><given-names>J-F</given-names></name><name><surname>Chang</surname><given-names>W-Y</given-names></name><name><surname>Lin</surname><given-names>M-F</given-names></name><name><surname>Chen</surname><given-names>C-F</given-names></name></person-group><article-title>Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan</article-title><source>Brain Res</source><year>1999</year><volume>821</volume><issue>2</issue><fpage>516</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1016/s0006-8993(99)01125-7</pub-id><pub-id pub-id-type="pmid">10064839</pub-id></element-citation></ref><ref id="CR248"><label>248.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verhagen Metman</surname><given-names>L</given-names></name><name><surname>Del Dotto</surname><given-names>P</given-names></name><name><surname>Natt&#x000e9;</surname><given-names>R</given-names></name><name><surname>van den Munckhof</surname><given-names>P</given-names></name><name><surname>Chase</surname><given-names>TN</given-names></name></person-group><article-title>Dextromethorphan improves levodopa-induced dyskinesias in Parkinson&#x02019;s disease</article-title><source>Neurology</source><year>1998</year><volume>51</volume><issue>1</issue><fpage>203</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1212/wnl.51.1.203</pub-id><pub-id pub-id-type="pmid">9674803</pub-id></element-citation></ref><ref id="CR249"><label>249.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Starr</surname><given-names>MS</given-names></name><name><surname>Starr</surname><given-names>BS</given-names></name><name><surname>Kaur</surname><given-names>S</given-names></name></person-group><article-title>Stimulation of basal and L-DOPA-induced motor activity by glutamate antagonists in animal models of Parkinson&#x02019;s disease</article-title><source>Neurosci Biobehav Rev</source><year>1997</year><volume>21</volume><issue>4</issue><fpage>437</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1016/s0149-7634(96)00039-5</pub-id><pub-id pub-id-type="pmid">9195601</pub-id></element-citation></ref><ref id="CR250"><label>250.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paquette</surname><given-names>MA</given-names></name><name><surname>Brudney</surname><given-names>EG</given-names></name><name><surname>Putterman</surname><given-names>DB</given-names></name><name><surname>Meshul</surname><given-names>CK</given-names></name><name><surname>Johnson</surname><given-names>SW</given-names></name><name><surname>Berger</surname><given-names>SP</given-names></name></person-group><article-title>Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias</article-title><source>NeuroReport</source><year>2008</year><volume>19</volume><issue>1</issue><fpage>111</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1097/WNR.0b013e3282f3b0d1</pub-id><pub-id pub-id-type="pmid">18281903</pub-id></element-citation></ref><ref id="CR251"><label>251.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C-T</given-names></name><name><surname>Kao</surname><given-names>L-T</given-names></name><name><surname>Shih</surname><given-names>J-H</given-names></name><name><surname>Chien</surname><given-names>W-C</given-names></name><name><surname>Chiu</surname><given-names>C-H</given-names></name><name><surname>Ma</surname><given-names>K-H</given-names></name><etal/></person-group><article-title>The effect of dextromethorphan use in Parkinson&#x02019;s disease: a 6-hydroxydopamine rat model and population-based study</article-title><source>Eur J Pharmacol</source><year>2019</year><volume>862</volume><fpage>172639</fpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2019.172639</pub-id><pub-id pub-id-type="pmid">31491406</pub-id></element-citation></ref><ref id="CR252"><label>252.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>SH</given-names></name><name><surname>Metman</surname><given-names>LV</given-names></name><name><surname>Nutt</surname><given-names>JG</given-names></name><name><surname>Brodsky</surname><given-names>M</given-names></name><name><surname>Factor</surname><given-names>SA</given-names></name><name><surname>Lang</surname><given-names>AE</given-names></name><etal/></person-group><article-title>Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson&#x02019;s disease</article-title><source>Mov Disord</source><year>2017</year><volume>32</volume><issue>6</issue><fpage>893</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1002/mds.26976</pub-id><pub-id pub-id-type="pmid">28370447</pub-id></element-citation></ref><ref id="CR253"><label>253.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verhagen Metman</surname><given-names>L</given-names></name><name><surname>Blanchet</surname><given-names>PJ</given-names></name><name><surname>van den Munckhof</surname><given-names>P</given-names></name><name><surname>Del Dotto</surname><given-names>P</given-names></name><name><surname>Natt&#x000e9;</surname><given-names>R</given-names></name><name><surname>Chase</surname><given-names>TN</given-names></name></person-group><article-title>A trial of dextromethorphan in parkinsonian patients with motor response complications</article-title><source>Mov Disord</source><year>1998</year><volume>13</volume><issue>3</issue><fpage>414</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1002/mds.870130307</pub-id><pub-id pub-id-type="pmid">9613730</pub-id></element-citation></ref><ref id="CR254"><label>254.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilhelm</surname><given-names>R</given-names></name><name><surname>Ahl</surname><given-names>B</given-names></name><name><surname>Anghelescu</surname><given-names>I-G</given-names></name></person-group><article-title>Dextrometorphan-paroxetine, but not dronabinol, effective for treatment-resistant aggression and agitation in an elderly patient with Lewy body dementia</article-title><source>J Clin Psychopharmacol</source><year>2017</year><volume>37</volume><issue>6</issue><fpage>745</fpage><lpage>747</lpage><pub-id pub-id-type="doi">10.1097/jcp.0000000000000805</pub-id><pub-id pub-id-type="pmid">29035934</pub-id></element-citation></ref><ref id="CR255"><label>255.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Logan</surname><given-names>BK</given-names></name><name><surname>Yeakel</surname><given-names>JK</given-names></name><name><surname>Goldfogel</surname><given-names>G</given-names></name><name><surname>Frost</surname><given-names>MP</given-names></name><name><surname>Sandstrom</surname><given-names>G</given-names></name><name><surname>Wickham</surname><given-names>DJ</given-names></name></person-group><article-title>Dextromethorphan abuse leading to assault, suicide, or homicide</article-title><source>J Forensic Sci</source><year>2012</year><volume>57</volume><issue>5</issue><fpage>1388</fpage><lpage>1394</lpage><pub-id pub-id-type="doi">10.1111/j.1556-4029.2012.02133.x</pub-id><pub-id pub-id-type="pmid">22537430</pub-id></element-citation></ref><ref id="CR256"><label>256.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>R</given-names></name><name><surname>Pioro</surname><given-names>E</given-names></name><name><surname>Myers</surname><given-names>K</given-names></name><name><surname>Sirdofsky</surname><given-names>M</given-names></name><name><surname>Goslin</surname><given-names>K</given-names></name><name><surname>Meekins</surname><given-names>G</given-names></name><etal/></person-group><article-title>Enhanced bulbar function in amyotrophic lateral sclerosis: the Nuedexta treatment trial</article-title><source>Neurotherapeutics</source><year>2017</year><volume>14</volume><issue>3</issue><fpage>762</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.1007/s13311-016-0508-5</pub-id><pub-id pub-id-type="pmid">28070747</pub-id></element-citation></ref><ref id="CR257"><label>257.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>JR</given-names></name><name><surname>Allison</surname><given-names>KM</given-names></name><name><surname>Cordella</surname><given-names>C</given-names></name><name><surname>Richburg</surname><given-names>BD</given-names></name><name><surname>Pattee</surname><given-names>GL</given-names></name><name><surname>Berry</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Additional evidence for a therapeutic effect of dextromethorphan/quinidine on bulbar motor function in patients with amyotrophic lateral sclerosis: a quantitative speech analysis</article-title><source>Br J Clin Pharmacol</source><year>2018</year><volume>84</volume><issue>12</issue><fpage>2849</fpage><lpage>2856</lpage><pub-id pub-id-type="doi">10.1111/bcp.13745</pub-id><pub-id pub-id-type="pmid">30152872</pub-id></element-citation></ref><ref id="CR258"><label>258.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sancho</surname><given-names>J</given-names></name><name><surname>Ferrer</surname><given-names>S</given-names></name><name><surname>Bur&#x000e9;s</surname><given-names>E</given-names></name><name><surname>D&#x000ed;az</surname><given-names>JL</given-names></name><name><surname>Torrecilla</surname><given-names>T</given-names></name><name><surname>Signes-Costa</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effect of one-year dextromethorphan/quinidine treatment on management of respiratory impairment in amyotrophic lateral sclerosis</article-title><source>Respir Med</source><year>2021</year><volume>186</volume><fpage>106536</fpage><pub-id pub-id-type="doi">10.1016/j.rmed.2021.106536</pub-id><pub-id pub-id-type="pmid">34260979</pub-id></element-citation></ref><ref id="CR259"><label>259.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chechneva</surname><given-names>OV</given-names></name><name><surname>Mayrhofer</surname><given-names>F</given-names></name><name><surname>Daugherty</surname><given-names>DJ</given-names></name><name><surname>Pleasure</surname><given-names>DE</given-names></name><name><surname>Hong</surname><given-names>J-S</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name></person-group><article-title>Low dose dextromethorphan attenuates moderate experimental autoimmune encephalomyelitis by inhibiting NOX2 and reducing peripheral immune cells infiltration in the spinal cord</article-title><source>Neurobiol Dis</source><year>2011</year><volume>44</volume><issue>1</issue><fpage>63</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2011.06.004</pub-id><pub-id pub-id-type="pmid">21704706</pub-id></element-citation></ref><ref id="CR260"><label>260.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lisak</surname><given-names>RP</given-names></name><name><surname>Nedelkoska</surname><given-names>L</given-names></name><name><surname>Benjamins</surname><given-names>JA</given-names></name></person-group><article-title>Effects of dextromethorphan on glial cell function: proliferation, maturation, and protection from cytotoxic molecules</article-title><source>Glia</source><year>2014</year><volume>62</volume><issue>5</issue><fpage>751</fpage><lpage>762</lpage><pub-id pub-id-type="doi">10.1002/glia.22639</pub-id><pub-id pub-id-type="pmid">24526455</pub-id></element-citation></ref><ref id="CR261"><label>261.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pioro</surname><given-names>EP</given-names></name><name><surname>Brooks</surname><given-names>BR</given-names></name><name><surname>Cummings</surname><given-names>J</given-names></name><name><surname>Schiffer</surname><given-names>R</given-names></name><name><surname>Thisted</surname><given-names>RA</given-names></name><name><surname>Wynn</surname><given-names>D</given-names></name><etal/></person-group><article-title>Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect</article-title><source>Ann Neurol</source><year>2010</year><volume>68</volume><issue>5</issue><fpage>693</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1002/ana.22093</pub-id><pub-id pub-id-type="pmid">20839238</pub-id></element-citation></ref><ref id="CR262"><label>262.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGrane</surname><given-names>I</given-names></name><name><surname>VandenBerg</surname><given-names>A</given-names></name><name><surname>Munjal</surname><given-names>R</given-names></name></person-group><article-title>Treatment of pseudobulbar affect with fluoxetine and dextromethorphan in a woman with multiple sclerosis</article-title><source>Ann Pharmacother</source><year>2017</year><volume>51</volume><issue>11</issue><fpage>1035</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.1177/1060028017720746</pub-id><pub-id pub-id-type="pmid">28691510</pub-id></element-citation></ref><ref id="CR263"><label>263.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehde</surname><given-names>DM</given-names></name><name><surname>Osborne</surname><given-names>TL</given-names></name><name><surname>Jensen</surname><given-names>MP</given-names></name></person-group><article-title>Chronic pain in persons with multiple sclerosis</article-title><source>Phys Med Rehabil Clin N Am</source><year>2005</year><volume>16</volume><issue>2</issue><fpage>503</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1016/j.pmr.2005.01.001</pub-id><pub-id pub-id-type="pmid">15893684</pub-id></element-citation></ref><ref id="CR264"><label>264.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merlos</surname><given-names>M</given-names></name><name><surname>Romero</surname><given-names>L</given-names></name><name><surname>Zamanillo</surname><given-names>D</given-names></name><name><surname>Plata-Salam&#x000e1;n</surname><given-names>C</given-names></name><name><surname>Vela</surname><given-names>JM</given-names></name></person-group><article-title>Sigma-1 receptor and pain</article-title><source>Handb Exp Pharmacol</source><year>2017</year><volume>244</volume><fpage>131</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1007/164_2017_9</pub-id><pub-id pub-id-type="pmid">28275913</pub-id></element-citation></ref><ref id="CR265"><label>265.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panitch</surname><given-names>HS</given-names></name><name><surname>Thisted</surname><given-names>RA</given-names></name><name><surname>Smith</surname><given-names>RA</given-names></name><name><surname>Wynn</surname><given-names>DR</given-names></name><name><surname>Wymer</surname><given-names>JP</given-names></name><name><surname>Achiron</surname><given-names>A</given-names></name><etal/></person-group><article-title>Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis</article-title><source>Ann Neurol</source><year>2006</year><volume>59</volume><issue>5</issue><fpage>780</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1002/ana.20828</pub-id><pub-id pub-id-type="pmid">16634036</pub-id></element-citation></ref><ref id="CR266"><label>266.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>KA</given-names></name><name><surname>Park</surname><given-names>KM</given-names></name><name><surname>Robinovitz</surname><given-names>E</given-names></name><name><surname>Tsigos</surname><given-names>C</given-names></name><name><surname>Max</surname><given-names>MB</given-names></name></person-group><article-title>High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia</article-title><source>Neurology</source><year>1997</year><volume>48</volume><issue>5</issue><fpage>1212</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.1212/wnl.48.5.1212</pub-id><pub-id pub-id-type="pmid">9153445</pub-id></element-citation></ref><ref id="CR267"><label>267.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abraham</surname><given-names>RB</given-names></name><name><surname>Marouani</surname><given-names>N</given-names></name><name><surname>Kollender</surname><given-names>Y</given-names></name><name><surname>Meller</surname><given-names>I</given-names></name><name><surname>Weinbroum</surname><given-names>AA</given-names></name></person-group><article-title>Dextromethorphan for phantom pain attenuation in cancer amputees: a double-blind crossover trial involving three patients</article-title><source>Clin J Pain</source><year>2002</year><volume>18</volume><issue>5</issue><fpage>282</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1097/00002508-200209000-00002</pub-id><pub-id pub-id-type="pmid">12218498</pub-id></element-citation></ref><ref id="CR268"><label>268.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlsson</surname><given-names>K</given-names></name><name><surname>Hoem</surname><given-names>N</given-names></name><name><surname>Moberg</surname><given-names>E</given-names></name><name><surname>Mathisen</surname><given-names>L</given-names></name></person-group><article-title>Analgesic effect of dextromethorphan in neuropathic pain</article-title><source>Acta Anaesthesiol Scand</source><year>2004</year><volume>48</volume><issue>3</issue><fpage>328</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1111/j.0001-5172.2004.0325.x</pub-id><pub-id pub-id-type="pmid">14982566</pub-id></element-citation></ref><ref id="CR269"><label>269.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilron</surname><given-names>I</given-names></name><name><surname>Booher</surname><given-names>S</given-names></name><name><surname>Rowan</surname><given-names>J</given-names></name><name><surname>Smoller</surname><given-names>B</given-names></name><name><surname>Max</surname><given-names>M</given-names></name></person-group><article-title>A randomized, controlled trial of high-dose dextromethorphan in facial neuralgias</article-title><source>Neurology</source><year>2000</year><volume>55</volume><issue>7</issue><fpage>964</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1212/wnl.55.7.964</pub-id><pub-id pub-id-type="pmid">11061252</pub-id></element-citation></ref><ref id="CR270"><label>270.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McQuay</surname><given-names>HJ</given-names></name><name><surname>Carroll</surname><given-names>D</given-names></name><name><surname>Jadad</surname><given-names>AR</given-names></name><name><surname>Glynn</surname><given-names>CJ</given-names></name><name><surname>Jack</surname><given-names>T</given-names></name><name><surname>Moore</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Dextromethorphan for the treatment of neuropathic pain: a double-blind randomised controlled crossover trial with integral n-of-1 design</article-title><source>Pain</source><year>1994</year><volume>59</volume><issue>1</issue><fpage>127</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/0304-3959(94)90056-6</pub-id><pub-id pub-id-type="pmid">7854793</pub-id></element-citation></ref><ref id="CR271"><label>271.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith-Hicks</surname><given-names>CL</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Ewen</surname><given-names>JB</given-names></name><name><surname>Hong</surname><given-names>M</given-names></name><name><surname>Kratz</surname><given-names>L</given-names></name><name><surname>Kelley</surname><given-names>R</given-names></name><name><surname>Tierney</surname><given-names>E</given-names></name><name><surname>Vaurio</surname><given-names>R</given-names></name><name><surname>Bibat</surname><given-names>G</given-names></name><name><surname>Sanyal</surname><given-names>A</given-names></name><name><surname>Yenokyan</surname><given-names>G</given-names></name><name><surname>Brereton</surname><given-names>N</given-names></name><name><surname>Johnston</surname><given-names>MV</given-names></name><name><surname>Naidu</surname><given-names>S</given-names></name></person-group><article-title>Randomized open-label trial of dextromethorphan in Rett syndrome</article-title><source>Neurology</source><year>2017</year><volume>89</volume><issue>16</issue><fpage>1684</fpage><lpage>1690</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000004515</pub-id><pub-id pub-id-type="pmid">28931647</pub-id></element-citation></ref><ref id="CR272"><label>272.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumagai</surname><given-names>K</given-names></name><name><surname>Shono</surname><given-names>K</given-names></name><name><surname>Nakayama</surname><given-names>H</given-names></name><name><surname>Ohno</surname><given-names>Y</given-names></name><name><surname>Sajai</surname><given-names>I</given-names></name></person-group><article-title>(2R-trans)-2-butyl-5-heptylpyrrolidine as a potent sigma receptor ligand produced by Streptomyces longispororuber</article-title><source>Journal Antibiot.</source><year>2000</year><volume>53</volume><issue>5</issue><fpage>467</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.53.467</pub-id></element-citation></ref><ref id="CR273"><label>273.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moebius</surname><given-names>FF</given-names></name><name><surname>Reiter</surname><given-names>RJ</given-names></name><name><surname>Hanner</surname><given-names>M</given-names></name><name><surname>Glossmann</surname><given-names>H</given-names></name></person-group><article-title>High affinity of sigma1-binding sites for sterol isomerization inhibitors: evidence for a pharmacological relationship with the yeast sterol C8&#x02013;C7 isomerase</article-title><source>Br J Pharmacol</source><year>1997</year><volume>121</volume><issue>1</issue><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0701079</pub-id><pub-id pub-id-type="pmid">9146879</pub-id></element-citation></ref><ref id="CR274"><label>274.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramachandran</surname><given-names>S</given-names></name><name><surname>Chu</surname><given-names>UB</given-names></name><name><surname>Mavlyutov</surname><given-names>TA</given-names></name><name><surname>Pal</surname><given-names>A</given-names></name><name><surname>Pyne</surname><given-names>S</given-names></name><name><surname>Ruoho</surname><given-names>AE</given-names></name></person-group><article-title>The sigma1 receptor interacts with N-alkyl amines and endogenous sphingolipids</article-title><source>Eur J Pharmacol</source><year>2009</year><volume>609</volume><issue>1&#x02013;3</issue><fpage>19</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2009.03.003</pub-id><pub-id pub-id-type="pmid">19285059</pub-id></element-citation></ref><ref id="CR275"><label>275.</label><mixed-citation publication-type="other">Li J, Satyshur K, Guo LW, Ruoho AE. Sphingoid bases regulate the Sigma-1 receptor&#x02014;sphingosine and N,N&#x02019;-dimethylsphingosine are endogenous agonists. Int J Mol Sci. 24(4):3103; <underline>Doi: </underline>10.3390/ijms24043103</mixed-citation></ref><ref id="CR276"><label>276.</label><mixed-citation publication-type="other">National-Institute-for-Health-and-Care-Excellence. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer&#x02019;s disease. In: National Institute for Heath Care Excelence. 2011;TA217:1-77; <ext-link ext-link-type="uri" xlink:href="https://www.nice.org.uk/guidance/ta217">https://www.nice.org.uk/guidance/ta217</ext-link><underline>.</underline> Accessed 1 Nov 2022.</mixed-citation></ref><ref id="CR277"><label>277.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>K</given-names></name><name><surname>Hayako</surname><given-names>H</given-names></name><name><surname>Ishihara</surname><given-names>Y</given-names></name><name><surname>Marui</surname><given-names>S</given-names></name><name><surname>Iwane</surname><given-names>M</given-names></name><name><surname>Miyamoto</surname><given-names>M</given-names></name></person-group><article-title>TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons</article-title><source>Neurosci Lett</source><year>1999</year><volume>260</volume><issue>1</issue><fpage>5</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/S0304-3940(98)00943-4</pub-id><pub-id pub-id-type="pmid">10027686</pub-id></element-citation></ref><ref id="CR278"><label>278.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramakrishnan</surname><given-names>NK</given-names></name><name><surname>Visser</surname><given-names>AK</given-names></name><name><surname>Schepers</surname><given-names>M</given-names></name><name><surname>Luurtsema</surname><given-names>G</given-names></name><name><surname>Nyakas</surname><given-names>CJ</given-names></name><name><surname>Elsinga</surname><given-names>PH</given-names></name><etal/></person-group><article-title>Dose-dependent sigma-1 receptor occupancy by donepezil in rat brain can be assessed with 11 C-SA4503 and microPET</article-title><source>Psychopharmacology</source><year>2014</year><volume>231</volume><issue>20</issue><fpage>3997</fpage><lpage>4006</lpage><pub-id pub-id-type="doi">10.1007/s00213-014-3533-2</pub-id><pub-id pub-id-type="pmid">24639047</pub-id></element-citation></ref><ref id="CR279"><label>279.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>K</given-names></name><name><surname>Urbano</surname><given-names>R</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Yamasaki</surname><given-names>F</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Jordan</surname><given-names>J</given-names></name><etal/></person-group><article-title>The effect of donepezil treatment on cardiovascular mortality</article-title><source>Clin Pharmacol Ther</source><year>2010</year><volume>88</volume><issue>3</issue><fpage>335</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1038/clpt.2010.98</pub-id><pub-id pub-id-type="pmid">20664535</pub-id></element-citation></ref><ref id="CR280"><label>280.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nordstr&#x000f6;m</surname><given-names>P</given-names></name><name><surname>Religa</surname><given-names>D</given-names></name><name><surname>Wimo</surname><given-names>A</given-names></name><name><surname>Winblad</surname><given-names>B</given-names></name><name><surname>Eriksdotter</surname><given-names>M</given-names></name></person-group><article-title>The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer&#x02019;s disease</article-title><source>Eur Heart J</source><year>2013</year><volume>34</volume><issue>33</issue><fpage>2585</fpage><lpage>2591</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/eht182</pub-id><pub-id pub-id-type="pmid">23735859</pub-id></element-citation></ref><ref id="CR281"><label>281.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhuiyan</surname><given-names>MS</given-names></name><name><surname>Fukunaga</surname><given-names>K</given-names></name></person-group><article-title>Targeting sigma-1 receptor signaling by endogenous ligands for cardioprotection</article-title><source>Expert Opin Ther Targets</source><year>2011</year><volume>15</volume><issue>2</issue><fpage>145</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1517/14728222.2011.546350</pub-id><pub-id pub-id-type="pmid">21204730</pub-id></element-citation></ref><ref id="CR282"><label>282.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishima</surname><given-names>T</given-names></name><name><surname>Nishimura</surname><given-names>T</given-names></name><name><surname>Iyo</surname><given-names>M</given-names></name><name><surname>Hashimoto</surname><given-names>K</given-names></name></person-group><article-title>Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by donepezil: role of sigma-1 receptors and IP3 receptors</article-title><source>Prog Neuropsychopharmacol Biol Psychiatry</source><year>2008</year><volume>32</volume><issue>7</issue><fpage>1656</fpage><lpage>1659</lpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2008.06.011</pub-id><pub-id pub-id-type="pmid">18647636</pub-id></element-citation></ref><ref id="CR283"><label>283.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Lian</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name></person-group><article-title>Efficacy and safety of donepezil for mild cognitive impairment: a systematic review and meta-analysis</article-title><source>Clin Neurol Neurosurg</source><year>2022</year><volume>213</volume><fpage>107134</fpage><pub-id pub-id-type="doi">10.1016/j.clineuro.2022.107134</pub-id><pub-id pub-id-type="pmid">35078087</pub-id></element-citation></ref><ref id="CR284"><label>284.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birks</surname><given-names>JS</given-names></name><name><surname>Harvey</surname><given-names>RJ</given-names></name></person-group><article-title>Donepezil for dementia due to Alzheimer&#x02019;s disease</article-title><source>Cochrane Database Syst Rev</source><year>2018</year><volume>6</volume><issue>6</issue><fpage>CD001190</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD001190.pub3</pub-id><pub-id pub-id-type="pmid">29923184</pub-id></element-citation></ref><ref id="CR285"><label>285.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zong</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name></person-group><article-title>Compared of efficacy and safety of high-dose donepezil vs standard-dose donepezil among elderly patients with Alzheimer&#x02019;s disease: a systematic review and meta-analysis</article-title><source>Expert Opin Drug Saf</source><year>2022</year><volume>21</volume><issue>3</issue><fpage>407</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1080/14740338.2022.2027905</pub-id><pub-id pub-id-type="pmid">35099343</pub-id></element-citation></ref><ref id="CR286"><label>286.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>R</given-names></name><name><surname>McShane</surname><given-names>R</given-names></name><name><surname>Lindesay</surname><given-names>J</given-names></name><name><surname>Ritchie</surname><given-names>C</given-names></name><name><surname>Baldwin</surname><given-names>A</given-names></name><name><surname>Barber</surname><given-names>R</given-names></name><etal/></person-group><article-title>Donepezil and memantine for moderate-to-severe Alzheimer&#x02019;s disease</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><issue>10</issue><fpage>893</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1106668</pub-id><pub-id pub-id-type="pmid">22397651</pub-id></element-citation></ref><ref id="CR287"><label>287.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tariot</surname><given-names>PN</given-names></name><name><surname>Cummings</surname><given-names>JL</given-names></name><name><surname>Katz</surname><given-names>IR</given-names></name><name><surname>Mintzer</surname><given-names>J</given-names></name><name><surname>Perdomo</surname><given-names>CA</given-names></name><name><surname>Schwam</surname><given-names>EM</given-names></name><etal/></person-group><article-title>A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer&#x02019;s disease in the nursing home setting</article-title><source>J Am Geriatr Soc</source><year>2001</year><volume>49</volume><issue>12</issue><fpage>1590</fpage><lpage>1599</lpage><pub-id pub-id-type="doi">10.1111/j.1532-5415.2001.49266.x</pub-id><pub-id pub-id-type="pmid">11843990</pub-id></element-citation></ref><ref id="CR288"><label>288.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>CY</given-names></name><name><surname>Lei</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>XC</given-names></name><name><surname>Zhang</surname><given-names>HY</given-names></name></person-group><article-title>Donepezil attenuates A&#x003b2;-associated mitochondrial dysfunction and reduces mitochondrial A&#x003b2; accumulation in vivo and in vitro</article-title><source>Neuropharmacology</source><year>2015</year><volume>95</volume><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.02.020</pub-id><pub-id pub-id-type="pmid">25744714</pub-id></element-citation></ref><ref id="CR289"><label>289.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>H</given-names></name><name><surname>Yuede</surname><given-names>CM</given-names></name><name><surname>Coughlan</surname><given-names>CA</given-names></name><name><surname>Murphy</surname><given-names>KM</given-names></name><name><surname>Csernansky</surname><given-names>JG</given-names></name></person-group><article-title>Effects of donepezil on amyloid-&#x003b2; and synapse density in the Tg2576 mouse model of Alzheimer&#x02019;s disease</article-title><source>Brain Res</source><year>2009</year><volume>1303</volume><fpage>169</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2009.09.097</pub-id><pub-id pub-id-type="pmid">19799879</pub-id></element-citation></ref><ref id="CR290"><label>290.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishibashi</surname><given-names>K</given-names></name><name><surname>Miura</surname><given-names>Y</given-names></name><name><surname>Wagatsuma</surname><given-names>K</given-names></name><name><surname>Ishiwata</surname><given-names>K</given-names></name><name><surname>Ishii</surname><given-names>K</given-names></name></person-group><article-title>Changes in brain amyloid-&#x003b2; accumulation after donepezil administration</article-title><source>J Clin Neurosci</source><year>2017</year><volume>45</volume><fpage>328</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1016/j.jocn.2017.08.025</pub-id><pub-id pub-id-type="pmid">28864409</pub-id></element-citation></ref><ref id="CR291"><label>291.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>RJ</given-names></name><name><surname>Juszczak</surname><given-names>E</given-names></name><name><surname>Ballard</surname><given-names>CG</given-names></name><name><surname>Bentham</surname><given-names>P</given-names></name><name><surname>Brown</surname><given-names>RG</given-names></name><name><surname>Bullock</surname><given-names>R</given-names></name><etal/></person-group><article-title>Donepezil for the treatment of agitation in Alzheimer&#x02019;s disease</article-title><source>N Engl J Med</source><year>2007</year><volume>357</volume><issue>14</issue><fpage>1382</fpage><lpage>1392</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa066583</pub-id><pub-id pub-id-type="pmid">17914039</pub-id></element-citation></ref><ref id="CR292"><label>292.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Keyser</surname><given-names>J</given-names></name><name><surname>Sulter</surname><given-names>G</given-names></name><name><surname>Luiten</surname><given-names>PG</given-names></name></person-group><article-title>Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing?</article-title><source>Trends Neurosci</source><year>1999</year><volume>22</volume><issue>12</issue><fpage>535</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1016/s0166-2236(99)01463-0</pub-id><pub-id pub-id-type="pmid">10542428</pub-id></element-citation></ref><ref id="CR293"><label>293.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Modell</surname><given-names>S</given-names></name><name><surname>Naber</surname><given-names>D</given-names></name><name><surname>Holzbach</surname><given-names>R</given-names></name></person-group><article-title>Efficacy and safety of an opiate sigma-receptor antagonist (SL 82.0715) in schizophrenic patients with negative symptoms: an open dose-range study</article-title><source>Pharmacopsychiatry</source><year>1996</year><volume>29</volume><issue>02</issue><fpage>63</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1055/s-2007-979546</pub-id><pub-id pub-id-type="pmid">8741023</pub-id></element-citation></ref><ref id="CR294"><label>294.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>K</given-names></name><name><surname>London</surname><given-names>ED</given-names></name></person-group><article-title>Interactions of erythro-ifenprodil, threo-ifenprodil, erythro-iodoifenprodil, and eliprodil with subtypes of &#x003c3; receptors</article-title><source>Eur J Pharmacol</source><year>1995</year><volume>273</volume><issue>3</issue><fpage>307</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1016/0014-2999(94)00763-w</pub-id><pub-id pub-id-type="pmid">7737340</pub-id></element-citation></ref><ref id="CR295"><label>295.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brooks</surname><given-names>S</given-names></name><name><surname>Kaur</surname><given-names>S</given-names></name><name><surname>Starr</surname><given-names>BS</given-names></name><name><surname>Starr</surname><given-names>MS</given-names></name></person-group><article-title>Motor actions of eliprodil in the normal and monoamine-depleted mouse: a role in the treatment of Parkinson&#x02019;s disease?</article-title><source>J Neural Transm (Vienna)</source><year>1996</year><volume>103</volume><issue>6</issue><fpage>737</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1007/bf01271233</pub-id><pub-id pub-id-type="pmid">8836935</pub-id></element-citation></ref><ref id="CR296"><label>296.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demerens</surname><given-names>C</given-names></name><name><surname>Stankoff</surname><given-names>B</given-names></name><name><surname>Zalc</surname><given-names>B</given-names></name><name><surname>Lubetzki</surname><given-names>C</given-names></name></person-group><article-title>Eliprodil stimulates CNS myelination: new prospects for multiple sclerosis?</article-title><source>Neurology</source><year>1999</year><volume>52</volume><issue>2</issue><fpage>346</fpage><pub-id pub-id-type="doi">10.1212/wnl.52.2.346</pub-id><pub-id pub-id-type="pmid">9932955</pub-id></element-citation></ref><ref id="CR297"><label>297.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silkina</surname><given-names>I</given-names></name><name><surname>Gan'shina</surname><given-names>T</given-names></name><name><surname>Seredin</surname><given-names>S</given-names></name><name><surname>Mirzoian</surname><given-names>R</given-names></name></person-group><article-title>Gabaergic mechanism of cerebrovascular and neuroprotective effects of afobazole and picamilon</article-title><source>E Eksp Klin Farmakol.</source><year>2005</year><volume>68</volume><issue>1</issue><fpage>20</fpage><lpage>24</lpage></element-citation></ref><ref id="CR298"><label>298.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antipova</surname><given-names>T</given-names></name><name><surname>Sapozhnikova</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Seredenin</surname><given-names>S</given-names></name></person-group><article-title>Selective anxiolytic afobazole increases the content of BDNF and NGF in cultured hippocampal HT-22 line neurons</article-title><source>Eksp Klin Farmakol</source><year>2009</year><volume>72</volume><issue>1</issue><fpage>12</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">19334503</pub-id></element-citation></ref><ref id="CR299"><label>299.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuevas</surname><given-names>J</given-names></name><name><surname>Rodriguez</surname><given-names>A</given-names></name><name><surname>Behensky</surname><given-names>A</given-names></name><name><surname>Katnik</surname><given-names>C</given-names></name></person-group><article-title>Afobazole modulates microglial function via activation of both &#x003c3;-1 and &#x003c3;-2 receptors</article-title><source>J Pharmacol Exp Ther</source><year>2011</year><volume>339</volume><issue>1</issue><fpage>161</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1124/jpet.111.182816</pub-id><pub-id pub-id-type="pmid">21715561</pub-id></element-citation></ref><ref id="CR300"><label>300.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behensky</surname><given-names>AA</given-names></name><name><surname>Yasny</surname><given-names>IE</given-names></name><name><surname>Shuster</surname><given-names>AM</given-names></name><name><surname>Seredenin</surname><given-names>SB</given-names></name><name><surname>Petrov</surname><given-names>AV</given-names></name><name><surname>Cuevas</surname><given-names>J</given-names></name></person-group><article-title>Stimulation of sigma receptors with afobazole blocks activation of microglia and reduces toxicity caused by amyloid-&#x003b2;25&#x02013;35</article-title><source>J Pharmacol Exp Ther</source><year>2013</year><volume>347</volume><issue>2</issue><fpage>458</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1124/jpet.113.208348</pub-id><pub-id pub-id-type="pmid">24006337</pub-id></element-citation></ref><ref id="CR301"><label>301.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behensky</surname><given-names>AA</given-names></name><name><surname>Yasny</surname><given-names>IE</given-names></name><name><surname>Shuster</surname><given-names>AM</given-names></name><name><surname>Seredenin</surname><given-names>SB</given-names></name><name><surname>Petrov</surname><given-names>AV</given-names></name><name><surname>Cuevas</surname><given-names>J</given-names></name></person-group><article-title>Afobazole activation of &#x003c3;-1 receptors modulates neuronal responses to amyloid-&#x003b2;25&#x02013;35</article-title><source>J Pharmacol Exp Ther</source><year>2013</year><volume>347</volume><issue>2</issue><fpage>468</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1124/jpet.113.208330</pub-id><pub-id pub-id-type="pmid">24006338</pub-id></element-citation></ref><ref id="CR302"><label>302.</label><mixed-citation publication-type="other">Martin P, de-Witte PAM, Maurice T, Gammaitoni A, Farfel G, Galer B. Fenfluramine acts as a positive modulator of sigma-1 receptors. Epilepsy Behav. 2020;105:106989. 10.1016/j.yebeh.2020.106989.</mixed-citation></ref><ref id="CR303"><label>303.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maurice</surname><given-names>T</given-names></name></person-group><article-title>Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders</article-title><source>Expert Opin Drug Discov</source><year>2021</year><volume>16</volume><issue>4</issue><fpage>373</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1080/17460441.2021.1838483</pub-id><pub-id pub-id-type="pmid">33070647</pub-id></element-citation></ref><ref id="CR304"><label>304.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knupp</surname><given-names>KG</given-names></name><name><surname>Scheffer</surname><given-names>IE</given-names></name><name><surname>Ceulemans</surname><given-names>B</given-names></name><name><surname>Sullivan</surname><given-names>JE</given-names></name><name><surname>Nickels</surname><given-names>KC</given-names></name><name><surname>Lagae</surname><given-names>L</given-names></name><etal/></person-group><article-title>Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized clinical trial</article-title><source>JAMA Neurol</source><year>2022</year><volume>79</volume><issue>6</issue><fpage>554</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2022.0829</pub-id><pub-id pub-id-type="pmid">35499850</pub-id></element-citation></ref><ref id="CR305"><label>305.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lagae</surname><given-names>L</given-names></name><name><surname>Sullivan</surname><given-names>J</given-names></name><name><surname>Knupp</surname><given-names>K</given-names></name><name><surname>Laux</surname><given-names>L</given-names></name><name><surname>Polster</surname><given-names>T</given-names></name><name><surname>Nikanorova</surname><given-names>M</given-names></name><etal/></person-group><article-title>Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial</article-title><source>Lancet</source><year>2019</year><volume>394</volume><issue>10216</issue><fpage>2243</fpage><lpage>2254</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(19)32500-0</pub-id><pub-id pub-id-type="pmid">31862249</pub-id></element-citation></ref><ref id="CR306"><label>306.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Specchio</surname><given-names>N</given-names></name><name><surname>Pietrafusa</surname><given-names>N</given-names></name><name><surname>Doccini</surname><given-names>V</given-names></name><name><surname>Trivisano</surname><given-names>M</given-names></name><name><surname>Darra</surname><given-names>F</given-names></name><name><surname>Ragona</surname><given-names>F</given-names></name><etal/></person-group><article-title>Efficacy and safety of Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a real-world study</article-title><source>Epilepsia</source><year>2020</year><volume>61</volume><issue>11</issue><fpage>2405</fpage><lpage>2414</lpage><pub-id pub-id-type="doi">10.1111/epi.16690</pub-id><pub-id pub-id-type="pmid">32945537</pub-id></element-citation></ref><ref id="CR307"><label>307.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chomchoei</surname><given-names>C</given-names></name><name><surname>Brimson</surname><given-names>J</given-names></name><name><surname>Brimson</surname><given-names>S</given-names></name></person-group><article-title>Repurposing fluoxetine to treat lymphocytic leukaemia: apoptosis induction, sigma-1 receptor upregulation, inhibition of IL-2 cytokine production, and autophagy induction</article-title><source>Expert Opin Ther Targets</source><year>2023</year><pub-id pub-id-type="doi">10.1080/14728222.2022.2166829</pub-id></element-citation></ref><ref id="CR308"><label>308.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>N&#x000e9;meth</surname><given-names>ZK</given-names></name><name><surname>Sz&#x000fb;cs</surname><given-names>A</given-names></name><name><surname>Vitrai</surname><given-names>J</given-names></name><name><surname>Juh&#x000e1;sz</surname><given-names>D</given-names></name><name><surname>N&#x000e9;meth</surname><given-names>JP</given-names></name><name><surname>Holl&#x000f3;</surname><given-names>A</given-names></name></person-group><article-title>Fluoxetine use is associated with improved survival of patients with COVID-19 pneumonia: a retrospective case-control study</article-title><source>Ideggyogy Sz</source><year>2021</year><volume>74</volume><issue>11&#x02013;12</issue><fpage>389</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.18071/isz.74.0389</pub-id><pub-id pub-id-type="pmid">34856085</pub-id></element-citation></ref><ref id="CR309"><label>309.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emilia</surname><given-names>M</given-names></name><name><surname>Rosso</surname><given-names>D</given-names></name><name><surname>Laura</surname><given-names>M</given-names></name><name><surname>Mar&#x000ed;a</surname><given-names>A</given-names></name></person-group><article-title>Immunomodulatory effects of fluoxetine: a new potential pharmacological action for a classic antidepressant drug ?</article-title><source>Pharmacol Res</source><year>2016</year><volume>109</volume><fpage>101</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2015.11.021</pub-id><pub-id pub-id-type="pmid">26644208</pub-id></element-citation></ref><ref id="CR310"><label>310.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Safrany</surname><given-names>ST</given-names></name><name><surname>Brimson</surname><given-names>JM</given-names></name></person-group><article-title>Are fluoxetine&#x02019;s effects due to sigma-1 receptor agonism?</article-title><source>Pharmacol Res</source><year>2016</year><volume>113</volume><fpage>707</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2016.05.031</pub-id><pub-id pub-id-type="pmid">27262678</pub-id></element-citation></ref><ref id="CR311"><label>311.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mostert</surname><given-names>JP</given-names></name><name><surname>Admiraal-Behloul</surname><given-names>F</given-names></name><name><surname>Hoogduin</surname><given-names>JM</given-names></name><name><surname>Luyendijk</surname><given-names>J</given-names></name><name><surname>Heersema</surname><given-names>DJ</given-names></name><name><surname>Van Buchem</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2008</year><volume>79</volume><issue>9</issue><fpage>1027</fpage><lpage>1031</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2007.139345</pub-id><pub-id pub-id-type="pmid">18450787</pub-id></element-citation></ref><ref id="CR312"><label>312.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Kang</surname><given-names>SR</given-names></name><name><surname>Yune</surname><given-names>TY</given-names></name></person-group><article-title>Fluoxetine prevents oligodendrocyte cell death by inhibiting microglia activation after spinal cord injury</article-title><source>J Neurotrauma</source><year>2015</year><volume>32</volume><issue>9</issue><fpage>633</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1089/neu.2014.3527</pub-id><pub-id pub-id-type="pmid">25366938</pub-id></element-citation></ref><ref id="CR313"><label>313.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sijens</surname><given-names>PE</given-names></name><name><surname>Mostert</surname><given-names>JP</given-names></name><name><surname>Irwan</surname><given-names>R</given-names></name><name><surname>Potze</surname><given-names>JH</given-names></name><name><surname>Oudkerk</surname><given-names>M</given-names></name><name><surname>De Keyser</surname><given-names>J</given-names></name></person-group><article-title>Impact of fluoxetine on the human brain in multiple sclerosis as quantified by proton magnetic resonance spectroscopy and diffusion tensor imaging</article-title><source>Psychiatry Res</source><year>2008</year><volume>164</volume><issue>3</issue><fpage>274</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1016/j.pscychresns.2007.12.014</pub-id><pub-id pub-id-type="pmid">19017554</pub-id></element-citation></ref><ref id="CR314"><label>314.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cambron</surname><given-names>M</given-names></name><name><surname>Mostert</surname><given-names>J</given-names></name><name><surname>D&#x02019;Hooghe</surname><given-names>M</given-names></name><name><surname>Nagels</surname><given-names>G</given-names></name><name><surname>Willekens</surname><given-names>B</given-names></name><name><surname>Debruyne</surname><given-names>J</given-names></name><etal/></person-group><article-title>Fluoxetine in progressive multiple sclerosis: the FLUOX-PMS trial</article-title><source>Mult Scler J</source><year>2019</year><volume>25</volume><issue>13</issue><fpage>1728</fpage><lpage>1735</lpage><pub-id pub-id-type="doi">10.1177/1352458519843051</pub-id></element-citation></ref><ref id="CR315"><label>315.</label><mixed-citation publication-type="other">Connick P, De Angelis F, Parker RA, Plantone D, Doshi A, John N, et al. Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis. BMJ Open. 2018;8(8):e021944. 10.1136/bmjopen-2018-021944.</mixed-citation></ref><ref id="CR316"><label>316.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Angelis</surname><given-names>F</given-names></name><name><surname>Connick</surname><given-names>P</given-names></name><name><surname>Parker</surname><given-names>RA</given-names></name><name><surname>Plantone</surname><given-names>D</given-names></name><name><surname>Doshi</surname><given-names>A</given-names></name><name><surname>John</surname><given-names>N</given-names></name><etal/></person-group><article-title>Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT</article-title><source>Efficacy Mech Eval.</source><year>2020</year><volume>7</volume><issue>3</issue><fpage>1</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.3310/eme07030</pub-id></element-citation></ref><ref id="CR317"><label>317.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chataway</surname><given-names>J</given-names></name><name><surname>De Angelis</surname><given-names>F</given-names></name><name><surname>Connick</surname><given-names>P</given-names></name><name><surname>Parker</surname><given-names>RA</given-names></name><name><surname>Plantone</surname><given-names>D</given-names></name><name><surname>Doshi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial</article-title><source>Lancet Neurol</source><year>2020</year><volume>19</volume><issue>3</issue><fpage>214</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(19)30485-5</pub-id><pub-id pub-id-type="pmid">31981516</pub-id></element-citation></ref><ref id="CR318"><label>318.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brimson</surname><given-names>JM</given-names></name><name><surname>Prasanth</surname><given-names>MI</given-names></name><name><surname>Malar</surname><given-names>DS</given-names></name><name><surname>Brimson</surname><given-names>S</given-names></name><name><surname>Thitilertdecha</surname><given-names>P</given-names></name><name><surname>Tencomnao</surname><given-names>T</given-names></name></person-group><article-title>Drugs that offer the potential to reduce hospitalization and mortality from SARS-CoV-2 infection: the possible role of the Sigma-1 receptor and autophagy</article-title><source>Expert Opin Ther Targets</source><year>2021</year><volume>25</volume><issue>6</issue><fpage>35</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1080/14728222.2021.1952987</pub-id></element-citation></ref><ref id="CR319"><label>319.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>T</given-names></name><name><surname>Ishima</surname><given-names>T</given-names></name><name><surname>Iyo</surname><given-names>M</given-names></name><name><surname>Hashimoto</surname><given-names>K</given-names></name></person-group><article-title>Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways</article-title><source>PLoS ONE</source><year>2008</year><volume>3</volume><issue>7</issue><fpage>e2558</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0002558</pub-id><pub-id pub-id-type="pmid">18596927</pub-id></element-citation></ref><ref id="CR320"><label>320.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benedetti</surname><given-names>F</given-names></name><name><surname>Campori</surname><given-names>E</given-names></name><name><surname>Colombo</surname><given-names>C</given-names></name><name><surname>Smeraldi</surname><given-names>E</given-names></name></person-group><article-title>Fluvoxamine treatment of major depression associated with multiple sclerosis</article-title><source>J Neuropsychiatry Clin Neurosci</source><year>2004</year><volume>16</volume><issue>3</issue><fpage>364</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1176/jnp.16.3.364</pub-id><pub-id pub-id-type="pmid">15377746</pub-id></element-citation></ref><ref id="CR321"><label>321.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghareghani</surname><given-names>M</given-names></name><name><surname>Zibara</surname><given-names>K</given-names></name><name><surname>Sadeghi</surname><given-names>H</given-names></name><name><surname>Dokoohaki</surname><given-names>S</given-names></name><name><surname>Sadeghi</surname><given-names>H</given-names></name><name><surname>Aryanpour</surname><given-names>R</given-names></name><etal/></person-group><article-title>Fluvoxamine stimulates oligodendrogenesis of cultured neural stem cells and attenuates inflammation and demyelination in an animal model of multiple sclerosis</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><issue>1</issue><fpage>4923</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-04968-z</pub-id><pub-id pub-id-type="pmid">28687730</pub-id></element-citation></ref><ref id="CR322"><label>322.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robson</surname><given-names>MJ</given-names></name><name><surname>Elliott</surname><given-names>M</given-names></name><name><surname>Seminerio</surname><given-names>MJ</given-names></name><name><surname>Matsumoto</surname><given-names>RR</given-names></name></person-group><article-title>Evaluation of sigma (&#x003c3;) receptors in the antidepressant-like effects of ketamine in vitro and in vivo</article-title><source>Eur Neuropsychopharmacol</source><year>2012</year><volume>22</volume><issue>4</issue><fpage>308</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2011.08.002</pub-id><pub-id pub-id-type="pmid">21911285</pub-id></element-citation></ref><ref id="CR323"><label>323.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikiforuk</surname><given-names>A</given-names></name><name><surname>Popik</surname><given-names>P</given-names></name></person-group><article-title>Ketamine prevents stress-induced cognitive inflexibility in rats</article-title><source>Psychoneuroendocrinology</source><year>2014</year><volume>40</volume><fpage>119</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1016/j.psyneuen.2013.11.009</pub-id><pub-id pub-id-type="pmid">24485483</pub-id></element-citation></ref><ref id="CR324"><label>324.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibakawa</surname><given-names>YS</given-names></name><name><surname>Sasaki</surname><given-names>Y</given-names></name><name><surname>Goshima</surname><given-names>Y</given-names></name><name><surname>Echigo</surname><given-names>N</given-names></name><name><surname>Kamiya</surname><given-names>Y</given-names></name><name><surname>Kurahashi</surname><given-names>K</given-names></name><etal/></person-group><article-title>Effects of ketamine and propofol on inflammatory responses of primary glial cell cultures stimulated with lipopolysaccharide</article-title><source>Br J Anaesth</source><year>2005</year><volume>95</volume><issue>6</issue><fpage>803</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1093/bja/aei256</pub-id><pub-id pub-id-type="pmid">16227338</pub-id></element-citation></ref><ref id="CR325"><label>325.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollinger</surname><given-names>A</given-names></name><name><surname>R&#x000fc;st</surname><given-names>CA</given-names></name><name><surname>Riegger</surname><given-names>H</given-names></name><name><surname>Gysi</surname><given-names>B</given-names></name><name><surname>Tran</surname><given-names>F</given-names></name><name><surname>Br&#x000fc;gger</surname><given-names>J</given-names></name><etal/></person-group><article-title>Ketamine vs haloperidol for prevention of cognitive dysfunction and postoperative delirium: a phase IV multicentre randomised placebo-controlled double-blind clinical trial</article-title><source>J Clin Anesth</source><year>2021</year><volume>68</volume><fpage>110099</fpage><pub-id pub-id-type="doi">10.1016/j.jclinane.2020.110099</pub-id><pub-id pub-id-type="pmid">33120302</pub-id></element-citation></ref><ref id="CR326"><label>326.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lara</surname><given-names>DR</given-names></name><name><surname>Bisol</surname><given-names>LW</given-names></name><name><surname>Munari</surname><given-names>LR</given-names></name></person-group><article-title>Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression</article-title><source>Int J Neuropsychopharmacol</source><year>2013</year><volume>16</volume><issue>9</issue><fpage>2111</fpage><lpage>2117</lpage><pub-id pub-id-type="doi">10.1017/S1461145713000485</pub-id><pub-id pub-id-type="pmid">23683309</pub-id></element-citation></ref><ref id="CR327"><label>327.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>MW</given-names></name><name><surname>Ho</surname><given-names>RC</given-names></name></person-group><article-title>Controversies of the effect of ketamine on cognition</article-title><source>Front Psychiatry.</source><year>2016</year><volume>7</volume><fpage>47</fpage><pub-id pub-id-type="doi">10.3389/fpsyt.2016.00047</pub-id><pub-id pub-id-type="pmid">27065891</pub-id></element-citation></ref><ref id="CR328"><label>328.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ownby</surname><given-names>RL</given-names></name><name><surname>Crocco</surname><given-names>E</given-names></name><name><surname>Acevedo</surname><given-names>A</given-names></name><name><surname>John</surname><given-names>V</given-names></name><name><surname>Loewenstein</surname><given-names>D</given-names></name></person-group><article-title>Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis</article-title><source>Arch Gen Psychiatry</source><year>2006</year><volume>63</volume><issue>5</issue><fpage>530</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.63.5.530</pub-id><pub-id pub-id-type="pmid">16651510</pub-id></element-citation></ref><ref id="CR329"><label>329.</label><mixed-citation publication-type="other">Aan Het Rot M, Zarate CA, Charney DS, Mathew SJ. Ketamine for depression: where do we go from here? Biol Psychiatry. 2012;72(7):537&#x02013;47. 10.1016/j.biopsych.2012.05.003.</mixed-citation></ref><ref id="CR330"><label>330.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rocha</surname><given-names>FL</given-names></name><name><surname>de Vasconcelos Cunha</surname><given-names>UG</given-names></name><name><surname>Paschoalin</surname><given-names>RC</given-names></name><name><surname>Hara</surname><given-names>C</given-names></name><name><surname>Thomaz</surname><given-names>DP</given-names></name></person-group><article-title>Use of subcutaneous ketamine to rapidly improve severe treatment-resistant depression in a patient with Alzheimer&#x02019;s disease</article-title><source>Int Clin Psychopharmacol</source><year>2021</year><volume>36</volume><issue>2</issue><fpage>104</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1097/YIC.0000000000000334</pub-id><pub-id pub-id-type="pmid">33230024</pub-id></element-citation></ref><ref id="CR331"><label>331.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Efficacy of antidepressant drugs in the treatment of depression in Alzheimer disease patients: a systematic review and network meta-analysis</article-title><source>J Psychopharmacol</source><year>2021</year><volume>35</volume><issue>8</issue><fpage>901</fpage><lpage>909</lpage><pub-id pub-id-type="doi">10.1177/02698811211030181</pub-id><pub-id pub-id-type="pmid">34238048</pub-id></element-citation></ref><ref id="CR332"><label>332.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeung</surname><given-names>L</given-names></name><name><surname>Wai</surname><given-names>MS</given-names></name><name><surname>Fan</surname><given-names>M</given-names></name><name><surname>Mak</surname><given-names>Y</given-names></name><name><surname>Lam</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Hyperphosphorylated tau in the brains of mice and monkeys with long-term administration of ketamine</article-title><source>Toxicol Lett</source><year>2010</year><volume>193</volume><issue>2</issue><fpage>189</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/j.toxlet.2010.01.008</pub-id><pub-id pub-id-type="pmid">20093173</pub-id></element-citation></ref><ref id="CR333"><label>333.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferro</surname><given-names>M</given-names></name><name><surname>Angelucci</surname><given-names>M</given-names></name><name><surname>Anselmo-Franci</surname><given-names>J</given-names></name><name><surname>Canteras</surname><given-names>N</given-names></name><name><surname>Da Cunha</surname><given-names>C</given-names></name></person-group><article-title>Neuroprotective effect of ketamine/xylazine on two rat models of Parkinson&#x02019;s disease</article-title><source>Braz J Med Biol Res</source><year>2007</year><volume>40</volume><fpage>89</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1590/s0100-879x2007000100012</pub-id><pub-id pub-id-type="pmid">17225001</pub-id></element-citation></ref><ref id="CR334"><label>334.</label><mixed-citation publication-type="other">Vecchia DD, Kanazawa LKS, Wendler E, Hocayen PdAS, Vital MABF, Takahashi RN, et al. Ketamine reversed short-term memory impairment and depressive-like behavior in animal model of Parkinson&#x02019;s disease. Brain Res Bull. 2021;168:63&#x02013;73. 10.1016/j.brainresbull.2020.12.011.</mixed-citation></ref><ref id="CR335"><label>335.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>J-C</given-names></name><name><surname>Song</surname><given-names>J-J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Hong</surname><given-names>D-X</given-names></name></person-group><article-title>Neuron-protective effect of subanesthestic-dosage ketamine on mice of Parkinson&#x02019;s disease</article-title><source>Asian Pac J Trop Med</source><year>2017</year><volume>10</volume><issue>10</issue><fpage>1007</fpage><lpage>1010</lpage><pub-id pub-id-type="doi">10.1016/j.apjtm.2017.09.014</pub-id><pub-id pub-id-type="pmid">29111184</pub-id></element-citation></ref><ref id="CR336"><label>336.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>JJ</given-names></name><name><surname>Goodnight</surname><given-names>PD</given-names></name><name><surname>McEvoy</surname><given-names>MD</given-names></name></person-group><article-title>The utility of ketamine for the preoperative management of a patient with Parkinson&#x02019;s disease</article-title><source>Anesth Analg</source><year>2009</year><volume>108</volume><issue>3</issue><fpage>980</fpage><lpage>982</lpage><pub-id pub-id-type="doi">10.1213/ane.0b013e3181924025</pub-id><pub-id pub-id-type="pmid">19224812</pub-id></element-citation></ref><ref id="CR337"><label>337.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salazar</surname><given-names>G</given-names></name><name><surname>Motamed</surname><given-names>C</given-names></name></person-group><article-title>A remifentanil/ketamine sedation in surgical cancer patients having severe Parkinson&#x02019;s disease: two case reports</article-title><source>J Opioid Manag</source><year>2012</year><volume>8</volume><issue>2</issue><fpage>133</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.5055/jom.2012.0106</pub-id><pub-id pub-id-type="pmid">22616319</pub-id></element-citation></ref><ref id="CR338"><label>338.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barenboim</surname><given-names>I</given-names></name><name><surname>Lafer</surname><given-names>B</given-names></name></person-group><article-title>Maintenance use of ketamine for treatment-resistant depression: an open-label pilot study</article-title><source>Braz J Psychiatry.</source><year>2018</year><volume>40</volume><issue>1</issue><fpage>110</fpage><pub-id pub-id-type="doi">10.1590/1516-4446-2017-2380</pub-id><pub-id pub-id-type="pmid">29590266</pub-id></element-citation></ref><ref id="CR339"><label>339.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathew</surname><given-names>SJ</given-names></name><name><surname>Shah</surname><given-names>A</given-names></name><name><surname>Lapidus</surname><given-names>K</given-names></name><name><surname>Clark</surname><given-names>C</given-names></name><name><surname>Jarun</surname><given-names>N</given-names></name><name><surname>Ostermeyer</surname><given-names>B</given-names></name><etal/></person-group><article-title>Ketamine for treatment-resistant unipolar depression</article-title><source>CNS Drugs</source><year>2012</year><volume>26</volume><issue>3</issue><fpage>189</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.2165/11599770-000000000-00000</pub-id><pub-id pub-id-type="pmid">22303887</pub-id></element-citation></ref><ref id="CR340"><label>340.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feifel</surname><given-names>D</given-names></name></person-group><article-title>Breaking sad: unleashing the breakthrough potential of k etamine&#x02019;s rapid antidepressant effects</article-title><source>Drug Dev Res</source><year>2016</year><volume>77</volume><issue>8</issue><fpage>489</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1002/ddr.21347</pub-id><pub-id pub-id-type="pmid">27888525</pub-id></element-citation></ref><ref id="CR341"><label>341.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiroma</surname><given-names>PR</given-names></name><name><surname>Johns</surname><given-names>B</given-names></name><name><surname>Kuskowski</surname><given-names>M</given-names></name><name><surname>Wels</surname><given-names>J</given-names></name><name><surname>Thuras</surname><given-names>P</given-names></name><name><surname>Albott</surname><given-names>CS</given-names></name><etal/></person-group><article-title>Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression</article-title><source>J Affect Disord</source><year>2014</year><volume>155</volume><fpage>123</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2013.10.036</pub-id><pub-id pub-id-type="pmid">24268616</pub-id></element-citation></ref><ref id="CR342"><label>342.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>Tan</surname><given-names>Y</given-names></name><name><surname>Qu</surname><given-names>Y</given-names></name><name><surname>Shan</surname><given-names>J</given-names></name><name><surname>Hashimoto</surname><given-names>K</given-names></name></person-group><article-title>(R)-ketamine ameliorates the progression of experimental autoimmune encephalomyelitis in mice</article-title><source>Brain Res Bull</source><year>2021</year><volume>177</volume><fpage>316</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1016/j.brainresbull.2021.10.013</pub-id><pub-id pub-id-type="pmid">34688833</pub-id></element-citation></ref><ref id="CR343"><label>343.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>Wan</surname><given-names>X</given-names></name><name><surname>Tan</surname><given-names>Y</given-names></name><name><surname>Qu</surname><given-names>Y</given-names></name><name><surname>Shan</surname><given-names>J</given-names></name><etal/></person-group><article-title>(R)-ketamine ameliorates demyelination and facilitates remyelination in cuprizone-treated mice: a role of gut&#x02013;microbiota&#x02013;brain axis</article-title><source>Neurobiol Dis</source><year>2022</year><volume>165</volume><fpage>105635</fpage><pub-id pub-id-type="doi">10.1016/j.nbd.2022.105635</pub-id><pub-id pub-id-type="pmid">35085752</pub-id></element-citation></ref><ref id="CR344"><label>344.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakai</surname><given-names>T</given-names></name><name><surname>Tomiyasu</surname><given-names>S</given-names></name><name><surname>Ono</surname><given-names>T</given-names></name><name><surname>Yamada</surname><given-names>H</given-names></name><name><surname>Sumikawa</surname><given-names>K</given-names></name></person-group><article-title>Multiple sclerosis with severe pain and allodynia alleviated by oral ketamine</article-title><source>Clin J Pain</source><year>2004</year><volume>20</volume><issue>5</issue><fpage>375</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1097/00002508-200409000-00016</pub-id><pub-id pub-id-type="pmid">15322448</pub-id></element-citation></ref><ref id="CR345"><label>345.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Messer</surname><given-names>MM</given-names></name><name><surname>Haller</surname><given-names>IV</given-names></name></person-group><article-title>Ketamine therapy for treatment-resistant depression in a patient with multiple sclerosis: a case report</article-title><source>Innov Clin Neurosci.</source><year>2017</year><volume>14</volume><issue>1&#x02013;2</issue><fpage>56</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">28386522</pub-id></element-citation></ref><ref id="CR346"><label>346.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patrizi</surname><given-names>A</given-names></name><name><surname>Picard</surname><given-names>N</given-names></name><name><surname>Simon</surname><given-names>AJ</given-names></name><name><surname>Gunner</surname><given-names>G</given-names></name><name><surname>Centofante</surname><given-names>E</given-names></name><name><surname>Andrews</surname><given-names>NA</given-names></name><etal/></person-group><article-title>Chronic administration of the N-methyl-D-aspartate receptor antagonist ketamine improves Rett syndrome phenotype</article-title><source>Biol Psychiatry</source><year>2016</year><volume>79</volume><issue>9</issue><fpage>755</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2015.08.018</pub-id><pub-id pub-id-type="pmid">26410354</pub-id></element-citation></ref><ref id="CR347"><label>347.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kron</surname><given-names>M</given-names></name><name><surname>Howell</surname><given-names>CJ</given-names></name><name><surname>Adams</surname><given-names>IT</given-names></name><name><surname>Ransbottom</surname><given-names>M</given-names></name><name><surname>Christian</surname><given-names>D</given-names></name><name><surname>Ogier</surname><given-names>M</given-names></name><etal/></person-group><article-title>Brain activity mapping in Mecp2 mutant mice reveals functional deficits in forebrain circuits, including key nodes in the default mode network, that are reversed with ketamine treatment</article-title><source>J Neurosci</source><year>2012</year><volume>32</volume><issue>40</issue><fpage>13860</fpage><lpage>13872</lpage><pub-id pub-id-type="doi">10.1523/jneurosci.2159-12.2012</pub-id><pub-id pub-id-type="pmid">23035095</pub-id></element-citation></ref><ref id="CR348"><label>348.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jolly</surname><given-names>T</given-names></name><name><surname>McLean</surname><given-names>HS</given-names></name></person-group><article-title>Use of ketamine during procedural sedation: indications, controversies, and side effects</article-title><source>J Infus Nurs</source><year>2012</year><volume>35</volume><issue>6</issue><fpage>377</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1097/NAN.0b013e31827068c1</pub-id><pub-id pub-id-type="pmid">23132086</pub-id></element-citation></ref><ref id="CR349"><label>349.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mount</surname><given-names>C</given-names></name><name><surname>Downton</surname><given-names>C</given-names></name></person-group><article-title>Alzheimer disease: progress or profit?</article-title><source>Nat Med</source><year>2006</year><volume>12</volume><issue>7</issue><fpage>780</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1038/nm0706-780</pub-id><pub-id pub-id-type="pmid">16829947</pub-id></element-citation></ref><ref id="CR350"><label>350.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name></person-group><article-title>Memantine, donepezil, or combination therapy&#x02014;what is the best therapy for Alzheimer&#x02019;s disease? A network meta-analysis</article-title><source>Brain Behav</source><year>2020</year><volume>10</volume><issue>11</issue><fpage>e01831</fpage><pub-id pub-id-type="doi">10.1002/brb3.1831</pub-id><pub-id pub-id-type="pmid">32914577</pub-id></element-citation></ref><ref id="CR351"><label>351.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitt</surname><given-names>HP</given-names></name></person-group><article-title>On the paradox of ion channel blockade and its benefits in the treatment of Alzheimer disease</article-title><source>Med Hypotheses</source><year>2005</year><volume>65</volume><issue>2</issue><fpage>259</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1016/j.mehy.2005.03.011</pub-id><pub-id pub-id-type="pmid">15922097</pub-id></element-citation></ref><ref id="CR352"><label>352.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parsons</surname><given-names>C</given-names></name><name><surname>Danysz</surname><given-names>W</given-names></name><name><surname>Quack</surname><given-names>G</given-names></name></person-group><article-title>Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist&#x02014;a review of preclinical data</article-title><source>Neuropharmacol</source><year>1999</year><volume>38</volume><issue>6</issue><fpage>735</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1016/s0028-3908(99)00019-2</pub-id></element-citation></ref><ref id="CR353"><label>353.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogawski</surname><given-names>MA</given-names></name><name><surname>Wenk</surname><given-names>GL</given-names></name></person-group><article-title>The neuropharmacological basis for the use of memantine in the treatment of Alzheimer&#x02019;s disease</article-title><source>CNS Drug Rev</source><year>2003</year><volume>9</volume><issue>3</issue><fpage>275</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1111/j.1527-3458.2003.tb00254.x</pub-id><pub-id pub-id-type="pmid">14530799</pub-id></element-citation></ref><ref id="CR354"><label>354.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martina</surname><given-names>M</given-names></name><name><surname>Turcotte</surname><given-names>MEB</given-names></name><name><surname>Halman</surname><given-names>S</given-names></name><name><surname>Bergeron</surname><given-names>R</given-names></name></person-group><article-title>The sigma-1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampus</article-title><source>J Physiol</source><year>2007</year><volume>578</volume><issue>1</issue><fpage>143</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.2006.116178</pub-id><pub-id pub-id-type="pmid">17068104</pub-id></element-citation></ref><ref id="CR355"><label>355.</label><mixed-citation publication-type="other">Chaki S, Okuyama S, Ogawa S-i, Tomisawa K. Regulation of NMDA-induced [3H] dopamine release from rat hippocampal slices through sigma-1 binding sites. Neurochem Int. 1998;33(1):29&#x02013;34. 10.1113/jphysiol.2006.116178.</mixed-citation></ref><ref id="CR356"><label>356.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sha</surname><given-names>S</given-names></name><name><surname>Qu</surname><given-names>WJ</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>ZH</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>WF</given-names></name><etal/></person-group><article-title>Sigma-1 receptor knockout impairs neurogenesis in dentate gyrus of adult hippocampus via down-regulation of NMDA receptors</article-title><source>CNS Neurosci Ther</source><year>2013</year><volume>19</volume><issue>9</issue><fpage>705</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1111/cns.12129</pub-id><pub-id pub-id-type="pmid">23745740</pub-id></element-citation></ref><ref id="CR357"><label>357.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pabba</surname><given-names>M</given-names></name><name><surname>Wong</surname><given-names>AY</given-names></name><name><surname>Ahlskog</surname><given-names>N</given-names></name><name><surname>Hristova</surname><given-names>E</given-names></name><name><surname>Biscaro</surname><given-names>D</given-names></name><name><surname>Nassrallah</surname><given-names>W</given-names></name><etal/></person-group><article-title>NMDA receptors are upregulated and trafficked to the plasma membrane after sigma-1 receptor activation in the rat hippocampus</article-title><source>J Neurosci</source><year>2014</year><volume>34</volume><issue>34</issue><fpage>11325</fpage><lpage>11338</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0458-14.2014</pub-id><pub-id pub-id-type="pmid">25143613</pub-id></element-citation></ref><ref id="CR358"><label>358.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stahl</surname><given-names>SM</given-names></name></person-group><article-title>Mechanism of action of ketamine</article-title><source>CNS Spectr</source><year>2013</year><volume>18</volume><issue>4</issue><fpage>171</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1017/S109285291300045X</pub-id><pub-id pub-id-type="pmid">23866089</pub-id></element-citation></ref><ref id="CR359"><label>359.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winblad</surname><given-names>B</given-names></name><name><surname>Jones</surname><given-names>RW</given-names></name><name><surname>Wirth</surname><given-names>Y</given-names></name><name><surname>St&#x000f6;ffler</surname><given-names>A</given-names></name><name><surname>M&#x000f6;bius</surname><given-names>HJ</given-names></name></person-group><article-title>Memantine in moderate to severe Alzheimer&#x02019;s disease: a meta-analysis of randomised clinical trials</article-title><source>Dement Geriatr Cogn Disord</source><year>2007</year><volume>24</volume><issue>1</issue><fpage>20</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1159/000102568</pub-id><pub-id pub-id-type="pmid">17496417</pub-id></element-citation></ref><ref id="CR360"><label>360.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atri</surname><given-names>A</given-names></name><name><surname>Molinuevo</surname><given-names>JL</given-names></name><name><surname>Lemming</surname><given-names>O</given-names></name><name><surname>Wirth</surname><given-names>Y</given-names></name><name><surname>Pulte</surname><given-names>I</given-names></name><name><surname>Wilkinson</surname><given-names>D</given-names></name></person-group><article-title>Memantine in patients with Alzheimer&#x02019;s disease receiving donepezil: new analyses of efficacy and safety for combination therapy</article-title><source>Alzheimers Res Ther.</source><year>2013</year><volume>5</volume><issue>1</issue><fpage>6</fpage><pub-id pub-id-type="doi">10.1186/alzrt160</pub-id><pub-id pub-id-type="pmid">23336974</pub-id></element-citation></ref><ref id="CR361"><label>361.</label><mixed-citation publication-type="other">Schmitt FA, van Dyck CH, Wichems CH, Olin JT, Group MM-M-S. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Dis Assoc Disord. 2006;20(4):255&#x02013;62. 10.1097/01.wad.0000213860.35355.d4.</mixed-citation></ref><ref id="CR362"><label>362.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez</surname><given-names>OL</given-names></name><name><surname>Becker</surname><given-names>JT</given-names></name><name><surname>Wahed</surname><given-names>AS</given-names></name><name><surname>Saxton</surname><given-names>J</given-names></name><name><surname>Sweet</surname><given-names>RA</given-names></name><name><surname>Wolk</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2009</year><volume>80</volume><issue>6</issue><fpage>600</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2008.158964</pub-id><pub-id pub-id-type="pmid">19204022</pub-id></element-citation></ref><ref id="CR363"><label>363.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tariot</surname><given-names>PN</given-names></name><name><surname>Farlow</surname><given-names>MR</given-names></name><name><surname>Grossberg</surname><given-names>GT</given-names></name><name><surname>Graham</surname><given-names>SM</given-names></name><name><surname>McDonald</surname><given-names>S</given-names></name><name><surname>Gergel</surname><given-names>I</given-names></name><etal/></person-group><article-title>Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial</article-title><source>JAMA</source><year>2004</year><volume>291</volume><issue>3</issue><fpage>317</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1001/jama.291.3.317</pub-id><pub-id pub-id-type="pmid">14734594</pub-id></element-citation></ref><ref id="CR364"><label>364.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendrix</surname><given-names>S</given-names></name><name><surname>Ellison</surname><given-names>N</given-names></name><name><surname>Stanworth</surname><given-names>S</given-names></name><name><surname>Otcheretko</surname><given-names>V</given-names></name><name><surname>Tariot</surname><given-names>PN</given-names></name></person-group><article-title>Post Hoc Evidence for an additive effect of memantine and donepezil: consistent findings from DOMINO-AD Study and Memantine Clinical Trial Program</article-title><source>J Prev Alzheimers Dis.</source><year>2015</year><volume>2</volume><issue>3</issue><fpage>165</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.14283/jpad.2015.66</pub-id><pub-id pub-id-type="pmid">29226942</pub-id></element-citation></ref><ref id="CR365"><label>365.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porsteinsson</surname><given-names>AP</given-names></name><name><surname>Grossberg</surname><given-names>GT</given-names></name><name><surname>Mintzer</surname><given-names>J</given-names></name><name><surname>Olin</surname><given-names>JT</given-names></name></person-group><article-title>Memantine treatment in patients with mild to moderate Alzheimer&#x02019;s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial</article-title><source>Curr Alzheimer Res</source><year>2008</year><volume>5</volume><issue>1</issue><fpage>83</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.2174/156720508783884576</pub-id><pub-id pub-id-type="pmid">18288936</pub-id></element-citation></ref><ref id="CR366"><label>366.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leroi</surname><given-names>I</given-names></name><name><surname>Overshott</surname><given-names>R</given-names></name><name><surname>Byrne</surname><given-names>EJ</given-names></name><name><surname>Daniel</surname><given-names>E</given-names></name><name><surname>Burns</surname><given-names>A</given-names></name></person-group><article-title>Randomized controlled trial of memantine in dementia associated with Parkinson&#x02019;s disease</article-title><source>Mov Disord</source><year>2009</year><volume>24</volume><issue>8</issue><fpage>1217</fpage><lpage>1221</lpage><pub-id pub-id-type="doi">10.1002/mds.22495</pub-id><pub-id pub-id-type="pmid">19370737</pub-id></element-citation></ref><ref id="CR367"><label>367.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emre</surname><given-names>M</given-names></name><name><surname>Tsolaki</surname><given-names>M</given-names></name><name><surname>Bonuccelli</surname><given-names>U</given-names></name><name><surname>Dest&#x000e9;e</surname><given-names>A</given-names></name><name><surname>Tolosa</surname><given-names>E</given-names></name><name><surname>Kutzelnigg</surname><given-names>A</given-names></name><etal/></person-group><article-title>Memantine for patients with Parkinson&#x02019;s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial</article-title><source>Lancet Neurol</source><year>2010</year><volume>9</volume><issue>10</issue><fpage>969</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(10)70194-0</pub-id><pub-id pub-id-type="pmid">20729148</pub-id></element-citation></ref><ref id="CR368"><label>368.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ondo</surname><given-names>WG</given-names></name><name><surname>Shinawi</surname><given-names>L</given-names></name><name><surname>Davidson</surname><given-names>A</given-names></name><etal/></person-group><article-title>Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial</article-title><source>Parkinsonism Relat Disord</source><year>2011</year><volume>17</volume><issue>3</issue><fpage>156</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2010.12.003</pub-id><pub-id pub-id-type="pmid">21193343</pub-id></element-citation></ref><ref id="CR369"><label>369.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreau</surname><given-names>C</given-names></name><name><surname>Delval</surname><given-names>A</given-names></name><name><surname>Tiffreau</surname><given-names>V</given-names></name><etal/></person-group><article-title>Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2013</year><volume>84</volume><issue>5</issue><fpage>552</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2012-303182</pub-id><pub-id pub-id-type="pmid">23077087</pub-id></element-citation></ref><ref id="CR370"><label>370.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>HF</given-names></name><name><surname>Yu</surname><given-names>JT</given-names></name><name><surname>Tang</surname><given-names>SW</given-names></name><name><surname>Jiang</surname><given-names>T</given-names></name><name><surname>Tan</surname><given-names>CC</given-names></name><name><surname>Meng</surname><given-names>XF</given-names></name><etal/></person-group><article-title>Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson&#x02019;s disease, Parkinson&#x02019;s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2015</year><volume>86</volume><issue>2</issue><fpage>135</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2014-307659</pub-id><pub-id pub-id-type="pmid">24828899</pub-id></element-citation></ref><ref id="CR371"><label>371.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanjay</surname><given-names>M</given-names></name><name><surname>Amir</surname><given-names>G</given-names></name><name><surname>John</surname><given-names>R</given-names></name><name><surname>Scott</surname><given-names>O</given-names></name><name><surname>Stephen</surname><given-names>D</given-names></name><etal/></person-group><article-title>Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study</article-title><source>Clin Ther</source><year>2008</year><volume>30</volume><fpage>9</fpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2008.09.006</pub-id></element-citation></ref><ref id="CR372"><label>372.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rickels</surname><given-names>K</given-names></name><name><surname>Mathew</surname><given-names>S</given-names></name><name><surname>Banov</surname><given-names>MD</given-names></name><name><surname>Zimbroff</surname><given-names>DL</given-names></name><name><surname>Oshana</surname><given-names>S</given-names></name><name><surname>Parsons</surname><given-names>EC</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial</article-title><source>J Clin Psychopharmacol</source><year>2008</year><volume>28</volume><issue>2</issue><fpage>235</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1097/JCP.0b013e31816774de</pub-id><pub-id pub-id-type="pmid">18344738</pub-id></element-citation></ref><ref id="CR373"><label>373.</label><mixed-citation publication-type="other">PRX-00023 Therapy in localization-related epilepsy. In: NIH U.S. National Library of Medicine clinical trials web site; 2011. https://clinicaltrials.gov/ct2/show/NCT01281956. Accessed 1 Dec 2022.</mixed-citation></ref><ref id="CR374"><label>374.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merritt</surname><given-names>HH</given-names></name><name><surname>Putnam</surname><given-names>TJ</given-names></name></person-group><article-title>Sodium diphenyl hydantoinate in the treatment of convulsive disorders</article-title><source>J Am Med Assoc</source><year>1938</year><volume>111</volume><issue>12</issue><fpage>1068</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.1001/jama.1938.02790380010004</pub-id></element-citation></ref><ref id="CR375"><label>375.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogawski</surname><given-names>MA</given-names></name><name><surname>L&#x000f6;scher</surname><given-names>W</given-names></name></person-group><article-title>The neurobiology of antiepileptic drugs</article-title><source>Nat Rev Neurosci</source><year>2004</year><volume>5</volume><issue>7</issue><fpage>553</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1038/nrn1430</pub-id><pub-id pub-id-type="pmid">15208697</pub-id></element-citation></ref><ref id="CR376"><label>376.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tchedre</surname><given-names>KT</given-names></name><name><surname>Huang</surname><given-names>RQ</given-names></name><name><surname>Dibas</surname><given-names>A</given-names></name><name><surname>Krishnamoorthy</surname><given-names>RR</given-names></name><name><surname>Dillon</surname><given-names>GH</given-names></name><name><surname>Yorio</surname><given-names>T</given-names></name></person-group><article-title>Sigma-1 receptor regulation of voltage-gated calcium channels involves a direct interaction</article-title><source>Invest Ophthalmol Vis Sci</source><year>2008</year><volume>49</volume><issue>11</issue><fpage>4993</fpage><lpage>5002</lpage><pub-id pub-id-type="doi">10.1167/iovs.08-1867</pub-id><pub-id pub-id-type="pmid">18641291</pub-id></element-citation></ref><ref id="CR377"><label>377.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mueller</surname><given-names>BH</given-names><suffix>II</suffix></name><name><surname>Park</surname><given-names>Y</given-names></name><name><surname>Daudt</surname><given-names>DR</given-names><suffix>III</suffix></name><name><surname>Ma</surname><given-names>H-Y</given-names></name><name><surname>Akopova</surname><given-names>I</given-names></name><name><surname>Stankowska</surname><given-names>DL</given-names></name><etal/></person-group><article-title>Sigma-1 receptor stimulation attenuates calcium influx through activated L-type voltage gated calcium channels in purified retinal ganglion cells</article-title><source>Exp Eye Res</source><year>2013</year><volume>107</volume><fpage>21</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.exer.2012.11.002</pub-id><pub-id pub-id-type="pmid">23183135</pub-id></element-citation></ref><ref id="CR378"><label>378.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Lan</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Sigma-1 receptor plays a negative modulation on N-type calcium channel</article-title><source>Front Pharmacol</source><year>2017</year><volume>8</volume><fpage>302</fpage><pub-id pub-id-type="doi">10.3389/fphar.2017.00302</pub-id><pub-id pub-id-type="pmid">28603497</pub-id></element-citation></ref><ref id="CR379"><label>379.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Cuevas</surname><given-names>J</given-names></name></person-group><article-title>Sigma receptors inhibit high-voltage&#x02013;activated calcium channels in rat sympathetic and parasympathetic neurons</article-title><source>J Neurophysiol</source><year>2002</year><volume>87</volume><issue>6</issue><fpage>2867</fpage><lpage>2879</lpage><pub-id pub-id-type="doi">10.1152/jn.2002.87.6.2867</pub-id><pub-id pub-id-type="pmid">12037190</pub-id></element-citation></ref><ref id="CR380"><label>380.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeHaven-Hudkins</surname><given-names>D</given-names></name><name><surname>Ford-Rice</surname><given-names>F</given-names></name><name><surname>Allen</surname><given-names>J</given-names></name><name><surname>Hudkins</surname><given-names>R</given-names></name></person-group><article-title>Allosteric modulation of ligand binding to [3H](+) pentazocine-defined &#x003c3; recognition sites by phenytoin</article-title><source>Life Sci</source><year>1993</year><volume>53</volume><issue>1</issue><fpage>41</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/0024-3205(93)90609-7</pub-id><pub-id pub-id-type="pmid">8515681</pub-id></element-citation></ref><ref id="CR381"><label>381.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braakman</surname><given-names>HM</given-names></name><name><surname>Verhoeven</surname><given-names>JS</given-names></name><name><surname>Erasmus</surname><given-names>CE</given-names></name><name><surname>Haaxma</surname><given-names>CA</given-names></name><name><surname>Willemsen</surname><given-names>MH</given-names></name><name><surname>Schelhaas</surname><given-names>HJ</given-names></name></person-group><article-title>Phenytoin as a last-resort treatment in SCN 8A encephalopathy</article-title><source>Epilepsia Open.</source><year>2017</year><volume>2</volume><issue>3</issue><fpage>343</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1002/epi4.12059</pub-id><pub-id pub-id-type="pmid">29588963</pub-id></element-citation></ref><ref id="CR382"><label>382.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dilena</surname><given-names>R</given-names></name><name><surname>Striano</surname><given-names>P</given-names></name><name><surname>Gennaro</surname><given-names>E</given-names></name><name><surname>Bassi</surname><given-names>L</given-names></name><name><surname>Olivotto</surname><given-names>S</given-names></name><name><surname>Tadini</surname><given-names>L</given-names></name><etal/></person-group><article-title>Efficacy of sodium channel blockers in SCN2A early infantile epileptic encephalopathy</article-title><source>Brain Dev</source><year>2017</year><volume>39</volume><issue>4</issue><fpage>345</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1016/j.braindev.2016.10.015</pub-id><pub-id pub-id-type="pmid">27876397</pub-id></element-citation></ref><ref id="CR383"><label>383.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>TP</given-names></name><name><surname>Wu</surname><given-names>XZ</given-names></name><name><surname>Cone</surname><given-names>EJ</given-names></name><name><surname>Shukla</surname><given-names>K</given-names></name><name><surname>Gund</surname><given-names>TM</given-names></name><name><surname>Dodge</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Sigma compounds derived from phencyclidine: identification of PRE-084, a new, selective sigma ligand</article-title><source>J Pharmacol Exp Ther</source><year>1991</year><volume>259</volume><issue>2</issue><fpage>543</fpage><lpage>550</lpage><pub-id pub-id-type="pmid">1658302</pub-id></element-citation></ref><ref id="CR384"><label>384.</label><mixed-citation publication-type="other">Motawe ZY, Abdelmaboud SS, Cuevas J, Breslin JW. PRE-084 as a tool to uncover potential therapeutic applications for selective sigma-1 receptor activation. Int J Biochem Cell Biol. 2020;126:105803; <underline>Doi: </underline>10.1016/j.biocel.2020.105803</mixed-citation></ref><ref id="CR385"><label>385.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motawe</surname><given-names>ZY</given-names></name><name><surname>Farsaei</surname><given-names>F</given-names></name><name><surname>Abdelmaboud</surname><given-names>SS</given-names></name><name><surname>Cuevas</surname><given-names>J</given-names></name><name><surname>Breslin</surname><given-names>JW</given-names></name></person-group><article-title>Sigma-1 receptor activation-induced glycolytic ATP production and endothelial barrier enhancement</article-title><source>Microcirculation</source><year>2020</year><volume>27</volume><issue>6</issue><fpage>e12620</fpage><pub-id pub-id-type="doi">10.1111/micc.12620</pub-id><pub-id pub-id-type="pmid">32279379</pub-id></element-citation></ref><ref id="CR386"><label>386.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>Y</given-names></name><name><surname>Qi</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Jia</surname><given-names>D</given-names></name></person-group><article-title>Activation of the sigma-1 receptor attenuates blood&#x02013;brain barrier disruption by inhibiting amyloid deposition in Alzheimer&#x02019;s disease mice</article-title><source>Neurosci Lett</source><year>2022</year><volume>774</volume><fpage>136528</fpage><pub-id pub-id-type="doi">10.1016/j.neulet.2022.136528</pub-id><pub-id pub-id-type="pmid">35157973</pub-id></element-citation></ref><ref id="CR387"><label>387.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penas</surname><given-names>C</given-names></name><name><surname>Pascual-Font</surname><given-names>A</given-names></name><name><surname>Mancuso</surname><given-names>R</given-names></name><name><surname>For&#x000e9;s</surname><given-names>J</given-names></name><name><surname>Casas</surname><given-names>C</given-names></name><name><surname>Navarro</surname><given-names>X</given-names></name></person-group><article-title>Sigma receptor agonist 2-(4-morpholinethyl) 1 phenylcyclohexanecarboxylate (Pre084) increases GDNF and BiP expression and promotes neuroprotection after root avulsion injury</article-title><source>J Neurotrauma</source><year>2011</year><volume>28</volume><issue>5</issue><fpage>831</fpage><lpage>840</lpage><pub-id pub-id-type="doi">10.1089/neu.2010.1674</pub-id><pub-id pub-id-type="pmid">21332255</pub-id></element-citation></ref><ref id="CR388"><label>388.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Francardo</surname><given-names>V</given-names></name><name><surname>Bez</surname><given-names>F</given-names></name><name><surname>Wieloch</surname><given-names>T</given-names></name><name><surname>Nissbrandt</surname><given-names>H</given-names></name><name><surname>Ruscher</surname><given-names>K</given-names></name><name><surname>Cenci</surname><given-names>MA</given-names></name></person-group><article-title>Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism</article-title><source>Brain</source><year>2014</year><volume>137</volume><issue>7</issue><fpage>1998</fpage><lpage>2014</lpage><pub-id pub-id-type="doi">10.1093/brain/awu107</pub-id><pub-id pub-id-type="pmid">24755275</pub-id></element-citation></ref><ref id="CR389"><label>389.</label><mixed-citation publication-type="other">Rao YL, Ganaraja B, Murlimanju BV, Joy T, Krishnamurthy A, Agrawal A. Hippocampus and its involvement in Alzheimer&#x02019;s disease: a review. 3 Biotech. 2022;12(2):55; <underline>Doi: </underline>10.1007/s13205-022-03123-4</mixed-citation></ref><ref id="CR390"><label>390.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eriksson</surname><given-names>PS</given-names></name><name><surname>Perfilieva</surname><given-names>E</given-names></name><name><surname>Bj&#x000f6;rk-Eriksson</surname><given-names>T</given-names></name><name><surname>Alborn</surname><given-names>A-M</given-names></name><name><surname>Nordborg</surname><given-names>C</given-names></name><name><surname>Peterson</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Neurogenesis in the adult human hippocampus</article-title><source>Nat Med</source><year>1998</year><volume>4</volume><issue>11</issue><fpage>1313</fpage><lpage>1317</lpage><pub-id pub-id-type="doi">10.1038/3305</pub-id><pub-id pub-id-type="pmid">9809557</pub-id></element-citation></ref><ref id="CR391"><label>391.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borb&#x000e9;ly</surname><given-names>E</given-names></name><name><surname>Varga</surname><given-names>V</given-names></name><name><surname>Sz&#x000f6;gi</surname><given-names>T</given-names></name><name><surname>Schuster</surname><given-names>I</given-names></name><name><surname>Bozs&#x000f3;</surname><given-names>Z</given-names></name><name><surname>Penke</surname><given-names>B</given-names></name><etal/></person-group><article-title>Impact of two neuronal Sigma-1 receptor modulators, PRE084 and DMT, on neurogenesis and neuroinflammation in an A&#x003b2;1&#x02013;42-injected, wild-type mouse model of AD</article-title><source>Int J Mol Sci</source><year>2022</year><volume>23</volume><issue>5</issue><fpage>2514</fpage><pub-id pub-id-type="doi">10.3390/ijms23052514</pub-id><pub-id pub-id-type="pmid">35269657</pub-id></element-citation></ref><ref id="CR392"><label>392.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Sokabe</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><article-title>DHEA prevents A&#x003b2;25&#x02013;35-impaired survival of newborn neurons in the dentate gyrus through a modulation of PI3K-Akt-mTOR signaling</article-title><source>Neuropharmacol</source><year>2010</year><volume>59</volume><issue>4&#x02013;5</issue><fpage>323</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2010.02.009</pub-id></element-citation></ref><ref id="CR393"><label>393.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Est&#x000e9;vez-Silva</surname><given-names>HM</given-names></name><name><surname>Cuesto</surname><given-names>G</given-names></name><name><surname>Romero</surname><given-names>N</given-names></name><name><surname>Brito-Armas</surname><given-names>JM</given-names></name><name><surname>Acevedo-Arozena</surname><given-names>A</given-names></name><name><surname>Acebes</surname><given-names>&#x000c1;</given-names></name><etal/></person-group><article-title>Pridopidine promotes synaptogenesis and reduces spatial memory deficits in the Alzheimer&#x02019;s disease APP/PS1 mouse model</article-title><source>Neurotherapeutics</source><year>2022</year><volume>19</volume><issue>5</issue><fpage>1566</fpage><lpage>1587</lpage><pub-id pub-id-type="doi">10.1007/s13311-022-01280-1</pub-id><pub-id pub-id-type="pmid">35917088</pub-id></element-citation></ref><ref id="CR394"><label>394.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guzm&#x000e1;n-Lenis</surname><given-names>MS</given-names></name><name><surname>Navarro</surname><given-names>X</given-names></name><name><surname>Casas</surname><given-names>C</given-names></name></person-group><article-title>Selective sigma receptor agonist 2-(4-morpholinethyl) 1-phenylcyclohexanecarboxylate (PRE084) promotes neuroprotection and neurite elongation through protein kinase C (PKC) signaling on motoneurons</article-title><source>Neuroscience</source><year>2009</year><volume>162</volume><issue>1</issue><fpage>31</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2009.03.067</pub-id><pub-id pub-id-type="pmid">19345724</pub-id></element-citation></ref><ref id="CR395"><label>395.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancuso</surname><given-names>R</given-names></name><name><surname>Oliv&#x000e1;n</surname><given-names>S</given-names></name><name><surname>Rando</surname><given-names>A</given-names></name><name><surname>Casas</surname><given-names>C</given-names></name><name><surname>Osta</surname><given-names>R</given-names></name><name><surname>Navarro</surname><given-names>X</given-names></name></person-group><article-title>Sigma-1R agonist improves motor function and motoneuron survival in ALS mice</article-title><source>Neurotherapeutics</source><year>2012</year><volume>9</volume><issue>4</issue><fpage>814</fpage><lpage>826</lpage><pub-id pub-id-type="doi">10.1007/s13311-012-0140-y</pub-id><pub-id pub-id-type="pmid">22935988</pub-id></element-citation></ref><ref id="CR396"><label>396.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancuso</surname><given-names>R</given-names></name><name><surname>Del Valle</surname><given-names>J</given-names></name><name><surname>Morell</surname><given-names>M</given-names></name><name><surname>Pall&#x000e1;s</surname><given-names>M</given-names></name><name><surname>Osta</surname><given-names>R</given-names></name><name><surname>Navarro</surname><given-names>X</given-names></name></person-group><article-title>Lack of synergistic effect of resveratrol and sigma-1 receptor agonist (PRE-084) in SOD1G93A ALS mice: overlapping effects or limited therapeutic opportunity?</article-title><source>Orphanet J Rare Dis</source><year>2014</year><volume>9</volume><issue>1</issue><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1186/1750-1172-9-78</pub-id><pub-id pub-id-type="pmid">24393603</pub-id></element-citation></ref><ref id="CR397"><label>397.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaja-Capdevila</surname><given-names>N</given-names></name><name><surname>Hern&#x000e1;ndez</surname><given-names>N</given-names></name><name><surname>Navarro</surname><given-names>X</given-names></name><name><surname>Herrando-Grabulosa</surname><given-names>M</given-names></name></person-group><article-title>Sigma-1 receptor is a pharmacological target to promote neuroprotection in the SOD1G93A ALS mice</article-title><source>Front Pharmacol</source><year>2021</year><volume>12</volume><fpage>780588</fpage><pub-id pub-id-type="doi">10.3389/fphar.2021.780588</pub-id><pub-id pub-id-type="pmid">34955848</pub-id></element-citation></ref><ref id="CR398"><label>398.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peviani</surname><given-names>M</given-names></name><name><surname>Salvaneschi</surname><given-names>E</given-names></name><name><surname>Bontempi</surname><given-names>L</given-names></name><name><surname>Petese</surname><given-names>A</given-names></name><name><surname>Manzo</surname><given-names>A</given-names></name><name><surname>Rossi</surname><given-names>D</given-names></name><etal/></person-group><article-title>Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation</article-title><source>Neurobiol Dis</source><year>2014</year><volume>62</volume><fpage>218</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2013.10.010</pub-id><pub-id pub-id-type="pmid">24141020</pub-id></element-citation></ref><ref id="CR399"><label>399.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barwick</surname><given-names>SR</given-names></name><name><surname>Siddiq</surname><given-names>MS</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>H</given-names></name><name><surname>Marshall</surname><given-names>B</given-names></name><name><surname>Perry</surname><given-names>E</given-names></name><etal/></person-group><article-title>Sigma 1 receptor co-localizes with NRF2 in retinal photoreceptor cells</article-title><source>Antioxidants</source><year>2021</year><volume>10</volume><issue>6</issue><fpage>981</fpage><pub-id pub-id-type="doi">10.3390/antiox10060981</pub-id><pub-id pub-id-type="pmid">34205384</pub-id></element-citation></ref><ref id="CR400"><label>400.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weng</surname><given-names>TY</given-names></name><name><surname>Hung</surname><given-names>DT</given-names></name><name><surname>Su</surname><given-names>TP</given-names></name><name><surname>Tsai</surname><given-names>SYA</given-names></name></person-group><article-title>Loss of Sigma-1 receptor chaperone promotes astrocytosis and enhances the Nrf2 antioxidant defense</article-title><source>Oxid Med Cell Longev</source><year>2017</year><volume>2017</volume><fpage>4582135</fpage><pub-id pub-id-type="doi">10.1155/2017/4582135</pub-id><pub-id pub-id-type="pmid">28883901</pub-id></element-citation></ref><ref id="CR401"><label>401.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lasbleiz</surname><given-names>C</given-names></name><name><surname>Peyrel</surname><given-names>A</given-names></name><name><surname>Tarot</surname><given-names>P</given-names></name><name><surname>Sarniguet</surname><given-names>J</given-names></name><name><surname>Crouzier</surname><given-names>L</given-names></name><name><surname>Cubedo</surname><given-names>N</given-names></name><etal/></person-group><article-title>Sigma-1 receptor agonist PRE-084 confers protection against TAR DNA-binding protein-43 toxicity through NRF2 signalling</article-title><source>Redox Biol</source><year>2022</year><volume>58</volume><fpage>102542</fpage><pub-id pub-id-type="doi">10.1016/j.redox.2022.102542</pub-id><pub-id pub-id-type="pmid">36442393</pub-id></element-citation></ref><ref id="CR402"><label>402.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hyrskyluoto</surname><given-names>A</given-names></name><name><surname>Pulli</surname><given-names>I</given-names></name><name><surname>T&#x000f6;rnqvist</surname><given-names>K</given-names></name><name><surname>Ho</surname><given-names>H</given-names></name><name><surname>Korhonen</surname><given-names>L</given-names></name><name><surname>Lindholm</surname><given-names>D</given-names></name></person-group><article-title>Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: involvement of calpastatin and the NF-&#x003ba;B pathway</article-title><source>Cell Death Dis</source><year>2013</year><volume>4</volume><issue>5</issue><fpage>e646</fpage><pub-id pub-id-type="doi">10.1038/cddis.2013.170</pub-id><pub-id pub-id-type="pmid">23703391</pub-id></element-citation></ref><ref id="CR403"><label>403.</label><mixed-citation publication-type="other">Bol&#x02019;Shakova A, Kraskovskaya N, Gainullina A, Kukanova E, Vlasova O, Bezprozvanny I. Neuroprotective effect of &#x003c3;1-receptors on the cell model of Huntington&#x02019;s disease. Bull Exp Biol Med. 2017;164:252&#x02013;8. 10.1007/s10517-017-3968-7.</mixed-citation></ref><ref id="CR404"><label>404.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnston</surname><given-names>TH</given-names></name><name><surname>Geva</surname><given-names>M</given-names></name><name><surname>Steiner</surname><given-names>L</given-names></name><name><surname>Orbach</surname><given-names>A</given-names></name><name><surname>Papapetropoulos</surname><given-names>S</given-names></name><name><surname>Savola</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Pridopidine, a clinic-ready compound, reduces 3, 4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques</article-title><source>Mov Disord</source><year>2019</year><volume>34</volume><issue>5</issue><fpage>708</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1002/mds.27565</pub-id><pub-id pub-id-type="pmid">30575996</pub-id></element-citation></ref><ref id="CR405"><label>405.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grachev</surname><given-names>ID</given-names></name><name><surname>Meyer</surname><given-names>PM</given-names></name><name><surname>Becker</surname><given-names>GA</given-names></name><name><surname>Bronzel</surname><given-names>M</given-names></name><name><surname>Marsteller</surname><given-names>D</given-names></name><name><surname>Pastino</surname><given-names>G</given-names></name><etal/></person-group><article-title>Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [(18)F] fluspidine and [(18)F] fallypride PET study</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2021</year><volume>48</volume><issue>4</issue><fpage>1103</fpage><lpage>1115</lpage><pub-id pub-id-type="doi">10.1007/s00259-020-05030-3</pub-id><pub-id pub-id-type="pmid">32995944</pub-id></element-citation></ref><ref id="CR406"><label>406.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahlholm</surname><given-names>K</given-names></name><name><surname>Sijbesma</surname><given-names>JWA</given-names></name><name><surname>Maas</surname><given-names>B</given-names></name><name><surname>Kwizera</surname><given-names>C</given-names></name><name><surname>Marcellino</surname><given-names>D</given-names></name><name><surname>Ramakrishnan</surname><given-names>NK</given-names></name><etal/></person-group><article-title>Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses</article-title><source>Psychopharmacology</source><year>2015</year><volume>232</volume><issue>18</issue><fpage>3443</fpage><lpage>3453</lpage><pub-id pub-id-type="doi">10.1007/s00213-015-3997-8</pub-id><pub-id pub-id-type="pmid">26159455</pub-id></element-citation></ref><ref id="CR407"><label>407.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourne</surname><given-names>J</given-names></name><name><surname>Harris</surname><given-names>KM</given-names></name></person-group><article-title>Do thin spines learn to be mushroom spines that remember?</article-title><source>Curr Opin Neurobiol</source><year>2007</year><volume>17</volume><issue>3</issue><fpage>381</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1016/j.conb.2007.04.009</pub-id><pub-id pub-id-type="pmid">17498943</pub-id></element-citation></ref><ref id="CR408"><label>408.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourne</surname><given-names>JN</given-names></name><name><surname>Harris</surname><given-names>KM</given-names></name></person-group><article-title>Balancing structure and function at hippocampal dendritic spines</article-title><source>Annu Rev Neurosci</source><year>2008</year><volume>31</volume><fpage>47</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1146/annurev.neuro.31.060407.125646</pub-id><pub-id pub-id-type="pmid">18284372</pub-id></element-citation></ref><ref id="CR409"><label>409.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi-Takagi</surname><given-names>A</given-names></name><name><surname>Yagishita</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Shirai</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>YI</given-names></name><name><surname>Loshbaugh</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Labelling and optical erasure of synaptic memory traces in the motor cortex</article-title><source>Nature</source><year>2015</year><volume>525</volume><issue>7569</issue><fpage>333</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1038/nature15257</pub-id><pub-id pub-id-type="pmid">26352471</pub-id></element-citation></ref><ref id="CR410"><label>410.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ionescu</surname><given-names>A</given-names></name><name><surname>Gradus</surname><given-names>T</given-names></name><name><surname>Altman</surname><given-names>T</given-names></name><name><surname>Maimon</surname><given-names>R</given-names></name><name><surname>Avraham</surname><given-names>NS</given-names></name><name><surname>Geva</surname><given-names>M</given-names></name><etal/></person-group><article-title>Targeting the sigma-1 receptor via pridopidine ameliorates central features of ALS pathology in a SOD1G93A model</article-title><source>Cell Death Dis</source><year>2019</year><volume>10</volume><issue>3</issue><fpage>210</fpage><pub-id pub-id-type="doi">10.1038/s41419-019-1451-2</pub-id><pub-id pub-id-type="pmid">30824685</pub-id></element-citation></ref><ref id="CR411"><label>411.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Est&#x000e9;vez-Silva</surname><given-names>HM</given-names></name><name><surname>Mediavilla</surname><given-names>T</given-names></name><name><surname>Giacobbo</surname><given-names>BL</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Sultan</surname><given-names>FR</given-names></name><name><surname>Marcellino</surname><given-names>DJ</given-names></name></person-group><article-title>Pridopidine modifies disease phenotype in a SOD1 mouse model of amyotrophic lateral sclerosis</article-title><source>Eur J Neurosci</source><year>2022</year><volume>55</volume><issue>5</issue><fpage>1356</fpage><lpage>1372</lpage><pub-id pub-id-type="doi">10.1111/ejn.15608</pub-id><pub-id pub-id-type="pmid">35080077</pub-id></element-citation></ref><ref id="CR412"><label>412.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S-M</given-names></name><name><surname>Wu</surname><given-names>H-E</given-names></name><name><surname>Yasui</surname><given-names>Y</given-names></name><name><surname>Geva</surname><given-names>M</given-names></name><name><surname>Hayden</surname><given-names>M</given-names></name><name><surname>Maurice</surname><given-names>T</given-names></name><etal/></person-group><article-title>Nucleoporin POM121 signals TFEB-mediated autophagy via activation of SIGMAR1/sigma-1 receptor chaperone by pridopidine</article-title><source>Autophagy</source><year>2023</year><volume>19</volume><issue>1</issue><fpage>126</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1080/15548627.2022.2063003</pub-id><pub-id pub-id-type="pmid">35507432</pub-id></element-citation></ref><ref id="CR413"><label>413.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Miralles</surname><given-names>M</given-names></name><name><surname>Geva</surname><given-names>M</given-names></name><name><surname>Tan</surname><given-names>JY</given-names></name><name><surname>Yusof</surname><given-names>NABM</given-names></name><name><surname>Cha</surname><given-names>Y</given-names></name><name><surname>Kusko</surname><given-names>R</given-names></name><etal/></person-group><article-title>Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice</article-title><source>JCI insight.</source><year>2017</year><volume>2</volume><fpage>23</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.95665</pub-id></element-citation></ref><ref id="CR414"><label>414.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>KQ</given-names></name><name><surname>Rymar</surname><given-names>VV</given-names></name><name><surname>Sadikot</surname><given-names>AF</given-names></name></person-group><article-title>Impaired TrkB signaling underlies reduced BDNF-mediated trophic support of striatal neurons in the R6/2 mouse model of Huntington&#x02019;s disease</article-title><source>Front Cell Neurosci</source><year>2016</year><volume>10</volume><fpage>37</fpage><pub-id pub-id-type="doi">10.3389/fncel.2016.00037</pub-id><pub-id pub-id-type="pmid">27013968</pub-id></element-citation></ref><ref id="CR415"><label>415.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kusko</surname><given-names>R</given-names></name><name><surname>Dreymann</surname><given-names>J</given-names></name><name><surname>Ross</surname><given-names>J</given-names></name><name><surname>Cha</surname><given-names>Y</given-names></name><name><surname>Escalante-Chong</surname><given-names>R</given-names></name><name><surname>Garcia-Miralles</surname><given-names>M</given-names></name><etal/></person-group><article-title>Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse</article-title><source>Mol Neurodegener</source><year>2018</year><volume>13</volume><issue>1</issue><fpage>25</fpage><pub-id pub-id-type="doi">10.1186/s13024-018-0259-3</pub-id><pub-id pub-id-type="pmid">29783994</pub-id></element-citation></ref><ref id="CR416"><label>416.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Hayden</surname><given-names>MR</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name></person-group><article-title>BDNF overexpression in the forebrain rescues Huntington&#x02019;s disease phenotypes in YAC128 mice</article-title><source>J Neurosci</source><year>2010</year><volume>30</volume><issue>44</issue><fpage>14708</fpage><lpage>14718</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1637-10.2010</pub-id><pub-id pub-id-type="pmid">21048129</pub-id></element-citation></ref><ref id="CR417"><label>417.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geva</surname><given-names>M</given-names></name><name><surname>Kusko</surname><given-names>R</given-names></name><name><surname>Soares</surname><given-names>H</given-names></name><name><surname>Fowler</surname><given-names>KD</given-names></name><name><surname>Birnberg</surname><given-names>T</given-names></name><name><surname>Barash</surname><given-names>S</given-names></name><etal/></person-group><article-title>Pridopidine activates neuroprotective pathways impaired in Huntington disease</article-title><source>Hum Mol Genet</source><year>2016</year><volume>25</volume><issue>18</issue><fpage>3975</fpage><lpage>3987</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddw238</pub-id><pub-id pub-id-type="pmid">27466197</pub-id></element-citation></ref><ref id="CR418"><label>418.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yagasaki</surname><given-names>Y</given-names></name><name><surname>Numakawa</surname><given-names>T</given-names></name><name><surname>Kumamaru</surname><given-names>E</given-names></name><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Su</surname><given-names>TP</given-names></name><name><surname>Kunugi</surname><given-names>H</given-names></name></person-group><article-title>Chronic antidepressants potentiate via sigma-1 receptors the brain-derived neurotrophic factor-induced signaling for glutamate release</article-title><source>J Biol Chem</source><year>2006</year><volume>281</volume><issue>18</issue><fpage>12941</fpage><lpage>12949</lpage><pub-id pub-id-type="doi">10.1074/jbc.M508157200</pub-id><pub-id pub-id-type="pmid">16522641</pub-id></element-citation></ref><ref id="CR419"><label>419.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Huntington Study Group HART Investigators</collab></person-group><article-title>A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington&#x02019;s disease</article-title><source>Mov Disord</source><year>2013</year><volume>28</volume><issue>10</issue><fpage>1407</fpage><lpage>1415</lpage><pub-id pub-id-type="doi">10.1002/mds.25362</pub-id><pub-id pub-id-type="pmid">23450660</pub-id></element-citation></ref><ref id="CR420"><label>420.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Yebenes</surname><given-names>JG</given-names></name><name><surname>Landwehrmeyer</surname><given-names>B</given-names></name><name><surname>Squitieri</surname><given-names>F</given-names></name><name><surname>Reilmann</surname><given-names>R</given-names></name><name><surname>Rosser</surname><given-names>A</given-names></name><name><surname>Barker</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Pridopidine for the treatment of motor function in patients with Huntington&#x02019;s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial</article-title><source>Lancet Neurol</source><year>2011</year><volume>10</volume><issue>12</issue><fpage>1049</fpage><lpage>1057</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(11)70233-2</pub-id><pub-id pub-id-type="pmid">22071279</pub-id></element-citation></ref><ref id="CR421"><label>421.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reilmann</surname><given-names>R</given-names></name><name><surname>McGarry</surname><given-names>A</given-names></name><name><surname>Grachev</surname><given-names>ID</given-names></name><name><surname>Savola</surname><given-names>J-M</given-names></name><name><surname>Borowsky</surname><given-names>B</given-names></name><name><surname>Eyal</surname><given-names>E</given-names></name><etal/></person-group><article-title>Safety and efficacy of pridopidine in patients with Huntington&#x02019;s disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study</article-title><source>Lancet Neurol</source><year>2019</year><volume>18</volume><issue>2</issue><fpage>165</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(18)30391-0</pub-id><pub-id pub-id-type="pmid">30563778</pub-id></element-citation></ref><ref id="CR422"><label>422.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGarry</surname><given-names>A</given-names></name><name><surname>Auinger</surname><given-names>P</given-names></name><name><surname>Kieburtz</surname><given-names>K</given-names></name><name><surname>Geva</surname><given-names>M</given-names></name><name><surname>Mehra</surname><given-names>M</given-names></name><name><surname>Abler</surname><given-names>V</given-names></name><etal/></person-group><article-title>Additional safety and exploratory efficacy data at 48 and 60 months from Open-HART, an open-label extension study of pridopidine in Huntington disease</article-title><source>J Huntingtons Dis.</source><year>2020</year><volume>9</volume><issue>2</issue><fpage>173</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.3233/JHD-190393</pub-id><pub-id pub-id-type="pmid">32508327</pub-id></element-citation></ref><ref id="CR423"><label>423.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ponten</surname><given-names>H</given-names></name><name><surname>Kullingsj&#x000f6;</surname><given-names>J</given-names></name><name><surname>Sonesson</surname><given-names>C</given-names></name><name><surname>Waters</surname><given-names>S</given-names></name><name><surname>Waters</surname><given-names>N</given-names></name><name><surname>Tedroff</surname><given-names>J</given-names></name></person-group><article-title>The dopaminergic stabilizer pridopidine decreases expression of l-DOPA-induced locomotor sensitisation in the rat unilateral 6-OHDA model</article-title><source>Eur J Pharmacol</source><year>2013</year><volume>698</volume><issue>1&#x02013;3</issue><fpage>278</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2012.10.039</pub-id><pub-id pub-id-type="pmid">23127496</pub-id></element-citation></ref><ref id="CR424"><label>424.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McFarthing</surname><given-names>K</given-names></name><name><surname>Prakash</surname><given-names>N</given-names></name><name><surname>Simuni</surname><given-names>T</given-names></name></person-group><article-title>Clinical trial highlights &#x02013; dyskinesia</article-title><source>J Parkinsons Dis</source><year>2019</year><volume>9</volume><fpage>449</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.3233/JPD-199002</pub-id><pub-id pub-id-type="pmid">31356217</pub-id></element-citation></ref><ref id="CR425"><label>425.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nadjar</surname><given-names>A</given-names></name><name><surname>Gerfen</surname><given-names>CR</given-names></name><name><surname>Bezard</surname><given-names>E</given-names></name></person-group><article-title>Priming for l-dopa-induced dyskinesia in Parkinson&#x02019;s disease: a feature inherent to the treatment or the disease?</article-title><source>Prog Neurobiol</source><year>2009</year><volume>87</volume><issue>1</issue><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.pneurobio.2008.09.013</pub-id><pub-id pub-id-type="pmid">18938208</pub-id></element-citation></ref><ref id="CR426"><label>426.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khoury</surname><given-names>R</given-names></name><name><surname>Rajamanickam</surname><given-names>J</given-names></name><name><surname>Grossberg</surname><given-names>GT</given-names></name></person-group><article-title>An update on the safety of current therapies for Alzheimer&#x02019;s disease: focus on rivastigmine</article-title><source>Ther Adv Drug Saf.</source><year>2018</year><volume>9</volume><issue>3</issue><fpage>171</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1177/2042098617750555</pub-id><pub-id pub-id-type="pmid">29492246</pub-id></element-citation></ref><ref id="CR427"><label>427.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terada</surname><given-names>K</given-names></name><name><surname>Migita</surname><given-names>K</given-names></name><name><surname>Matsushima</surname><given-names>Y</given-names></name><name><surname>Sugimoto</surname><given-names>Y</given-names></name><name><surname>Kamei</surname><given-names>C</given-names></name><name><surname>Matsumoto</surname><given-names>T</given-names></name><etal/></person-group><article-title>Cholinesterase inhibitor rivastigmine enhances nerve growth factor-induced neurite outgrowth in PC12 cells via sigma-1 and sigma-2 receptors</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><issue>12</issue><fpage>e0209250</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0209250</pub-id><pub-id pub-id-type="pmid">30557385</pub-id></element-citation></ref><ref id="CR428"><label>428.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corey-Bloom</surname><given-names>J</given-names></name></person-group><article-title>A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer&#x02019;s disease</article-title><source>Int J Geriatr Psyopharmacol.</source><year>1998</year><volume>1</volume><fpage>55</fpage><lpage>65</lpage></element-citation></ref><ref id="CR429"><label>429.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>R&#x000f6;sler</surname><given-names>M</given-names></name><name><surname>Anand</surname><given-names>R</given-names></name><name><surname>Cicin-Sain</surname><given-names>A</given-names></name><name><surname>Gauthier</surname><given-names>S</given-names></name><name><surname>Agid</surname><given-names>Y</given-names></name><name><surname>Dal-Bianco</surname><given-names>P</given-names></name><etal/></person-group><article-title>Efficacy and safety of rivastigmine in patients with Alzheimer&#x02019;s disease: international randomised controlled trial</article-title><source>BMJ</source><year>1999</year><volume>318</volume><issue>7184</issue><fpage>633</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1136/bmj.318.7184.633</pub-id><pub-id pub-id-type="pmid">10066203</pub-id></element-citation></ref><ref id="CR430"><label>430.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finkel</surname><given-names>SI</given-names></name></person-group><article-title>Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer&#x02019;s disease</article-title><source>Clin Ther</source><year>2004</year><volume>26</volume><issue>7</issue><fpage>980</fpage><lpage>990</lpage><pub-id pub-id-type="doi">10.1016/s0149-2918(04)90172-5</pub-id><pub-id pub-id-type="pmid">15336465</pub-id></element-citation></ref><ref id="CR431"><label>431.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>B</given-names></name><name><surname>Sahn</surname><given-names>JJ</given-names></name><name><surname>Ardestani</surname><given-names>PM</given-names></name><name><surname>Evans</surname><given-names>AK</given-names></name><name><surname>Scott</surname><given-names>LL</given-names></name><name><surname>Chan</surname><given-names>JZ</given-names></name><etal/></person-group><article-title>Small molecule modulator of sigma 2 receptor is neuroprotective and reduces cognitive deficits and neuroinflammation in experimental models of Alzheimer&#x02019;s disease</article-title><source>J Neurochem</source><year>2017</year><volume>140</volume><issue>4</issue><fpage>561</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1111/jnc.13917</pub-id><pub-id pub-id-type="pmid">27926996</pub-id></element-citation></ref><ref id="CR432"><label>432.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yano</surname><given-names>T</given-names></name><name><surname>Tanabe</surname><given-names>H</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Kobayashi</surname><given-names>H</given-names></name><name><surname>Nabetani</surname><given-names>A</given-names></name><name><surname>Sakai</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Sigma-1 receptor is a molecular target for novel neuroprotectant T-817MA</article-title><source>Alzheimer Dement.</source><year>2015</year><volume>11</volume><issue>7</issue><fpage>P861</fpage><pub-id pub-id-type="doi">10.1016/j.jalz.2015.08.038</pub-id></element-citation></ref><ref id="CR433"><label>433.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>PTH</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Ho</surname><given-names>SA</given-names></name><name><surname>Tran</surname><given-names>AH</given-names></name><name><surname>Ono</surname><given-names>T</given-names></name><name><surname>Nishijo</surname><given-names>H</given-names></name></person-group><article-title>Ameliorative effects of a neuroprotective agent, T-817MA, on place learning deficits induced by continuous infusion of amyloid-&#x003b2; peptide (1&#x02013;40) in rats</article-title><source>Hippocampus</source><year>2007</year><volume>17</volume><issue>6</issue><fpage>443</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1002/hipo.20281</pub-id><pub-id pub-id-type="pmid">17397046</pub-id></element-citation></ref><ref id="CR434"><label>434.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Hong Nguyen</surname><given-names>PT</given-names></name><name><surname>Ho</surname><given-names>SA</given-names></name><name><surname>Tran</surname><given-names>AH</given-names></name><name><surname>Ono</surname><given-names>T</given-names></name><name><surname>Nishijo</surname><given-names>H</given-names></name></person-group><article-title>T-817MA, a neurotrophic agent, ameliorates the deficits in adult neurogenesis and spatial memory in rats infused icv with amyloid-&#x003b2; peptide</article-title><source>Br J Pharmacol</source><year>2009</year><volume>157</volume><issue>3</issue><fpage>451</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2009.00141.x</pub-id><pub-id pub-id-type="pmid">19371351</pub-id></element-citation></ref><ref id="CR435"><label>435.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>LS</given-names></name><name><surname>Thomas</surname><given-names>RG</given-names></name><name><surname>Hendrix</surname><given-names>S</given-names></name><name><surname>Rissman</surname><given-names>RA</given-names></name><name><surname>Brewer</surname><given-names>JB</given-names></name><name><surname>Salmon</surname><given-names>DP</given-names></name><etal/></person-group><article-title>Safety and efficacy of edonerpic maleate for patients with mild to moderate alzheimer disease: a phase 2 randomized clinical trial</article-title><source>JAMA Neurol</source><year>2019</year><volume>76</volume><issue>11</issue><fpage>1330</fpage><lpage>1339</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2019.1868</pub-id><pub-id pub-id-type="pmid">31282954</pub-id></element-citation></ref><ref id="CR436"><label>436.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>L</given-names></name><name><surname>Porsteinsson</surname><given-names>A</given-names></name><name><surname>Farlow</surname><given-names>M</given-names></name><name><surname>Shimakura</surname><given-names>A</given-names></name><name><surname>Nakagawa</surname><given-names>M</given-names></name><name><surname>Iwakami</surname><given-names>N</given-names></name></person-group><article-title>The neuroprotective and neurotrophic agent T-817MA for Alzheimer&#x02019;s disease: randomized, double-blind, placebo-controlled proof-of-concept trial outcomes</article-title><source>Alzheimers Dement</source><year>2013</year><volume>9</volume><issue>4</issue><fpage>P530</fpage><lpage>P531</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2013.04.272</pub-id></element-citation></ref><ref id="CR437"><label>437.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Audronyt&#x00117;</surname><given-names>E</given-names></name><name><surname>Kaubrys</surname><given-names>G</given-names></name></person-group><article-title>Odor identification and discrimination as markers of early Alzheimer&#x02019;s disease</article-title><source>Alzheimers Dement</source><year>2022</year><volume>18</volume><fpage>e063101</fpage><pub-id pub-id-type="doi">10.1002/alz.063101</pub-id></element-citation></ref><ref id="CR438"><label>438.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hudd</surname><given-names>F</given-names></name><name><surname>Shiel</surname><given-names>A</given-names></name><name><surname>Harris</surname><given-names>M</given-names></name><name><surname>Bowdler</surname><given-names>P</given-names></name><name><surname>Wood</surname><given-names>B</given-names></name><name><surname>Tsivos</surname><given-names>D</given-names></name><etal/></person-group><article-title>novel blood biomarkers that correlate with cognitive performance and hippocampal volumetry: potential for early diagnosis of Alzheimer&#x02019;s disease</article-title><source>J Alzheimers Dis</source><year>2019</year><volume>67</volume><issue>3</issue><fpage>931</fpage><lpage>947</lpage><pub-id pub-id-type="doi">10.3233/JAD-180879</pub-id><pub-id pub-id-type="pmid">30689581</pub-id></element-citation></ref><ref id="CR439"><label>439.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>JM</given-names></name><name><surname>Wroblewski</surname><given-names>KE</given-names></name><name><surname>Kern</surname><given-names>DW</given-names></name><name><surname>Schumm</surname><given-names>LP</given-names></name><name><surname>McClintock</surname><given-names>MK</given-names></name></person-group><article-title>Olfactory dysfunction predicts 5-year mortality in older adults</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><issue>10</issue><fpage>e107541</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0107541</pub-id><pub-id pub-id-type="pmid">25271633</pub-id></element-citation></ref><ref id="CR440"><label>440.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>DR</given-names></name><name><surname>Kern</surname><given-names>DW</given-names></name><name><surname>Wroblewski</surname><given-names>KE</given-names></name><name><surname>McClintock</surname><given-names>MK</given-names></name><name><surname>Dale</surname><given-names>W</given-names></name><name><surname>Pinto</surname><given-names>JM</given-names></name></person-group><article-title>Olfactory dysfunction predicts subsequent dementia in older US adults</article-title><source>J Am Geriatr Soc</source><year>2018</year><volume>66</volume><issue>1</issue><fpage>140</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1111/jgs.15048</pub-id><pub-id pub-id-type="pmid">28944467</pub-id></element-citation></ref><ref id="CR441"><label>441.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Harrou</surname><given-names>F</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name></person-group><article-title>Early detection of Parkinson&#x02019;s disease using deep learning and machine learning</article-title><source>IEEE Access.</source><year>2020</year><volume>8</volume><fpage>147635</fpage><lpage>147646</lpage><pub-id pub-id-type="doi">10.1109/ACCESS.2020.3016062</pub-id></element-citation></ref><ref id="CR442"><label>442.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>C-H</given-names></name><name><surname>Wang</surname><given-names>F-C</given-names></name><name><surname>Kuo</surname><given-names>T-Y</given-names></name><name><surname>Huang</surname><given-names>P-W</given-names></name><name><surname>Chen</surname><given-names>S-F</given-names></name><name><surname>Fu</surname><given-names>L-C</given-names></name></person-group><article-title>Early detection of Parkinson&#x02019;s disease by neural network models</article-title><source>IEEE Access.</source><year>2022</year><volume>10</volume><fpage>19033</fpage><lpage>19044</lpage><pub-id pub-id-type="doi">10.1109/ACCESS.2022.3150774</pub-id></element-citation></ref></ref-list></back></article>